Document:

<PAGE>

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

                                                                   EXHIBIT 10.24

                    JOINT COLLABORATION AND LICENSE AGREEMENT

         THIS JOINT COLLABORATION AND LICENSE AGREEMENT (the "Agreement") is
made effective as of the 16th day of March, 2004 (the "Effective Date") by and
between GTx, Inc., a Delaware corporation having its principal place of business
at 3 North Dunlap St., 3rd Floor, Memphis, Tennessee 38163 ("GTx") and Ortho
Biotech Products L.P., a limited partnership having its principal place of
business at Route 22 East, Bridgewater, NJ 08807 ("Ortho"), each on behalf of
itself and its Affiliates. GTx and Ortho are sometimes referred to herein
individually as a "Party" and collectively as the "Parties", and references to
"GTx" and "Ortho" shall include their respective Affiliates.

                                    RECITALS

         Ortho is a wholly owned subsidiary of Johnson & Johnson, a
multinational healthcare company with research, development and marketing
activities worldwide, which desires to obtain additional potential drug products
for osteoporosis and wasting, and possible other indications.

         GTx is a men's healthcare company, which is developing compounds,
including Andarine, an orally active, non-steroidal, selective androgen receptor
modulator (SARM). GTx has conducted several Phase I clinical trials of Andarine
and is planning Phase II and III clinical trials of such compound.

         The Parties desire to develop and commercialize Andarine and possibly
other specified SARM compounds throughout the world.

                                   ARTICLE I

                                   DEFINITIONS

         The following terms shall have the following meanings as used in this
Agreement:

         1.1 "Active Ingredient" means the material(s) in the Collaboration
Product which provide its pharmacological activity.

         1.2 "Additional Collaboration Compound" means any Collaboration
Compound selected for Development other than, and in addition to, Andarine or a
Replacement Collaboration Compound for Andarine.

         1.3 "Affiliate" means an entity that, directly or indirectly, through
one or more intermediaries, controls, is controlled by or is under common
control with GTx or Ortho. For the purposes of this definition, the term
"control" (including, with correlative

<PAGE>

meanings, the terms "controlled by" and "under common control with") as used
with respect to a Party, shall mean the possession, directly or indirectly, of
the power to direct, or cause the direction of, the management or policies of
such person or entity, whether through the ownership of voting securities, by
contract or otherwise.

         1.4 "Andarine" means [ * ], and [ * ] that have the activity described
in Section 1.36(2).

         1.5 "Business Day" means a day on which banking institutions in New
York, NY are open for business.

         1.6 "Clinical Studies" means human studies designed to measure the
Safety, efficacy, Tolerability and appropriate dosage of a Collaboration
Compound and/or Collaboration Product. Clinical Studies includes Phase I
Clinical Trial, Phase IIA Clinical Trial, Phase IIB Clinical Trial, Phase III
Clinical Trial, Phase IIIB Clinical Trial, and Phase IV Clinical Trial, as
defined herein.

         1.7 "Collaboration Compound" means (i) initially, Andarine and (ii) any
other GTx SARM Compound selected by Ortho for Development pursuant to this
Agreement. Collaboration Compounds include without limitation Additional
Collaboration Compounds and Replacement Collaboration Compounds.

         1.8 "Collaboration Product" means a drug product for use in humans in a
form suitable for sale to an end user and/or for use in conducting Clinical
Studies, containing as an Active Ingredient at least one Collaboration Compound.

         1.9 "Combination Product" means (i) any pharmaceutical product that
consists of a Collaboration Product that also contains another Active Ingredient
that is not a Collaboration Compound, or (ii) any combination of a Collaboration
Product and another pharmaceutical product that is not a Collaboration Product
where such products are not formulated together but are sold together for a
single invoiced price.

         1.10 "Commercialization Activities" means activities relating to the
manufacture of a Collaboration Product for sale to end users, or to the
marketing and sale of a Collaboration Product, including Pre-Marketing
activities, which in the Co-Promotion Territory is undertaken pursuant to a
Marketing and Sales Plan.

         1.11 "Confidential Information" shall have the meaning set forth in
Section 9.1.

         1.12 "Control" or "Controlled" means the possession of the right to
grant a license or sublicense to intangible property rights (including patent
rights, know-how and/or trade secret information), and the right to provide
access to or cross-reference to regulatory filings or other data or information,
in each case to the extent not in violation of the terms of any pre-existing
agreement or other arrangement with any Third Party. "Control" expressly
includes the right of ownership, in whole or in part, unless the Party having
such right is restricted by contract or under law from granting such a license,
access or right to reference.

                                       2

<PAGE>

         1.13 "Co-Promotion" shall have the meaning set forth in Article VI, and
"Co-Promote" shall have a correlative meaning.

         1.14 "Co-Promotion Territory" means the United States, but only after
GTx exercises its option to Co-Promote a Collaboration Product to the GTx
Audience, on a Collaboration Product by Collaboration Product basis.

         1.15 "Detail" (or "Details" and "Detailing") means, with respect to the
Collaboration Product, the activity undertaken by a sales representative [ * ]
to provide [ * ] of the Collaboration Product, in a fair and balanced manner
consistent with the requirements of the Food Drug and Cosmetics Act, including
but not limited to, the regulations of 21 C.F.R. 202, and [ * ] in an effort to
increase the number of physicians prescribing the Collaboration Product and/or
the number of prescriptions for Collaboration Product, but excluding [ * ].

         1.16 "Development" or "Develop" means activities relating to obtaining
Regulatory Approval of Collaboration Products, and activities relating to
developing and scaling up the ability to manufacture and to continue to
manufacture Collaboration Compounds and Collaboration Products, including
activities of Third Party manufacturers to develop such manufacturing
capabilities for Collaboration Products. Development includes but is not limited
to Pre-Clinical Studies, pharmacology studies, toxicology studies, formulation,
manufacturing process development and scale-up (including bulk compound
production), quality assurance and quality control, technical support,
pharmacokinetic studies, Clinical Studies, regulatory affairs activities and
outside counsel regulatory legal services. For clarity, Development shall not
include medicinal chemistry efforts directed at the production of new chemical
variants of any GTx SARM Compound that are not themselves GTx SARM Compounds,
but may include (to the extent provided in the Development Plan) the production
of modified GTx SARM Compounds that contain radioactive isotopes (whether or not
such modified compounds are included in GTx SARM Compounds) or other labeling or
tracing residues that are used in analyzing the activity, pharmacokinetics or
pharmacodynamics of Collaboration Compounds as provided in the Development Plan,
and activities directed toward developing a process for manufacturing
Collaboration Compounds.

         1.17 "Development Budget" shall have the meaning set forth in Article
IV.

         1.18 "Development Expenses" means the expenses incurred by a Party or
for its account by a Third Party (including capital expenditures made by a Third
Party and reimbursed by a Party) which are generally consistent with a
Development Plan and Development Budget and are specifically attributable to the
Development of a Collaboration Compound or Collaboration Product not otherwise
recovered or reimbursed. Development Expenses shall include, but are not limited
to, the cost of labor (calculated, as to GTx, as provided in Section 4.5) and
materials incurred in connection with Pre-Clinical and Clinical Studies (whether
conducted internally or by a Third Party, individual investigators or
consultants), toxicological, pharmacological, pharmacokinetic, metabolic,
analytical, formulation, and chemical studies, final product scale-up, and
qualification and validation batches as required by the FDA for the purpose of
obtaining

                                       3

<PAGE>

Regulatory Approval of a Collaboration Product, and costs (and related fees) for
preparing, submitting, reviewing or developing data or information for the
purpose of submission to a governmental authority to obtain and/or maintain
Regulatory Approval of a Collaboration Product.

         1.19 "Development Plan" shall have the meaning set forth in Article IV.

         1.20 "Drug Approval Application" means an application for Regulatory
Approval required before commercial sale or use of a Product as a drug in a
regulatory jurisdiction.

         1.21 "Education" means professional and customer education, through any
means, including (i) articles appearing in journals, newspapers, magazines, or
other media, including direct mail and electronic media; (ii) seminars, exhibits
and conventions; (iii) educational literature, visual aids, three dimensional
educational items, and other educational materials; (iv) market research; and
(v) symposia, advisory boards and opinion leader development activities;
provided, however, that such term shall exclude direct sales force activity. All
such Education means must be within current healthcare compliance guidelines.

         1.22 "Effective Date" shall have the meaning set forth on page one of
this Agreement.

         1.23 "EMEA" means the European Medicine Evaluation Agency or any
successor thereto.

         1.24 "Executive Officers" means the Chief Executive Officer of GTx (or
a senior officer of GTx designated by GTx's Chief Executive Officer) and the
President of Ortho (or a senior officer of Ortho or one of its Affiliates).

         1.25 "FDA" means the United States Food and Drug Administration or any
successor thereto.

         1.26 "First Collaboration Compound" means Andarine or its Replacement
Collaboration Compound.

         1.27 "[ * ]" means [ * ].

         1.28 "FTE" means the equivalent of the work of one (1) employee full
time for one (1) calendar year (consisting of at least a total of [ * ] per
calendar year) of work pursuant to the Development Plan with respect to
Collaboration Products. Any employee who devotes less than [ * ] per calendar
year shall be treated as an FTE on a pro-rata basis calculated by dividing the
actual number of hours worked during such calendar year by [ * ].

         1.29 "FTE Cost" means the cost to GTx of its [ * ] personnel directly
dedicated to the execution of the Development Plan [ * ], and shall be
calculated by multiplying the

                                       4

<PAGE>

FTE Rate by the number of GTx employees, agents or independent contractors
performing such Development pursuant to the Development Plan.

         1.30 "FTE Rate" means, as of the Effective Date, [ * ] per FTE. Such
rate shall be adjusted annually to reflect the total percentage increase in the
U.S. Consumer Price Index for the time period from the Effective Date until the
time at which such index was recalculated at the time of adjustment (with the
first adjustment to occur January 1, 2005, with subsequent adjustments on each
anniversary thereof).

         1.31 "Generic" means a product that contains the same chemical entity
as a Collaboration Product and that has received regulatory approval to be
marketed and sold for an Indication for which the Collaboration Product is
marketed and sold. In the United States, Generics shall only include those
products approved under an ANDA based on the NDA of the Collaboration Product.

         1.32 "GTx Audience" means those urologists who are licensed to practice
in the United States to whom GTx will promote Collaboration Product, as
designated pursuant to Section 6.3.

         1.33 "GTx Know-how" means Information which (i) GTx discloses to Ortho
under this Agreement and (ii) is within the Control of GTx. Notwithstanding
anything herein to the contrary, GTx Know-how shall exclude GTx Patents.

         1.34 "GTx/Ortho Development" means Development of Collaboration
Compounds for Indications that are primarily directed to the treatment of male
health diseases and/or conditions.

         1.35 "GTx Patent" means the rights granted by any governmental
authority under a Patent which claims Andarine and/or GTx SARM Compounds, or
methods of using and processes for making such compounds, which Patent is owned
or Controlled by GTx. A list of the GTx Patents identified as of the Effective
Date is attached hereto as Exhibit A. GTx Patents include without limitation
GTx's interest in any Joint Patents.

         1.36 "GTx SARM Compounds" means Andarine and/or non-steroidal selective
androgen receptor modulators that (1) [ * ], are [ * ], any [ * ] issued, any [
* ] and [ * ]; and (2) (a) [ * ]; (b) [ * ]; and (c)(i) [ * ]; or (ii) [ * ]; or
(iii) [ * ]. GTx SARM Compounds shall also include [ * ] described in (1) that
also [ * ] in (2). For avoidance of doubt, if a compound is described in (1) but
does not also meet the requirements of (2), such compound shall not be a GTx
SARM Compound and GTx shall retain all rights to such compound. It is understood
by the Parties that GTx has [ * ] and that [ * ] may include GTx SARM Compounds
and/or Excluded SARM Compounds. "Excluded SARM Compounds" means compounds that
are [ * ] and/or compounds that are included in Exhibit D2. For example, the GTx
Patents listed on Exhibit A includes continuation-in-part applications which
include Excluded SARM Compounds. GTx shall retain all rights to Excluded SARM
Compounds. For avoidance of doubt, the parties have set forth on Exhibit D1
certain compounds that, as of the Effective Date, are [ * ] and are included
within clause (1) of the first sentence of this Section 1.36 (and are therefore
eligible to be

                                       5

<PAGE>

GTx SARM Compounds if they also fulfill the requirements of clause (2) of this
Section 1.36), and on Exhibit D2 certain compounds that are, as of the Effective
Date, Excluded SARM Compounds.

         1.37 "IND" shall mean (i) an Investigational New Drug Application as
defined in the United States Food, Drug and Cosmetic Act and applicable
regulations promulgated thereunder by the FDA, or (ii) the equivalent
application to the equivalent agency in any other country or group of countries,
the filing of which is necessary to commence clinical testing of a
pharmaceutical product in humans in a particular jurisdiction.

         1.38 "Indication" means any disease or condition for which a
Collaboration Compound may have therapeutic, ameliorative or preventive activity
and for which a Collaboration Compound can be Developed.

         1.39 "Information" means (i) techniques and data relating to
Collaboration Compounds, Collaboration Products, Combination Products or GTx
SARM Compounds to the extent provided to a Party for use in joint Development,
or for Commercialization thereof, including (but not limited to) inventions,
practices, methods, knowledge, know-how, skill, experience, test data including
pharmacological, toxicological, Pre-Clinical Studies and clinical test data,
analytical and quality control data, marketing, pricing, distribution, cost,
sales and manufacturing data or descriptions, and compounds, compositions of
matter, assays and biological materials related thereto.

         1.40 "Joint Development Committee" or "JDC" means the committee
established pursuant to Article II.

         1.41 "Joint Patent" shall have the meaning set forth in Section 10.4.

         1.42 "Koseisho" means the Japanese Ministry of Health and Welfare, or
any successor agency thereto.

         1.43 "Launch Date" means the date of the first offer for commercial
sale, following Regulatory Approval, of a Collaboration Product.

         1.44 "Major European Country" means any of the United Kingdom, France,
Germany, Spain and Italy.

         1.45 "Market Exclusivity" means, as to a given country, a given product
and a given time period, that no Generic version of such product is then being
sold in such country.

         1.46 "Marketing" means the sale, promotion and advertising of a
Collaboration Product in the Co-Promotion Territory as set forth in Article VI
and in the Marketing and Sales Plan.

         1.47 "Marketing Expenses" means the costs that are generally consistent
with a Marketing and Sales Plan that are incurred after the Launch Date of a
Collaboration

                                       6

<PAGE>

Product and are specifically attributable to the sale, promotion, advertising,
and marketing of such Collaboration Product. Marketing Expenses shall include
costs of Phase IV Clinical Trials.

         1.48 "Marketing and Sales Committee" shall have the meaning set forth
in Section 6.4.

         1.49 "Marketing and Sales Plan" shall have the meaning set forth in
Section 6.5.

         1.50 "Material Breach" shall have the meaning set forth in Section
13.2(e).

         1.51 "NDA" means a complete New Drug Application and all amendments and
supplements thereto filed with the FDA, including all documents, data, and other
information concerning a Collaboration Product, which are necessary for, or
included in, an application for Regulatory Approval by the FDA to market such
Collaboration Product, as more fully defined in 21 C.F.R. Section 314.5 et seq.

         1.52 "NDA Approval" means the approval of an NDA by the FDA required
before commercial sale or use of a Collaboration Product as a drug in the United
States.

         1.53 "Net Sales" means, consistent with, in the United States,
generally accepted accounting principles and, in the rest of the Royalty Bearing
Territory, Ortho worldwide practices and procedures, and in each such case as
consistently applied across the Ortho pharmaceutical product line, the amount
invoiced by Ortho, its Affiliates, and its distributors and sub-licensees to
Customers for sales of licensed Product in the Royalty Bearing Territory, less
accruals estimated, credits taken, and actual payments (to the extent not
previously accrued) made for:

                  (a) discounts, credits, retroactive price reductions, rebates,
refunds, charge backs, allowances and adjustments granted to non-sublicensee
Third Parties, including Medicaid, and managed care and similar types of
rebates, rejections, market withdrawals, recalls (provided such recalls are in
accordance with Section 6.22 of this Agreement) and returns, and administrative
fees charged by hospital buying groups and managed care organizations in the
United States, each to the extent consistent with Ortho's usual course of
dealing for its products other than the Products;

                  (b) trade, quantity and cash discounts and rebates actually
allowed or given (other than to a distributor that is an Affiliate of Ortho),
each to the extent consistent with Ortho's usual course of dealing for its
products other than the Product;

                  (c) sales, excise, turnover, value-added, and similar taxes
assessed on the sale of the Product (other than income taxes of Ortho, its
Affiliates or sublicensees), and import and customs duties;

                  (d) shipping and insurance charges, postage, and freight out;
and

                  (e) government imposed rebates or discounts.

                                       7

<PAGE>

Sales of Product by and between Ortho and its Affiliates and sublicensees are
not sales to Third Parties and shall be excluded from Net Sales calculations for
all purposes. Sales of Product for use in conducting clinical trials of Product
in a country in order to obtain the first Regulatory Approval of Product in such
country shall be excluded from Net Sales calculations for all purposes. Net
Sales shall be determined in a manner consistent for all products sold by or on
behalf of Ortho and in accordance with applicable U.S. generally accepted
accounting principles.

In the event the Product is sold as part of a Combination Product in a country,
the Net Sales of the Product, for the purposes of determining payments based on
Net Sales, shall be determined by multiplying the Net Sales of the Combination
Product in such country, during the applicable Net Sales reporting period, by
the fraction, A/(A+B), where:

A is the average sale price of the Product by Ortho, its Affiliates or
sublicensees when sold separately in finished form in such country and B is the
average sale price by Ortho, its Affiliates or sublicensees of the other
product(s) included in the Combination Product when sold separately in finished
form in such country, in each case during the applicable Net Sales reporting
period.

In the event the Product is sold as part of a Combination Product and is sold
separately in finished form in such country, but the other product(s) included
in the Combination Product are not sold separately in finished form in such
country, the Net Sales of the Product, for the purposes of determining payments
based on Net Sales, shall be determined by multiplying the Net Sales of the
Combination Product in such country by the fraction C/D where:

C is the average sale price, in such country, of the Product contained in such
Combination Product when sold separately and D is the average sale price, in
such country, for the Combination Product, in each case during the applicable
Net Sales reporting period. Under no circumstances can C/D exceed one hundred
percent (100%).

In the event that the Product is not sold separately in finished form in the
country, but all of the other product(s) included in the Combination Product in
such country are sold separately, the Net Sales of the Product, for the purposes
of determining payments based on Net Sales, shall be determined by multiplying
the Net Sales of the Combination Product in such country by the fraction
(D-E)/D, where:

D is the average sale price, in such country, of the Combination Product, and E
is the average sale price of the other product(s) included in the Combination
Product in finished form in such country, in each case during the applicable Net
Sales reporting period, provided that in no event shall (D-E)/D be [ * ].

In the event that the Net Sales of the Product when included in a Combination
Product cannot be determined using the methods above, Net Sales for the purposes
of determining payments based on Net Sales shall be calculated by multiplying
the Net Sales of the Combination Product by the fraction of F/(F+G) where:

                                       8

<PAGE>

F is the fair market value of the Product and G is the fair market value of all
other pharmaceutical product(s) included in the Combination Product, as
reasonably determined in good faith by the Parties.

         1.54 "Ortho Development" means all Development other than the GTx/Ortho
Development.

         1.55 "Ortho Know-how" means Information which (i) Ortho discloses to
GTx under this Agreement and (ii) is within the Control of Ortho.
Notwithstanding anything herein to the contrary, Ortho Know-how shall exclude
Ortho Patents.

         1.56 "Ortho Patent" means the rights granted by any governmental
authority under a Patent which covers an invention relating to the composition
of matter, formulation, method of making or method of using Collaboration
Compounds or Collaboration Products, which Patent is Controlled by Ortho. As of
the Effective Date, Ortho has not identified any Ortho Patents. Ortho Patents
include Ortho's interest in any Joint Patents.

         1.57 "Osteoporosis Indication" means the treatment of [ * ].

         1.58 "[ * ]" means [ * ].

         1.59 "Patent" means (i) valid and enforceable United States or foreign
patents, reexaminations, reissues, renewals, extensions, term restorations, and
foreign counterparts thereof, and (ii) pending applications for United States or
foreign patents thereof.

         1.60 "Patent Expenses" means the fees, expenses and disbursements of
outside counsel, and payments to Third Party agents, incurred in connection with
the preparation, filing, prosecution and maintenance of GTx Patents or Ortho
Patents covering Collaboration Compounds or Collaboration Products, including
the costs of patent interference and opposition proceedings but excluding the
costs of any other Patent enforcement proceedings.

         1.61 "Phase I Clinical Trial" means that portion of the clinical
development program which provides for the first introduction into humans of a
Product with the purpose of determining human toxicity, metabolism, absorption,
elimination and other pharmacological action, as more fully defined in 21 C.F.R.
Section 312.21(a).

         1.62 "Phase IIA Clinical Trial" means that portion of the clinical
development program which provides for the initial trials of a Collaboration
Compound on a limited number of patients for the purpose of determining whether
the Collaboration Compound affects a surrogate marker or indicator of
pharmacological or clinical activity in the proposed therapeutic indication.

         1.63 "Phase IIB Clinical Trial" means that portion of the clinical
development program which provides for the definitive, well controlled clinical
trials of a Collaboration Compound in patients for the purpose of determining
the safe and effective

                                       9

<PAGE>

dose range in the proposed therapeutic indication, as more fully described in 21
C.F.R. Section 312.21(b).

         1.64 "Phase III Clinical Trials" means that portion of the clinical
development program which provides for continued trials of a Product on
sufficient numbers of patients to establish the safety and efficacy of a Product
and generate pharmaco-economic data to support Regulatory Approval in the
proposed therapeutic indication, as more fully defined in 21 C.F.R. Section
312.21(c).

         1.65 "Phase IIIB Clinical Trials" means product support clinical trials
of a Collaboration Product, which is not required for receipt of initial
Regulatory Approval but which may be useful in providing additional drug profile
data or expansion of the Collaboration Product's label claim, and which is
commenced after NDA filing but before NDA Approval.

         1.66 "Phase IV Clinical Trials" means product support clinical trials,
including but not limited to trials including new drug delivery systems, of a
Collaboration Product with an approved label claim that is commenced after
receipt of Regulatory Approval in the country where such trial is being
conducted. These trials shall be considered a part of Commercialization.

         1.67 "Pre-Clinical Studies" means studies of a Collaboration Product in
animals other than humans, including those studies conducted in whole animals
and other test systems, designed to determine the toxicity, bioavailability, and
pharmacokinetics of a Collaboration Compound and whether the Collaboration
Compound has a desired effect.

         1.68 "Pre-Marketing" means Commercialization Activities undertaken
prior to and in preparation for the launch of a Collaboration Product,
consistent with a Marketing and Sales Plan and prior to the first commercial
launch of such Collaboration Product. Pre-Marketing activities shall include,
but are not limited to, advertising, Education, market research, Phase IIIB
Clinical Trials, Phase IV Clinical Trials, sales force training, trademark
activities (including selection, filing, prosecution and enforcement) and other
activities included within the Marketing and Sales Plan prior to the first
commercial launch of such Collaboration Product.

         1.69 "Products" means Collaboration Products.

         1.70 "Proof of Concept Trial" means any Phase IIA Clinical Trial or
Phase IIB Clinical Trial that is designed to demonstrate that a Collaboration
Product meets clinical criteria established by the JDC with respect to a given
indication.

         1.71 "Regulatory Agency" means any governmental authority, including
without limitation the FDA or EMEA, with responsibility for granting any
licenses or approvals or granting pricing and/or reimbursement approvals
necessary for the marketing and sale of a Collaboration Product in any country
or group of countries.

                                       10
<PAGE>

         1.72 "Regulatory Approval" means any approvals by government pricing or
health authorities in a country or supra-national organization (including, but
not limited to, FDA and EMEA), product and/or establishment licenses,
registrations or authorizations of any federal, state or local regulatory
agency, department, bureau or other governmental entity, in each case that are
necessary for the commercial manufacture, use, storage, importation, export,
transport or sale of Collaboration Products in a regulatory jurisdiction.

         1.73 "Replacement Collaboration Compound" means a GTx SARM Compound
that is selected to replace a Collaboration Compound then under development as
described in Section 4.6.

         1.74 "Royalty Bearing Product" means a Collaboration Product marketed
directly or indirectly by Ortho, its Affiliate or sublicensee alone or together
with GTx or its Affiliates in the Royalty Bearing Territory.

         1.75 "Royalty Bearing Sales" means the Net Sales in the Royalty Bearing
Territory.

         1.76 "Royalty Bearing Territory" means the world.

         1.77 "Royalty Term" shall have the meaning set forth in Section 3.5.

         1.78 "Safety" means the absence of adverse experiences associated with
the administration of a drug to a patient that are significant, serious or life
threatening to the patient or demonstrate significant toxicological effect(s) of
such drug on one or more body tissues that are not balanced by a countervailing
benefit to the patient. The Safety of a product will be determined in view of
the risk to benefit relationship of such product in the relevant patient
population.

         1.79 "[ * ]" means [ * ].

         1.80 "Third Party" means any entity other than GTx or Ortho and their
respective Affiliates.

         1.81 "Tolerability" means the absence of adverse experiences, other
than those that are Safety-related experiences, associated with administration
of a drug to patients that such patients, or their physicians, deem unpleasant
to an extent that can materially and adversely affect market potential or market
penetration of a Collaboration Product.

         1.82 "Trademark Expenses" means the fees, expenses and disbursements of
outside counsel, and payments to Third Party agents incurred in connection with
the preparation, filing, prosecution, registration and maintenance of trademarks
covering Collaboration Compounds or Collaboration Products, including the costs
of trademark interference and opposition proceedings, but excluding other
trademark enforcement proceedings.

                                       11

<PAGE>

         1.83 "Unit Net Sales Price" means the average Net Sales amount received
during either the applicable calendar quarter (as used in Section 7.1) or during
the applicable period (as used in Section 13.6) by Ortho, its Affiliates or
sublicensees for each tablet or other dosage form of a Collaboration Product
written by a Urologist and filled and sold by a pharmacist in the United States.

         1.84 "Urologist" means a urologist licensed to practice in the United
States, or a nurse practitioner or physician assistant who works for such a
urologist.

         1.85 "UTRF" means the University of Tennessee Research Foundation.

         1.86 "Valid Patent Claim" means a claim (a) of any issued, unexpired
patent that has not been revoked or held unenforceable or invalid by a decision
of a court or governmental agency of competent jurisdiction from which no appeal
can be taken, or with respect to which an appeal is not taken within the time
allowed for appeal, and that has not been disclaimed or admitted to be invalid
or unenforceable through reissue, disclaimer or otherwise, or (b) of any patent
application that has not been cancelled, withdrawn or abandoned or been pending
more than seven (7) years.

         1.87 "Wasting Indication" means the treatment of the effects of
diseases involving a reduction in lean body weight, whether due to [ * ] or
other chronic medical conditions.

                                   ARTICLE II

                                   MANAGEMENT

         2.1 Joint Development Committee.

                  (a) Formation of JDC. GTx and Ortho shall form a Joint
Development Committee ("JDC"). The JDC shall be comprised of equal numbers (up
to three (3) from each Party) of appropriately expert and experienced
individuals, with one such person assigned by each Party as such Party's
co-chair. Either Party may designate a substitute for a committee member to
participate in the event one of that Party's regular committee members is unable
to be present at a meeting.

                  (b) Meetings. Meetings of each of the JDC may be called by
either Party on ten (10) calendar days written notice to the other unless such
notice is waived by the Parties. Such committees may be convened, polled or
consulted from time to time by means of telecommunication, video communication,
or correspondence. The JDC will meet at least quarterly, at sites to be
designated by the chairpersons of such committees or through teleconference or
video conference, as agreed upon by the JDC.

                  (c) Agendas. Each Party will disclose to the other proposed
agenda items along with appropriate Information at least five (5) calendar days
in advance of each meeting of the JDC.

                                       12

<PAGE>

                  (d) Responsibilities of the JDC. The JDC will oversee the
Parties' efforts for Ortho Development and will oversee and coordinate the
Parties' efforts with respect to GTx/Ortho Development. The JDC will review and
comment on the Development Plans and Development Budgets and make
recommendations with respect to adjustment of GTx/Ortho Development, budget and
timetables and the assessment of whether a Collaboration Compound shall proceed
to the next stage of Development. Ortho will update the JDC periodically, but at
least quarterly, of all Development activities. The JDC will review and approve,
with respect to GTx/Ortho Development, the addition of new indications, the
ceasing of Development of Andarine, and the addition of a Replacement
Collaboration Compound or an Additional Compound. In, addition, the JDC shall
review and approve any proposal by GTx to designate a compound not to be a GTx
SARM Compound, as defined herein. In this regard, GTx agrees to provide the JDC
with sufficient information and data in connection with [ * ] so that the JDC
can agree or disagree with GTx's position. Such information shall be provided at
a JDC meeting and the JDC shall have thirty (30) calendar days after it receives
the information and data to decide whether or not it agrees with GTx. If the JDC
disagrees with GTx's position, GTx may proceed to develop and commercialize its
compound independent of this collaboration, provided, however, Ortho shall
retain its rights to arbitrate the classification of such compound under Article
XV (and GTx may also initiate such an arbitration in order to clarify its rights
to such compound). If the JDC agrees that the compound is not a GTx SARM
Compound, Ortho shall promptly provide to GTx a written statement confirming
that Ortho has no rights under this Agreement in or to such compound.

                  (e) Decisions by the JDC.

                           (i) Ortho shall present to the JDC the portion of the
Development Plan and Development Budget that relates to the Ortho Development at
the same level of detail as is contained in the portion of the Development Plan
and Development Budget that relates to the GTx/Ortho Development. However, this
presentation and any subsequent discussion of the contents of the portion of the
Development Plan and Development Budget related to the Ortho Development shall
be for advisory purposes only.

                           (ii) All decisions by the JDC that relate to
GTx/Ortho Development shall be made unanimously, after an open and informed
discussion of the matters as to which decisions are being made, including, but
not limited to those matters relating to the portion of the Development Plan and
Budget directed to GTx/Ortho Development. If the JDC is unable to make a
unanimous decision on such matters, the matter will be referred to the Executive
Officers of GTx and Ortho. If such officers do not reach agreement on such
matter within twenty (20) calendar days after it is referred to them, then
subject to Section 4.1, the decision of Ortho on such matter will be final and
determinative, so long as such decision does not contradict or modify the terms
of this Agreement.

                                       13

<PAGE>

                  (f) Subcommittees of the JDC. The JDC will have the power to
form subcommittees with equal (unless otherwise agreed in writing) and
appropriate representation from GTx and Ortho.

                                  ARTICLE III

            LICENSING FEES; MILESTONE PAYMENTS; ROYALTIES; REPORTING

         3.1 Licensing Fee.

                  (a) As partial payment for the licenses granted by GTx
pursuant to this Agreement, Ortho shall pay to GTx a non-refundable,
non-creditable $6.0 Million license fee within fifteen (15) Business Days after
the Effective Date of this Agreement. Payment shall be made by wire transfer.

                  (b) As a partial payment for the licenses granted by GTx
pursuant to this Agreement, Ortho shall pay to GTx a non-refundable,
non-creditable [ * ] at the time that [ * ] of a Collaboration Product for [ *
]. Ortho will pay such amount within fifteen (15) Business Days after receipt of
an invoice from GTx. Payment shall be made by wire transfer.

         3.2 Milestone Payments. In addition to the payments due to GTx under
Section 3.1, Ortho shall make the following non-refundable, non-creditable
milestone payments to GTx after the first occurrence of each milestone that
follows, unless, at anytime prior to the date on which such milestone payment is
due, Ortho has provided notice of termination, which termination thereafter
becomes effective. The payments set forth herein shall each be due and payable
by Ortho within [ * ] Business Days following receipt from GTx of a notice and
invoice regarding the achievement of the milestone event set forth herein.
Payment shall be made by wire transfer.

                  (a) First Collaboration Compound:

<TABLE>
<CAPTION>
                         MILESTONE EVENT                                  PAYMENT
                         ---------------                                  -------
<S>                                                                       <C>
[ * ] in a Proof of Concept Trial of a Collaboration Product for
the [ * ].**                                                              $[ * ]

[ * ] in a Proof of Concept Trial of a Collaboration Product for
the [ * ].**                                                              $[ * ]

[ * ] in a Phase III Clinical Trial of a Collaboration Product [
* ] for the [ * ].                                                        $[ * ]

[ * ] in a Phase III Clinical Trial of a Collaboration Product [
* ] for the [ * ].                                                        $[ * ]

Regulatory Approval by the FDA of a Collaboration Product [ * ]
for the [ * ].                                                            $[ * ]
</TABLE>

                                       14

<PAGE>

<TABLE>
<CAPTION>
                         MILESTONE EVENT                                  PAYMENT
                         ---------------                                  -------
<S>                                                                       <C>
Regulatory Approval by the FDA of a Collaboration Product [ * ]
for the [ * ].                                                            $[ * ]

Regulatory Approval by the EMEA of a Collaboration Product [ * ]
for the [ * ].*                                                           $[ * ]

Regulatory Approval by the EMEA of a Collaboration Product [ * ]
for the [ * ].*                                                           $[ * ]

Regulatory Approval by the Koseisho of a Collaboration Product
[ * ] for the [ * ].                                                      $[ * ]

Regulatory Approval by the Koseisho of a Collaboration Product
[ * ] for the [ * ].                                                      $[ * ]
</TABLE>

*If a centralized filing with the EMEA is not made for the relevant
Collaboration Product for the [ * ], but the JDC decides to pursue Regulatory
Approval in Europe using the mutual recognition procedure or on an individual
country basis, then the milestone shall be deemed to be achieved upon the Launch
Date for such Collaboration Product in the first Major European Country.

** This trial is [ * ] as proposed in [ * ], as applicable, is the [ * ].

For clarity, if a Collaboration Product is developed initially for [ * ], such [
* ] shall be the [ * ]. If such development is successful and such product is
commercialized for such [ * ], and Ortho develops such Collaboration Product for
[ * ], such [ * ] shall be a [ * ]. If development of such Collaboration Product
for such [ * ] is terminated, but such product is then developed and
commercialized for a [ * ], then for the purpose of calculating milestones
hereunder, any milestones that are due with respect to a [ * ] that were not
previously paid by Ortho for the Collaboration Product for a [ * ] shall be due
when such milestone is achieved for the [ * ] (i.e., the [ * ] would function as
a [ * ] for the purposes of this Section 3.2).

                  (b) Additional Collaboration Compounds:

<TABLE>
<CAPTION>
                         MILESTONE EVENT                                 PAYMENT
                         ---------------                                 -------
<S>                                                                      <C>
[ * ] in a Proof of Concept Trial of a Collaboration Product [ * ].      $[ * ]

[ * ] in a Phase III Clinical Trial of a Collaboration Product [ * ].    $[ * ]
</TABLE>

                                       15

<PAGE>

<TABLE>
<CAPTION>
                         MILESTONE EVENT                                 PAYMENT
                         ---------------                                 -------
<S>                                                                      <C>
Regulatory Approval by the FDA of a Collaboration Product [ * ].         $[ * ]

Regulatory Approval by the EMEA of a Collaboration Product [ * ].*       $[ * ]

Regulatory Approval by the Koseisho of a Collaboration Product [ * ].    $[ * ]

</TABLE>

*If a centralized filing with the EMEA is not made for the relevant
Collaboration Product for the [ * ], but the JDC decides to pursue Regulatory
Approval in Europe using the mutual recognition procedure or on an individual
country basis, then the milestone shall be deemed to be achieved upon the Launch
Date for such Collaboration Product in the first Major European Country.

                  (c) Replacement Collaboration Compound. If the JDC (or Ortho,
with respect to Ortho Development) decides to cease Development of Andarine or
another Collaboration Compound that the Parties Develop in addition to Andarine
and decides to Develop, instead of the Collaboration Compound for which
Development was so terminated, another Collaboration Compound (a "Replacement
Collaboration Compound"), Ortho shall not be obligated to make the same
milestone payments for the Replacement Collaboration Compound as it already made
in connection with the Collaboration Compound which was replaced, and shall only
be obligated to make any milestone payments for the Replacement Collaboration
Compound that were not made for the Collaboration Compound that was replaced by
such Replacement Collaboration Compound. It is understood that in no event shall
Ortho be obligated to make the payment due pursuant to this Section 3.2 on any
milestone more than once with respect to the same Collaboration Compound (or its
"Replacement Collaboration Compound") regardless of the number of different
forms or formulations of the Collaboration Compound that are developed[ * ].

         3.3 Limitation on Milestone Payments. Other than the milestone payments
recited in Section 3.2, Ortho shall not be obligated to make any other milestone
payments in connection with Andarine, a Replacement Collaboration Compound, or
any Additional Collaboration Compound.

         3.4 Royalty Rates. Ortho shall pay to GTx an incremental, tiered
royalty equal to the applicable royalty rate set forth below multiplied by the
relevant portion of annual Royalty Bearing Sales of each Collaboration Product
sold in the Royalty Bearing Territory as follows:

                                       16

<PAGE>

<TABLE>
<CAPTION>
Portion of Annual Net Sales of Each Collaboration Product                   Rate
---------------------------------------------------------                   ----
<S>                                                                        <C>
First $[ * ]                                                               [ * ]

> $[ * ] and < or = $[ * ]                                                 [ * ]

> $[ * ] and < or = $[ * ]                                                 [ * ]

> $[ * ] and < or = $[ * ]                                                 [ * ]

> $[ * ] and < or = $[ * ]                                                 [ * ]

> $[ * ]                                                                   [ * ]
</TABLE>

Said royalty shall be calculated as follows: Assume [ * ] of Net Sales of a
Collaboration Product in a calendar year, the royalty would be [ * ] = a royalty
of [ * ].

         3.5 Payment of Royalties. Within twenty (20) Business Days after the
end of each calendar quarter for which royalty fees are payable by Ortho to GTx
with respect to Net Sales in the Royalty Bearing Territory pursuant to Section
3.4, Ortho shall submit to GTx a report, on a country by country basis,
providing in reasonable detail an accounting of all Net Sales (including an
accounting of all unit sales of Product) made during such calendar quarter and
the calculation of such applicable royalty fees under Section 3.4. Within twenty
(20) Business Days after submission of such report, Ortho shall pay GTx all
royalties payable by it under Section 3.4 as indicated in the report by wire
transfer. Ortho will pay GTx royalties on Net Sales of each Collaboration
Product invoiced by Ortho, its Affiliates and its sublicensees at the rates
shown in Section 3.4 above.

                  (a) Royalties shall be payable on a product by product and
country by country basis until the later of (i) the expiration of the last to
expire Valid Claim of a GTx Patent or a Joint Patent claiming the composition of
matter for such Collaboration Product in such country (either, a "Relevant Valid
Claim"), or (ii) ten (10) years following the Launch Date of such Collaboration
Product in such country (such period of time, the "Royalty Term") where there
are no patents.

                  (b) Royalties shall be paid at the rate set forth in Section
3.4 during the Royalty Term, except in a given country where (A) no Relevant
Valid Claim covering the composition of matter of such Collaboration Product
exists during a calendar quarter for which royalties are being calculated under
Section 3.4, and (B) Market Exclusivity does not exist for such Collaboration
Product in such country [ * ] immediately prior to the [ * ]. If the conditions
of (A) and (B) are satisfied, then the royalty rates set forth in Section 3.4
shall be reduced for sales occurring during such calendar quarter by:

                  [ * ], if the number of units of Collaboration Products
                  invoiced by Ortho, its Affiliates or sublicensees in such
                  country are [ * ] of the number of all units of products
                  (including Collaboration Products) containing the Active
                  Ingredient contained in such Collaboration Product (such
                  number, "All Units") that are sold in such country;

                  [ * ], if the number of units of Collaboration Products
                  invoiced by Ortho, its Affiliates or sublicensees in such
                  country are [ * ] of All Units that are sold in such country;

                                       17

<PAGE>

                  [ * ], if the number of units of Collaboration Products
                  invoiced by Ortho, its Affiliates or sublicensees in such
                  country are [ * ] of All Units that are sold in such country;
                  or

                  [ * ], if the number of units of Collaboration Products
                  invoiced by Ortho, its Affiliates or sublicensees in such
                  country are [ * ] of All Units that are sold in such country.

         Market Exclusivity shall be deemed to exist during the [ * ] following
the Launch Date in each country.

         3.6 Payment of Third Party Royalties.

                  (a) In addition to the royalties of Section 3.4, [ * ] shall [
* ] any royalties due by GTx to UTRF under the Amended and Restated License
Agreement between GTx and UTRF dated June 3, 2002, and the Amended and Restated
License Agreement between GTx and UTRF dated June 14, 2002 (collectively, the
"UTRF Agreements"), with respect to the sale of Collaboration Products by Ortho,
its Affiliates or sublicensees. [ * ] shall make such payments [ * ].
Specifically, [ * ] shall deliver to UTRF true and accurate reports as required
under Section 5.2 of the UTRF Agreements, and shall pay all royalties due to
UTRF under Section 4.2 of the UTRF Agreements within the time periods required
therein. [ * ] shall provide copies of each such report to [ * ] simultaneously
with its delivery of such report to UTRF. In no event shall any amounts paid by
[ * ] hereunder be included as [ * ].

                  (b) If a Royalty Bearing Product is being sold in any country
with respect to which a Third Party owns or Controls a patent, from which GTx
has not obtained a license, and such Third Party is entitled to receive
royalties pursuant to a patent license required in order to make or sell the
composition of matter of the Collaboration Compound included in such Royalty
Bearing Product, then Ortho shall be entitled to [ * ] of any royalty paid to
such Third Party against amounts due to GTx pursuant to Sections 3.4 and 3.5,
provided, however, that in no event shall the royalty due to GTx pursuant to
Sections 3.4 and 3.5 be reduced by means of such offset to [ * ] of the royalty
otherwise payable thereunder.

         3.7 Ortho's Rights Upon Expiration of Royalty Term. Upon expiration of
the royalty term for a Royalty Bearing Product in a country as described above,
Ortho shall thereafter have a paid-up, non-exclusive license under the GTx
Know-How to make, have made, use, sell, offer for sale, have sold and import
that Royalty Bearing Product in that country.

         3.8 Compulsory License. If at any time and from time to time a Third
Party in any country shall, under the right of a compulsory license granted or
ordered to be granted by a competent governmental authority, manufacture, use or
sell any Collaboration Product, with respect to which royalties would be payable
to GTx pursuant to this Article, then Ortho may reduce the royalty on sales in
such country of such Collaboration Product, to [ * ].

                                       18

<PAGE>

         3.9 Sales by Sublicensees. In the event Ortho, subject to the
provisions of this Agreement, grants licenses or sublicenses to others to make
or sell Royalty Bearing Products, such licenses or sublicenses shall include an
obligation for the licensee or the sublicensee to account for and report its
Royalty Bearing Sales of such Royalty Bearing Products on the same basis as if
such sales were Royalty Bearing Sales by Ortho, and Ortho shall pay royalties to
GTx as if the Royalty Bearing Sales of Ortho.

         3.10 Tax Matters.

                  (a) Ortho Payments to GTx Without Withholding. Ortho will make
all payments to GTx under this Agreement without deduction or withholding for
Taxes except to the extent that any such deduction or withholding is required by
law in effect at the time of payment; provided that Ortho shall use commercially
reasonable efforts to minimize any such required deductions or withholdings to
the extent permitted by applicable laws, rules and regulations.

                  (b) Ortho Payment of Tax. Any Tax required to be withheld on
amounts payable under this Agreement will promptly be paid by Ortho on behalf of
GTx to the appropriate governmental authority, and Ortho will furnish GTx with
proof of payment of such Tax. Any such Tax required to be withheld will be an
expense of and borne by GTx. Ortho will give notice of its intention to begin
withholding any such Tax in advance and cooperate to use reasonable and legal
efforts to reduce such Tax on payments made to GTx hereunder.

                  (c) Cooperation Between Ortho and GTx. Ortho and GTx will
cooperate with respect to all documentation required by any government taxing
authority or reasonably requested by Ortho to secure a reduction in the rate of
applicable withholding Taxes.

                  (d) GTx Indemnification for Ortho's Failure to Withhold. If
Ortho had a duty to withhold Taxes in connection with any payment it made to GTx
under this Agreement but Ortho failed to withhold, and such Taxes were assessed
against and paid by Ortho, then GTx will indemnify and hold harmless Ortho from
and against such Taxes. Notwithstanding anything to the contrary in this
Section, GTx shall not be responsible for indemnifying Ortho for interest and
penalties attributable to any period [ * ] written notice of such assessment or
proposed assessment to Ortho and ending on the date Ortho provides GTx written
notice of such assessment or proposed assessment, and provided further that GTx
shall be entitled to protest the assessment of such Tax. If Ortho makes a claim
under this Section 3.10(d), it will comply with the obligations imposed by
Section 3.10(b) as if Ortho had withheld Taxes from a payment to GTx.

                  (e) Tax. Solely for purposes of this Section, "Tax" or "Taxes"
means any present or future taxes, levies, imposts, duties, charges, assessments
or fees of any nature (including interest, penalties and additions thereto) that
are imposed by a government taxing authority on GTx's receipt of payments
hereunder. Notwithstanding the foregoing, "Tax" or "Taxes" shall not include
charges, value-added taxes, taxes

                                       19

<PAGE>

imposed on Ortho's income, or assessments or fees of any nature (or any
interest, penalties or additions thereto) imposed by the FDA or any related or
successor agency.

                  (f) Protest. Ortho shall promptly notify GTx in writing of any
assessment, proposed assessment or other claim for any additional amount of Tax
assessed by the United States. Notwithstanding any other provision of this
Section, GTx may, at its own expense, protest any assessment, proposed
assessment, or other claim by any governmental authority for any additional
amount of Tax or seek a refund of such amounts paid if permitted to do so by law
or if the payment of such amounts are its ultimate contractual responsibility
under the terms of this Agreement. Ortho shall cooperate with GTx in any protest
by providing records, giving testimony and providing such additional information
or assistance as may reasonably be necessary to pursue such protest.

         3.11 United States Dollars. All dollar ($) amounts specified in this
Agreement are United States dollar amounts.

         3.12 Payments to or Reports by Affiliates. Any payment required under
any provision of this Agreement to be made to either Party, or any report
required to be made by any Party, shall be made to or by an Affiliate of that
Party if such Affiliate is designated by that Party as the appropriate recipient
or reporting entity.

         3.13 Payment of Additional Royalties. GTx shall receive an additional
royalty on sales of Collaboration Products that it Co-Promotes, as set forth in
Sections 7.1 and, if applicable, 13.6.

         3.14 Payments by Wire Transfer. Any payments due to GTx hereunder shall
be made by wire transfer to the following (or as provided in any alternative
instructions that GTx may provide by written notice to Ortho from time to time):
[ * ].

                                   ARTICLE IV

                                   DEVELOPMENT

         4.1 Development Responsibility. Ortho will be solely responsible for
Development of all Collaboration Products and, as a result, shall be responsible
for carrying out Development pursuant to the Development Plan including both
Ortho Development and GTx/Ortho Development. While Ortho is solely responsible
for Development, GTx agrees to carry out tasks under the Development Plan, if
any, reasonably assigned to it with respect to GTx/Ortho Development, pursuant
to the mutual agreement of the Parties.

         4.2 Development Plan.

                  (a) Development Carried Out Pursuant to Development Plan and
Development Budget. The Development of each Collaboration Compound shall be

                                       20

<PAGE>

carried out pursuant to a development plan ("Development Plan") and development
budget ("Development Budget"). An outline of the Development activities the
Parties intend to carry out during 2004 and 2005 is attached as Exhibit C (the
"Initial Plan"). The Parties will agree upon a preliminary Development Plan and
Development Budget [ * ] after the Effective Date that sets forth the
Development activities to be performed by the Parties during 2004 and 2005,
together with a budget therefor. [ * ] after the Effective Date, such
Development Plan and Development Budget shall be expanded to include other
Development activities and related budgets to be conducted for Collaboration
Products. The Development Plan and Development Budget will be updated by Ortho
on an annual basis.

                  (b) GTx to Provide Ortho With Information Necessary for
Development. GTx shall provide Ortho with access to (and copies of, which may be
in partially or wholly electronic form, to the extent requested) all of the raw
data and reports related to the Development of any of the Collaboration
Compounds and/or Collaboration Products, including those Developed by the
GTx/Ortho Development and those Developed by the Ortho Development, provided
that in no event will GTx be obligated to provide to Ortho any such information
that relates also to compounds described in Section 1.36(1) but not Section
1.36(2), unless such information is reasonably necessary for the Development of
Collaboration Compounds.

                  (c) Content of Development Plan. The Development Plan shall
describe the proposed overall program of all the Development, including, but not
limited to, Pre-Clinical Studies, toxicology, formulation, chemical process
development, Clinical Studies, regulatory plans and other elements of obtaining
Regulatory Approval, and projected timelines for the Development events. The
Development Plan will specify Party-specific execution responsibilities of the
program expected during the Development (consistent with this Agreement) through
obtaining Regulatory Approval for each Collaboration Compound and/or
Collaboration Product, and shall further include a Development Budget for all
Development proposed. The Development Plan for the Development will identify
endpoints needed for initiation of the next phase of the Development.

         4.3 Development Efforts.

                  (a) In carrying out the Development and the Development Plan,
Ortho agrees to use the level of time, effort and funding as is consistent with
that expended on other Ortho projects at a similar stage of Development with a
target market of similar size and importance. Ortho's failure to comply with
such diligence obligations shall constitute a breach of this Agreement.

                  (b) Specifically, and without limiting Section 4.3(a), Ortho
shall use commercially reasonable efforts to conduct the activities set forth in
the Initial Plan.

         4.4 Drug Approval Applications. Consistent with the Development Plan,
Ortho shall be responsible for the filing of all Drug Approval Applications and
seeking Regulatory Approvals for Collaboration Compounds and/or Collaboration
Products. The

                                       21

<PAGE>

Parties shall consult and cooperate in the preparation of each such Drug
Approval Application and in obtaining Regulatory Approvals. Ortho shall solely
own all Drug Approval Applications and Regulatory Approvals. [ * ] after GTx
provides Ortho with a top line summary of completion of the clinical trial that
GTx is currently conducting that it has deemed to be a Phase ID clinical trial
as described in the Initial Plan [ * ] (the "Phase ID Clinical Trial"), GTx
shall transfer or assign its ownership of IND No. [ * ] to Ortho or its
Affiliate as designated by Ortho, and shall take such other actions and execute
such other instruments, assignments and documents as may be necessary to effect
the transfer of rights hereunder to Ortho or its Affiliate as designated by
Ortho.

         4.5 Development Expenses.

                  (a) GTx Development Expenses. GTx's Development Expenses
incurred after the Effective Date in connection with its personnel's Development
efforts shall be calculated [ * ], and Development Expenses incurred by GTx
shall also include any amounts paid by GTx to Third Parties that otherwise
qualify as Development Expenses, which shall be reimbursed as provided in
subsection (b) below.

                  (b) Ortho to Reimburse GTx for Development Expenses. Ortho
shall reimburse GTx for its costs of conducting the Phase ID Clinical Trial that
GTx incurs prior to the Effective Date by paying to GTx an amount not to exceed
$ 687,000 within thirty (30) Business Days after receipt of an invoice. In the
event that GTx incurs any Development Expenses after the Effective Date, such
expenses shall initially be borne by GTx, subject to reimbursement as provided
herein. Each Party shall calculate and maintain records of Development Expenses
incurred by it. GTx shall report quarterly to Ortho its Development Expenses,
with such reports to be submitted within twenty (20) Business Days after the end
of each calendar quarter of each calendar year. The Parties shall seek to
resolve any questions related to such accounting statements within ten (10)
Business Days following receipt. Ortho shall reimburse GTx for any undisputed
Development Expenses GTx incurred within thirty (30) Business Days of receiving
the GTx report. If Ortho disputes its obligation to reimburse any Development
Expenses for which GTx seeks reimbursement hereunder, such dispute shall be
submitted for resolution pursuant to Article XV.

         4.6 Replacement Collaboration Compounds; Additional Collaboration
Compounds. At any time, Ortho may select a Collaboration Compound other than
Andarine for Development pursuant to this Agreement in addition to Andarine,
which shall be an Additional Collaboration Compound. Furthermore, if the Ortho
determines that further Development of Andarine or an Additional Collaboration
Compound, if any, is not desirable, then it may select another Collaboration
Compound to replace Andarine or such Additional Collaboration Compound (and such
replacement compound shall be a "Replacement Collaboration Compound"). In either
of the foregoing events, within forty-five (45) calendar days after the
selection of such Additional Collaboration Compound or Replacement Collaboration
Compound, then Ortho shall update the then-current Development Plan and
Development Budget to provide for Development of such compound.

                                       22

<PAGE>

                                   ARTICLE V

                                    LICENSES

         5.1 Patent Licenses to Conduct Development.

                  (a) Subject to the terms and conditions of this Agreement, GTx
grants to Ortho an exclusive (except as to GTx), royalty-bearing, worldwide
license under the GTx Patents to conduct Development of Collaboration Products
pursuant to the Development Plan.

                  (b) Subject to the terms and conditions of this Agreement,
Ortho grants to GTx a non-exclusive, paid-up, worldwide license under the Ortho
Patents to conduct GTx's responsibilities under the Development Plan with
respect to Collaboration Products.

         5.2 Patent Licenses to Conduct Commercialization Activities.

                  (a) Subject to the terms and conditions of this Agreement, GTx
hereby grants to Ortho an exclusive (even as to GTx), royalty-bearing, worldwide
license, with the right to grant sublicenses, under GTx Patents for GTx SARM
Compounds to make, have made, use, sell, have sold, offer for sale, import,
export, and distribute Collaboration Products. Notwithstanding the foregoing,
GTx shall retain the right under the GTx Patents to Co-Promote Collaboration
Products in the Co-Promotion Territory to the GTx Audience if it exercises its
right to Co-Promote such Collaboration Products under Section 6.2.

                  (b) Subject to the terms and conditions of this Agreement,
Ortho hereby grants to GTx a non-exclusive, fully-paid, worldwide license,
without the right to grant sublicenses, under the Ortho Patents to use, sell,
and offer for sale Collaboration Products in the Co-Promotion Territory to the
GTx Audience if it exercises its right to Co-Promote such Collaboration Products
under Section 6.2.

         5.3 Know-how Licenses.

                  (a) Subject to the terms and conditions of this Agreement, GTx
grants Ortho, an exclusive (except as to GTx), royalty-bearing, worldwide
license to use GTx Know-how to Develop and/or Commercialize Collaboration
Products pursuant to the terms of this Agreement.

                  (b) Subject to the terms and conditions of this Agreement,
Ortho hereby grants to GTx a non-exclusive, fully-paid, worldwide license,
without the right to grant sublicenses, under the Ortho Know-How to perform its
obligations under the Development Plan to Develop Collaboration Products, and to
use, sell, and offer for sale Collaboration Products in the Co-Promotion
Territory to the GTx Audience if it exercises its right to Co-Promote such
Collaboration Products under Section 6.2.

                                       23

<PAGE>

         5.4 Distribution Through Third Party Distributors. GTx grants Ortho the
right to sell or distribute Collaboration Products through its Affiliates or
Third Parties in any country, except as otherwise provided in Section 5.5.

         5.5 Sublicensing. Ortho may grant sublicenses under Sections 5.1, 5.2,
5.3 and 5.6 provided, however, that Ortho may not grant sublicenses or rights to
any Third Party (but may grant sublicenses or rights to its Affiliates) for the
purpose of selling, offering for sale, or distributing Collaboration Products in
the Co-Promotion Territory.

         5.6 Third Party Technology. The licenses granted under this Article
include sublicenses of Third Party technology to the extent that such
sublicenses can be so granted. To the extent the licenses include sublicenses of
Third Party technology, the licenses and rights granted to either Party under
such Third Party technology in any event, shall be subject to the terms and
conditions of the license agreement pursuant to which the underlying license,
and the sublicensing rights thereunder, were granted.

         5.7 No Implied Licenses; Retained Rights. Each Party retains all rights
under its Patents and know-how that are not expressly granted to the other Party
pursuant to this Agreement. Additionally, notwithstanding anything to the
contrary in this Article V, GTx retains the right under the GTx Patents and GTx
Know-how to use Collaboration Compounds and Collaboration Products in its
internal research and development efforts other than for the purpose of
Developing or Commercializing Collaboration Compounds or Collaboration Products,
which it shall perform only pursuant to this Agreement. Furthermore, Ortho
acknowledges that the licenses provided to it in Sections 5.1 through 5.3 do not
grant to Ortho any rights to practice the technology claimed in the GTx Patents
in connection with the development or commercialization of compounds that are
not Collaboration Compounds, including without limitation Excluded SARM
Compounds.

         5.8 Independent Research. Except with respect to the GTx SARM Compounds
defined in Section 1.36, each Party is free to develop other pharmaceutical
products independent of this Agreement, including without limitation, any other
SARM products that are not Collaboration Products. Neither Party has an
obligation to disclose information relating to medicinal chemistry or other
topics relating to SARMs, except to the extent such information may relate to
Collaboration Compounds or Collaboration Products.

                                   ARTICLE VI

                                COMMERCIALIZATION

         6.1 Ortho as Marketing Party. Ortho will be the marketing Party with
respect to all Collaboration Products. As marketing Party Ortho shall have full
and exclusive decision making authority with respect to all Commercialization
Activities for all Collaboration Products, provided that such decisions are
consistent with this Agreement and except as otherwise set forth in this
Agreement.

                                       24

<PAGE>

         6.2 GTx's Option to Co-Promote in the United States. GTx shall have an
option to provide Details in the United States for each Collaboration Product
Developed pursuant to the GTx/Ortho Development to urologists who are licensed
to practice in the United States, provided that GTx meets the requirements set
forth in this Article VI, and subject to the provisions of Section 6.3 and 6.7.
Any such activities conducted by GTx pursuant to this Article VI, if GTx
exercises such option, shall be deemed "Co-Promotion." GTx may exercise its
option to Co-Promote on a Product by Product basis, and a decision not to
Co-Promote a specific Product shall not affect GTx's rights to Co-Promote any
other Product under this Agreement. However, if GTx fails to exercise its option
to Co-Promote any specific Product, or later terminates its Co-Promotion of such
Product, such non-exercise or termination shall be irrevocable as for such
Product. Additional Collaboration Products will be Co-Promoted under the same
terms as recited herein with respect to the first Collaboration Product.

         6.3 GTx to Notify Ortho of its Election to Co-Promote; Changes in the
GTx Audience.

                  (a) GTx may exercise its option by informing Ortho in writing
of its decision to exercise the Co-Promotion option for a Collaboration Product
[ * ] after [ * ]. Upon GTx's exercise of such option, the United States shall
become the Co-Promotion Territory with respect to such Collaboration Product,
GTx shall have the right to perform Details targeting the GTx Audience
(determined in accordance with Section 6.3(b)) with respect to such
Collaboration Product, and the provisions of Article VII shall be used in
determining additional compensation to be paid to GTx.

                  (b) GTx shall have the right to Co-Promote Collaboration
Products to all of the practicing urologists in the United States, and to elect
to include a portion of, or all of, such physicians in the GTx Audience, subject
to Section 6.7 and this Section 6.3. Within [ * ] after GTx first exercises its
right to Co-Promote, GTx shall provide to Ortho a list of urologists licensed to
practice in the United States that will constitute the GTx Audience, for Ortho's
approval thereof, which shall not be unreasonably withheld or delayed, and which
approval or disapproval shall be consistent with this Agreement. GTx shall
periodically [ * ] update the list of urologists that constitute the GTx
Audience, provided that any such change shall not become effective until [ * ]
after Ortho receives any updated list from GTx, and further provided that such
changes shall be in accordance with Section 6.3(c). Ortho shall have [ * ], and
[ * ] consistent with this Agreement. Except as provided in Section 6.7, GTx
shall have the exclusive right to provide Details for the GTx Audience.

                  (c) During the time GTx is Co-Promoting a Product, GTx shall
not have the right to alter the number of physicians included in the GTx
Audience for a given Product by [ * ] in any given [ * ] commencing after GTx
begins to Co-Promote such Product without Ortho's approval, which shall not be
unreasonably withheld or delayed and which shall be consistent with this
Agreement. GTx shall notify Ortho in writing of any such change in the number of
physicians included in the GTx Audience [ * ] before the end of any relevant [ *
] for which it desires such increase to apply. Additionally, if GTx has elected
to Co-Promote Products pursuant to this Article VI but has not

                                       25

<PAGE>

performed its obligations under Section 6.6(a)(iv), and therefore has [ * ],
then GTx shall have the right to increase the proportion of the GTx Audience to
which it has the right to provide Details by [ * ] in each [ * ] following the [
* ] of GTx's commencement of Co-Promotion of such Products, provided that GTx
gives written notice to Ortho [ * ] before the end of any relevant [ * ] during
which it is then Co-Promoting such Product to less than all of the GTx Audience
stating the proportion of the GTx Audience by which GTx desires to increase its
Detailing efforts during the [ * ]. For clarity, GTx may only increase the
proportion of the GTx Audience to which it will Co-Promote if GTx has [ * ].

         6.4 Marketing and Sales Committee. Ortho and GTx will form a Marketing
and Sales Committee [ * ] to the first anticipated Launch Date. The Marketing
and Sales Committee shall meet from time to time [ * ], at mutual agreeable
times and locations, to discuss and coordinate the Marketing and Co-Promotion of
the Collaboration Product, including but not limited to, the assignment of
Details and to discuss the Marketing and Sales Plan. Ortho will have the final
responsibility (subject to GTx's rights to Co-Promote), with the cooperation and
assistance of GTx for defining the resources required for the marketing and sale
of the Collaboration Product, and for establishing Detailing, Marketing, pricing
and promotion strategies with respect to the Collaboration Product and budgets
therefor. Any disagreements or disputes arising from the Marketing and Sales
Committee shall be resolved in a matter consistent with [ * ] this Agreement.

         6.5 Marketing and Sales Plan. [ * ] to the first anticipated Launch
Date, Ortho shall prepare and present to the Marketing and Sales Committee for
its review and comment on a Marketing and Sales Plan. The Marketing and Sales
Plan shall set forth, among other items, Detailing and Marketing strategies for
each Collaboration Product, and shall specify the level of marketing efforts
anticipated for licensed urologists in the United States. The Marketing and
Sales Plan shall be updated at least annually by Ortho and presented to the
Marketing and Sales Committee for review and comment. The Marketing and Sales
Plan shall set the required number of Details to be provided by each of the
Parties (as applicable). Additionally, the Marketing and Sales Plan may not be
modified to provide for material increases in the number of Details to be
provided by GTx for Collaboration Products to be Co-Promoted by GTx in the [ * ]
following the effective date of such update without GTx's prior written consent.

         6.6 Requirements for GTx Co-Promotion. In order for GTx to be eligible
for Co-Promotion of a given Collaboration Product, GTx must meet the following
requirements:

                  (a) GTx shall have the following infrastructure in place for
each Collaboration Product at the following times:

                           (i) [ * ] after providing Ortho with written notice
of its intent to Co-Promote under Section 6.3, GTx shall [ * ];

                           (ii) [ * ] to the estimated Marketing Date (as
defined below in this Section 6.6) for the Collaboration Product, GTx must have
[ * ];

                                       26

<PAGE>

                           (iii) [ * ] to the estimated Marketing Date for the
Collaboration Product, GTx must have [ * ]; and

                           (iv) [ * ] to the estimated Marketing Date for the
Collaboration Product, GTx must [ * ], and shall have [ * ].

                  (b) To enable GTx to plan its compliance with the requirements
of this Section 6.6, Ortho shall keep GTx informed of its good faith estimates
of the Marketing Date of each Collaboration Product in the United States. If any
such estimate provided by Ortho is subsequently modified so that the Marketing
Date is projected to occur earlier than previously estimated, then GTx shall not
be in breach of this Section 6.6 so long as it is using commercially reasonable
efforts to perform its obligations under this Section 6.6.

                  (c) "Marketing Date" shall mean, for a Collaboration Product,
either the Launch Date of such Collaboration Product, if such date has not
occurred prior to the time that GTx exercised its option to Co-Promote such
Product, or the first anticipated date upon which Ortho plans to commence its
marketing campaign for such Collaboration Product [ * ] for which the GTx
Audience may prescribe such products, if the Launch Date for such Collaboration
Product has previously occurred.

         6.7 Co-Promotion Sales Forces.

                  (a) If GTx exercises its option to Co-Promote a given
Collaboration Product, Ortho and GTx shall deploy their respective sales forces
to Detail the Collaboration Product as required by the Marketing and Sales Plan.
In conducting such Detailing, Ortho and GTx shall comply with all applicable
laws and shall use commercially reasonable efforts consistent with accepted
pharmaceutical industry business practices (including, but not limited to, the
relevant American Medical Association Guidelines). No Party shall be required to
undertake any activity under this Agreement which it believes, in good faith,
may violate any law. The GTx sales force shall abide by the same ethical conduct
guidelines as the Ortho sales force, including, but not limited to any
healthcare compliance guidelines issued by any U.S. government organization.

                  (b) The GTx sales force promoting Collaboration Products shall
include [ * ].

                  (c) GTx shall keep Ortho informed of the status of its efforts
to meet its Co-Promotion requirements. If GTx believes it will not meet the
requirements set forth in Section 6.6(a), GTx shall notify Ortho. If Ortho
believes that GTx has failed, or is likely to fail, to meet the foregoing
requirements, it shall so notify GTx in writing and the Parties shall thereafter
discuss whether any such failure has occurred, and appropriate steps and time
periods for GTx to thereafter cure any such failure, for a period of [ * ].
Resolution of any outstanding issues will be conducted through the Marketing and
Sales Committee pursuant to Section 6.4.

                           (i) Any failure by GTx to comply with the
requirements of Section 6.6 (other than subsection 6.6(a)(iv)) shall give rise
to Ortho's ability to terminate

                                       27

<PAGE>

GTx's ability to Co-Promote the relevant Collaboration Product upon written
notice to GTx (which shall not become effective until expiration of the
foregoing discussion or cure period), but shall not be deemed to be a breach of
this Agreement giving Ortho the right to terminate this Agreement. In the event
of any failure by GTx to comply with subsection (iv), GTx shall continue to have
the right to Co-Promote Collaboration Products to the GTx Audience, but [ * ],
and Ortho may [ * ]. For example, if GTx [ * ], then it may [ * ] and Ortho may
[ * ]. In such event, after such [ * ], GTx shall have the right to [ * ],
provided that it has then [ * ], and further provided that [ * ].

         6.8 Sales Force Training. GTx sales representatives who will be
Co-Promoting Collaboration Product hereunder will be trained by Ortho together
with Ortho's sales representatives at a location to be determined by Ortho.
Ortho shall [ * ], provided that GTx shall [ * ].

         6.9 GTx Sales Force. All Detailing carried out hereunder by GTx shall
be [ * ]. Except as provided in Section 6.8, [ * ], including, but not limited
to, [ * ]. In addition, GTx shall, consistent with customary pharmaceutical
business practice and all applicable laws, rules and regulations, [ * ] in
accordance with the Marketing and Sales Plan. GTx may not [ * ], unless approved
in writing by Ortho in advance.

         6.10 Detail Reports. GTx, [ * ] after the end of each month, will
provide to Ortho on an electronic medium a record of its Detailing activity by [
* ]. This file will provide information on all Details [ * ], along with
information regarding samples, if any, that [ * ]. Once submitted to Ortho, such
Detail report described herein may not be revised by GTx and payments described
in Section 7.1 shall be based on the information contained in such Detail
report, subject, however, to revisions, if any, to the detail report from an
audit under Section 6.11.

         6.11 Co-Promotion Audit of Performance. Ortho shall have the right to
review and audit, not more than once per year, GTx's Detail records during
regular business hours, upon reasonable notice, to confirm satisfaction of the
obligations set forth in this Article VI. GTx may redact such records if
necessary to protect confidentiality of portions of such records unrelated to
Collaboration Products. Ortho shall provide to GTx a copy of the results of any
such audit. If, after such review, the Parties are unable to agree as to the
results of Ortho's audit, Ortho may demand a verification of such audit of GTx's
Detail reports to be conducted by a mutually agreed upon auditor, such
verification to be at Ortho's sole expense. In addition, Ortho representatives
may accompany GTx sales representative on Details to monitor their performance.
Furthermore, Ortho may audit GTx's Detailing performance using [ * ] or other
commercially developed service or product.

         6.12 Failure to Perform. If, based on the Detail reports GTx submits
(as revised based on any audit described in Section 6.11), GTx fails to conduct
[ * ] of the Details it is required to provide (taking into consideration the
adjustments to such level that GTx is permitted to make pursuant to Section
6.7(c)), as set forth in the Marketing and Sales Plan, for [ * ], it shall be
considered in breach of this Article VI and Ortho may terminate GTx's right to
Co-Promote hereunder by giving GTx thirty (30) calendar days'

                                       28

<PAGE>

advance written notice of the termination of its Co-Promotion right hereunder.
However, such breach shall not be considered a material breach giving Ortho the
right to terminate this Agreement under Section 13.2.

         6.13 Medical Inquiries. Ortho shall respond to all medical questions or
inquiries relating to the Collaboration Product being Co-Promoted hereunder,
which are directed to each Parties' respective sales representatives, unless
such question or inquiry can be answered by reference to the FDA approved
labeling and package insert. Ortho shall designate a medical liaison to whom GTx
shall instruct the GTx sales force to direct medical questions or inquiries
relating to the Co-Promoted Collaboration Product.

         6.14 Governmental Contact. GTx shall notify Ortho's Regulatory Affairs
Department upon being contacted by the FDA or any state drug regulatory agency
or any comparable governmental agency in the Co-Promotion Territory with respect
to the Co-Promoted Collaboration Product. Ortho shall retain responsibility for
communicating with all such governmental agencies and responding to any contacts
or inquiries of such agencies.

         6.15 Regulatory Disputes/Lawsuits. Ortho shall retain exclusive
authority and responsibility for handling, in any manner it deems appropriate,
any disputes or law suits with any agencies regarding the regulatory status of
the Co-Promoted Collaboration Product.

         6.16 Sales. All sales of Collaboration Products in the Co-Promotion
Territory shall be booked by Ortho. Ortho shall have the right to reject any
order received by it for a Collaboration Product; provided, however, that Ortho
shall not reject orders on an arbitrary basis, but only with reasonable
justification and consistent with the general policies applied by it with
respect to orders for other similar pharmaceutical products sold by it.

         6.17 Orders. A sales representative's only in-state activity is
solicitation of orders by company representatives for sales of tangible personal
property, which orders are sent outside the state (except NJ) for approval or
rejection and if approved, are filled by shipment or delivery from a point
outside the state (except NJ). "Solicitation of Orders" is defined as
encompassing "requests for purchases" as well as "those activities that are
ancillary to requests for purchases, those that serve no independent business
function apart from their connection to the soliciting of orders. GTx is not
authorized to solicit or accept any sales orders for the Co-Promoted
Collaboration Products. If, for any reason, GTx receives a sales order for the
Co-Promoted Collaboration Product, GTx shall promptly forward such orders to
Ortho.

         6.18 Co-Promotion Limitation of Scope. The scope of the Co-Promotion
for GTx will be limited specifically to [ * ]. The Marketing and Sales Plan
shall set the required number of Details for each of the Parties.

         6.19 Commercialization Efforts. Ortho shall use reasonable efforts
consistent with its normal business practices to Commercialize the Collaboration
Product in those

                                       29

<PAGE>

countries in which it has obtained Regulatory Approval. Without limiting the
foregoing, Ortho shall effect a Marketing Date in the United States [ * ] of
obtaining Regulatory Approval of a Collaboration Product by the FDA.

         6.20 Commercialization in Royalty Bearing Territory. Commercialization
of Collaboration Products in the Royalty Bearing Territory, except to the extent
of GTx's right to Co-Promote Collaboration Products to the GTx Audience, shall
be conducted independently by Ortho and decisions regarding, for example,
pricing, advertising, and product recalls shall be the sole responsibility of
Ortho.

         6.21 Pricing, Pricing Approvals and Product Distribution. Ortho shall
set all prices for all Collaboration Products in all territories, shall obtain
pricing and reimbursement approvals for Collaboration Products as may be
required, shall be responsible for distribution of each Collaboration Product
worldwide Territory and shall book all sales for Collaboration Products.

         6.22 Product Recalls. If Ortho believes that a recall of a
Collaboration Product is necessary, Ortho shall promptly undertake, at its sole
expense, such recall following notification to GTx. The decision of Ortho
concerning such recall shall be final.

         6.23 Advertising and Promotion. With respect to printed promotional
(including all advertisements and DTC-programs appearing in journals) materials
or printed educational materials for Collaboration Products, Ortho shall be
solely responsible for the content of such materials and the preparation
thereof, at Ortho's sole expense.

         6.24 GTx Right to Opt Out of Co-Promotion. At any time after it
exercises its option to Co-Promote a given Collaboration Product, GTx may elect
by [ * ] advance written notice to Ortho to cease Co-Promotion of such
Collaboration Product. After any such election by GTx, GTx shall cooperate with
Ortho to transition responsibility for providing Details to the GTx Audience for
such Collaboration Product to Ortho. GTx's rights under this Section 6.24 shall
apply on a product by product basis.

         6.25 Additional Support by GTx. If Ortho desires GTx to participate in
Marketing Activities other than providing Details for Collaboration Products,
such as by [ * ], the Parties shall discuss the proposed activities. If GTx
agrees in writing to conduct such activities, the Marketing and Sales Plan shall
be revised to reflect such activities [ * ].

                                       30

<PAGE>

                                   ARTICLE VII

                              CO-PROMOTION PAYMENT

         7.1 Additional Royalty. For any Collaboration Product that is
Co-Promoted by GTx to the GTx Audience, GTx shall at a minimum first earn a
royalty as set forth in Section 3.4 in the Co-Promotion Territory. GTx shall
also earn an Additional Royalty with respect to sales of Collaboration Products
that GTx Co-Promotes, which will be calculated as follows:

                  (a) Twenty (20) Business Days after the end of each calendar
quarter, Ortho will determine, using data obtained from Third Party sources
reasonably acceptable to GTx, the total number of prescriptions written for the
Collaboration Product(s) by the GTx Audience and filled by the pharmacy during
the preceding quarter, and shall provide to GTx a detailed calculation of the
royalty due to GTx pursuant to this Section 7.1 along with a copy of the Third
Party information upon which such calculation is based. Ortho shall pay all
royalties due to GTx pursuant to this Section 7.1 within twenty (20) Business
Days after submission of such report to GTx.

                  (b) The following formula will be used to calculate the
Additional Royalty owed to GTx for the preceding quarter:

                      [ * ]

wherein

                      [ * ]

         The Additional Royalty shall not be subject to any offsets or
reductions that may be applicable to royalties due to GTx pursuant to Section
3.4. GTx shall have the right to audit Ortho's records to confirm the accuracy
of payments made hereunder as provided in Section 12.4.

         7.2 Term. Ortho shall pay the Additional Royalty as provided under this
Article 7 with respect to each Collaboration Product Co-Promoted in the
Co-Promotion Territory to the GTx Audience until such Collaboration Product is
permanently withdrawn from, or is no longer being Co-Promoted in, the
Co-Promotion Territory.

                                  ARTICLE VIII

                             MANUFACTURE AND SUPPLY

         8.1 Manufacture and Supply During Development. Ortho will be solely
responsible for the manufacture of Collaboration Products for use during the
Development of Collaboration Products as provided in this Agreement, except that
following the Effective Date, GTx shall remain responsible for the manufacture
of Collaboration Products until the Parties transition to Ortho responsibility
for the manufacture of Collaboration Products, or components thereof, for which
GTx has been

                                       31

<PAGE>

responsible prior to the Effective Date. Promptly following the Effective Date,
the Parties shall agree upon and implement a plan for effecting such transition,
which may include without limitation GTx continuing to be a party to Third Party
manufacturing agreements existing as of the Effective Date for the remainder of
the term of such agreements, or GTx assigning to Ortho (if it is permitted to do
so under the relevant agreement) its interest in such agreements; provided that
if any such agreement also relates to the supply of products other than
Collaboration Products, then GTx shall have no obligation to effect any such
assignment. In this regard, Ortho and not GTx shall be a party to all future
manufacturing agreements with Third Parties for the supply of Collaboration
Products during Development. Payments to manufacturers of Collaboration Products
for Development purposes and related costs will be [ * ]. For clarity, if GTx [
* ] after the Effective Date for such purpose, then Ortho shall [ * ]. As used
in this Article, "manufacture" means manufacture of Collaboration Products in
bulk form and finished dosage form.

         8.2 Manufacture and Supply During Commercialization. Ortho shall be
solely responsible for the commercial manufacture of Collaboration Products in
such a manner as to assure quality assurance as stringent as such quality
assurance standards used by Ortho and its Affiliates in the manufacture of its
other pharmaceutical products, continuity and security of supply, compliance
with cGMP, and compliance with all applicable regulatory requirements. In this
regard, Ortho shall be a party to all agreements covering the commercial supply
of Collaboration Products. Such manufacturer(s) may include Third Parties.

         8.3 Clinical Supplies. In cases where GTx supplies Ortho with
Collaboration Compound or Collaboration Product for clinical studies, such
supplies will be provided [ * ].

         8.4 Quality Assurance. Ortho shall also have day to day responsibility
for commercial manufacturing and formulation issues related to product safety
and regulatory compliance. GTx shall provide technical support reasonably
required by Ortho or Third Parties for the manufacture of Collaboration
Products. Ortho shall [ * ].

         8.5 Technology Transfer in Event of Termination by Ortho. In the event
that this Agreement terminates (other than for a Material Breach by GTx), then
Ortho shall continue to manufacture and supply (either itself or through its
Affiliates or Third Parties) Collaboration Products in the manner and to the
extent provided prior to notice of such termination, from the time notice of
such termination is provided until such time as GTx is able to secure an
equivalent alternative commercial manufacturing source; said time [ * ],
provided that GTx using its commercially reasonable efforts is unable to secure
such an alternative source during such time period. To this end, as of the
effective date of such termination, Ortho shall use commercially reasonable
efforts to [ * ]. For any Collaboration Products supplied by Ortho or its
Affiliates, [ * ] pursuant to this Section for the [ * ] shall [ * ]. Such [ *
]. For example, [ * ]. If termination is the result of a serious Safety issue,
Ortho shall not be obligated to continue manufacturing the Collaboration Product
associated with the serious Safety issue.

                                       32

<PAGE>

                                   ARTICLE IX

                                 CONFIDENTIALITY

         9.1 Confidentiality Exceptions. Except to the extent expressly
authorized by this Agreement or otherwise agreed in writing, the Parties agree
that, for the term of this Agreement and for [ * ] thereafter, the receiving
Party shall keep confidential and shall not publish or otherwise disclose or use
for any purpose other than as permitted in this Agreement any Information and
other information and materials furnished to it by the other Party pursuant to
this Agreement; any provisions of this Agreement that are the subject of an
effective order of the Securities Exchange Commission granting confidential
treatment pursuant to the Securities Act of 1934, as amended; and any
Information developed during the term of, and pursuant to, this Agreement
(collectively, "Confidential Information"), except to the extent that it can be
established by the receiving Party that such Confidential Information:

                  (a) was already known to the receiving Party, other than under
an obligation of confidentiality, at the time of disclosure by the other Party;

                  (b) was generally available to the public or otherwise part of
the public domain at the time of its disclosure to the receiving Party;

                  (c) became generally available to the public or otherwise part
of the public domain after its disclosure and other than through any act or
omission of the receiving Party in breach of this Agreement;

                  (d) was disclosed to the receiving Party, other than under an
obligation of confidentiality, by a Third Party who had no obligation to the
disclosing Party not to disclose such information to others; and

                  (e) was independently developed by the receiving Party without
reliance on Confidential Information of the other Party as shown by documentary
evidence.

         9.2 Authorized Disclosure.

                  (a) Each Party may disclose Confidential Information hereunder
to the extent such disclosure is reasonably necessary in filing or prosecuting
patent applications, prosecuting or defending litigation, complying with
applicable governmental regulations, or conducting Pre-Clinical Studies or
Clinical Trials; provided, however, that if a Party is required by law or
regulation to make any such disclosures of the other Party's Confidential
Information it will, except where impracticable for necessary disclosures, for
example in the event of medical emergency, give reasonable advance notice to the
other Party of such disclosure requirement (e.g., filings with the SEC and stock
markets) and, except to the extent inappropriate in the case of patent
applications, will use its reasonable efforts to secure confidential treatment
of such Confidential Information required to be disclosed, unless in the opinion
of such disclosing Party's legal counsel such Confidential Information is
legally required to be fully disclosed. In addition, and

                                       33

<PAGE>

with prior notice to the other Party of each Third Party with whom a
confidential disclosure agreement is being entered into, each Party shall be
entitled to disclose, under a binder of confidentiality containing provisions as
protective as those of this Article, Confidential Information to any Third Party
for the purpose of carrying out the purposes of this Agreement. Nothing in this
Article shall restrict any Party from using for any purpose any Confidential
Information independently developed by it without access to or use of the other
Party's Confidential Information during the term of this Agreement, or from
using Confidential Information that is specifically derived from Pre-Clinical
Studies or Clinical Studies to perform marketing, sales or professional services
support functions as is customary in the pharmaceutical industry.

                  (b) Notwithstanding anything herein to the contrary, either
Party (and any employee, representative, or other agent of either Party) may
disclose to any and all persons, without limitation of any kind, the tax
treatment and tax structure of the transactions contemplated by this Agreement
and all materials of any kind (including opinions or other tax analyses) that
are provided to it relating to such tax treatment and tax structure; provided
however, that such disclosure shall not be made to the extent reasonably
necessary to comply with any applicable federal or state securities laws. For
the purposes of the foregoing sentence, (i) the "tax treatment" of a transaction
means the purported or claimed federal income tax treatment of the transaction,
and (ii) the "tax structure" of a transaction means any fact that may be
relevant to understanding the purported or claimed federal income tax treatment
of the transaction.

         9.3 Survival. Sections 9.1 through 9.4 of this Article shall survive
the termination or expiration of this Agreement for a period of [ * ].

         9.4 Termination of Prior Agreement. This Agreement supersedes the
Confidentiality Agreement between GTx and Ortho dated October 8, 2002 and
amended on June 2, 2003. All Information exchanged between the Parties under
that Agreement shall be deemed Confidential Information and shall be subject to
the terms of this Article, and shall be included, respectively, within the
definitions of GTx Know-how if GTx is the disclosing Party and Ortho Know-how if
Ortho is the disclosing Party.

         9.5 Publications. Except to the extent set forth in Sections 9.2 and
9.6, each Party shall provide to the other the opportunity to review any
proposed scientific/technical publications or scientific presentations which
relate to Collaboration Compounds or Collaboration Products as early as
reasonably practical, but [ * ] to the intended submission for publication
(except with the written consent of the other Party). The reviewing Party will
provide the publishing Party with its response to the publishing Party's request
to publish [ * ] of receipt of such request. No publication shall be made by any
Party without the written agreement of or approval by the other Party. However,
the failure of the receiving Party to respond to such request [ * ] period shall
be deemed to be approval of such request and the publishing Party shall then be
free to proceed with said publication or presentation. Notwithstanding the
foregoing, publications regarding Commercialization Activities or that are
reasonably needed to effectively Commercialize the Collaboration Product may be
made by Ortho even if GTx does not approve, provided

                                       34

<PAGE>

that GTx may request a reasonable delay on such publication to seek patent
protection on any patentable inventions disclosed therein.

         9.6 Public Disclosures. Subject to the further provisions of this
Section, neither Party shall originate any written publicity, news release or
public announcement, whether to the public or press, concerning this Agreement,
including the subject matter to which it relates, performance under it or any of
its terms, or any amendment hereto save only such announcements that are
required by law (or the applicable rules of any securities exchange or market on
which a Party's securities are listed or traded) to be made or that are
otherwise agreed by the Parties or expressly permitted in this Agreement. Such
announcements shall be factual and as brief as reasonable under the
circumstances. In addition, each Party agrees to submit to the other Party, for
review and written approval, any question and answer sheet or similar materials
("Q & A") prior to using such materials as the basis for written or oral
disclosures, which written or oral disclosures must, in any event, be consistent
in content with the information contained in the approved Q & A. Routine
references to this Agreement and the arrangements hereunder shall be allowed in
the usual course of business, and shall be consistent with any approved Q & A
relating thereto. Once information has been approved for disclosure as part of
an approved Q & A or publication under this Section, either Party may use such
approved information in written publicity, news releases, public announcements
and other future communications with Third Parties. If a Party decides to make
an announcement or any filing with a governmental agency or securities exchange
or market as required by law or the applicable rules of any securities exchange
or market on which a Party's securities are listed or traded, it will give the
other Party [ * ] advance notice, where possible, of the text of the
announcement or content of the filing so that the other Party will have an
opportunity to comment upon the announcement or filing. To the extent that the
receiving Party reasonably requests that any information in the materials
proposed to be disclosed be maintained as confidential, the disclosing Party
shall use commercially reasonable efforts to request confidential treatment of
such information pursuant to Rule 406 of the Securities Act of 1933 or Rule
25b-2 of the Securities Exchange Act of 1934, as applicable (or any other
applicable regulation relating to the confidential treatment of information),
except to the extent that the disclosing Party receives advice from its legal
counsel that such Confidential Information is required to be disclosed under
applicable laws or regulations. Notwithstanding the foregoing, publications
regarding [ * ] may be made by Ortho even if GTx does not approve.

                                   ARTICLE X

              OWNERSHIP OF INTELLECTUAL PROPERTY AND PATENT RIGHTS

         10.1 Ownership. Each Party shall solely own, and that Party alone shall
have the right to apply for, Patents within and outside of the United States for
any inventions made solely by that Party's employees or independent contractors
in the course of performing work under this Agreement. Inventions made jointly
by employees or independent contractors of GTx and Ortho shall be owned jointly
by GTx and Ortho, without a duty of accounting. For clarity, either Party shall
be free to grant licenses or other rights under Inventions jointly owned by the
Parties, to the extent consistent with

                                       35

<PAGE>

the licenses granted to the other Party pursuant to this Agreement. The law of
joint ownership of inventions of the United States shall apply to any joint
ownership of Patents claiming joint inventions of the Parties.

         10.2 Invention Disclosures. Each Party shall promptly provide to the
other any invention disclosure submitted in the normal course of its operations
and disclosing an invention arising during the course of and pursuant to this
Agreement (such inventions, "Inventions").

         10.3 Disclosure of Provisional and Non-Provisional Patent Applications.
In addition to the disclosures required under Article XII, each Party shall
provide to the other, within a reasonable time prior to filing, a copy of each
non-provisional patent application proposed to be filed by such Party disclosing
an Invention arising during the course of and pursuant to this Agreement and
each Party shall provide to the other, immediately after filing, a copy of each
provisional patent application actually filed by such Party disclosing an
Invention. The contents of any patent application submitted to either Party
pursuant to this Section 10.3 covering an invention solely owned by such Party
shall be deemed the Confidential Information of the Party providing such
application.

         10.4 Patent Filings.

                  (a) Ortho Patent, GTx Patent and Joint Patent Filings. Each
Party, at its sole discretion, responsibility, and cost shall prepare, file,
prosecute and maintain Patents to cover Inventions made solely by its own
employees or independent contractors and use reasonable efforts to file
initially all such applications in the United States or the appropriate forum
under the circumstances. Ortho shall file, prosecute and maintain Patents to
cover Inventions relating to the discovery, evaluation, manufacture, use or sale
of Collaboration Compounds or Collaboration Products that are made jointly by
employees or independent contractors of GTx and Ortho and the JDC shall select
the Party that shall be responsible for filing, prosecuting and maintaining
patent applications and other Patents claiming other jointly owned Inventions
(all Patents or jointly owned Inventions, herein referred to as "Joint
Patents"). [ * ]. The determination of the countries in which to file Joint
Patents shall be made [ * ]. The Party responsible for filing a Joint Patent
shall have the right to direct and control all material actions relating to the
prosecution or maintenance of Joint Patents, subject to the other Party's
ability to comment on such filings and the filing Party's reasonable
consideration of such comments. The Party responsible for filing a Joint Patent
shall provide prior written notice to the other Party of the countries in which
it intends to file, including conflict proceedings, reexaminations, reissuance,
oppositions and revocation proceedings, provided, however, that such other Party
shall have the right to file or continue prosecution in countries in which the
filing Party determines it wishes to abandon or not file such Joint Patent.

                  (b) Ortho and GTx Patent Strategy. Each Party shall keep the
other Party apprised of the status of each Joint Patent for which it is
responsible and shall seek the advice of such other Party with respect to patent
strategy and drafting applications

                                       36

<PAGE>

and shall give reasonable consideration to any suggestions or recommendations
concerning the preparation, filing, prosecution, maintenance and defense
thereof. The Parties shall cooperate reasonably in the prosecution of all Joint
Patents and other GTx Patents or Ortho Patents covering Collaboration Products
and shall share all material information relating thereto, including all
material communications from patent offices, promptly after receipt of such
information. If the Parties are unable to agree as to who is the filing Party or
as to any aspect of patent prosecution of a Joint Patent or a Patent covering a
Collaboration Product, each Party at its expense shall be free to take whatever
action it deems appropriate to protect the joint Invention or Collaboration
Product, including the filing of patent applications subject to prior
notification of the other Party. If, during the term of this Agreement, the
filing Party intends to allow any Patent covering a Product to which the Party
has license rights under this Agreement to lapse or become abandoned without
having first filed a substitute, the filing Party shall, whenever practicable,
notify the other Party of such intention [ * ] to the date upon which such
Patent shall lapse or become abandoned, and the other Party shall thereupon have
the right, but not the obligation, to assume responsibility for the prosecution,
maintenance and defense thereof and all expenses related thereto.

                  (c) Diligence in Patent Filings. The Parties agree to use
reasonable efforts to ensure that any Patent filed outside of the United States
prior to a filing in the United States will be in a form sufficient to establish
the date of original filing as a priority date for the purposes of a subsequent
filing in the United States.

                  (d) Cooperation by Ortho and GTx in Patent and Regulatory
Filings. The Parties shall cooperate in order to avoid loss of any rights that
may otherwise be available to the Parties under the U.S. Drug Price Competition
and Patent Term Restoration Act of 1984, the Supplementary Certificate of
Protection of the Member States of the European Union and other similar measures
in any other country. Without limiting the foregoing, Ortho shall notify GTx
upon receipt of Regulatory Approval to market a Collaboration Compound or
Collaboration Product in the United States, and timely supply GTx with all
information necessary to file an application for patent term extension for a
relevant GTx Patent, [ * ] following Regulatory Approval. GTx agrees to timely
file any such application, unless it reasonably objects to seeking such
extension for such Patent (in which case the dispute shall be resolved pursuant
to Article XV). The obligations set forth in this Section shall apply with
respect to patent term extensions, or the equivalent, in any other country. Any
application for patent term extension in the United States shall be made by the
Party who Controls the relevant patent.

         10.5 Third Party Patent Rights. Except as expressly provided in Section
11.1, neither Party makes any warranty with respect to the validity, perfection
or dominance of any Patent or other proprietary right or with respect to the
absence of rights in Third Parties which may be infringed by the manufacture or
sale of any Product. Each Party agrees to bring to the attention of the other
Party any Patent or Patent application it discovers, or has discovered, and
which relates to GTx SARM Compounds.

                                       37

<PAGE>

         10.6 Enforcement Rights.

                  (a) Notification of Infringement. If either Party learns of
any infringement or threatened infringement by a Third Party of the GTx Patents
or Ortho Patents, such Party shall promptly notify the other Party and shall
provide such other Party with all available evidence of such infringement.

                  (b) Enforcement. GTx shall have the right, but not the
obligation, to institute, prosecute and control at its own expense any action or
proceeding with respect to infringement by any Third Party of any GTx Patents
(other than Joint Patents) covering the manufacture, use, importation,
exportation, sale or offer for sale of Collaboration Products by reason of the
manufacture, use or sale of products competitive with Collaboration Products,
using counsel of its own choice. Ortho shall have the right, at its own expense,
to be represented in any such action by counsel of its own choice. If GTx fails
to bring such an action or proceeding or otherwise take appropriate action to
abate such infringement [ * ] of notice by Ortho to GTx requesting action, Ortho
will have the right but not the obligation to bring and control, at its expense,
any such action or proceeding relating to GTx Patents by counsel of its own
choice and GTx will have the right to be represented in any such action by
counsel of its own choice and at its own expense. With respect to Ortho Patents
(including Joint Patents), Ortho shall have the right, but not the obligation,
to institute, prosecute and control at its own expense any action or proceeding
with respect to infringement by any Third Party of any Joint Patents or Ortho
Patents covering the manufacture, use, importation, exportation, sale or offer
for sale of Collaboration Products by reason of the manufacture, use or sale of
products competitive with Collaboration Products, using counsel of its own
choice. GTx shall have the right, at its own expense, to be represented in any
such action by counsel of its own choice in connection with any such litigation.
If one Party brings any such action or proceeding, the other Party agrees to be
joined as a party plaintiff if necessary to prosecute the action or proceeding
and to give the first Party reasonable assistance and authority to file and
prosecute the suit. If any GTx Patent or Ortho Patent (other than a Joint
Patent) is infringed other than by the manufacture, use or sale of products
competitive with Collaboration Products, then the Party Controlling such Patent
shall be free to seek to terminate such infringement without obligation to the
other Party. If a Joint Patent is infringed other than by the manufacture, use
or sale of a product competitive with a Collaboration Product, the Parties shall
discuss whether to proceed in terminating such infringement jointly, but in the
absence of their agreement to do so, either Party may seek to terminate such
infringement.

                  (c) Settlement with a Third Party. The Party that controls the
prosecution of a given action shall also have the right to control settlement of
such action; provided, however, that if one Party controls such action, no
settlement shall be entered into without the written consent of the other Party
if such settlement would materially and adversely affect the interests of such
other Party. If the other Party shall refuse to grant such consent, then the
dispute will be resolved pursuant to Article XV.

                  (d) Damage Award or Settlement Payments. Any damage award or
settlement payments made to either or both of GTx or Ortho in connection with
any such

                                       38

<PAGE>

action relating to infringement of a GTx Patent or an Ortho Patent, whether
obtained by judgment, settlement or otherwise shall be allocated, (i) first, [ *
], (ii) second, to [ * ], and (iii) third, [ * ].

         10.7 Defense and Settlement of Third Party Claims. If a Third Party
asserts that a patent, trademark or other intangible right owned by it is
infringed by the manufacture, use, or sale of any Collaboration Product, Ortho
will be solely responsible for defending against any such assertions at its cost
and expense, but no settlement may be entered into without the written consent
of GTx if such settlement would materially and adversely affect GTx's interests
or the GTx Patents.

         10.8 Allocation of Patent Expenses. On a country-by-country basis,
Patent Expenses arising from GTx Patents shall be borne [ * ], Patent Expenses
arising from Ortho Patents shall be borne [ * ], and Patent Expenses arising
from Joint Patents shall be borne [ * ], unless otherwise agreed.

         10.9 Assignment of Joint Patents. Neither Party may assign its rights
under any Joint Patent except with the prior written consent of the other Party;
provided, however, that either Party may assign such rights without consent to
an Affiliate or other permitted assignee under this Agreement in connection with
a merger or similar reorganization or the sale of all or substantially all of
its assets.

         10.10 Trademarks and Trademark Expenses. Ortho shall be solely
responsible for the selection, registration, and maintenance of all trademarks
which it employs in connection with the marketing, promotion and sale of
Collaboration Product(s) and shall solely own and control such trademarks in the
Royalty Bearing Territory. Each Party recognizes the exclusive ownership by the
other Party of any proprietary names, logotypes or trademarks furnished by it
(including its Affiliates) that are not specific to Collaboration Products for
use exclusively in connection with Collaboration Products. Either Party shall
not, either while this Agreement is in effect, or at any time thereafter,
register, use or attempt to obtain any right in or to any such name, logotype or
trademark of the other Party or in and to any name, logotype or trademark
confusingly similar to the other Party's.

                                   ARTICLE XI

                         REPRESENTATIONS AND WARRANTIES

         11.1 Representations and Warranties.

                  (a) Parties' Representations and Warranties. Each of the
Parties hereby represents and warrants to the other Party as follows:

                           (i) Parties' Authority to Enter Into Agreement. This
Agreement is a legal and valid obligation binding upon such Party and
enforceable in accordance with its terms. The execution, delivery and
performance of the Agreement by such Party does not conflict with any agreement,
instrument or understanding, oral or written, to which it is a Party or by which
it is bound, nor violate any law or regulation of

                                       39

<PAGE>

any court, governmental body or administrative or other agency having
jurisdiction over it. Each Party expressly represents and warrants that it has
the full power and authority to enter into this Agreement and to carry out the
obligations contemplated hereby.

                           (ii) Parties Will Not Provide Third Parties With
Conflicting Rights. Such Party has not, and during the term of the Agreement
will not, grant any right to any Third Party under its Patents and know-how that
are licensed to the other Party pursuant to this Agreement which would conflict
with the licenses granted to the other Party hereunder.

                           (iii) GTx Prior Obligations. To the best of its
knowledge, GTx is obligated under only the UTRF Agreements to pay to any Third
Party royalties with respect to Collaboration Products [ * ].

                  (b) GTx Representations and Warranties to Ortho. GTx hereby
represents and warrants to Ortho as follows:

                           (i) Validity of GTx Patents. As of the Effective
Date, GTx has supplied Ortho with all information known to GTx and in GTx's
possession that relates to the validity of the issued GTx Patents.

                           (ii) Infringement. As of the Effective Date, it has
not received any notices of infringement or any written communications relating
in any way to a possible infringement with respect to Andarine, and it is not
aware that the manufacture, use or sale of Andarine as set forth herein
infringes any Third Party patent rights which have not been licensed to GTx.

                           (iii) GTx's Power and Authority. GTx expressly
represents and warrants that it has the full power and authority to enter into
this Agreement and to carry out the obligations contemplated hereby. GTx
expressly represents and warrants that it owns (in whole or in part) or
otherwise Controls all Patents and know-how that are the subject of the licenses
granted to Ortho herein.

         11.2 Performance by Affiliates. The Parties recognize that each Party
may perform some or all of its obligations under this Agreement through
Affiliates, provided, however, that each Party shall remain responsible for and
be a guarantor of the performance by its Affiliates and shall cause its
Affiliates to comply with the provisions of this Agreement in connection with
such performance.

                                  ARTICLE XII

                             INFORMATION AND REPORTS

         12.1 Information and Reports During Development and Commercialization.
Ortho and GTx will disclose and make available to each other upon written
request and without charge (other than reimbursement to the providing Party for
reasonable duplicating, postage and related expenses) all pre-clinical,
clinical, regulatory, commercial, marketing, promotion, pricing, sales and other
Information, including copies

                                       40

<PAGE>

of all preclinical and clinical reports, known by Ortho or GTx that directly
concern Collaboration Compounds or Collaboration Products, as provided for in
this Agreement. Each Party will use commercially reasonable and diligent efforts
to disclose to the other Party all significant Information relating to
Collaboration Compounds or Collaboration Products promptly after it is learned
or its significance is appreciated. Ortho shall [ * ]. Without limitation of the
foregoing, each Party shall supply to the other the Information required by the
other Party and reasonably requested by it (either as a routine practice or as a
specific request) for purposes of compliance with regulatory requirements
relating to Collaboration Compounds or Collaboration Products.

         12.2 Complaints. Each Party shall maintain a record of all complaints
it receives with respect to any Collaboration Product. Each Party shall notify
the other Party of any complaint with regulatory implications received by it in
sufficient detail and [ * ] after the event, and in any event in sufficient time
to allow the responsible Party to comply with any and all regulatory
requirements imposed upon it in any country.

         12.3 Adverse Event Reporting. The Parties recognize that Ortho as the
holder of Drug Approval Applications for Collaboration Products may be required
to submit information and file reports to various governmental agencies on
Collaboration Products under clinical investigation, Collaboration Products
proposed for marketing, or marketed Collaboration Products. Such information
must be submitted at the time of initial filing for investigational use in
humans and at the time of a request for Regulatory Approval of a new
Collaboration Product. In addition, Ortho may be required to provide
supplemental information on Collaboration Products at periodic intervals and to
report adverse drug experiences at more frequent intervals depending on the
severity of the experience and whether or not the event is unexpected. GTx will
(a) provide Ortho with all adverse event information and Safety-related data
from pre-clinical laboratory, animal toxicology, and pharmacology studies, and
Clinical Studies, in its Control that are necessary for Ortho to comply with all
applicable laws with respect to the Products, and (b) report and provide such
information to Ortho in such a manner and time so as to enable Ortho to comply
with all applicable laws. Each Party shall adhere to the adverse event reporting
procedures set forth in Exhibit B.

         12.4 Records of Revenues and Expenses.

                  (a) Maintenance; Audits. Each Party shall keep complete and
accurate records which are relevant to revenues, costs, reimbursements and other
payments to be made under this Agreement, including, without limitation,
information used to calculate Net Sales, Royalty Bearing Sales and royalty
calculations, existing Third Party royalty payments due for licenses granted by
such Third Parties, other license fees and other payments and royalties due
under this Agreement. Such records shall be open at the location(s) where such
records are maintained, upon reasonable notice, during regular business hours
and under obligations of confidence, [ * ]. The inspecting Party may examine
such records at its expense (not more often than once each year) by an
independent, certified public accountant, reasonably acceptable to the other
Party, for the sole purpose of verifying for the inspecting Party the accuracy
of calculations, amounts and classifications of such revenues, costs or payments
made under this Agreement. In

                                       41

<PAGE>

the absence of material discrepancies (i.e., in those instances where
discrepancy [ * ] the amounts payable under this Agreement) identified in any
such audit, the accounting expenses shall be paid by the Party requesting the
audit. If material discrepancies are identified, the audited Party shall bear
all accounting expenses. If the review of such records reveals that the audited
Party has failed to accurately report information, then the relevant Party shall
promptly pay any amounts due to the inspecting Party together with interest on
such amount, calculated at a rate equal to [ * ] Any records or accounting
information received by a Party from the other Party shall be Confidential
Information for purposes of Article IX. Results of any such audit shall be
provided to both Parties, subject to Article IX. Audits of Detail reports shall
be governed by Section 6.11 and not by this Section 12.4.

                  (b) Audit Disagreement. If there is a dispute between the
Parties following any audit performed pursuant to Section 12.4(a), either Party
may refer the issue (an "Audit Disagreement") to an independent certified public
accountant for resolution. In the event an Audit Disagreement is submitted for
resolution by either Party, the Parties shall comply with the following
procedures:

                           (i) The Party submitting the Audit Disagreement for
resolution shall provide written notice to the other Party that it is invoking
the procedures of this Section.

                           (ii) Within thirty (30) calendar days of the giving
of such notice, the Parties shall jointly select a recognized international
accounting firm to act as an independent expert to resolve such Audit
Disagreement.

                           (iii) The Audit Disagreement submitted for resolution
shall be described by the Parties to the independent expert, which description
may be in written or oral form, within ten (10) calendar days of the selection
of such independent expert.

                           (iv) The independent expert shall render a decision
on the matter as soon as practicable.

                           (v) The decision of the independent expert shall be
final and binding and shall not be subject to Article XV hereof, unless such
Audit Disagreement involves alleged fraud, breach of this Agreement or
construction or interpretation of any of the terms and conditions hereof.

                           (vi) All fees and expenses of the independent expert,
including any Third Party support staff or other costs incurred with respect to
carrying out the procedures specified at the direction of the independent expert
in connection with such Audit Disagreement, shall be borne by the Party against
whom such expert rules.

                                       42

<PAGE>

                                  ARTICLE XIII

                              TERM AND TERMINATION

         13.1 Term. This Agreement shall commence as of the Effective Date and,
unless sooner terminated as provided in this Article XIII, (a) the provisions
relating to Development and Commercialization shall continue in effect until the
Parties are not Developing or Commercializing any Collaboration Compounds or
Collaboration Products within the Royalty-Bearing Territory; and (b) the
provisions relating to Commercialization shall continue in effect until the date
on which Ortho is no longer obligated to pay a royalty to GTx on Royalty Bearing
Sales of Products or any Additional Royalty.

         13.2 Termination for Material Breach.

                  (a) Right to Terminate. Subject to the provisions of this
Section, if either Party (the "Breaching Party") shall have committed a Material
Breach and such Material Breach shall remain uncured and shall be continuing for
a period of one hundred twenty (120) calendar days following receipt of notice
thereof by the other Party (the "Non-Breaching Party"), then, in addition to any
and all other rights and remedies that may be available, the Non-Breaching Party
shall have the right to terminate this Agreement effective upon the expiration
of such one hundred twenty (120) calendar day period. Any such notice of alleged
Material Breach by one party (the "Accusing Party") shall include a reasonably
detailed description of all relevant facts and circumstances demonstrating,
supporting and/or relating to each such alleged Material Breach by the other
party ("Accused Breaching Party).

                  (b) Excuse. If the Accused Breaching Party, upon written
notice delivered to the Accusing Party prior to the expiration of such one
hundred twenty (120) calendar day period, shall assert in good faith that any
such alleged Material Breach described in the Accusing Party's notice, whether
in payment of moneys or otherwise, was not a Material Breach, or was excused by
reason of material failure of performance by the other Party or Third Parties or
by reason of Force Majeure, or shall otherwise in good faith dispute such
alleged Material Breach, then the Parties shall continue to perform under this
Agreement, subject to all of its terms and conditions, and the matter shall be
resolved pursuant to the provisions of Article XV. In such event, the Accusing
Party shall not be entitled to terminate this Agreement pursuant to this Section
unless and until (i) it shall be determined pursuant to Article XV that the
Accused Breaching Party has committed a Material Breach and (ii) such Material
Breach has not been cured prior to such determination pursuant to Article XV. To
the extent that it is determined pursuant to a final and non-appealable decision
under Article XV that the Accused Breaching Party did commit a Material Breach
and failed to cure the same within the period provided for in clause (ii) above,
then the Accusing Party may immediately terminate this Agreement and, in
addition to all damages determined pursuant to the provisions of Article XV to
be due and owing from the Breaching Party to the Non-Breaching Party under this
Agreement, the Breaching Party shall be liable for the Non-Breaching Party's
reasonable attorneys' fees incurred in connection with resolving such matter
pursuant to

                                       43

<PAGE>

Article XV. If a final and non-appealable decision is made under Article XV that
no Material Breach was committed by the Accused Breaching Party, then the
decision maker under Article XV may elect to require the Accusing Party to pay
the Accused Breaching Party's attorneys' fees incurred in connection with
resolving such matter if he or she determines that the Accusing Party's basis
for providing a notice of Material Breach to the other Party was not reasonable.

                  (c) Termination. If the Non-Breaching Party terminates this
Agreement pursuant to the provisions of Sections 13.2(a) and (b), then the
following provisions shall apply:

                           (i) the Non-Breaching Party shall receive an
exclusive (even as to the Breaching Party), worldwide right and license, with
the right to grant sublicenses, to all Patents and Product-specific trademarks
Controlled by the Breaching Party as of the date of termination to the extent
that a license under such Patents and Trademarks is necessary to enable the
other Party to make, have made, import, export, use, sell, offer for sale and
have sold Collaboration Products without infringing such Patents or Trademarks.
The Non-Breaching Party shall also have the exclusive right (but not the
obligation), subject to the rights of Third Parties existing prior to the
Effective Date to enforce such Patents against competitive product infringement
relating to Collaboration Products, and the exclusive right (but not the
obligation) to enforce such Product-specific trademark rights against
infringers;

                           (ii) if Ortho is the Non-Breaching Party, pursuant to
Section 13.2(c)(i), the Co-Promotion shall cease and the royalty percentages
recited in Section 3.4 shall be offset by any damages incurred by the
Non-Breaching Party in connection with such Material Breach, provided that in no
event shall the royalty due pursuant to Section 3.4 be reduced by more than [ *
].

                           (iii) all licenses and rights to the Breaching Party
under the Non-Breaching Party's patents, trademarks, and know-how shall
terminate; and

                           (iv) all Confidential Information supplied by the
Non-Breaching Party to the Breaching Party shall be returned to the
Non-Breaching Party, except that the Breaching Party may retain one copy of such
information solely for legal archive purposes.

                  (d) Remaining Obligations. Except where expressly provided for
otherwise in this Agreement, termination of this Agreement shall not relieve the
Parties hereto of any liability, including any obligation to make payments
hereunder, which accrued hereunder prior to the effective date of such
termination, nor preclude any Party from pursuing all rights and remedies it may
have hereunder or at law or in equity with respect to any breach of this
Agreement nor prejudice any Party's right to obtain performance of any
obligation.

                  (e) "Material Breach". For purposes of this Agreement and
except as expressly provided otherwise in this Agreement, "Material Breach"
means the breach of

                                       44

<PAGE>

or failure to perform, in a material respect, a Party's material obligations
under this Agreement. Without limiting the foregoing and by way of example only,
the term "Material Breach" shall be deemed to include [ * ]. In no event shall a
failure to [ * ], in and of itself, be deemed to constitute a Material Breach,
unless such failure is a result of acts, events or conduct that is otherwise a
Material Breach. The Parties acknowledge and agree that a failure to exercise
any right or option with respect to any Product shall not be deemed to
constitute a Material Breach hereunder.

                  (f) Survival. The provisions of this Section 13.2 shall
survive termination of this Agreement.

         13.3 Termination by Ortho. Ortho may terminate Development and/or
Commercialization of a Collaboration Compound and/or a Collaboration Product
upon [ * ] prior written notice to GTx; provided, however, that in the event
that termination is the result of a concern over Safety, termination shall be
effective [ * ] after written notice. Notwithstanding the foregoing, if Ortho
terminates the Agreement under this Section 13.3, and such termination is
effective prior to the completion of a clinical trial that has already begun,
Ortho shall be obligated to complete the clinical trial at its expense unless
the termination was for Safety-related reasons.

         13.4 Effect of Termination by GTx Under Section 13.2 or by Ortho
Pursuant to Section 13.3. If GTx terminates this Agreement for material breach
by Ortho pursuant to Section 13.2, or Ortho terminates this Agreement pursuant
to Section 13.3, Ortho shall continue to be obligated during the termination
notice period to perform all of its obligations under this Agreement, including
its obligation to pay Development Expenses; provided, however, that if such
termination occurred pursuant to Section 13.3, Ortho shall have no obligation to
make any milestone payments with respect to any milestone achieved during the
termination notice period. In addition, as a result of any such termination:

                  (a) all licenses and rights to GTx Patents and GTx Know-how
granted to Ortho hereunder shall terminate;

                  (b) all Confidential Information supplied by GTx to Ortho
shall be returned to GTx, except that Ortho may retain one copy of such
information solely for legal archive purposes;

                  (c) Ortho shall be obligated to GTx under Section 8.5 to the
extent provided therein, except wherein termination is under Section 13.3 as the
result of a Safety issue;

                  (d) Ortho shall promptly transfer and assign ownership of all
INDs, Drug Approval Applications and Regulatory Approvals related to
Collaboration Compounds, Collaboration Products to GTx, and shall take such
other actions and execute such other instruments, assignments and documents as
may be necessary to effect the transfer of rights hereunder to GTx; and

                                       45

<PAGE>

                  (e) Ortho shall grant GTx (i) an exclusive, royalty-free,
worldwide license to all Joint Patents to make, use, sell, offer for sale and
import Collaboration Products, (ii) an exclusive, worldwide royalty-bearing
license under Ortho Patents covering Inventions to make use, sell, offer for
sale and import Collaboration Products, and (iii) an exclusive, royalty-free,
worldwide license under all trademarks Controlled by Ortho that are used, or
intended for use, specifically with Collaboration Products. GTx shall have the
right to grant sublicenses under the foregoing licenses. If such termination
occurs after completion of a Phase IIB Clinical Trial for a Collaboration
Product (determined by the completion of the final report for the study), GTx
shall pay to Ortho a royalty on Collaboration Products covered by a Valid Claim
of an Ortho Patent equal to [ * ] of Net Sales of such Collaboration Products
(calculated as if such sales were by Ortho) provided that the offsets and
reductions set forth in Sections 3.5 and 3.6 shall apply mutatis mutandis to the
calculation of the royalty due to Ortho pursuant to this Section 13.4.
Additionally, in any termination by GTx pursuant to Section 13.2 or by Ortho
pursuant to Section 13.3, GTx shall have the exclusive right (but not the
obligation) to enforce such Patents against competitive product infringement
relating to Collaboration Products, and such trademarks against infringers.

         13.5 Surviving Rights. The rights and obligations set forth in this
Agreement shall extend beyond the term or termination of the Agreement only to
the extent expressly provided for herein, or the extent that the survival of
such rights or obligations are necessary to permit their complete fulfillment or
discharge. Without limiting the foregoing, Sections 3.7, 8.5, 10.1, 12.2 and
12.3 (as to activities occurring during the term of the Agreement), 12.4, 13.4
(if applicable to such termination), and 13.5, and Articles 14 (as applicable to
activities conducted during the term of the Agreement or pursuant to licenses
retained by a party thereafter, and as to Section 14.4, as provided therein), 15
and 16 shall survive expiration or termination of this Agreement.

         13.6 Change of Control. In the event of a GTx Change of Control
(defined below), Ortho shall have the following rights and options with respect
to this Agreement:

                  (a) Notice by Ortho. In the event that a GTx Change of Control
occurs during the term of this Agreement, Ortho shall have the right and option,
exercisable upon written notice to GTx delivered at any time within sixty (60)
calendar days after the effective date of such Change of Control, to terminate
GTx's right of Co-Promotion.

                  (b) Royalty Payment Upon Termination by Ortho of Co-Promotion.
Upon a Change of Control, if Ortho elects to terminate GTx's rights of
Co-Promotion pursuant to Section 13.6(a), then Ortho shall pay to GTx (or its
successor, if not GTx) a Royalty Payment under this Section 13.6(b) on Net Sales
of Collaboration Products by Ortho, its Affiliates or sublicensees in the United
States to Urologists, to compensate GTx for the Additional Royalty that GTx
would have had the opportunity to earn had Co-Promotion not terminated, as
follows:

                           (i) Termination If GTx has Co-Promoted [ * ]. If at
the time Ortho terminates Co-Promotion, GTx has been Co-Promoting at least one
(1)

                                       46

<PAGE>

Collaboration Product for [ * ], then Ortho would pay to GTx for each
Collaboration Product that has then been Co-Promoted by GTx for [ * ] a Royalty
Payment B, calculated as follows:

                           [ * ]

                                            [ * ]

Ortho would pay to GTx all Royalty Payments due to it pursuant to this Section
13.6(b)(i) from the date that GTx's Co-Promotion right terminates [ * ].

                           (ii) Termination If GTx Has [ * ]. If at the time
Ortho terminates GTx's right of Co-Promotion, [ * ], or GTx has been
Co-Promoting a Collaboration Product to the GTx Audience for [ * ], then Ortho
would pay to GTx a Royalty Payment B2 calculated as follows:

                           [ * ]

                                    [ * ]

Ortho would pay to GTx such Royalty Payment for each such Collaboration Product
from either (i) the Marketing Date for such Product, if such date had not
occurred when GTx's right of Co-Promotion terminated, or (ii) the date of
termination of GTx's right of Co-Promotion, if the Marketing Date had occurred
prior thereto (either (i) or (ii), as applicable, the "Start Date"), [ * ].

                           EXAMPLE 1 (Section 13.6(b)(i) Scenario):

                           [ * ]

                           EXAMPLE 2 (Section 13.6(b)(i) Scenario):

                           [ * ]

                           EXAMPLE 3 (Section 13.6(b)(ii) Scenario):

                           [ * ]

                           (iii) Payments. The foregoing Royalty Payment for the
relevant calendar quarter would be paid at the times and in the manner set forth
in Article III for royalties due to GTx. Additional Royalties due pursuant to
this Section 13.6 shall not be subject to any offsets or reductions that may be
applicable to royalties due to GTx pursuant to Section 3.4. GTx shall have the
right to audit Ortho's records to confirm the accuracy of payments made
hereunder as provided in Section 12.4.

                           (iv) Limitation; Clarification. For clarity, if at
the time GTx's right of Co-Promotion terminates, GTx is [ * ] that is later [ *
], then a Royalty Payment would be due to GTx with respect to [ * ].

                                       47

<PAGE>

                  (c) Definitions. For the purposes of this Section 13.6, the
following terms shall have the following definitions:

                           (i) "GTx Change of Control" means any transaction or
series of related transactions in which a Major Health Care Company acquires or
becomes the beneficial owner of (i) more than [ * ] of the outstanding voting
securities of GTx or the surviving entity, whether by merger, consolidation,
reorganization, tender offer or similar means, or (ii) all or substantially all
of the assets of GTx.

                           (ii) "Major Health Care Company" shall mean a Third
Party pharmaceutical or biotechnology company (including a "group" within the
meaning of Section 13(d)(3) of the Securities Exchange Act of 1934 but excluding
Ortho and any affiliates of Ortho) whose worldwide net sales of human
pharmaceutical products, including consumer over-the-counter pharmaceutical
products, in the most recently completed fiscal year for which audited financial
statements are publicly available at the time such Change of Control occurs,
causes such company (or group) [ * ], or if such information is not publicly
available, as appropriately provided by GTx.

                                  ARTICLE XIV

                                 INDEMNIFICATION

         14.1 Ortho and GTx. Ortho and GTx shall each indemnify, defend and hold
harmless the other Party and their officers, directors, agents, employees and
Affiliates against and from any and all Third Party actions, proceedings,
claims, suits, judgments, expenses (including reasonable attorney fees), losses,
liabilities and damages (collectively, "Indemnification Claims" or "Claims")
which the other Party may incur or suffer to the extent such arise out of or are
based upon (i) the material default by such Party in the performance of any
obligation of a Party in this Agreement or the material breach of any warranty,
representation, or agreement made by such Party in this Agreement, (ii) the
intentional misconduct or negligent acts or omissions to act, (iii) any
noncompliance by such Party of applicable laws, rules or regulations in the
course of its conduct under this Agreement.

         14.2 Ortho. Ortho further agrees to defend, indemnify and hold harmless
GTx, its officers, directors, agents, employees and Affiliates, from and against
(i) all Claims incurred by or assessed against GTx for activities prior to any
termination of this Agreement on account of any claim that the manufacture, use
or sale of Collaboration Product in the Territory infringes the patent,
trademark or other intellectual property right of any third party, or (ii) any
Claims relating to personal injuries (including death) or product liability or
other loss or damage by Third Parties resulting from or relating to the
manufacture, labeling, sale, use, storage, transportation, distribution or
handling of Collaboration Product, unless and to the extent such loss or damage
was primarily due to the negligence, recklessness or willful misconduct of GTx
(whether committed by affirmative act or by omission).

                                       48

<PAGE>

         14.3 Procedure. The Party seeking indemnification (the "Indemnified
Party") shall inform the other Party promptly of any such Indemnifiable Claim
which is brought against it and shall, to the extent such Indemnifiable Claim is
brought by a Third Party, at the other Party's request, cooperate fully with the
other Party in defending such Indemnifiable Claim. The Indemnified Party, at its
expense, shall have the right to advise and consult on and participate in any
related suit or proceeding, subject to the ultimate control of the Indemnifying
Party. The other Party ("Indemnifying Party") shall have full control over the
suit or proceedings, including the right to settle, through counsel of its
choice who is reasonably acceptable to the Indemnified Party; provided, however,
the Indemnifying Party will not, absent the consent of the Indemnified Party
(which consent will not be unreasonably withheld), consent to the entry of any
judgment or enter into any settlement that (1) provides for any relief other
than the payment of monetary damages for which the Indemnifying Party shall be
solely liable and (2) where the claimant or plaintiff does not release the
Indemnified Party from all liability in respect thereof. If the Indemnifying
Party declines to accept control of the defense of such claim or action, the
Indemnified Party may retain counsel at the expense of the Indemnifying Party
and control the defense of the claim or action, provided that the claim or
action may not be settled by the Indemnified Party without the approval of the
Indemnifying Party, which approval shall not be unreasonably withheld or
delayed. Any payment made by the Indemnifying Party to settle any claim or
action hereunder shall be at its own cost and expense.

         14.4 Insurance. GTx agrees during the term of the Agreement and for a
period of at least three (3) years thereafter to maintain (a) workers'
compensation insurance for all of its employees, the limits of which shall be as
required under statute; and (b) commercial general liability insurance
(including but not limited to product liability insurance, including for
clinical trials and contractual liability coverage) on a claims made form having
limits of not less than [ * ] and [ * ]. When GTx hires sales representatives
(if it exercises its right to Co-Promote), it shall expand its coverage to
include automobile insurance, and it shall increase its commercial general
liability insurance and product liability insurance to have limits of not less
than [ * ] and [ * ]. For all insurance coverage written on a claims made basis,
the retroactive date, if any, shall precede the Effective Date. In addition, GTx
shall [ * ] if the policy or policies are cancelled or not renewed and not
replaced by another claims made policy with the same (or an earlier) retroactive
date either [ * ]. All insurance companies must be rated A or better in the most
recent AM Best Rating Guide. GTx, upon request, agrees to provide Ortho with a
certificate of insurance evidencing its retention of such insurance coverage and
any updates thereto.

                                   ARTICLE XV

                               DISPUTE RESOLUTION

         15.1 Disputes. The Parties recognize that disputes as to certain
matters may from time to time arise during the term of this Agreement that
relate to either Party's rights and/or obligations hereunder. It is the
objective of the Parties to establish procedures to facilitate the resolution of
disputes arising under this Agreement in an

                                       49

<PAGE>

expedient manner by mutual cooperation and without resort to litigation. To
accomplish this objective, the Parties agree to follow the procedures set forth
in this if and when a dispute arises under this Agreement.

         15.2 Disputes Referred First to Executive Officers. Unless otherwise
specifically recited in this Agreement, disputes between the Parties shall be
referred to the Parties' respective Executive Officers or their successors, for
attempted resolution by negotiations [ * ] after such issue is submitted for
resolution to such officers.

         15.3 Resolution of Dispute by Alternate Means. In the event the
designated Executive Officers are not able to resolve such dispute, either Party
may at any time after the [ * ] period seek to resolve the dispute through other
means as provided herein; provided, however, disputes regarding strategies for
Development or the content of the Development Plan or Development Budget and
those that arise with respect to marketing strategies or the content of the
Marketing and Sales Plan shall be resolved in favor of Ortho (to the extent
consistent with this Agreement) and not subject to the Alternative Dispute
Resolution provided in this Article XV.

         15.4 Alternative Dispute Resolution. Any dispute controversy or claim
arising out of or relating to the validity, construction, enforceability or
performance of this Agreement, including disputes relating to an alleged breach
or to termination of this Agreement, but excluding (i) any dispute, controversy
or claim arising out of or relating to the validity, enforceability, or
infringement of any GTx Patent or any Ortho Patent and (ii) other than disputes
which are expressly prohibited herein from being resolved by this mechanism,
shall be settled by binding Alternative Dispute Resolution ("DR") in the manner
described below:

                  (a) If a Party intends to begin a DR to resolve a dispute,
such Party shall provide written notice (the "DR Request") to counsel for the
other Party informing such other Party of such intention and the issues to be
resolved.

                  (b) [ * ] after receipt of the DR Request, the other Party
may, by written notice to counsel for the Party initiating DR, add additional
issues to be resolved.

         15.5 Arbitration Procedures. A DR initiated under this Agreement will
proceed in accordance with the Commercial Arbitration Rules of the American
Arbitration Association for Large, Complex Cases then in effect, insofar as such
rules are not inconsistent with the provisions expressly set forth in this
Agreement, unless the Parties mutually agree otherwise. However, the Parties do
not intend to submit the issue for resolution by such association unless they
mutually agree to do so, in writing.

         15.6 Arbitrators. The arbitration shall be carried out by a single
arbitrator who shall be a retired United States judge or justice and shall be
selected by the Parties [ * ] of receipt of the DR Request in accordance with
the procedure described below:

                  (a) The Parties shall select the arbitrator as described
below, which may but need not be selected from a list of arbitrators such as the
CPR Panel of Distinguished Neutrals of the Center for Public Resources, subject
to: (1) his/her

                                       50

<PAGE>

availability and willingness to serve, (2) his/her availability to commence the
arbitration within a reasonable period of time, (3) his/her agreement to charge
fees and expenses that are reasonable under the circumstances, and (4) his/her
commitment to render his/her award within the time periods provided in this
Section.

                  (b) Each Party will exchange a list of [ * ] qualified
arbitrators and in the event that both Parties agree on a single person then
such person shall be the arbitrator. In submitting the ten names, each Party
shall prioritize from one to ten the persons on their respective lists. In the
event that there is more than one common name on the Parties' lists, the person
having the lowest combined priority number shall be selected as the arbitrator.
The combined priority number shall be the sum of the order numbers assigned to
that person by the Parties. Thus, if one person was GTx's number two priority
and Ortho's number three priority, and another person was GTx's number two
priority and Ortho's number four priority, the former would be appointed. If
more than one person has the lowest combined priority number, the person for
whom there is less difference between the order numbers assigned by the Parties
shall be appointed. Thus, if one person was GTx's number one priority and
Ortho's number four priority, and another person was GTx's number two priority
and Ortho's number three priority, the latter person would be appointed. If this
method does not produce an arbitrator, or if there are no common names, the
Parties shall alternatively strike from the combined list until only one name
remains, which shall be selected as the arbitrator. The Party to strike first
shall be determined by the toss of a coin.

                  (c) In the event the arbitrator is unable to meet the
requirements set forth in (a) above, then, in the event the first selected
arbitrator was common to both lists and there was more than one common name on
the Parties' lists, the arbitrator having the next lowest combined priority
number who is able and willing to serve pursuant to these requirements shall be
selected. If there is no such individual, then the Parties shall use the
alternate strike method set forth above. In the event an arbitrator selected by
the alternate strike methodology is unable or unwilling to serve consistent with
the requirements set forth above, then the alternate striking procedure shall be
retraced in reverse order until the arbitrator is selected.

                  (d) The arbitrator shall be neutral, disinterested, impartial,
and independent of the Parties and others having any known interest in the
outcome, and shall abide by the AAA/ABA Code of Ethics for Arbitrators in
Commercial Disputes. There shall be no ex parte communications with the
arbitrator either before or during the arbitration, relating to the dispute or
issues involved in the dispute or the arbitrator's views on any such issue.

         15.7 Interim Review. Either Party may apply to any court having
jurisdiction hereof and seek preliminary injunctive relief until such time as
the arbitration award is rendered or the controversy is otherwise resolved.

         15.8 Location. Any arbitration under this Section shall be conducted in
New York, NY.

                                       51

<PAGE>

         15.9 Discovery Proceedings. The Parties shall have the right to
undertake complete discovery, as contemplated by and pursuant to Federal Rules
26-37 of the Federal Rules of Civil Procedure (with references to "court" in
those Rules being considered references to the "arbitrator") except as they may
be modified by the following:

                  (a) [ * ] after selection of the arbitrator, each Party may
serve on any other Party (i) interrogatories for the purpose of identification
of documents and witnesses, (ii) requests for admissions, and (iii) requests for
the production of documents and things. These discovery requests will be
answered [ * ] of receipt.

                  (b) At any time but not more than [ * ] after the selection of
the arbitrator, each Party may take depositions of employees or other witnesses
of an opposing Party as a matter of right, subject to applicable limitations set
forth in Rules 26-37.

                  (c) Any Party may conduct depositions of its own witnesses
which may be introduced as evidence at the arbitration hearing if the other
Party was given fair opportunity to attend the deposition and cross-examine.

                  (d) As they become aware of new documents or information,
including experts who may be called upon to testify, all Parties remain under a
continuing obligation to provide documents upon which they rely, to supplement
their responses, and to honor any informal agreements or understandings between
the Parties regarding documents or information to be exchanged. The arbitrator
at the hearing will not consider documents that have not been previously
exchanged, unless agreed by the Parties or used for purposes of impeachment.

                  (e) The Parties will promptly notify the arbitrator when an
unresolved dispute exists regarding discovery issues. The arbitrator will
discuss the matter with the Parties to determine the nature of the dispute and
will attempt to resolve that dispute. If the arbitrator does not resolve the
dispute, the arbitrators will arrange a conference concerning the dispute before
the arbitrator by telephone, or in person, and the arbitrator will decide the
dispute.

                  (f) All discovery shall be completed [ * ] from selection of
the arbitrator, unless extended by agreement of the Parties or by the arbitrator
for good cause shown.

         15.10 Hearings and Proceedings. The arbitrator will determine the
specific location within New York, NY and the date and time of the arbitration
hearing(s) and other proceedings after consultation with the arbitrator and the
Parties and will provide reasonable notice of the hearing(s) date and time. The
arbitrator will make every effort to schedule the arbitration hearing [ * ] of
the completion of all discovery, absent unusual circumstances.

                  (a) The Parties may mutually agree on or the arbitrator for
good cause may order a rescheduling of the hearing date.

                                       52

<PAGE>

                  (b) The arbitrator will ordinarily conduct the arbitration
hearing in the manner set forth in this Section except that (i) the Federal
Rules of Evidence shall apply and (ii) the arbitrator shall render its decision
in writing in the manner provided by Rule 52 of the Federal Rules of Civil
Procedure, including a full and precise statement of the factual and legal bases
for such decision. If the AAA rules and the rules of this Section conflict in
any manner, the rules of this Section shall prevail. The arbitrator must hold an
oral hearing, but may impose reasonable time limits on each phase of the
proceeding and may limit testimony to exclude evidence that would be immaterial
or unduly repetitive, provided that all Parties are afforded the opportunity to
present material and relevant evidence and that each Party is given at least an
approximately equal amount of time for presentation of its case.

                  (c) Written briefs may be filed up to [ * ] before the
hearing.

                  (d) The arbitrator will require witnesses to testify under
oath if requested by any Party.

                  (e) Any Party desiring a stenographic record may secure a
court reporter to attend the proceedings.

                  (f) The arbitrator will determine the order of proof, which
will generally be similar to that of a court trial, including opening and
closing statements.

                  (g) When the arbitrator determines that all relevant and
material evidence and arguments have been presented, the arbitrator will declare
the hearing closed. The arbitrator may defer the closing of the hearing for up
to [ * ] to permit the Parties to submit post-hearing briefs and or to make
closing arguments, as the arbitrator deems appropriate, before rendering an
award.

                  (h) The arbitrator will render the award and its decisions
pursuant to Fed. R. Civ. P. 52 [ * ] after the date of the closing of the
hearing or, if an arbitration hearing has been waived, [ * ] after the date of
the arbitrator's receiving all materials specified by the Parties. The decision
and award of the arbitrator will constitute the Arbitration Award and will be
binding on the Parties.

                  (i) The arbitrator shall, in rendering his or her decision and
award, apply the substantive law of the State of New York, without regard to its
conflict of laws provisions, except that the interpretation of and enforcement
of this Article shall be governed by the Federal Arbitration Act. The costs of
the winning Party and the fees of the arbitrator shall be paid by the losing
Party as determined by the arbitrator. If the arbitrator is unable to designate
a losing party, it shall so state and each Party shall bear its own costs and
the fees of the arbitrator shall be split equally between the Parties.

         15.11 Award. The arbitrator is empowered to award any remedy allowed by
law, including money damages, prejudgment interest and attorneys' fees, and to
grant final, complete, interim, or interlocutory relief, including injunctive
relief. Notwithstanding the foregoing, punitive or multiple damages may not be
awarded.

                                       53

<PAGE>

         15.12 Legal Fees. Except as set forth in Section 15.10(i) above, each
Party shall bear its own legal fees.

         15.13 Confidentiality. The DR proceeding shall be confidential and the
arbitrator shall issue appropriate protective orders to safeguard each Party's
Confidential Information. Except as required by law, no Party shall make (or
instruct the arbitrator to make) any public announcement with respect to the
proceedings or decision of the arbitrator without prior written consent of each
other Party. The existence of any dispute submitted to DR, and the award, shall
be kept in confidence by the Parties and the arbitrator, except as required in
connection with the enforcement of such award or as otherwise required by
applicable law.

         15.14 Survivability. Any duty to arbitrate under this Agreement shall
remain in effect and enforceable after termination of this Agreement for any
reason.

         15.15 Jurisdiction. For the purposes of this Article each Party agrees
to abide by the award rendered in any arbitration, and the Parties agree to
accept the jurisdiction of any court having jurisdiction over the Parties for
the purposes of enforcing awards entered pursuant to this Article and for
enforcing the agreements reflected in this Article, provided that the foregoing
shall not be deemed to waive any rights of either Party under the Federal
Arbitration Act.

                                  ARTICLE XVI

                                  MISCELLANEOUS

         16.1 Assignment.

                  (a) Affiliates. Either Party may assign any of its rights or
obligations under this Agreement in any country to its Affiliates and may
delegate its obligations under this Agreement in any country to its Affiliates;
provided, however, that such assignment or delegation shall not relieve the
assigning Party of its responsibilities for performance of its obligations under
this Agreement.

                  (b) (i) Non-Affiliates. Except as provided in subsection
(b)(ii) below, neither Party may assign its rights or obligations under this
Agreement to a non-Affiliate without the prior written consent of the other
Party, except in connection with a merger or similar reorganization or the sale
of all or substantially all of its assets. This Agreement shall survive any such
merger or reorganization of either Party with or into, or such sale of assets
to, another party and no consent for such merger, reorganization or sale shall
be needed; provided, that in the event of such merger, reorganization or sale,
no intellectual property rights of the acquiring corporation shall be included
in the technology licensed hereunder.

                      (ii) GTx's Right to Assign Rights to Receive Payment.
GTx may assign its rights to receive payments hereunder to a Third Party or
grant a security interest in its rights to receive payments hereunder.

                                       54

<PAGE>

                  (c) Benefit to Successors. This Agreement shall be binding
upon and inure to the benefit of the successors and permitted assigns of the
Parties. Any assignment not in accordance with this Agreement shall be void.

         16.2 Retained Rights. Nothing in this Agreement shall limit in any
respect the right of either Party to conduct research and development and to
market products using such Party's technology other than as herein expressly
provided.

         16.3 Consents Not Unreasonably Withheld or Delayed. Whenever provision
is made in this Agreement for either Party to secure the consent or approval of
the other, that consent or approval shall not unreasonably be withheld or
delayed, and whenever in this Agreement provision is made for one Party to
object to or disapprove a matter, such objection or disapproval shall not
unreasonably be exercised, even when not so expressly stated.

         16.4 Force Majeure. Neither Party shall lose any rights hereunder or be
liable to the other Party for damages or losses on account of failure of
performance by the defaulting Party if the failure is occasioned by government
action, war, fire, explosion, flood, strike, lockout, embargo, act of God, or
any other similar cause beyond the control of the defaulting Party, provided
that the Party claiming force majeure has exerted all reasonable efforts to
avoid or remedy such force majeure and has given the other Party prompt notice
describing such event, the effect thereof and the actions being taken to avoid
or remedy such force majeure; provided, however, that in no event shall a Party
be required to settle any labor dispute or disturbance.

         16.5 Further Actions. Each Party agrees to execute, acknowledge and
deliver such further instruments, and to do all such other acts, as may be
necessary or appropriate in order to carry out the purposes and intent of this
Agreement.

         16.6 No Trademark Rights. Except as otherwise provided herein, no
right, express or implied, is granted by the Agreement to use in any manner any
name or any trade name or trademark of the other Party or its Affiliates in
connection with the performance of this Agreement.

         16.7 Notices. All notices hereunder shall be in writing and shall be
deemed given if delivered personally or by facsimile transmission (receipt
verified), telexed, mailed by registered or certified mail (return receipt
requested), postage prepaid, or sent by express courier service, to the Parties
at the following addresses (or at such other address for a Party as shall be
specified by like notice; provided that notices of a change of address shall be
effective only upon receipt thereof).

                                       55

<PAGE>

         If to GTx:             GTx, Inc.
                                3 North Dunlap St.
                                3rd Floor
                                Memphis, Tennessee 38163
                                U.S.A.
                                Attention:  President
                                Facsimile No.:  [ * ]

         With a copy to:        GTx, Inc.
                                3 North Dunlap St.
                                3rd Floor
                                Memphis, Tennessee 38163
                                U.S.A.
                                Attention:  General Counsel
                                Facsimile No.: [ * ]

         If to Ortho:           Ortho Biotech Products, L.P.
                                Route 22 East
                                Bridgewater, NJ 08807
                                U.S.A.
                                Attention:  President
                                Facsimile No.:  [ * ]

         16.8 Waiver. Except as specifically provided for herein, the waiver
from time to time by either of the Parties of any of their rights or their
failure to exercise any remedy shall not operate or be construed as a continuing
waiver of same or any other of such Party's rights or remedies provided in this
Agreement.

         16.9 Severability. If any term, covenant or condition of this Agreement
or the application thereof to any Party or circumstances shall, to any extent or
in any country, be held to be invalid or unenforceable, then (i) the remainder
of this Agreement, or the application of such term, covenant or condition to
Parties or circumstances other than those as to which it is held invalid or
unenforceable, shall not be affected thereby and each term, covenant or
condition of this Agreement shall be valid and be enforced to the fullest extent
permitted by law; and (ii) the Parties hereto covenant and agree to renegotiate
any such term, covenant or application thereof in good faith in order to provide
a reasonably acceptable alternative to the term, covenant or condition of this
Agreement or the application thereof that is invalid or unenforceable, it being
the intent of the Parties that the basic purposes of this Agreement are to be
effectuated.

         16.10 Ambiguities. Ambiguities, if any, in this Agreement shall not be
construed against any Party, irrespective of which Party may be deemed to have
authored the ambiguous provision.

         16.11 Governing Law. This Agreement shall be governed by and
interpreted under the laws of the State of New Jersey as applied to contracts
entered into and performed entirely in New Jersey by New Jersey residents.

                                       56

<PAGE>

         16.12 Headings. The Sections and paragraph headings contained herein
are for the purposes of convenience only and are not intended to define or limit
the contents of said Sections or paragraphs.

         16.13 Counterparts. This Agreement may be executed in one or more
counterparts, each of which shall be deemed an original, but all of which
together shall constitute one and the same instrument.

         16.14 Entire Agreement; Amendments. This Agreement, including all
Exhibits attached hereto, and all documents delivered concurrently herewith, set
forth all the covenants, promises, agreements, warranties, representations,
conditions and understandings between the Parties hereto and supersede and
terminate all prior agreements and understandings between the Parties. There are
no covenants, promises, agreements, warranties, representations, conditions or
understandings, either oral or written, between the Parties other than as set
forth herein. No subsequent alteration, amendment, change or addition to this
Agreement shall be binding upon the Parties hereto unless reduced to writing and
signed by the respective authorized officers of the Parties. This Agreement,
including without limitation the exhibits, schedules and attachments hereto, are
intended to define the full extent of the legally enforceable undertakings of
the Parties hereto, and no promise or representation, written or oral, which is
not set forth explicitly is intended by either party to be legally binding.

Both Parties acknowledge that in deciding to enter into the Agreement and to
consummate the transaction contemplated thereby neither Party has relied upon
any statement or representations, written or oral, other than those explicitly
set forth herein.

         16.15 Independent Contractors. The status of the Parties under this
Agreement shall be that of independent contractors. Neither Party shall have the
right to enter into any agreements on behalf of the other Party, nor shall it
represent to any person that it has any such right or authority. Nothing in this
Agreement shall be construed as establishing a partnership or joint venture
relationship between the Parties.

         16.16 Currency Exchange. All payments to be made by Ortho to GTx shall
be made in U.S. Dollars, to a GTx bank account able to receive U.S. Dollars.
Payments by Ortho to GTx shall be converted to U.S. Dollars in accordance with
the following: the rate of currency conversion shall be calculated using a
simple average of the mid-month and month-end rates as provided by Brown
Brothers Harriman, 59 Wall Street, NY, NY 10005, for each relevant period, or if
such rate is not available, the spot rate as published by The Wall Street
Journal, Eastern Edition for such accounting period. This method of conversion
is and shall be consistent with Ortho's then current methods, provided that such
method shall utilize Third Party indices that are publicly available. Ortho
shall give GTx prompt written notice of any changes to Ortho's customary and
usual procedures for currency conversion, which shall only apply after such
notice has been delivered and provided that such changes continue to maintain a
set methodology for currency conversion.

                                       57

<PAGE>

         IN WITNESS WHEREOF, GTx and Ortho have caused this Agreement to be
executed as of the Effective Date first written above by their respective
officers thereunto duly authorized.

         GTX, INC.

         Signed By: /s/ Mitchell S. Steiner, M.D.
                    ----------------------------------
         Title:     CEO / Vice Chairman

         ORTHO BIOTECH PRODUCTS L.P.

         Signed By: /s/ J. H. Johnson
                    ----------------------------------
         Title:     President

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

                                       58

<PAGE>

Exhibits

         Exhibit A - List of GTx Patents

         Exhibit B - Adverse Event Reporting Procedures

         Exhibit C - Initial Plan

         Exhibit D1 - Compounds that Fall Within Section 1.36(1)

         Exhibit D2 - Excluded SARM Compounds

                                       59

<PAGE>

                                   EXHIBIT A

<TABLE>
<CAPTION>
U.S. PATENT APPLICATION OR
        PATENT NO.             FILING DATE         STATUS          ISSUE DATE       ASSIGNEES
---------------------------- ----------------- ---------------- ----------------- -----------------
<S>                          <C>               <C>              <C>               <C>
           [ * ]                  [ * ]            [ * ]             [ * ]
---------------------------------------------------------------------------------------------------
           [ * ]                  [ * ]            [ * ]             [ * ]
---------------------------------------------------------------------------------------------------
           [ * ]                  [ * ]            [ * ]             [ * ]
---------------------------------------------------------------------------------------------------
           [ * ]                  [ * ]            [ * ]             [ * ]
---------------------------------------------------------------------------------------------------
           [ * ]                  [ * ]            [ * ]             [ * ]
---------------------------------------------------------------------------------------------------
           [ * ]                  [ * ]            [ * ]             [ * ]
---------------------------------------------------------------------------------------------------
           [ * ]                  [ * ]            [ * ]             [ * ]
---------------------------------------------------------------------------------------------------
</TABLE>

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

                                       60

<PAGE>

EXHIBIT B

                       ADVERSE EVENT REPORTING PROCEDURES

There will be one common database for both clinical and post-marketing adverse
event data, which shall be the responsibility of Ortho. Ortho shall be
responsible for furnishing timely notice of adverse events, including drug
interactions, as required by applicable regulations, to all competent
governmental agencies with respect to the Collaboration Products. GTx shall
provide Ortho with all necessary assistance in complying with all adverse event
reporting requirements established by, or required under, any applicable IND,
NDA or Regulatory Approval and/or applicable law.

GTx shall furnish Ortho with timely notice of adverse events relating to
Andarine or Collaboration Product(s), that it becomes aware of within the U.S.
Ortho shall perform active follow-up to obtain adequate details of reports
received to allow evaluation of reports of adverse events and drug interactions.
Each party shall retain all documents, reports, studies and other materials
relating to any and all adverse events.

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

                                       61

<PAGE>

EXHIBIT C

                                  INITIAL PLAN

                                      [* ]

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

                                       62

<PAGE>

EXHIBIT D1

                   COMPOUNDS THAT FALL WITHIN SECTION 1.36(1)

                                      [ * ]

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

                                       63

<PAGE>

EXHIBIT D2 - EXCLUDED SARM COMPOUNDS

<TABLE>
<CAPTION>
TYPE OF SARM
 COMPOUNDS                                 EXCLUDED SARM COMPOUNDS
------------------    -------------------  -----------------------
<S>                   <C>                  <C>
[ * ]                                            [ * ]
                                                      [ * ]
                                                      [ * ]
                                                      [ * ]
                                                      [ * ]

------------------    -------------------  -----------------------
[ * ]                                            [ * ]

                                                 [ * ]
                                                      [ * ]
                                                      [ * ]
                                                      [ * ]
                                                      [ * ]
                                                      [ * ]

------------------    -------------------  -----------------------
[ * ]                                            [ * ]
                                                 [ * ]
                                                      [ * ]
                                                      [ * ]
                                                      [ * ]
                                                      [ * ]
                                                      [ * ]
------------------    -------------------  -----------------------
[ * ]                                            [ * ]
                                                 [ * ]
                                                      [ * ]
                                                      [ * ]
                                                      [ * ]
                                                      [ * ]
                                                      [ * ]
------------------    -------------------  -----------------------
</TABLE>

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

                                       64

<PAGE>

                                TABLE OF CONTENTS

<TABLE>
<CAPTION>
                                                                                                     PAGE
                                                                                                     ----
<S>                                                                                                  <C>
ARTICLE I             DEFINITIONS.................................................................      1

         1.1      "Active Ingredient".............................................................      1

         1.2      "Additional Collaboration Compound".............................................      1

         1.3      "Affiliate".....................................................................      1

         1.4      "Andarine"......................................................................      2

         1.5      "Business Day" .................................................................      2

         1.6      "Clinical Studies"..............................................................      2

         1.7      "Collaboration Compound"........................................................      2

         1.8      "Collaboration Product".........................................................      2

         1.9      "Combination Product"...........................................................      2

         1.10     "Commercialization Activities"..................................................      2

         1.11     "Confidential Information"......................................................      2

         1.12     "Control" or "Controlled".......................................................      2

         1.13     "Co-Promotion"..................................................................      2

         1.14     "Co-Promotion Territory"........................................................      3

         1.15     "Detail"........................................................................      3

         1.16     "Development" or "Develop"......................................................      3

         1.17     "Development Budget"............................................................      3

         1.18     "Development Expenses"..........................................................      3

         1.19     "Development Plan"..............................................................      4

         1.20     "Drug Approval Application".....................................................      4

         1.21     "Education".....................................................................      4

         1.22     "Effective Date"................................................................      4

         1.23     "EMEA"..........................................................................      4

         1.24     "Executive Officers"............................................................      4

         1.25     "FDA"...........................................................................      4

         1.26     "First Collaboration Compound"..................................................      4

         1.27     "[ * ]".........................................................................      4

         1.28     "FTE"...........................................................................      4

         1.29     "FTE Cost"......................................................................      5

         1.30     "FTE Rate"......................................................................      5

         1.31     "Generic".......................................................................      5
</TABLE>

                                      -i-

<PAGE>

                                TABLE OF CONTENTS
                                   (CONTINUED)

<TABLE>
<CAPTION>
                                                                                                     PAGE
                                                                                                     ----
<S>                                                                                                  <C>
         1.32     "GTx Audience"..................................................................      5

         1.33     "GTx Know-how"..................................................................      5

         1.34     "GTx/Ortho Development".........................................................      5

         1.35     "GTx Patent"....................................................................      5

         1.36     "GTx SARM Compounds"............................................................      5

         1.37     "IND"...........................................................................      6

         1.38     "Indication"....................................................................      6

         1.39     "Information"...................................................................      6

         1.40     "Joint Development Committee" or "JDC"..........................................      7

         1.41     "Joint Patent"..................................................................      7

         1.42     "Koseisho"......................................................................      7

         1.43     "Launch Date"...................................................................      7

         1.44     "Major European Country"........................................................      7

         1.45     "Market Exclusivity"............................................................      7

         1.46     "Marketing".....................................................................      7

         1.47     "Marketing Expenses"............................................................      7

         1.48     "Marketing and Sales Committee".................................................      7

         1.49     "Marketing and Sales Plan"......................................................      7

         1.50     "Material Breach"...............................................................      7

         1.51     "NDA"...........................................................................      7

         1.52     "NDA Approval"..................................................................      7

         1.53     "Net Sales".....................................................................      7

         1.54     "Ortho Development".............................................................      9

         1.55     "Ortho Know-how"................................................................      9

         1.56     "Ortho Patent"..................................................................      9

         1.57     "Osteoporosis Indication".......................................................      9

         1.58     "[ * ]".........................................................................      9

         1.59     "Patent"........................................................................     10

         1.60     "Patent Expenses"...............................................................     10

         1.61     "Phase I Clinical Trial"........................................................     10
</TABLE>

                                      -ii-

<PAGE>

                                TABLE OF CONTENTS
                                   (CONTINUED)

<TABLE>
<CAPTION>
                                                                                                     PAGE
                                                                                                     ----
<S>                                                                                                  <C>
         1.62     "Phase IIA Clinical Trial"......................................................     10

         1.63     "Phase IIB Clinical Trial"......................................................     10

         1.64     "Phase III Clinical Trials".....................................................     10

         1.65     "Phase IIIB Clinical Trials"....................................................     10

         1.66     "Phase IV Clinical Trials"......................................................     10

         1.67     "Pre-Clinical Studies"..........................................................     11

         1.68     "Pre-Marketing".................................................................     11

         1.69     "Products"......................................................................     11

         1.70     "Proof of Concept Trial"........................................................     11

         1.71     "Regulatory Agency".............................................................     11

         1.72     "Regulatory Approval"...........................................................     11

         1.73     "Replacement Collaboration Compound"............................................     11

         1.74     "Royalty Bearing Product".......................................................     11

         1.75     "Royalty Bearing Sales".........................................................     11

         1.76     "Royalty Bearing Territory".....................................................     11

         1.77     "Royalty Term"..................................................................     11

         1.78     "Safety"........................................................................     12

         1.79     "[ * ]".........................................................................     12

         1.80     "Third Party"...................................................................     12

         1.81     "Tolerability"..................................................................     12

         1.82     "Trademark Expenses"............................................................     12

         1.83     "Unit Net Sales Price"..........................................................     12

         1.84     "Urologist".....................................................................     12

         1.85     "UTRF"..........................................................................     12

         1.86     "Valid Patent Claim"............................................................     12

         1.87     "Wasting Indication"............................................................     12

ARTICLE II            MANAGEMENT..................................................................     13

         2.1      Joint Development Committee.....................................................     13

ARTICLE III           LICENSING FEES; MILESTONE PAYMENTS; ROYALTIES; REPORTING....................     14
</TABLE>

                                     -iii-

<PAGE>

                                TABLE OF CONTENTS
                                   (CONTINUED)

<TABLE>
<CAPTION>
                                                                                                     PAGE
                                                                                                     ----
<S>                                                                                                  <C>
         3.1      Licensing Fee...................................................................     14

         3.2      Milestone Payments..............................................................     14

         3.3      Limitation on Milestone Payments................................................     17

         3.4      Royalty Rates...................................................................     18

         3.5      Payment of Royalties............................................................     18

         3.6      Payment of Third Party Royalties................................................     20

         3.7      Ortho's Rights Upon Expiration of Royalty Term..................................     20

         3.8      Compulsory License..............................................................     20

         3.9      Sales by Sublicensees...........................................................     20

         3.10     Tax Matters.....................................................................     20

         3.11     United States Dollars...........................................................     22

         3.12     Payments to or Reports by Affiliates............................................     22

         3.13     Payment of Additional Royalties.................................................     22

         3.14     Payments by Wire Transfer.......................................................     22

ARTICLE IV            DEVELOPMENT.................................................................     22

         4.1      Development Responsibility......................................................     22

         4.2      Development Plan................................................................     22

         4.3      Development Efforts.............................................................     23

         4.4      Drug Approval Applications......................................................     23

         4.5      Development Expenses............................................................     24

         4.6      Replacement Collaboration Compounds; Additional Collaboration Compounds.........     24

ARTICLE V             LICENSES....................................................................     25

         5.1      Patent Licenses to Conduct Development..........................................     25

         5.2      Patent Licenses to Conduct Commercialization Activities.........................     25

         5.3      Know-how Licenses...............................................................     25

         5.4      Distribution Through Third Party Distributors...................................     26

         5.5      Sublicensing....................................................................     26

         5.6      Third Party Technology..........................................................     26

         5.7      No Implied Licenses; Retained Rights............................................     26
</TABLE>

                                      -iv-

<PAGE>

                                TABLE OF CONTENTS
                                   (CONTINUED)

<TABLE>
<CAPTION>
                                                                                                     PAGE
                                                                                                     ----
<S>                                                                                                  <C>
         5.8      Independent Research............................................................     26

ARTICLE VI            COMMERCIALIZATION...........................................................     26

         6.1      Ortho as Marketing Party........................................................     27

         6.2      GTx's Option to Co-Promote in the United States.................................     27

         6.3      GTx to Notify Ortho of its Election to Co-Promote; Changes in the GTx Audience..     27

         6.4      Marketing and Sales Committee...................................................     28

         6.5      Marketing and Sales Plan........................................................     28

         6.6      Requirements for GTx Co-Promotion...............................................     29

         6.7      Co-Promotion Sales Forces.......................................................     29

         6.8      Sales Force Training............................................................     30

         6.9      GTx Sales Force.................................................................     31

         6.10     Detail Reports..................................................................     31

         6.11     Co-Promotion Audit of Performance...............................................     31

         6.12     Failure to Perform..............................................................     31

         6.13     Medical Inquiries...............................................................     32

         6.14     Governmental Contact............................................................     32

         6.15     Regulatory Disputes/Lawsuits....................................................     32

         6.16     Sales...........................................................................     32

         6.17     Orders..........................................................................     32

         6.18     Co-Promotion Limitation of Scope................................................     32

         6.19     Commercialization Efforts.......................................................     33

         6.20     Commercialization in Royalty Bearing Territory..................................     33

         6.21     Pricing, Pricing Approvals and Product Distribution.............................     33

         6.22     Product Recalls.................................................................     33

         6.23     Advertising and Promotion.......................................................     33

         6.24     GTx Right to Opt Out of Co-Promotion............................................     33

         6.25     Additional Support by GTx.......................................................     33

article VII           CO-PROMOTION PAYMENT........................................................     34

         7.1      Additional Royalty..............................................................     34
</TABLE>

                                      -v-

<PAGE>

                                TABLE OF CONTENTS
                                   (CONTINUED)

<TABLE>
<CAPTION>
                                                                                                     PAGE
                                                                                                     ----
<S>                                                                                                  <C>
         7.2      Term............................................................................     34

ARTICLE VIII          MANUFACTURE AND SUPPLY......................................................     35

         8.1      Manufacture and Supply During Development.......................................     35

         8.2      Manufacture and Supply During Commercialization.................................     35

         8.3      Clinical Supplies...............................................................     35

         8.4      Quality Assurance...............................................................     35

         8.5      Technology Transfer in Event of Termination by Ortho............................     36

ARTICLE IX            CONFIDENTIALITY.............................................................     36

         9.1      Confidentiality Exceptions......................................................     36

         9.2      Authorized Disclosure...........................................................     37

         9.3      Survival........................................................................     38

         9.4      Termination of Prior Agreement..................................................     38

         9.5      Publications....................................................................     38

         9.6      Public Disclosures..............................................................     38

ARTICLE X             OWNERSHIP OF INTELLECTUAL PROPERTY AND PATENT RIGHTS........................     39

         10.1     Ownership.......................................................................     39

         10.2     Invention Disclosures...........................................................     39

         10.3     Disclosure of Provisional and Non-Provisional Patent Applications...............     39

         10.4     Patent Filings..................................................................     40

         10.5     Third Party Patent Rights.......................................................     41

         10.6     Enforcement Rights..............................................................     41

         10.7     Defense and Settlement of Third Party Claims....................................     42

         10.8     Allocation of Patent Expenses...................................................     43

         10.9     Assignment of Joint Patents.....................................................     43

         10.10    Trademarks and Trademark Expenses...............................................     43

ARTICLE XI            REPRESENTATIONS AND WARRANTIES..............................................     43

         11.1     Representations and Warranties..................................................     43

         11.2     Performance by Affiliates.......................................................     44

ARTICLE XII           INFORMATION AND REPORTS.....................................................     44
</TABLE>

                                      -vi-

<PAGE>

                                TABLE OF CONTENTS
                                   (CONTINUED)

<TABLE>
<CAPTION>
                                                                                                     PAGE
                                                                                                     ----
<S>                                                                                                  <C>
         12.1     Information and Reports During Development and Commercialization................     44

         12.2     Complaints......................................................................     45

         12.3     Adverse Event Reporting.........................................................     45

         12.4     Records of Revenues and Expenses................................................     45

ARTICLE XIII          TERM AND TERMINATION........................................................     46

         13.1     Term............................................................................     46

         13.2     Termination for Material Breach.................................................     47

         13.3     Termination by Ortho............................................................     49

         13.4     Effect of Termination by GTx Under Section 13.2 or by Ortho Pursuant to
                  Section 13.3....................................................................     49

         13.5     Surviving Rights................................................................     50

         13.6     Change of Control...............................................................     50

ARTICLE XIV           INDEMNIFICATION.............................................................     54

         14.1     Ortho and GTx...................................................................     54

         14.2     Ortho...........................................................................     55

         14.3     Procedure.......................................................................     55

         14.4     Insurance.......................................................................     55

ARTICLE XV            DISPUTE RESOLUTION..........................................................     56

         15.1     Disputes........................................................................     56

         15.2     Disputes Referred First to Executive Officers...................................     56

         15.3     Resolution of Dispute by Alternate Means........................................     56

         15.4     Alternative Dispute Resolution..................................................     56

         15.5     Arbitration Procedures..........................................................     57

         15.6     Arbitrators.....................................................................     57

         15.7     Interim Review..................................................................     58

         15.8     Location........................................................................     58

         15.9     Discovery Proceedings...........................................................     58

         15.10    Hearings and Proceedings........................................................     59

         15.11    Award...........................................................................     60
</TABLE>

                                     -vii-

<PAGE>

                                TABLE OF CONTENTS
                                   (CONTINUED)

<TABLE>
<CAPTION>
                                                                                                     PAGE
                                                                                                     ----
<S>                                                                                                  <C>
         15.12    Legal Fees......................................................................     60

         15.13    Confidentiality.................................................................     60

         15.14    Survivability...................................................................     60

         15.15    Jurisdiction....................................................................     60

ARTICLE XVI           MISCELLANEOUS...............................................................     61

         16.1     Assignment......................................................................     61

         16.2     Retained Rights.................................................................     61

         16.3     Consents Not Unreasonably Withheld or Delayed...................................     61

         16.4     Force Majeure...................................................................     61

         16.5     Further Actions.................................................................     62

         16.6     No Trademark Rights.............................................................     62

         16.7     Notices.........................................................................     62

         16.8     Waiver..........................................................................     62

         16.9     Severability....................................................................     63

         16.10    Ambiguities.....................................................................     63

         16.11    Governing Law...................................................................     63

         16.12    Headings........................................................................     63

         16.13    Counterparts....................................................................     63

         16.14    Entire Agreement; Amendments....................................................     63

         16.15    Independent Contractors.........................................................     64

         16.16    Currency Exchange...............................................................     64
</TABLE>

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

                                     -viii-<PAGE>

                                                                    EXHIBIT 10.1

                                                               EXECUTION VERSION

================================================================================

                                CREDIT AGREEMENT

                                      among

                               EXIDE TECHNOLOGIES,

                     EXIDE GLOBAL HOLDING NETHERLANDS C.V.,

                          VARIOUS LENDING INSTITUTIONS,

                           CREDIT SUISSE FIRST BOSTON
                                       AND
                             FLEET SECURITIES, INC.,
                             as Syndication Agents,

                                       and

                        DEUTSCHE BANK AG NEW YORK BRANCH,
                             as Administrative Agent

                             Dated as of May 5, 2004

                        --------------------------------

      DEUTSCHE BANK SECURITIES INC.,          CREDIT SUISSE FIRST BOSTON,
 as Sole Lead Arranger and Book Running         as Book Running Manager
                 Manager

================================================================================

<PAGE>

            CREDIT AGREEMENT, dated as of May 5, 2004, among EXIDE TECHNOLOGIES,
a Delaware corporation (the "U.S. Borrower"), EXIDE GLOBAL HOLDING NETHERLANDS
C.V., a limited partnership organized under the laws of The Netherlands (the
"European Borrower", and together with the U.S. Borrower, the "Borrowers"), the
Lenders from time to time party hereto, CREDIT SUISSE FIRST BOSTON and FLEET
SECURITIES, INC., as Syndication Agents (in such capacity, the "Syndication
Agents"), DEUTSCHE BANK AG NEW YORK BRANCH, as Administrative Agent (in such
capacity, the "Administrative Agent"), CREDIT SUISSE FIRST BOSTON, as Book
Running Manager (in such capacity, the "Co-Book Running Manager") and DEUTSCHE
BANK SECURITIES INC., as Sole Lead Arranger and Book Running Manager (in such
capacity, the "Sole Lead Arranger" and, together with the Co-Book Running
Manager, the "Book Running Managers").

                              W I T N E S S E T H:

            WHEREAS, subject to and upon the terms and conditions herein set
forth, the Lenders are willing to make available to the Borrowers on a several
(but not joint) basis the credit facilities provided for herein;

            NOW, THEREFORE, IT IS AGREED:

            SECTION 1. Amount and Terms of Credit.

            1.01 Commitments.

            (a) U.S. Borrower Term Loans. Subject to and upon the terms and
conditions set forth herein, each Lender with a U.S. Borrower Term Loan
Commitment severally agrees to make a term loan (each, a "U.S. Borrower Term
Loan" and, collectively, the "U.S. Borrower Term Loans") to the U.S. Borrower,
which U.S. Borrower Term Loans:

            (i) shall be incurred by the U.S. Borrower pursuant to a single
      drawing on the Initial Borrowing Date for the purposes described in
      Section 7.05(a);

            (ii) shall be denominated in Dollars;

            (iii) except as hereafter provided, shall, at the option of the U.S.
      Borrower, be incurred and maintained as, and/or converted into, Base Rate
      Loans or Eurodollar Loans, provided that (A) except as otherwise
      specifically provided in Section 1.10(b), all U.S. Borrower Term Loans
      made as part of the same Borrowing shall at all times consist of U.S.
      Borrower Term Loans of the same Type and (B) unless the Administrative
      Agent has determined that the Syndication Date has occurred (at which time
      this clause (B) shall no longer be applicable), prior to the 60th day
      after the Initial Borrowing Rate, Euro Rate Loans shall be restricted to
      one month Interest Periods (or such shorter periods as may be required by
      the Administrative Agent) at all times, with the first such Interest
      Period for Eurodollar Loans to begin not sooner than 7 Business Days after
      the Initial Borrowing Date and with any subsequent Interest Periods for
      each Tranche to begin on the last day of the prior Interest Period
      theretofore in effect for such Tranche; and

<PAGE>

            (iv) shall be made by each Lender in that initial aggregate
      principal amount as is equal to the U.S. Borrower Term Loan Commitment of
      such Lender on the Initial Borrowing Date (before giving effect to the
      termination thereof on such date pursuant to Section 3.03(b)).

Once repaid, U.S. Borrower Term Loans incurred hereunder may not be reborrowed.

            (b) European Borrower Dollar Term Loans. Subject to and upon the
terms and conditions set forth herein, each Lender with a European Borrower
Dollar Term Loan Commitment severally agrees to make a term loan (each, an
"European Borrower Dollar Term Loan" and, collectively, the "European Borrower
Dollar Term Loans") to the European Borrower, which European Borrower Dollar
Term Loans:

            (i) shall be incurred by the European Borrower pursuant to a single
      drawing on the Initial Borrowing Date for the purposes described in
      Section 7.05(a);

            (ii) shall be denominated in Dollars;

            (iii) except as hereafter provided, shall, at the option of the
      European Borrower, be incurred and maintained as, and/or converted into,
      Base Rate Loans or Eurodollar Loans, provided that (A) except as otherwise
      specifically provided in Section 1.10(b), all European Borrower Dollar
      Term Loans made as part of the same Borrowing shall at all times consist
      of European Borrower Dollar Term Loans of the same Type and (B) unless the
      Administrative Agent has determined that the Syndication Date has occurred
      (at which time this clause (B) shall no longer be applicable), prior to
      the 60th day after the Initial Borrowing Date, Euro Rate Loans shall be
      restricted to one month Interest Periods (or such shorter periods as may
      be required by the Administrative Agent) at all times, with the first such
      Interest Period for Eurodollar Loans to begin not sooner than 7 Business
      Days after the Initial Borrowing Date and with any subsequent Interest
      Periods for each Tranche to begin on the last day of the prior Interest
      Period theretofore in effect for such Tranche; and

            (iv) shall be made by each Lender in that initial aggregate
      principal amount as is equal to the European Borrower Dollar Term Loan
      Commitment of such Lender on the Initial Borrowing Date (before giving
      effect to the termination thereof on such date pursuant to Section
      3.03(c)).

Once repaid, European Borrower Dollar Term Loans incurred hereunder may not be
reborrowed.

            (c) European Borrower Euro Term Loans. Subject to and upon the terms
and conditions set forth herein, each Lender with a European Borrower Euro Term
Loan Commitment severally agrees to make a term loan (each, an "European
Borrower Euro Term Loan" and, collectively, the "European Borrower Euro Term
Loans") to the European Borrower, which European Borrower Euro Term Loans:

            (i) shall be incurred by the European Borrower pursuant to a single
      drawing on the Initial Borrowing Date for the purposes described in
      Section 7.05(a);

                                      -2-
<PAGE>

            (ii) shall (subject to Section 1.14) be denominated in Euros;

            (iii) except as hereafter provided, shall, at the option of the
      European Borrower, be incurred and maintained as, and/or (subject to
      Section 1.09) split into, one or more Borrowings of European Borrower Euro
      Term Loans; provided that unless the Administrative Agent has determined
      that the Syndication Date has occurred, (at which time this proviso shall
      no longer be applicable), prior to the 60th day after the Initial
      Borrowing Date, Euro Rate Loans shall be restricted to one month Interest
      Periods (or such shorter periods as may be required by the Administrative
      Agent) at all times, with the first such Interest Period for European
      Borrower Euro Term Loans to begin on the Initial Borrowing Date and with
      any subsequent Interest Periods for European Borrower Euro Term Loans to
      begin on the last day of the prior Interest Period theretofore in effect
      for such Tranche; and

            (iv) shall be made by each Lender in that initial aggregate
      principal amount as is equal to the European Borrower Euro Term Loan
      Commitment of such Lender on the Initial Borrowing Date (before giving
      effect to the termination thereof on such date pursuant to Section
      3.03(d)).

Once repaid, European Borrower Euro Term Loans incurred hereunder may not be
reborrowed.

            (d) Multicurrency Facility Revolving Loans. Subject to and upon the
terms and conditions set forth herein, each Multicurrency Facility RL Lender
severally agrees to make, at any time and from time to time on or after the
Initial Borrowing Date and prior to the Revolving Loan Maturity Date, (I) a
revolving loan or revolving loans to the U.S. Borrower (each, a "U.S. Borrower
Multicurrency Facility Revolving Loan" and, collectively, the "U.S. Borrower
Multicurrency Facility Revolving Loans") and (II) a revolving loan or revolving
loans to the European Borrower (each, a "European Borrower Multicurrency
Facility Revolving Loan" and, collectively, the "European Borrower Multicurrency
Facility Revolving Loans" and with the revolving loans made to the U.S. Borrower
or the European Borrower pursuant to this Section 1.01(d) being each called a
"Multicurrency Facility Revolving Loan"), which Multicurrency Facility Revolving
Loans:

            (i) shall (subject to Section 1.14) be made and maintained in the
      respective Available Currency elected by the U.S. Borrower or the European
      Borrower, as the case may be;

            (ii) except as hereafter provided, shall, at the option of the U.S.
      Borrower or the European Borrower, be incurred and maintained as, and/or
      converted into, one or more Borrowings of Base Rate Loans or, Eurodollar
      Loans (if the Available Currency elected is Dollars) or Euro Denominated
      Revolving Loans, (if the Available Currency elected is Euros), provided
      that (A) except as otherwise specifically provided in Section 1.10(b), all
      Multicurrency Facility Revolving Loans made as part of the same Borrowing
      shall at all times consist of Multicurrency Facility Revolving Loans of
      the same Type, and (B) unless the Administrative Agent has determined that
      the Syndication Date has occurred (at which time this clause (B) shall no
      longer be applicable), (1) Borrowings of Multicurrency Facility Revolving
      Loans to be maintained as Eurodollar Loans shall be

                                      -3-
<PAGE>

      restricted to one month Interest Periods (or such shorter periods as may
      be required by the Administrative Agent) at all times with the first such
      Interest Period for such Eurodollar Loans to begin not sooner than 7
      Business Days after the Initial Borrowing Date and with any subsequent
      Interest Periods applicable to Eurodollar Loans of such Tranche to begin
      on the last day of the prior Interest Period theretofore in effect for
      Eurodollar Loans of such Tranche and (2) all Borrowings of Euro
      Denominated Revolving Loans shall have Interest Periods of one month (or
      such shorter periods as may be required by the Administrative Agent);

            (iii) may be repaid and reborrowed in accordance with the provisions
      hereof;

            (iv) shall not be made (and shall not be required to be made) by any
      Multicurrency Facility RL Lender in any instance where the incurrence
      thereof (after giving effect to the use of the proceeds thereof on the
      date of the incurrence thereof to repay any amounts theretofore
      outstanding pursuant to this Agreement) would cause the Individual
      Multicurrency Facility RL Exposure of such Multicurrency Facility RL
      Lender to exceed the amount of its Multicurrency Facility Revolving Loan
      Commitment at such time; and

            (v) shall not be made (and shall not be required to be made) by any
      Multicurrency Facility RL Lender if the making of same would cause the
      Aggregate Multicurrency Facility RL Exposure (after giving effect to the
      use of the proceeds thereof on the date of the incurrence thereof to repay
      any amounts theretofore outstanding pursuant to this Agreement) to exceed
      the Total Multicurrency Facility Revolving Loan Commitment as then in
      effect;

provided that (subject to any requirement to provide a Subsidiaries Guaranty
pursuant to Section 8.12) the European Borrower shall have no liability under
this Agreement with respect to any U.S. Borrower Multicurrency Facility
Revolving Loans which may be extended to, and which shall constitute obligations
of, the U.S. Borrower.

            (e) Swingline Loans. Subject to and upon the terms and conditions
set forth herein, the Swingline Lender agrees to make, at any time and from time
to time on or after the Initial Borrowing Date and prior to the Swingline Expiry
Date, (I) a revolving loan or revolving loans to the U.S. Borrower (each, a
"U.S. Borrower Swingline Loan" and, collectively, the "U.S. Borrower Swingline
Loans") and (II) a revolving loan or revolving loans to the European Borrower
(each, a "European Borrower Swingline Loan" and, collectively, the "European
Borrower Swingline Loans" and with the revolving loans made to the U.S. Borrower
or the European Borrower pursuant to this Section 1.01(e) being each called a
"Swingline Loan"), which Swingline Loans:

            (i) shall (subject to Section 1.14) be made and maintained in the
      respective Available Currency elected by the U.S. Borrower or the European
      Borrower, as the case may be;

                                      -4-
<PAGE>

            (ii) shall be made and maintained as Base Rate Loans (if the
      Available Currency elected is Dollars) or Euro Denominated Swingline Loans
      (if the Available Currency elected is Euros);

            (iii) may be repaid and reborrowed in accordance with the provisions
      hereof;

            (iv) shall not be made (and shall not be required to be made) if the
      making of same would cause the Aggregate Multicurrency Facility RL
      Exposure (after giving effect to the use of the proceeds thereof on the
      date of the incurrence thereof to repay any amounts theretofore
      outstanding pursuant to this Agreement) to exceed the Total Multicurrency
      Facility Revolving Loan Commitment at such time; and

            (v) shall not exceed in aggregate principal amount at any time
      outstanding (taking the Dollar Equivalents of all amounts in Euros), the
      Maximum Swingline Amount.

Notwithstanding anything to the contrary contained in this Section 1.01(e), (x)
the Swingline Lender shall not be obligated to make any Swingline Loans at a
time when a Lender Default exists with respect to any Multicurrency Facility RL
Lender unless the Swingline Lender has entered into arrangements satisfactory to
it to eliminate the Swingline Lender's risk with respect to the Defaulting
Lender's or Defaulting Lenders' refunding obligations (through the requirement
that Mandatory Borrowings be made from time to time) in respect of such
Swingline Loans, including by cash collateralizing (in the relevant currency or
currencies) such Defaulting Lender's or Defaulting Lenders' Multicurrency
Facility RL Percentages of the outstanding Swingline Loans and (y) the Swingline
Lender shall not make any Swingline Loan after it has received written notice
from either Borrower or the Required Lenders stating that a Default or an Event
of Default exists and is continuing until such time as the Swingline Lender
shall have received written notice (A) of rescission of all such notices from
the party or parties originally delivering such notice or notices or (B) of the
waiver of such Default or Event of Default by the Required Lenders. Subject to
any requirement to provide a Subsidiaries Guaranty pursuant to Section 8.12, the
European Borrower shall have no liability under this Agreement with respect to
any U.S. Borrower Swingline Loans which may be extended to, and shall constitute
obligations of, the U.S. Borrower.

            (f) Refunding of Swingline Loans. On any Business Day, the Swingline
Lender may, in its sole discretion, give notice to the Multicurrency Facility RL
Lenders that the outstanding U.S. Borrower Swingline Loans or European Borrower
Swingline Loans in a given Available Currency shall be funded with a Borrowing
of U.S. Borrower Multicurrency Facility Revolving Loans or European Borrower
Multicurrency Facility Revolving Loans, as the case may be, in such Available
Currency (provided that (x) such notice shall be deemed to have been
automatically given with respect to all outstanding Swingline Loans upon the
occurrence of a Default or an Event of Default under Section 10.05 or upon the
exercise of any of the remedies provided in the last paragraph of Section 10 and
(y) if a Sharing Event shall have occurred, all such Swingline Loans shall be
denominated in Dollars in accordance with the provisions of Section 1.14, and
refunded through a Mandatory Borrowing denominated in Dollars as provided
below), in which case a Borrowing of U.S. Borrower Multicurrency Facility
Revolving Loans or European Borrower Multicurrency Facility Revolving Loans, as
the case may be, denominated in

                                      -5-
<PAGE>

the respective Available Currency (subject to the provisions of clause (y) of
the immediately preceding parenthetical sentence) (each such Borrowing, a
"Mandatory Borrowing") shall be made on the third succeeding Business Day by all
Multicurrency Facility RL Lenders pro rata based on each such Multicurrency
Facility RL Lender's Multicurrency Facility RL Percentage and the proceeds
thereof shall be applied directly to the Swingline Lender to repay the Swingline
Lender for such outstanding Swingline Loans. Each Multicurrency Facility RL
Lender hereby irrevocably agrees to make U.S. Borrower Multicurrency Facility
Revolving Loans (in the case of a refunding of U.S. Borrower Swingline Loans)
and European Borrower Multicurrency Facility Revolving Loans (in the case of a
refunding of European Borrower Swingline Loans) in the relevant Available
Currency or Available Currencies upon three Business Days' notice pursuant to
each Mandatory Borrowing in the amount and in the manner specified in the
preceding sentence and on the date specified in writing by the Swingline Lender
notwithstanding (i) that the amount of the Mandatory Borrowing may not comply
with the minimum amount for Borrowings otherwise required hereunder, (ii)
whether any conditions specified in Section 6 are then satisfied, (iii) whether
a Default or an Event of Default then exists, (iv) the date of such Mandatory
Borrowing, (v) the amount of the Total Multicurrency Facility Revolving Loan
Commitment at such time and (vi) the amount of the Multicurrency Facility
Revolving Loan Commitment of such Multicurrency Facility RL Lender at such time.
In the event that any Mandatory Borrowing cannot for any reason be made on the
date otherwise required above (including, without limitation, as a result of the
commencement of a proceeding under any bankruptcy, reorganization, dissolution,
insolvency, receivership, administration or liquidation or similar law with
respect to either Borrower), then each Multicurrency Facility RL Lender hereby
agrees that it shall forthwith purchase (as of the date the Mandatory Borrowing
would otherwise have occurred, but adjusted for any payments received from
either Borrower on or after such date and prior to such purchase) from the
Swingline Lender such participations in such outstanding Swingline Loans as
shall be necessary to cause such Multicurrency Facility RL Lenders to share in
such Swingline Loans ratably based upon their respective Multicurrency Facility
RL Percentages, provided that (x) all interest payable on the Swingline Loans
shall be for the account of the Swingline Lender until the date as of which the
respective participation is required to be purchased and, to the extent
attributable to the purchased participation, shall be payable to the participant
from and after such date and (y) at the time any purchase of participations
pursuant to this sentence is actually made, the purchasing Multicurrency
Facility RL Lender shall be required to pay the Swingline Lender interest on the
principal amount of the participation purchased for each day from and including
the day upon which the Mandatory Borrowing would otherwise have occurred to but
excluding the date of payment for such participation, at the rate otherwise
applicable to Multicurrency Facility Revolving Loans made in the relevant
Available Currency. Notwithstanding anything to the contrary contained above in
this Section 1.01(f), upon the occurrence of a Sharing Event, all outstanding
Swingline Loans shall, as provided in Section 1.14, be automatically converted
into U.S. Dollar denominated Swingline Loans and, to the extent the respective
Mandatory Borrowing has not already occurred in respect of such Swingline Loans,
a Mandatory Borrowing shall be effected with respect thereto in accordance with
the provisions of this Section 1.01(f).

            1.02 Minimum Borrowing Amounts, etc. The aggregate principal amount
of each Borrowing of Loans shall not be less than the Minimum Borrowing Amount
applicable to Borrowings of the respective Type and Tranche of Loans to be made
or maintained pursuant to the respective Borrowing, provided that Mandatory
Borrowings shall be made in the amounts

                                      -6-
<PAGE>

required by Section 1.01(f). More than one Borrowing may be incurred on any day,
but at no time shall there be outstanding more than 10 Borrowings of Euro Rate
Loans.

            1.03 Notice of Borrowing. (a) Whenever a Borrower desires to make a
Borrowing of Loans hereunder (excluding Borrowings of Swingline Loans and
Mandatory Borrowings), an Authorized Officer of such Borrower shall give the
Administrative Agent at its Notice Office at least one Business Day's prior
written (or telephonic notice promptly confirmed in writing) notice of each Base
Rate Loan, at least three Business Days' prior written (or telephonic notice
promptly confirmed in writing) notice of each Eurodollar Rate Loan to be made in
Dollars and at least three Business Days' prior written (or telephonic notice
promptly confirmed in writing) notice of each Euro Rate Loan to be made in Euros
hereunder, provided that any such notice shall be deemed to have been given on a
certain day only if given before 12:00 P.M. (New York time) on such day. Each
such written notice or written confirmation of telephonic notice (each, a
"Notice of Borrowing"), except as otherwise expressly provided in Section 1.10,
shall be irrevocable and shall be given by or on behalf of the respective
Borrower in the form of Exhibit A-1, appropriately completed to specify: (i) the
aggregate principal amount of the Loans to be made pursuant to such Borrowing
(stated in the relevant Available Currency), (ii) the date of such Borrowing
(which shall be a Business Day), (iii) whether the respective Borrowing shall
consist of U.S. Borrower Term Loans, European Borrower Dollar Term Loans,
European Borrower Euro Term Loans, U.S. Borrower Multicurrency Facility
Revolving Loans or European Borrower Multicurrency Facility Revolving Loans,
(iv) in the case of Dollar Denominated Loans, whether the Dollar Denominated
Loans being made pursuant to such Borrowing are to be initially maintained as
Base Rate Loans or Eurodollar Loans and (v) in the case of Euro Rate Loans, the
initial Interest Period to be applicable thereto. The Administrative Agent shall
promptly give each Lender which is required to make Loans of the Tranche
specified in the respective Notice of Borrowing notice of such proposed
Borrowing, of such Lender's proportionate share thereof (determined in
accordance with Section 1.07) and of the other matters required by the
immediately preceding sentence to be specified in the Notice of Borrowing.

            (b) (i) Whenever either Borrower desires to make a Borrowing of
Swingline Loans hereunder, an Authorized Officer of such Borrower shall give the
Swingline Lender, (i) not later than 1:00 P.M. (New York time) on the date that
a Dollar Denominated Swingline Loan is to be made and (ii) not later than 1:00
P.M. (New York time) on the Business Day prior to the date that a Euro
Denominated Swingline Loan is to be made, written notice or telephonic notice
promptly confirmed in writing of each Swingline Loan to be made hereunder. Each
such notice shall be irrevocable and shall be given by or on behalf of the
respective Borrower in the form of Exhibit A-1, appropriately completed to
specify: (A) the date of Borrowing (which shall be a Business Day), (B) the
aggregate principal amount of the Swingline Loans to be made pursuant to such
Borrowing (stated in the relevant currency) and (C) whether the respective
Swingline Loans shall constitute U.S. Borrower Swingline Loans or European
Borrower Swingline Loans.

            (ii) Mandatory Borrowings shall be made upon the notice specified in
Section 1.01(f), as applicable, with each Borrower irrevocably agreeing, by its
incurrence of any Swingline Loan, to the making of the Mandatory Borrowings as
set forth in Section 1.01(f).

                                      -7-
<PAGE>

            (c) Without in any way limiting the obligation of either Borrower to
confirm in writing any telephonic notice permitted to be given hereunder, the
Administrative Agent or the Swingline Lender (in the case of a Borrowing of
Swingline Loans) or the respective Issuing Lender (in the case of the issuance
of Letters of Credit), as the case may be, may, prior to receipt of written
confirmation, act without liability upon the basis of such telephonic notice,
believed by the Administrative Agent, the Swingline Lender or such Issuing
Lender, as the case may be, in good faith to be from an Authorized Officer of
such Borrower. In each such case, the Administrative Agent's, the Swingline
Lender's or the respective Issuing Lender's record of the terms of such
telephonic notice shall be conclusive evidence of the contents of such notice,
absent manifest error.

            1.04 Disbursement of Funds. Not later than 1:00 P.M. (New York time)
on the date specified in each Notice of Borrowing (or (x) in the case of
Swingline Loans, not later than 3:00 P.M. (New York time) on the date specified
pursuant to Section 1.03(b)(i) and (y) in the case of Mandatory Borrowings, not
later than 10:00 A.M. (New York time) on the date specified in Section 1.01(f)),
each Lender with a Commitment under the respective Tranche (or each Lender
required to make Loans pursuant to the respective Mandatory Borrowing), will
make available its pro rata portion (determined in accordance with Section 1.07)
of each such Borrowing requested to be made on such date (or in the case of
Swingline Loans, the Swingline Lender shall make available the full amount
thereof). All such amounts shall be made available in Dollars (in the case of
Dollar Denominated Loans) or in Euros (in the case of Euro Denominated Loans),
as the case may be, and in immediately available funds at the Payment Office of
the Administrative Agent, and the Administrative Agent will make available to
the respective Borrower at the Payment Office or such other location as may be
reasonably satisfactory to the Administrative Agent and specified in the
relevant Notice of Borrowing (or to the Swingline Lender in the case of a
Mandatory Borrowing) the aggregate of the amounts so made available by the
Lenders prior to (x) 3:00 P.M. (New York time) on such day (excluding Swingline
Loans and Revolving Loans made pursuant to Mandatory Borrowings) and (y) 4:00
P.M. (New York time) on such day, in the case of any Swingline Loan, in each
case to the extent of funds actually received by the Administrative Agent prior
to such times on such day. Unless the Administrative Agent shall have been
notified by any Lender prior to the date of Borrowing that such Lender does not
intend to make available to the Administrative Agent such Lender's portion of
any Borrowing to be made on such date, the Administrative Agent may assume that
such Lender has made such amount available to the Administrative Agent on such
date of Borrowing and the Administrative Agent may, in reliance upon such
assumption, make available to the relevant Borrower a corresponding amount. If
such corresponding amount is not in fact made available to the Administrative
Agent by such Lender, the Administrative Agent shall be entitled to recover such
corresponding amount on demand from such Lender. If such Lender does not pay
such corresponding amount forthwith upon the Administrative Agent's demand
therefor, the Administrative Agent shall promptly notify the relevant Borrower
to pay immediately such corresponding amount to the Administrative Agent and
such Borrower shall immediately pay such corresponding amount to the
Administrative Agent. The Administrative Agent shall also be entitled to recover
on demand from such Lender or the U.S. Borrower or the European Borrower, as the
case may be, interest on such corresponding amount in respect of each day from
the date such corresponding amount was made available by the Administrative
Agent to the respective Borrower until the date such corresponding amount is
recovered by the Administrative Agent, at a rate per annum equal to (i) if
recovered from such Lender, the

                                      -8-
<PAGE>

overnight Federal Funds Rate and (ii) if recovered from the respective Borrower,
the rate of interest applicable to the respective Borrowing, as determined
pursuant to Section 1.08. Nothing in this Section 1.04 shall be deemed to
relieve any Lender from its obligation to make Loans hereunder or to prejudice
any rights which the relevant Borrower may have against any Lender as a result
of any failure by such Lender to make Loans hereunder.

            1.05 Notes. (a) Subject to the provisions of Section 1.05(j), the
European Borrower's (in the case of European Borrower Dollar Term Loans,
European Borrower Euro Term Loans, European Borrower Multicurrency Facility
Revolving Loans and European Borrower Swingline Loans) and the U.S. Borrower's
(in the case of U.S. Borrower Term Loans, U.S. Borrower Multicurrency Facility
Revolving Loans and U.S. Borrower Swingline Loans) obligation to pay the
principal of, and interest on, the Loans made by each Lender shall be evidenced
(i) if U.S. Borrower Term Loans, by a promissory note duly executed and
delivered by the U.S. Borrower substantially in the form of Exhibit B-1 with
blanks appropriately completed in conformity herewith (each, a "U.S. Borrower
Term Note" and, collectively, the "U.S. Borrower Term Notes"), (ii) if European
Borrower Dollar Term Loans, by a promissory note duly executed and delivered by
the European Borrower substantially in the form of Exhibit B-2 with blanks
appropriately completed in conformity herewith (each, a "European Borrower
Dollar Term Note" and, collectively, the "European Borrower Dollar Term Notes"),
(iii) if European Borrower Euro Term Loans, by a promissory note duly executed
and delivered by the European Borrower substantially in the form of Exhibit B-3
with blanks appropriately completed in conformity herewith (each, a "European
Borrower Euro Term Note" and, collectively, the "European Borrower Euro Term
Notes"), (iv) if U.S. Borrower Multicurrency Facility Revolving Loans, by a
promissory note duly executed and delivered by the U.S. Borrower substantially
in the form of Exhibit B-4A, with blanks appropriately completed in conformity
herewith (each, a "U.S. Borrower Multicurrency Facility Revolving Note" and,
collectively, the "U.S. Borrower Multicurrency Facility Revolving Notes"), (v)
if European Borrower Multicurrency Facility Revolving Loans, by a promissory
note duly executed and delivered by the European Borrower substantially in the
form of Exhibit B-4B, with blanks appropriately completed in conformity herewith
(each, a "European Borrower Multicurrency Facility Revolving Note" and,
collectively, the "European Borrower Multicurrency Facility Revolving Notes"),
(vi) if U.S. Borrower Swingline Loans, by a promissory note duly executed and
delivered by the U.S. Borrower substantially in the form of Exhibit B-5A, with
blanks appropriately completed in conformity herewith (the "U.S. Borrower
Swingline Note"), and (vii) if European Borrower Swingline Loans, by a
promissory note duly executed and delivered by the European Borrower
substantially in the form of Exhibit B-5B, with blanks appropriately completed
in conformity herewith (the "European Borrower Swingline Note").

            (b) The U.S. Borrower Term Note issued to each Lender with a U.S.
Borrower Term Loan Commitment or outstanding U.S. Borrower Term Loans shall (i)
be executed by the U.S. Borrower, (ii) be payable to such Lender or its
registered assigns and be dated the Initial Borrowing Date (or, in the case of
any U.S. Borrower Term Note issued after the Initial Borrowing Date, the date of
issuance thereof), (iii) be in a stated principal amount (expressed in Dollars)
equal to the U.S. Borrower Term Loan Commitment of such Lender on the Initial
Borrowing Date before giving effect to any reductions thereto on such date (or,
in the case of any U.S. Borrower Term Note issued after the Initial Borrowing
Date, in a stated principal amount (expressed in Dollars) equal to the
outstanding principal amount of the U.S.

                                      -9-
<PAGE>

Borrower Term Loan of such Lender on the date of the issuance thereof) and be
payable (in Dollars) in the principal amount of the U.S. Borrower Term Loan
evidenced thereby from time to time, (iv) mature on the Term Loan Maturity Date,
(v) bear interest as provided in the appropriate clauses of Section 1.08 in
respect of the Base Rate Loans and Eurodollar Loans, as the case may be,
evidenced thereby, (vi) be subject to voluntary prepayment as provided in
Section 4.01 and mandatory repayment as provided in Section 4.02 and (vii) be
entitled to the benefits of this Agreement and the other Credit Documents.

            (c) The European Borrower Dollar Term Note issued to each Lender
with a European Borrower Dollar Term Loan Commitment or outstanding European
Borrower Dollar Term Loans shall (i) be executed by the European Borrower, (ii)
be payable to such Lender (or an affiliate designated by such Lender) or its
registered assigns and be dated the Initial Borrowing Date (or, in the case of
any European Borrower Dollar Term Note issued after the Initial Borrowing Date,
the date of issuance thereof), (iii) be in a stated principal amount (expressed
in Dollars) equal to the European Borrower Dollar Term Loan Commitment of such
Lender on the Initial Borrowing Date (or, in the case of any European Borrower
Dollar Term Note issued after the Initial Borrowing Date, in a stated principal
amount (expressed in Dollars) equal to the outstanding principal amount of the
European Borrower Dollar Term Loan of such Lender on the date of the issuance
thereof) and be payable (in Dollars) in the principal amount of the European
Borrower Dollar Term Loan evidenced thereby from time to time, (iv) mature on
the Term Loan Maturity Date, (v) bear interest as provided in the appropriate
clause of Section 1.08 in respect of the Base Rate Loans and Eurodollar Loans,
as the case may be, evidenced thereby, (vi) be subject to voluntary repayment as
provided in Section 4.01 and mandatory prepayment as provided in Section 4.02
and (vii) be entitled to the benefits of this Agreement and the other Credit
Documents.

            (d) The European Borrower Euro Term Note issued to each Lender with
an European Borrower Euro Term Loan Commitment or outstanding European Borrower
Euro Term Loans shall (i) be executed by the European Borrower, (ii) be payable
to such Lender (or an affiliate designated by such Lender) or its registered
assigns and be dated the Initial Borrowing Date (or, in the case of any European
Borrower Euro Term Note issued after the Initial Borrowing Date, the date of
issuance thereof), (iii) be in a stated principal amount (expressed in Euros)
equal to the European Borrower Euro Term Loan Commitment of such Lender on the
Initial Borrowing Date (or, in the case of any European Borrower Euro Term Note
issued after the Initial Borrowing Date, in a stated principal amount (expressed
in Euros) equal to the outstanding principal amount of the European Borrower
Euro Term Loan of such Lender on the date of the issuance thereof) and be
payable (in Euros) in the principal amount of the European Borrower Euro Term
Loan evidenced thereby from time to time, provided that the obligations with
respect to the European Borrower Euro Term Loan evidenced thereby shall be
subject to conversion into a Dollar Denominated Loan as provided (and in the
circumstances contemplated by) Section 1.14, (iv) mature on the Term Loan
Maturity Date, (v) bear interest as provided in the appropriate clause of
Section 1.08 in respect of the Euro Denominated Term Loans evidenced thereby,
(vi) be subject to voluntary prepayment as provided in Section 4.01 and
mandatory repayment as provided in Section 4.02 and (vii) be entitled to the
benefits of this Agreement and the other Credit Documents.

                                      -10-
<PAGE>

            (e) The U.S. Borrower Multicurrency Facility Revolving Note issued
to each Multicurrency Facility RL Lender shall (i) be executed by the U.S.
Borrower, (ii) be payable to the order of such Multicurrency Facility RL Lender
(or an affiliate designated by such Multicurrency Facility RL Lender) or its
registered assigns and be dated the Initial Borrowing Date (or, if issued
thereafter, the date of issuance thereof), (iii) be in a stated principal amount
(expressed in Dollars) equal to the Multicurrency Facility Revolving Loan
Commitment of such Multicurrency Facility RL Lender on the date of issuance
thereof (or, if issued after the termination of such Multicurrency Facility
Revolving Loan Commitment, in an amount equal to the Individual U.S. Borrower
Multicurrency Facility RL Exposure of the respective Multicurrency Facility RL
Lender), provided that if, because of fluctuations in exchange rates after the
date of issuance thereof, the U.S. Borrower Multicurrency Facility Revolving
Note of any Multicurrency Facility RL Lender would not be at least as great as
the outstanding principal amount (taking the Dollar Equivalent of all Euro
Denominated Loans evidenced thereby) of the U.S. Borrower Multicurrency Facility
Revolving Loans made by such Multicurrency Facility RL Lender at any time
outstanding, the respective Multicurrency Facility RL Lender may request (and in
such case the U.S. Borrower shall promptly execute and deliver) a new U.S.
Borrower Multicurrency Facility Revolving Note in an amount equal to the
aggregate principal amount (taking the Dollar Equivalent of all Euro Denominated
Loans evidenced thereby) of the U.S. Borrower Multicurrency Facility Revolving
Loans of such Multicurrency Facility RL Lender outstanding on the date of the
issuance of such new U.S. Borrower Multicurrency Facility Revolving Note, (iv)
with respect to each U.S. Borrower Multicurrency Facility Revolving Loan
evidenced thereby, be payable in the respective Available Currency in which such
U.S. Borrower Multicurrency Facility Revolving Loan was made, provided that the
obligations with respect to each Euro Denominated Loan evidenced thereby shall
be subject to conversion into Dollar Denominated Loans as provided in (and in
the circumstances contemplated by) Section 1.14, (v) mature on the Revolving
Loan Maturity Date, (vi) bear interest as provided in the appropriate clauses of
Section 1.08 in respect of the U.S. Borrower Multicurrency Facility Revolving
Loans evidenced thereby from time to time, (vii) be subject to voluntary
prepayment as provided in Section 4.01 and mandatory repayment as provided in
Section 4.02 and (viii) be entitled to the benefits of this Agreement and the
other Credit Documents.

            (f) The European Borrower Multicurrency Facility Revolving Note
issued to each Multicurrency Facility RL Lender shall (i) be executed by the
European Borrower, (ii) be payable to the order of such Multicurrency Facility
RL Lender (or an affiliate designated by such Multicurrency Facility RL Lender)
or its registered assigns and be dated the Initial Borrowing Date (or, if issued
thereafter, the date of issuance thereof), (iii) be in a stated principal amount
(expressed in Dollars) equal to the Multicurrency Facility Revolving Loan
Commitment of such Multicurrency Facility RL Lender on the date of issuance
thereof (or, if issued after the termination of such Multicurrency Facility
Revolving Loan Commitment, in an amount equal to the Individual European
Borrower Multicurrency Facility RL Exposure of the respective Multicurrency
Facility RL Lender), provided that if, because of fluctuations in exchange rates
after the date of issuance thereof, the European Borrower Multicurrency Facility
Revolving Note of any Multicurrency Facility RL Lender would not be at least as
great as the outstanding principal amount (taking the Dollar Equivalent of all
Euro Denominated Loans evidenced thereby) of the European Borrower Multicurrency
Facility Revolving Loans made by such Multicurrency Facility RL Lender at any
time outstanding, the respective Multicurrency Facility RL Lender may request
(and in such case the European Borrower shall promptly execute and

                                      -11-
<PAGE>

deliver) a new European Borrower Multicurrency Facility Revolving Note in an
amount equal to the aggregate principal amount (taking the Dollar Equivalent of
all Euro Denominated Loans evidenced thereby) of the European Borrower
Multicurrency Facility Revolving Loans of such Multicurrency Facility RL Lender
outstanding on the date of the issuance of such new European Borrower
Multicurrency Facility Revolving Note, (iv) with respect to each European
Borrower Multicurrency Facility Revolving Loan evidenced thereby, be payable in
the respective Available Currency in which such European Borrower Multicurrency
Facility Revolving Loan was made, provided that the obligations with respect to
each Euro Denominated Loan evidenced thereby shall be subject to conversion into
Dollar Denominated Loans as provided in (and in the circumstances contemplated
by) Section 1.14, (v) mature on the Revolving Loan Maturity Date, (vi) bear
interest as provided in the appropriate clauses of Section 1.08 in respect of
the European Borrower Multicurrency Facility Revolving Loans evidenced thereby
from time to time, (vii) be subject to voluntary prepayment as provided in
Section 4.01 and mandatory repayment as provided in Section 4.02 and (viii) be
entitled to the benefits of this Agreement and the other Credit Documents.

            (g) The U.S. Borrower Swingline Note issued to the Swingline Lender
shall (i) be executed by the U.S. Borrower, (ii) be payable to the order of the
Swingline Lender and be dated the Initial Borrowing Date (or, if issued
thereafter, the date of the issuance thereof), (iii) be in a stated principal
amount (expressed in Dollars) equal to the Maximum Swingline Amount, provided
that if, because of fluctuations in exchange rates after the date of issuance
thereof, the U.S. Borrower Swingline Note would not be at least as great as the
outstanding principal amount (taking the Dollar Equivalent of all U.S. Borrower
Swingline Loans denominated in Euros) of U.S. Borrower Swingline Loans at any
time outstanding, the Swingline Lender may request that the U.S. Borrower (and
in such case the U.S. Borrower shall) promptly execute and deliver a new U.S.
Borrower Swingline Note in an amount equal to the aggregate principal amount
(taking the Dollar Equivalent of all U.S. Borrower Swingline Loans outstanding
in Euros) of U.S. Borrower Swingline Loans outstanding, (iv) be payable with
respect to each U.S. Borrower Swingline Loan in the respective Available
Currency in which such U.S. Borrower Swingline Loan was made, provided that the
obligations evidenced by the U.S. Borrower Swingline Note with respect to U.S.
Borrower Swingline Loans incurred in Euros shall be subject to conversion into
Dollar Denominated Loans as provided in (and in the circumstances contemplated
by) Section 1.14, (v) mature on the Swingline Expiry Date, (vi) bear interest as
provided in the appropriate clause of Section 1.08 in respect of the U.S.
Borrower Swingline Loans evidenced thereby from time to time, (vii) be subject
to voluntary prepayment as provided in Section 4.01 and mandatory repayment as
provided in Section 4.02 and (viii) be entitled to the benefits of this
Agreement and the other Credit Documents.

            (h) The European Borrower Swingline Note issued to the Swingline
Lender shall (i) be executed by the European Borrower, (ii) be payable to the
order of the Swingline Lender and be dated the Initial Borrowing Date (or, if
issued thereafter, the date of the issuance thereof), (iii) be in a stated
principal amount (expressed in Dollars) equal to the Maximum Swingline Amount,
provided that if, because of fluctuations in exchange rates after the date of
issuance thereof, the European Borrower Swingline Note would not be at least as
great as the outstanding principal amount (taking the Dollar Equivalent of all
European Borrower Swingline Loans denominated in Euros) of European Borrower
Swingline Loans at any time outstanding, the Swingline Lender may request that
the European Borrower (and in such case the European

                                      -12-
<PAGE>

Borrower shall) promptly execute and deliver a new European Borrower Swingline
Note in an amount equal to the aggregate principal amount (taking the Dollar
Equivalent of all European Borrower Swingline Loans outstanding in Euros) of
European Borrower Swingline Loans outstanding, (iv) be payable with respect to
each European Borrower Swingline Loan in the respective Available Currency in
which such European Borrower Swingline Loan was made, provided that the
obligations evidenced by the European Borrower Swingline Note with respect to
European Borrower Swingline Loans incurred in Euros shall be subject to
conversion into Dollar Denominated Loans as provided in (and in the
circumstances contemplated by) Section 1.14, (v) mature on the Swingline Expiry
Date, (vi) bear interest as provided in the appropriate clause of Section 1.08
in respect of the European Borrower Swingline Loans evidenced thereby from time
to time, (vii) be subject to voluntary prepayment as provided in Section 4.01
and mandatory repayment as provided in Section 4.02 and (viii) be entitled to
the benefits of this Agreement and the other Credit Documents.

            (i) Each Lender will note on its internal records the amount of each
Loan made by it and each payment in respect thereof and will prior to any
transfer of any of its Notes endorse on the reverse side thereof the outstanding
principal amount of Loans evidenced thereby. Failure to make any such notation
or any error in any such notation or endorsement shall not affect either
Borrower's obligations in respect of any Loans.

            (j) Notwithstanding anything to the contrary contained above or
elsewhere in this Agreement, Notes shall only be delivered to Lenders that at
any time specifically request the delivery of such Notes. No failure of any
Lender to request or obtain a Note evidencing its Loans to either Borrower shall
affect or in any manner impair the obligations of the respective Borrower to pay
the Loans (and all related Obligations) which would otherwise be evidenced
thereby in accordance with the requirements of this Agreement, and shall not in
any way affect the security or guaranties therefor provided pursuant to the
various Credit Documents. Any Lender that does not have a Note evidencing its
outstanding Loans shall in no event be required to make the notations otherwise
described in preceding clause (i). At any time when any Lender requests the
delivery of a Note to evidence any of its Loans, the relevant Borrower shall
promptly execute and deliver to the respective Lender the requested Note or
Notes in the appropriate amount or amounts to evidence such Loans.

            1.06 Conversions. Each Borrower shall have the option to convert, on
any Business Day occurring after the Initial Borrowing Date, all or a portion
equal to at least the applicable Minimum Borrowing Amount (and, if greater, in
an integral multiple of $500,000) of the outstanding principal amount of Dollar
Denominated Loans (other than Dollar Denominated Swingline Loans, which shall at
all times be maintained as Base Rate Loans) made pursuant to one or more
Borrowings of one or more Types of Dollar Denominated Loans under a single
Tranche into a Borrowing or Borrowings of another Type of Dollar Denominated
Loan under such Tranche, provided that (i) except as otherwise provided in
Section 1.10(b) or unless the respective Borrower pays all amounts owing
pursuant to Section 1.11 concurrently with any such conversion, Eurodollar Loans
may be converted into Base Rate Loans only on the last day of an Interest Period
applicable to the Eurodollar Loans being converted and no such partial
conversion of Eurodollar Loans shall reduce the outstanding principal amount of
such Eurodollar Loans made pursuant to a single Borrowing to less than the
applicable Minimum Borrowing Amount applicable thereto, (ii) unless the Required
Lenders otherwise agree, Base Rate Loans may only

                                      -13-
<PAGE>

be converted into Eurodollar Loans if no Default or Event of Default is in
existence on the date of conversion, (iii) unless the Administrative Agent has
determined that the Syndication Date has occurred (at which time this clause
(iii) shall no longer be applicable), prior to the 60th day after the Initial
Borrowing Date, conversions of Base Rate Loans into Eurodollar Loans may only be
made if any such conversion is effective on the first day of an Interest Period
referred to in clause (B) of the proviso of Section 1.01(a)(iii) or 1.01(b)(iii)
or clause (B)(1) of the proviso to Section 1.01(d)(ii) and so long as such
conversion does not result in a greater number of Borrowings of Eurodollar Loans
prior to the 60th day after the Initial Borrowing Date as are permitted under
the provisos to Sections 1.01(a)(iii) and 1.01(b)(iii) and clause (1) of Section
1.01(d)(ii) and (iv) no conversion pursuant to this Section 1.06 shall result in
a greater number of Borrowings of Euro Rate Loans than is permitted under
Section 1.02. Each such conversion shall be effected by a Borrower by giving the
Administrative Agent at its Notice Office prior to 2:00 P.M. (New York time) at
least three Business Days' prior notice (each, a "Notice of
Conversion/Continuation") in the form of Exhibit A-2, appropriately completed to
specify the Dollar Denominated Loans to be so converted, the Borrowing or
Borrowings pursuant to which such Dollar Denominated Loans were made and, if to
be converted into Eurodollar Loans, the Interest Period to be initially
applicable thereto. The Administrative Agent shall give each Lender prompt
notice of any such proposed conversion affecting any of its Dollar Denominated
Loans.

            1.07 Pro Rata Borrowings. All Borrowings of U.S. Borrower Term
Loans, European Borrower Dollar Term Loans, European Borrower Euro Term Loans
and Multicurrency Facility Revolving Loans (including U.S. Borrower
Multicurrency Facility Revolving Loans, European Borrower Multicurrency Facility
Revolving Loans and Mandatory Borrowings) under this Agreement shall be incurred
from the Lenders pro rata on the basis of such Lenders' U.S. Borrower Term Loan
Commitments, European Borrower Dollar Term Loan Commitments, European Borrower
Euro Term Loan Commitments or Multicurrency Facility RL Percentages, as the case
may be. All Borrowings of Swingline Loans shall be incurred from the Swingline
Lender. It is understood that no Lender shall be responsible for any default by
any other Lender of its obligation to make Loans hereunder and that each Lender
shall be obligated to make the Loans provided to be made by it hereunder,
regardless of the failure of any other Lender to make its Loans hereunder.

            1.08 Interest. (a) The U.S. Borrower hereby agrees to pay (in the
case of U.S. Borrower Term Loans, U.S. Borrower Multicurrency Facility Revolving
Loans and U.S. Borrower Swingline Loans, in each case maintained as Base Rate
Loans (including any Euro Denominated Loan made to the U.S. Borrower and
converted into a Dollar Denominated Loan pursuant to Section 1.14)) and the
European Borrower hereby agrees to pay (in the case of European Borrower Dollar
Term Loans, European Borrower Euro Term Loans, European Borrower Multicurrency
Facility Revolving Loans and European Borrower Swingline Loans, in each case
maintained as Base Rate Loans (including any Euro Denominated Loan made to the
European Borrower and converted into a Dollar Denominated Loan pursuant to
Section 1.14)), interest in respect of the unpaid principal amount of each Base
Rate Loan made to it from the date the proceeds thereof are made available to it
(or, in the case of a conversion of any Euro Denominated Loan into a Dollar
Denominated Loan pursuant to Section 1.14, from the date of the conversion of
such Loan) until the earlier of (i) the maturity (whether by acceleration or
otherwise) of such Base Rate Loan and (ii) the conversion of such Base Rate Loan
to a Eurodollar Loan pursuant to Section 1.06, at a rate per annum which shall
be equal to the sum of

                                      -14-
<PAGE>

the Base Rate in effect from time to time during the period such Base Rate Loan
is outstanding plus the relevant Applicable Margin as in effect from time to
time.

            (b) The U.S. Borrower hereby agrees to pay (in the case of U.S.
Borrower Term Loans and U.S. Borrower Multicurrency Facility Revolving Loans
maintained as Eurodollar Loans) and the European Borrower hereby agrees to pay
(in the case of European Borrower Dollar Term Loans and European Borrower
Multicurrency Facility Revolving Loans maintained as Eurodollar Loans), interest
in respect of the unpaid principal amount of each Eurodollar Loan made to it
from the date the proceeds thereof are made available to it until the earlier of
(i) the maturity (whether by acceleration or otherwise) of such Eurodollar Loan
and (ii) the conversion of such Eurodollar Loan to a Base Rate Loan pursuant to
Section 1.06, 1.09 or 1.10, as applicable, at a rate per annum which shall,
during each Interest Period applicable thereto, be equal to the sum of the
Eurodollar Rate for such Interest Period plus the relevant Applicable Margin as
in effect from time to time.

            (c) Each Borrower hereby agrees to pay interest in respect of the
unpaid principal amount of each Euro Denominated Revolving Loan and each Euro
Denominated Term Loan made to it from the date the proceeds thereof are made
available to it until the maturity thereof (whether by acceleration, prepayment
or otherwise) at a rate per annum which shall, during each Interest Period
applicable thereto, be equal to the sum of the relevant Applicable Margin as in
effect from time to time plus Euro LIBOR for such Interest Period plus any
Mandatory Costs.

            (d) Each Borrower hereby agrees to pay interest in respect of the
unpaid principal amount of each Euro Denominated Swingline Loan made to it from
the date the proceeds thereof are made available to it until the maturity
thereof (whether by acceleration, prepayment or otherwise) at a rate per annum
which shall be equal to the sum of the Applicable Margin for Euro Denominated
Revolving Loans as in effect from time to time plus the Overnight Euro Rate in
effect from time to time during the period such Euro Denominated Swingline Loan
is outstanding plus any Mandatory Costs.

            (e) Overdue principal and, to the extent permitted by law, overdue
interest in respect of each Loan and any other overdue amount payable hereunder
shall, in each case, bear interest at a rate per annum (1) in the case of
overdue principal of, and interest or other overdue amounts owing with respect
to, Euro Denominated Revolving Loans, Euro Denominated Term Loans and overdue
amounts owing with respect to Euro Denominated Letter of Credit Outstandings,
equal to 2% per annum in excess of the relevant Applicable Margin as in effect
from time to time plus Euro LIBOR for such successive periods not exceeding
three months as the Administrative Agent may determine from time to time in
respect of amounts comparable to the amount not paid plus any Mandatory Costs,
(2) in the case of overdue principal of, and interest or other amounts owing
with respect to, Euro Denominated Swingline Loans, equal to 2% per annum in
excess of the Applicable Margin for Euro Denominated Revolving Loans as in
effect from time to time plus the Overnight Euro Rate as in effect from time to
time plus any Mandatory Costs, and (3) in all other cases, equal to the greater
of (x) 2% per annum in excess of the rate otherwise applicable to Base Rate
Loans maintained pursuant to the respective Tranche (or, if the overdue amount
owing does not relate to any specific Tranche, the rate otherwise applicable to
Multicurrency Facility Revolving Loans which are maintained as Base Rate Loans)

                                      -15-
<PAGE>

from time to time and (y) the rate which is 2% in excess of the rate then borne
by such Loans, in each case with such interest to be payable on demand.

            (f) Accrued (and theretofore unpaid) interest shall be payable (i)
in respect of each Base Rate Loan and each Swingline Loan, quarterly in arrears
on each Quarterly Payment Date, (ii) in respect of each Euro Rate Loan (other
than a Euro Denominated Swingline Loan), on the last day of each Interest Period
applicable thereto and, in the case of an Interest Period in excess of three
months, on each date occurring at three month intervals after the first day of
such Interest Period and (iii) in respect of each Loan, on any repayment or
prepayment (on the amount repaid or prepaid) (except that repayments of
Multicurrency Facility Revolving Loans and Swingline Loans shall not be required
to be accompanied by a payment of accrued, and theretofore unpaid, interest
thereon, unless the Total Multicurrency Facility Revolving Loan Commitment has
terminated or will be terminated concurrently with such repayment or
prepayment), at maturity (whether by acceleration or otherwise) and, after such
maturity, on demand.

            (g) Upon each Interest Determination Date, the Administrative Agent
shall determine the Euro Rate for the respective Interest Period or Interest
Periods and shall promptly notify the respective Borrower and the respective
Lenders thereof. Each such determination shall, absent manifest error, be final
and conclusive and binding on all parties hereto.

            1.09 Interest Periods. At the time a Borrower gives any Notice of
Borrowing or Notice of Conversion/Continuation in respect of the making of, or
conversion into, any Euro Rate Loan (other than a Euro Denominated Swingline
Loan) (in the case of the initial Interest Period applicable thereto) or on the
third Business Day prior to the expiration of an Interest Period applicable to
such Euro Rate Loan (in the case of any subsequent Interest Period), the
respective Borrower shall have the right to elect, by having an Authorized
Officer of such Borrower give the Administrative Agent notice thereof, the
interest period (each, an "Interest Period") applicable to such Euro Rate Loan,
which Interest Period shall, at the option of such Borrower (but otherwise
subject to clause (B) of Sections 1.01(a)(iii), 1.01(b)(iii) and 1.01(c)(iii)
and clause (B) of the proviso to Section 1.01(d)(ii) and clause (iii) of the
proviso appearing in Section 1.06) be a one, two, three or six-month period or,
to the extent agreed to by all Lenders required to make Loans under the
respective Tranche, a nine or twelve-month period (or, in each case during the
period ended on the first to occur of the Syndication Date or the 60th day after
the Initial Borrowing Date, such shorter periods as may be required by the
Administrative Agent);

            (i) all Euro Rate Loans comprising the same Borrowing shall at all
      times have the same Interest Period;

            (ii) the initial Interest Period for any Euro Rate Loan shall
      commence on the date of Borrowing of such Euro Rate Loan (including, in
      the case of Dollar Denominated Loans, the date of any conversion thereto
      from a Borrowing of Base Rate Loans) and each Interest Period occurring
      thereafter in respect of such Euro Rate Loan shall commence on the day on
      which the next preceding Interest Period applicable thereto expires;

                                      -16-
<PAGE>

            (iii) if any Interest Period relating to a Euro Rate Loan begins on
      a day for which there is no numerically corresponding day in the calendar
      month at the end of such Interest Period, such Interest Period shall end
      on the last Business Day of such calendar month;

            (iv) if any Interest Period for a Euro Rate Loan would otherwise
      expire on a day which is not a Business Day, such Interest Period shall
      expire on the next succeeding Business Day; provided, however, that if any
      Interest Period for a Euro Rate Loan would otherwise expire on a day which
      is not a Business Day but is a day of the month after which no further
      Business Day occurs in such month, such Interest Period shall expire on
      the preceding Business Day;

            (v) no Interest Period in respect of any Borrowing under a given
      Tranche of Loans shall be selected which extends beyond the respective
      Maturity Date for such Tranche of Loans; and

            (vi) no Interest Period in respect of any Borrowing of U.S. Borrower
      Term Loans, European Borrower Dollar Term Loans or European Borrower Euro
      Term Loans shall be elected which extends beyond any date upon which a
      Scheduled Repayment for the respective Tranche of Term Loans will be
      required to be made under Section 4.02(b) if, after giving effect to the
      election of such Interest Period, the aggregate principal amount of such
      U.S. Borrower Term Loans, European Borrower Dollar Term Loans or European
      Borrower Euro Term Loans, as the case may be, which have Interest Periods
      which will expire after such date will be in excess of the aggregate
      principal amount of such U.S. Borrower Term Loans, European Borrower
      Dollar Term Loans or European Borrower Euro Term Loans, as the case may
      be, then outstanding less the aggregate amount of such required Scheduled
      Repayment.

With respect to any Euro Denominated Loans (other than Euro Denominated
Swingline Loans), at the end of any Interest Period applicable to a Borrowing
thereof, the U.S. Borrower or the European Borrower, as applicable, may elect to
split the respective Borrowing into two or more Borrowings of the same Type or
combine two or more Borrowings of the same Type into a single Borrowing, in each
case, by having an Authorized Officer of the relevant Borrower give notice
thereof together with its election of one or more Interest Periods, in each case
so long as each resulting Borrowing (x) has an Interest Period which complies
with the foregoing requirements of this Section 1.09 and (y) does not cause a
violation of the requirements of Section 1.02. If upon the expiration of any
Interest Period applicable to a Borrowing of Euro Rate Loans, the U.S. Borrower
or the European Borrower, as applicable, has failed to elect, or is not
permitted to elect, a new Interest Period to be applicable to such Euro Rate
Loans as provided above, the relevant Borrower shall be deemed to have elected
(x) if Eurodollar Loans, to convert such Eurodollar Loans into Base Rate Loans
and (y) if Euro Denominated Loans, to select a one-month Interest Period for
such Euro Denominated Loans, in any such case effective as of the expiration
date of such current Interest Period.

            1.10 Increased Costs; Illegality; etc. (a) In the event that any
Lender shall have determined in good faith (which determination shall, absent
manifest error, be final and

                                      -17-
<PAGE>

conclusive and binding upon all parties hereto but, with respect to clause (i)
below, may be made only by the Administrative Agent):

            (i) on any Interest Determination Date that, by reason of any
      changes arising after the Effective Date affecting the applicable
      interbank market, adequate and fair means do not exist for ascertaining
      the applicable interest rate on the basis provided for in the definition
      of the respective Euro Rate; or

            (ii) at any time, that such Lender shall incur increased costs or
      reductions in the amounts received or receivable hereunder with respect to
      any Euro Rate Loan because of (x) any change since the Effective Date in
      any applicable law or governmental rule, regulation, order, guideline or
      request (whether or not having the force of law) or in the interpretation
      or administration thereof and including the introduction of any new law or
      governmental rule, regulation, order, guideline or request, such as, for
      example, but not limited to (A) a change in the basis of taxation of
      payments to a Lender of the principal of or interest on the Loans or any
      other amounts payable hereunder (except for changes in the rate of tax on,
      or determined by reference to, the net income or net profits of such
      Lender imposed by the jurisdiction in which its principal office or
      applicable lending office is located), or (B) a change in official reserve
      requirements, but, in all events, excluding reserves required under
      Regulation D to the extent included in the computation of the Eurodollar
      Rate and/or (y) other circumstances arising since the date of this
      Agreement affecting such Lender, the interbank market or the position of
      such Lender in such market (whether or not such Lender was a Lender at the
      time of such occurrence); or

            (iii) at any time after the Effective Date, that the making or
      continuance of any Euro Rate Loan has been made unlawful by any law or
      governmental rule, regulation or order (or would conflict with any
      governmental rule, regulation, guideline, request or order not having the
      force of law but with which such Lender customarily complies even though
      the failure to comply therewith would not be unlawful), or impracticable
      as a result of a contingency occurring after the Effective Date which
      materially and adversely affects the applicable interbank market;

then, and in any such event, such Lender (or the Administrative Agent, in the
case of clause (i) above) shall promptly give notice (by telephone confirmed in
writing) to the affected Borrower, and, except in the case of clause (i) above,
to the Administrative Agent of such determination (which notice the
Administrative Agent shall promptly transmit to each of the other Lenders).
Thereafter (w) in the case of clause (i) above, (A) in the event Eurodollar
Loans are so affected, Eurodollar Loans shall no longer be available until such
time as the Administrative Agent notifies any affected Borrower and the Lenders
that the circumstances giving rise to such notice by the Administrative Agent no
longer exist, and any Notice of Borrowing or Notice of Conversion/Continuation
given by either Borrower with respect to Eurodollar Loans which have not yet
been incurred (including by way of conversion) shall be deemed rescinded by such
Borrower and (B) in the event that any Euro Denominated Loan is so affected, the
relevant Euro Rate shall be determined on the basis provided in the proviso to
the definition of Overnight Euro Rate or Euro LIBOR, as the case may be, (x) in
the case of clause (ii) above, the respective Borrower or Borrowers agrees to
pay to such Lender, upon written demand therefor, such

                                      -18-
<PAGE>

additional amounts (in the form of an increased rate of, or a different method
of calculating, interest or otherwise as such Lender in its sole discretion
shall determine) as shall be required to compensate such Lender for such
increased costs or reductions in amounts received or receivable hereunder (with
the written notice as to the additional amounts owed to such Lender, submitted
to the respective Borrower or Borrowers by such Lender in accordance with the
foregoing to be, absent manifest error, final and conclusive and binding on all
the parties hereto, although the failure to give any such notice shall not
release or diminish any of the respective Borrower's or Borrowers' obligations
to pay additional amounts pursuant to this Section 1.10(a) upon the subsequent
receipt of such notice) and (y) in the case of clause (iii) above, the
respective Borrower or Borrowers shall take one of the actions specified in
Section 1.10(b) as promptly as possible and, in any event, within the time
period required by law. Each of the Administrative Agent and each Lender agrees
that if it gives notice to either Borrower of any of the events described in
clause (i), (ii) or (iii) above, it shall promptly notify such Borrower and, in
the case of any such Lender, the Administrative Agent, if such event ceases to
exist.

            (b) At any time that any Euro Rate Loan is affected by the
circumstances described in Section 1.10(a)(ii) or (iii), the affected Borrower
may (and in the case of a Euro Rate Loan affected by the circumstances described
in Section 1.10(a)(iii) shall) either (x) if the affected Euro Rate Loan is then
being made initially or pursuant to a conversion, cancel the respective
Borrowing by giving the Administrative Agent telephonic notice (confirmed in
writing) on the same date that such Borrower was notified by the affected Lender
or the Administrative Agent pursuant to Section 1.10(a)(ii) or (iii) or (y) if
the affected Euro Rate Loan is then outstanding, upon at least three Business
Days' written notice to the Administrative Agent, (A) in the case of a
Eurodollar Loan, require the affected Lender to convert such Eurodollar Loan
into a Base Rate Loan (which conversion, in the case of the circumstance
described in Section 1.10(a)(iii), shall occur no later than the last day of the
Interest Period then applicable to such Eurodollar Loan or such earlier day as
shall be required by applicable law) and (B) in the case of any Euro Rate Loan
(other than a Eurodollar Loan), repay all outstanding Borrowings which include
such affected Euro Rate Loans in full in accordance with the applicable
requirements of Section 4.01; provided that (i) if the circumstances described
in Section 1.10(a)(iii) apply to any Euro Denominated Loan, the U.S. Borrower or
the European Borrower, as the case may be, may, in lieu of taking the actions
described above, maintain such Euro Denominated Loan outstanding, in which case,
(x) in the case of Euro Denominated Revolving Loans or Euro Denominated Term
Loans, the applicable Euro Rate shall be determined on the basis provided in the
proviso to the definition of Euro LIBOR and (y) in the case of Euro Denominated
Swingline Loans, the applicable interest rate shall be determined on the basis
provided in the proviso to the definition of Overnight Euro Rate, as the case
may be, unless the maintenance of such Euro Denominated Loan outstanding on such
basis would not stop the conditions described in Section 1.10(a)(iii) from
existing (in which case the actions described above, without giving effect to
the proviso, shall be required to be taken) and (ii) if more than one Lender is
affected at any time, then all affected Lenders must be treated the same
pursuant to this Section 1.10(b).

            (c) If any Lender shall have determined after the Effective Date
that the adoption or effectiveness after the Effective Date of any applicable
law, rule or regulation regarding capital adequacy, or any change therein, or
any change after the Effective Date in the interpretation or administration
thereof by any governmental authority, central bank or comparable agency

                                      -19-
<PAGE>

charged with the interpretation or administration thereof, or compliance by such
Lender or any corporation controlling such Lender with any request or directive
regarding capital adequacy (whether or not having the force of law) of any such
authority, central bank or comparable agency, has or would have the effect of
reducing the rate of return on such Lender's or such other corporation's capital
or assets as a consequence of such Lender's Commitment or Commitments hereunder
or its obligations hereunder to a level below that which such Lender or such
other corporation could have achieved but for such adoption, effectiveness,
change or compliance (taking into consideration such Lender's or such other
corporation's policies with respect to capital adequacy), then from time to
time, upon written demand by such Lender (with a copy to the Administrative
Agent), accompanied by the notice referred to in the next succeeding sentence of
this clause (c), and subject to Section 13.23, the Borrowers jointly and
severally agree to pay to such Lender such additional amount or amounts as will
compensate such Lender or such other corporation for such reduction in the rate
of return to such Lender or such other corporation. Each Lender, upon
determining in good faith that any additional amounts will be payable pursuant
to this Section 1.10(c), will give prompt written notice thereof to the relevant
Borrower (a copy of which shall be sent by such Lender to the Administrative
Agent), which notice shall set forth such Lender's basis for asserting its
rights under this Section 1.10(c) and the calculation, in reasonable detail, of
such additional amounts claimed hereunder, although the failure to give any such
notice shall not release or diminish either Borrower's obligations to pay
additional amounts pursuant to this Section 1.10(c) upon the subsequent receipt
of such notice. A Lender's good faith determination of compensation owing under
this Section 1.10(c) shall, absent manifest error, be final and conclusive and
binding on all the parties hereto. For the avoidance of doubt, nothing in this
Section 1.10(c) shall require either Borrower to pay to any Lender any amount
for which such Lender is compensated by way of payment of Mandatory Costs.

            (d) In the event that any Lender shall in good faith determine
(which determination shall, absent manifest error, be final and conclusive and
binding on all parties hereto) at any time that such Lender is required to
maintain reserves (including, without limitation, any marginal, emergency,
supplemental, special or other reserves required by applicable law) which have
been established by any Federal, state, local or foreign court or governmental
agency, authority, instrumentality or regulatory body with jurisdiction over
such Lender (including any branch, Affiliate or funding office thereof) in
respect of any Euro Denominated Loans or any category of liabilities which
includes deposits by reference to which the interest rate on any Euro
Denominated Loan is determined or any category of extensions of credit or other
assets which includes loans by a non-United States office of any Lender to
non-United States residents, then, unless such reserves are included in the
calculation of the interest rate applicable to such Euro Denominated Loans or in
Section 1.10(a)(ii), such Lender shall promptly notify the U.S. Borrower and/or
the European Borrower in writing specifying the additional amounts required to
indemnify such Lender against the cost of maintaining such reserves (such
written notice to provide in reasonable detail a computation of such additional
amounts) and, subject to Section 13.23, the U.S. Borrower (in the case of U.S.
Borrower Multicurrency Facility Revolving Loans and U.S. Borrower Swingline
Loans owing by it and, in each case, denominated in Euros) shall pay, and the
European Borrower (in the case of Euro Denominated Term Loans, European Borrower
Multicurrency Facility Revolving Loans and European Borrower Swingline Loans
owing by it and, in each case, denominated in Euros) shall pay, to such Lender
such specified amounts as additional interest at the time that the U.S. Borrower
or the European Borrower is

                                      -20-
<PAGE>

otherwise required to pay interest in respect of such Euro Denominated Loan or,
if later, on written demand therefor by such Lender.

            1.11 Compensation. Subject to section 13.23, the Borrowers jointly
and severally agree to compensate each Lender, upon its written request (which
request shall set forth in reasonable detail the basis for requesting such
compensation), for all losses, reasonable expenses and liabilities (including,
without limitation, any loss, expense or liability incurred by reason of the
liquidation or reemployment of deposits or other funds required by such Lender
to fund its Euro Rate Loans but excluding any loss of anticipated profit) which
such Lender may sustain: (i) if for any reason (other than a default by such
Lender or any Agent) a Borrowing of, or conversion from or into, Euro Rate Loans
does not occur on a date specified therefor in a Notice of Borrowing or Notice
of Conversion/Continuation (whether or not withdrawn by the respective Borrower
or Borrowers or deemed withdrawn pursuant to Section 1.10(a)); (ii) if any
repayment (including any repayment made pursuant to Section 4.01 or 4.02 or as a
result of an acceleration of the Loans pursuant to Section 10 or as a result of
the replacement of a Lender, other than due to a Lender Default of such Lender,
pursuant to Section 1.13, 4.01 or 13.12(b)) or conversion of any of its Euro
Rate Loans occurs on a date which is not the last day of an Interest Period
applicable thereto; (iii) if any prepayment of any of its Euro Rate Loans is not
made on any date specified in a notice of prepayment given by the respective
Borrower or Borrowers; or (iv) as a consequence of (x) any other default by the
respective Borrower to repay its Loans when required by the terms of this
Agreement or any Note held by such Lender or (y) any election made pursuant to
Section 1.10(b). Each Lender's calculation of the amount of compensation owing
pursuant to this Section 1.11 shall be made in good faith. A Lender's basis for
requesting compensation pursuant to this Section 1.11 and a Lender's calculation
of the amount thereof, shall, absent manifest error, be final and conclusive and
binding on all parties hereto.

            1.12 Change of Lending Office. (a) Each Lender may at any time or
from time to time designate, by written notice to the Administrative Agent to
the extent not already reflected on Schedule II, one or more lending offices
(which, for this purpose, may include Affiliates of the respective Lender) for
the various Loans made, and Letters of Credit participated in, by such Lender
(including, without limitation, by designating a separate lending office (or
Affiliate) to act as such with respect to Dollar Denominated Loans and Dollar
Denominated Letter of Credit Outstandings or Euro Denominated Loans and Euro
Denominated Letter of Credit Outstandings); provided that, for designations made
after the Effective Date (unless such designation is made after the occurrence
of a Sharing Event as a result of any Lender's purchase of Loans pursuant to
Section 1.14), to the extent such designation shall result in increased costs
under Section 1.10, 2.06 or 4.04 in excess of those which would be charged in
the absence of the designation of a different lending office (including a
different Affiliate of the respective Lender), then the Borrowers shall not be
obligated to pay such excess increased costs (although if such designation
results in increased costs, the Borrowers shall be obligated to pay the costs
which would have applied in the absence of such designation and any subsequent
increased costs of the type described above resulting from changes after the
date of the respective designation). Except as provided in the immediately
preceding sentence, each lending office and Affiliate of any Lender designated
as provided above shall, for all purposes of this Agreement, be treated in the
same manner as the respective Lender (and shall be entitled to all indemnities
and similar provisions in respect of its acting as such hereunder).

                                      -21-
<PAGE>

            (b) Each Lender agrees that upon the occurrence of any event giving
rise to the operation of Section 1.10(a)(ii) or (iii), Section 1.10(c), Section
2.06 or Section 4.04 with respect to such Lender, it will, if requested by the
applicable Borrower by notice to such Lender, use reasonable efforts (subject to
overall policy considerations of such Lender) to designate another lending
office for any Loans or Letters of Credit affected by such event, provided that
such designation is made on such terms that such Lender and its lending office
suffer no economic, legal or regulatory disadvantage, with the object of
avoiding the consequence of the event giving rise to the operation of such
Section. Nothing in this Section 1.12 shall affect or postpone any of the
obligations of either Borrower or the rights of any Lender provided in Sections
1.10, 2.06 and 4.04.

            1.13 Replacement of Lenders. (x) If any Lender becomes a Defaulting
Lender, (y) upon the occurrence of any event giving rise to the operation of
Section 1.10(a)(ii) or (iii), Section 1.10(c) or (d), Section 2.06 or Section
4.04 with respect to any Lender which results in such Lender charging to either
Borrower increased costs materially in excess of the average costs being charged
by the other Lenders in respect of such contingency or (z) in the case of a
refusal by a Lender to consent to a proposed change, waiver, discharge or
termination with respect to this Agreement which has been approved by the
Required Lenders as provided in Section 13.12(b), the U.S. Borrower shall have
the right, in accordance with the requirements of Section 13.04(b), if no Event
of Default then exists or would exist after giving effect to such replacement,
to replace such Lender (the "Replaced Lender") with one or more Eligible
Transferees (collectively, the "Replacement Lender"), none of whom shall
constitute a Defaulting Lender at the time of such replacement and each of whom
shall be reasonably acceptable to the Administrative Agent or, in the case of a
replacement as provided in Section 13.12(b) where the consent of the respective
Lender is required with respect to less than all Tranches of its Loans or
Commitments, at the option of the U.S. Borrower, to replace only the Commitments
and/or outstanding Loans of such Lender in respect of each Tranche where the
consent of such Lender would otherwise be individually required, with identical
Commitments and/or Loans of the respective Tranche provided by the Replacement
Lender; provided that:

            (i) at the time of any replacement pursuant to this Section 1.13,
      the Replacement Lender shall enter into one or more Assignment and
      Assumption Agreements pursuant to Section 13.04(b) (and with all fees
      payable pursuant to said Section 13.04(b) to be paid by the Replacement
      Lender) pursuant to which the Replacement Lender shall acquire all of the
      Commitments and all then outstanding Loans (or, in the case of the
      replacement of less than all the Tranches of Commitments and outstanding
      Loans of the respective Replaced Lender, all the Commitments and/or all
      then outstanding Loans relating to the Tranche or Tranches with respect to
      which such Lender is being replaced) of, and all participations in all
      then outstanding Letters of Credit issued pursuant to the respective
      Tranche or Tranches where the respective Lender is being replaced by, the
      Replaced Lender and, in connection therewith, shall pay to (w) the
      Replaced Lender in respect thereof an amount equal to the sum (in the
      relevant currency or currencies) of (A) an amount equal to the principal
      of, and all accrued interest on, all then outstanding Loans of the
      respective Replaced Lender under each Tranche with respect to which such
      Replaced Lender is being replaced, (B) an amount equal to all Unpaid
      Drawings (if any) under each Tranche with respect to which the respective
      Replaced Lender is being replaced, in each case that have been funded by
      (and not

                                      -22-
<PAGE>

      reimbursed to) such Replaced Lender at such time, together with all then
      unpaid interest with respect thereto at such time and (C) an amount equal
      to all accrued, but theretofore unpaid, Fees owing to the Replaced Lender
      (but only with respect to the relevant Tranche or Tranches, in the case of
      the replacement of less than all Tranches then held by the respective
      Replaced Lender) pursuant to Section 3.01, (x) in the case of the
      replacement of any Multicurrency Facility Revolving Loan Commitment, the
      respective Issuing Lender amounts equal to such Replaced Lender's
      Multicurrency Facility RL Percentage of any Unpaid Drawings pursuant to
      Letters of Credit issued pursuant to the respective Tranche evidenced by
      such Commitments (which at such time remain Unpaid Drawings) with respect
      to Letters of Credit issued by such Issuing Lender to the extent such
      amount was not theretofore funded by such Replaced Lender and (y) in the
      case of any replacement of Multicurrency Facility Revolving Loan
      Commitments, the Swingline Lender an amount equal to such Replaced
      Lender's pro rata share of any Mandatory Borrowing (determined in
      accordance with Sections 1.01(f), as appropriate, and 1.07), to the extent
      such amount was not theretofore funded by such Replaced Lender, without
      duplication; and

            (ii) all obligations of the Borrowers owing to the Replaced Lender
      in respect of each Tranche where such Replaced Lender is being replaced
      (other than those specifically described in clause (i) above in respect of
      which the assignment purchase price has been, or is concurrently being,
      paid) shall be paid in full to such Replaced Lender concurrently with such
      replacement.

Upon the execution of the respective Assignment and Assumption Agreement, the
payment of amounts referred to in clauses (i) and (ii) above, recordation of the
assignment on the Register by the Administrative Agent pursuant to Section 13.17
and, if so requested by the Replacement Lender (when applicable), delivery to
the Replacement Lender of the appropriate Note or Notes executed by the
respective Borrower, (x) the Replacement Lender shall become a Lender hereunder
and, unless the respective Replaced Lender continues to have outstanding Term
Loans or any Commitment hereunder, the Replaced Lender shall cease to constitute
a Lender hereunder, except with respect to indemnification provisions under this
Agreement (including, without limitation, Sections 1.10, 1.11, 2.06, 4.04, 13.01
and 13.06), which shall survive as to such Replaced Lender and (y) in the case
of the replacement of any Multicurrency Facility Revolving Loan Commitment
pursuant to this Section 1.13, the Multicurrency Facility RL Percentages of the
Lenders shall be automatically adjusted at such time to give effect to such
replacement. In connection with any replacement of Lenders pursuant to, and as
contemplated by, this Section 1.13, the European Borrower hereby irrevocably
authorizes the U.S. Borrower to take all necessary action, in the name of the
European Borrower, as described above in this Section 1.13 in order to effect
the replacement of the respective Lender or Lenders in accordance with the
preceding provisions of this Section 1.13.

            1.14 Special Provisions Applicable to Lenders Upon the Occurrence of
a Sharing Event. (a) On the date of the occurrence of a Sharing Event,
automatically (and without the taking of any action) (x) all then outstanding
Euro Denominated Loans and all Unpaid Drawings in respect of Letters of Credit
issued for either Borrower's account owed in Euros, shall be automatically
converted into Loans of the respective Tranche maintained in or Unpaid Drawings
of the respective Tranche owing in, Dollars (in an amount equal to the Dollar
Equivalent of the

                                      -23-
<PAGE>

aggregate principal amount of the respective Loans or Unpaid Drawings on the
date such Sharing Event first occurred, which Loans and Unpaid Drawings (i)
shall continue to be owed by the U.S. Borrower or the European Borrower, as the
case may be, (ii) shall at all times thereafter be deemed to be Base Rate Loans
and (iii) shall be immediately due and payable on the date such Sharing Event
has occurred) and (y) all principal, accrued and unpaid interest and other
amounts owing with respect to such Euro Denominated Loans and Unpaid Drawings
shall be immediately due and payable in Dollars, in the Dollar Equivalent of
such principal, accrued and unpaid interest and other amounts. The occurrence of
any conversion of Euro Denominated Loans or Unpaid Drawing to Base Rate Loans as
provided above in this Section 1.14(a) shall be deemed to constitute, for
purposes of Section 1.11, a prepayment of Loans before the last day of any
Interest Period relating thereto.

            (b) On the date of the occurrence of any Sharing Event, (i) if any
Swingline Loans are outstanding, a Mandatory Borrowing shall be made by the
respective Multicurrency Facility Lenders in accordance with the provisions of
Section 1.01(f) and (ii) if there have been any Drawings pursuant to Letters of
Credit which have not yet been reimbursed to the respective Issuing Lender
pursuant to Section 2, the various L/C Participants in the respective Letters of
Credit shall make payments to the Issuing Lender therefor in accordance with the
requirements of Section 2.04. Each Lender which is required to make payments
pursuant to the immediately preceding sentence shall be obligated to do so in
accordance with the terms of this Agreement. For purposes of making calculations
pursuant to the following provisions of this Section 1.14, such payments shall
be deemed to have been made on the date of the occurrence of the Sharing Event,
before making such calculations. Notwithstanding anything to the contrary
contained in the immediately preceding sentence, any Lender which has failed, or
fails, to make any payments required to be made by it as described in this
clause (b) (and/or the other relevant Sections of this Agreement) shall remain
obligated to make such payments, together with interest thereon, and shall be
obligated to the Swingline Lender or the respective Issuing Lender, as the case
may be, for any damages caused by its delay or failure in making any payments
required to be made by it as described above.

            (c) In the event that upon the occurrence of a Sharing Event any
Letter of Credit shall be outstanding and undrawn in whole or in part, each
Multicurrency Facility RL Lender shall on the date of the occurrence of such
Sharing Event, but before giving effect to the purchases and sales of
participations on such date pursuant to Section 1.14(d), promptly pay over to
the Administrative Agent, in immediately available funds in the currency in
which such Letter of Credit is denominated, an amount equal to such
Multicurrency Facility RL Lender's Multicurrency Facility RL Percentage of such
undrawn face amount, together with interest thereon (denominated in the relevant
currency) from the date of the Sharing Event to the date on which such amount
shall be paid to the Administrative Agent at a rate per annum equal to that rate
determined by the Administrative Agent in accordance with banking industry rules
or practice on interbank compensation. The Administrative Agent shall establish
a separate account or accounts for each Multicurrency Facility RL Lender in an
amount equal to the amount received from such Lender pursuant to the preceding
sentence. The Administrative Agent shall have sole dominion and control over
each such account (each, a "Special Reserve Account"), and the amounts deposited
in each Special Reserve Account shall be held in such Special Reserve Account
until withdrawn as provided in clause (e), (f) or (g) below in this Section
1.14. The Administrative Agent shall maintain records enabling it to determine
the amounts paid over to it

                                      -24-
<PAGE>

and deposited in the Special Reserve Accounts. As amounts are drawn under
outstanding Letters of Credit in respect of which amounts have been paid into
the various Special Reserve Accounts pursuant to this Section 1.14(c), amounts
shall be drawn ratably from the Special Reserve Accounts of the various
Multicurrency Facility RL Lenders (in accordance with their Multicurrency
Facility RL Percentages) to pay such amounts. The amounts paid to the
Administrative Agent pursuant to this clause (c) shall be held as a reserve
against the Letter of Credit Outstandings, shall not constitute Loans or
extensions of credit to either Borrower and shall not give rise to any
obligation on the part of either Borrower to pay interest to any Lender, it
being agreed that the Borrowers' reimbursement obligations in respect of Letters
of Credit shall arise only at such times as drawings or payments are made
thereunder as provided in Section 2.04.

            (d) Upon the occurrence of a Sharing Event, but after giving effect
to the actions required to be taken pursuant to preceding clause (a) through (c)
(although any failure by any Lender to take the actions required of it pursuant
to said clauses shall not prevent the actions required hereby, but the
respective Lender shall continue to be obligated to perform its obligations as
required above and the Administrative Agent shall be authorized to make any
equitable adjustments as may be deemed necessary or desirable pursuant to
following clause (h) of this Section 1.14), the Lenders shall purchase
participations from other Lenders in the respective Tranches of Loans
(including, in the case of the Total Multicurrency Facility Revolving Loan
Commitment, participations in each outstanding Letter of Credit and each Unpaid
Drawing) so that, after giving effect to such purchases, each Lender shall have
the same credit exposure in each Tranche, at such time (including, (x) in the
case of the Total Multicurrency Facility Revolving Loan Commitment, a
participation in each outstanding Letter of Credit and each Unpaid Drawing and
(y) a participation in each Special Reserve Account established pursuant to
Section 1.14(c) and all amounts deposited therein from time to time or to be
returned to the Lenders in accordance with the provisions of Section 1.14(f)),
whether or not such Lender shall previously have participated therein, equal to
such Lender's Exchange Percentage thereof. The foregoing actions shall be
accomplished pursuant to this clause (d) through purchases and sales of
participations in the various Tranches as required hereby, and at the request of
the Administrative Agent each Lender hereby agrees to enter into customary
participation agreements approved by the Administrative Agent to evidence same.
All purchases and sales of participations pursuant to this Section 1.14(d) shall
be made in Dollars. At the request of the Administrative Agent, each Lender
which has sold participations in any of its Tranches and/or Special Reserve
Accounts as provided above (through the Administrative Agent) will deliver to
each Lender (through the Administrative Agent) which has so purchased a
participation therein a participation certificate in the appropriate amount as
determined in conjunction with the Administrative Agent. It is understood that
the amount of funds delivered by each Lender shall be calculated on a net basis,
giving effect to both the sales and purchases of participations by the various
Lenders as required above.

            (e) In the event that after the occurrence of a Sharing Event any
drawing or payment shall be made in respect of a Letter of Credit, the
Administrative Agent shall, at the request of the respective Issuing Lender,
withdraw from the Special Reserve Account of each of the Lenders (in accordance
with each Lender's Multicurrency Facility RL Percentage) any amounts, up to the
amount of such drawing or payment, deposited in the respective Special Reserve
Account and remaining on deposit and deliver such amounts to such Issuing Lender
in

                                      -25-
<PAGE>

satisfaction of the reimbursement obligations of the various Multicurrency
Facility RL Lenders under Section 2.04(c) (but not of the applicable Borrower
under Section 2.05(a)). In the event that any Lender shall default on its
obligation to pay over any amount to the Administrative Agent in respect of any
Letter of Credit as provided in Section 1.14(c), the respective Issuing Lender
shall, in the event of a drawing or payment thereunder, have a claim against
such Lender to the same extent as if such Lender had defaulted on its
obligations under Section 2.04(c) but shall have no claim against any other
Lender, notwithstanding the exchange of interests in the applicable Borrower's
reimbursement obligations pursuant to Section 1.14(d). Each other Lender shall
have a claim against such defaulting Lender for any damages sustained by it as a
result of such default.

            (f) In the event that after the occurrence of a Sharing Event any
Letter of Credit shall terminate or expire undrawn or unpaid upon, then, if and
so long as the Administrative Agent determines (in its reasonable discretion)
that adequate funds remain on deposit in the Special Reserve Accounts of the
various Multicurrency Facility RL Lenders to fund (without giving effect to the
purchases of participation pursuant to Section 1.14(d)) all remaining drawings
or payments which could come due in respect of outstanding Letters of Credit,
the Administrative Agent shall withdraw from the Special Reserve Account of each
Lender the amount remaining on deposit therein in respect of such Letter of
Credit (or in any case, such lesser amount as the Administrative Agent
reasonably determines can be distributed without causing the amount on deposit
from the various Multicurrency Facility RL Lenders to be less than the remaining
exposure on outstanding Letters of Credit) and distribute such amount to such
Lender, provided that, if such amount is not denominated in Dollars, the
Administrative Agent shall distribute to each such Lender the Dollar Equivalent
of such amount. All amounts received by any Lender pursuant to this clause (f)
shall, to the extent it has sold participations therein in accordance with the
requirements of Section 1.14(d), be distributed by it to the various
participants therein in accordance with their participating interests.

            (g) Pending the withdrawal of any amounts from its Special Reserve
Account as contemplated above in this Section 1.14, the Administrative Agent
may, and shall, at the direction of the Required Lenders and subject to such
rules as the Administrative Agent may prescribe for the avoidance of
inconvenience, invest such amounts in Cash Equivalents.

            (h) All determinations by the Administrative Agent pursuant to this
Section 1.14 shall be made by it in accordance with the provisions herein and
with the intent being to equitably share the credit risk for all Tranches
hereunder in accordance with the provisions hereof. Absent manifest error, all
determinations by the Administrative Agent hereunder shall be binding on the
Borrowers and each of the Lenders. The Administrative Agent shall have no
liability to either Borrower or Lender hereunder for any determinations made by
it hereunder except to the extent resulting from the Administrative Agent's
gross negligence or willful misconduct (as determined by a court of competent
jurisdiction in a final and non-appealable decision).

            (i) Upon, and after, the occurrence of a Sharing Event (i) no
further Credit Events shall be made or occur, (ii) all amounts from time to time
accruing with respect to, and all amounts from time to time payable on account
of, Euro Denominated Loans (including, without limitation, any interest and
other amounts which were accrued but unpaid on the date of such

                                      -26-
<PAGE>

Sharing Event) shall be payable in Dollars (taking the Dollar Equivalents of all
such amounts on the date of the occurrence of the respective Sharing Event, with
all calculations for periods after the Sharing Event being made as if the
respective such Loan had originally been made in Dollars) and shall be
distributed by the Administrative Agent for the account of the Lenders which
made such Loans or are participating therein and (iii) all Multicurrency
Facility Revolving Loan Commitments of all the Multicurrency Facility RL Lenders
shall be automatically terminated. Notwithstanding anything to the contrary
contained above, the failure of any Lender to purchase its participating
interests as required above in any extensions of credit upon the occurrence of a
Sharing Event shall not relieve any other Lender of its obligation hereunder to
purchase its participating interests in a timely manner, but no Lender shall be
responsible for the failure of any other Lender to purchase the participating
interest to be purchased by such other Lender on any date.

            (j) If any amount required to be paid by any Lender pursuant to this
Section 1.14 is not paid to the Administrative Agent on the date upon which the
Sharing Event occurred, such Lender shall, in addition to such aforementioned
amount, also pay to the Administrative Agent on demand an amount equal to the
product of (i) the amount so required to be paid by such Lender for the purchase
of its participations, (ii) the daily average Federal Funds Rate, during the
period from and including the date of request for payment to the date on which
such payment is immediately available to the Administrative Agent and (iii) a
fraction the numerator of which is the number of days that elapsed during such
period and the denominator of which is 360. A certificate of the Administrative
Agent submitted to any Lender with respect to any amounts payable under this
Section 1.14 shall be conclusive in the absence of manifest error. Amounts
payable by any Lender pursuant to this Section 1.14 shall be paid to the
Administrative Agent for the account of the relevant Lenders, provided that, if
the Administrative Agent (in its sole discretion) has elected to fund on behalf
of such other Lender the amounts owing to such other Lenders, then the amounts
shall be paid to the Administrative Agent for its own account.

            (k) Whenever, at any time after the relevant Lenders have received
from any other Lenders purchases of participations pursuant to this Section
1.14, the various Lenders receive any payment on account thereof, such Lenders
will distribute to the Administrative Agent, for the account of the various
Lenders participating therein, such Lenders' participating interests in such
amounts (appropriately adjusted, in the case of interest payments, to reflect
the period of time during which such participations were outstanding) in like
funds as received, provided, however, that in the event that such payment
received by any Lenders is required to be returned, the Lenders who received
previous distributions in respect of their participating interests therein will
return to the respective Lenders any portion thereof previously so distributed
to them in like funds as such payment is required to be returned by the
respective Lenders.

            (l) Each Lender's obligation to purchase participating interests
pursuant to this Section 1.14 shall be absolute and unconditional and shall not
be affected by any circumstance including, without limitation, (i) any setoff,
counterclaim, recoupment, defense or other right which such Lender may have
against any other Lender, either Borrower or any other Person for any reason
whatsoever, (ii) the occurrence or continuance of an Event of Default, (iii) any
adverse change in the condition (financial or otherwise) of either Borrower or
any other Person, (iv) any breach of this Agreement by either Borrower, any
Lender or any other Person, or (v) any

                                      -27-
<PAGE>

other circumstance, happening or event whatsoever, whether or not similar to any
of the foregoing.

            (m) Notwithstanding anything to the contrary contained elsewhere in
this Agreement, upon any purchase of participations as required above, (i) the
relevant Borrower shall pay to each Lender granting any participations as
required above, for the account of the respective Lender which has purchased
such participations, any increased costs and indemnities (including, without
limitation, pursuant to Sections 1.11, 1.12, 2.06 and 4.04) to the same extent
as if such Lender which has purchased such participations were the direct Lender
as opposed to a participant therein, which increased costs shall be calculated
without regard to Section 1.13, Section 13.04(a) or the penultimate sentence of
Section 13.04(b) and (ii) each Lender which has sold such participations shall
be entitled to receive from the relevant Borrower indemnification from and
against any and all taxes imposed as a result of the sale of the participations
pursuant to this Section 1.14. Each Borrower acknowledges and agrees that, upon
the occurrence of a Sharing Event and after giving effect to the requirements of
this Section 1.14, increased Taxes may be owing by it pursuant to Section 4.04,
which Taxes shall be paid (to the extent provided in Section 4.04) by the
respective Borrower or Borrowers, without any claim that the increased Taxes are
not payable because same resulted from the participations effected as otherwise
required by this Section 1.14.

            SECTION 2. Letters of Credit.

            2.01 Letters of Credit. (a) Subject to and upon the terms and
conditions herein set forth, a Borrower may request an Issuing Lender, at any
time and from time to time on and after the Initial Borrowing Date and prior to
the fifth Business Day (or the 30th day in the case of Trade Letters of Credit)
preceding the Revolving Loan Maturity Date, to issue, (x) for the account of the
U.S. Borrower (in the case of requests made by it) or the account of the
European Borrower (in the case of requests made by it) and for the benefit of
any holder (or any trustee, agent or other similar representative for any such
holders) of L/C Supportable Indebtedness of the respective Account Party or any
of its or their Subsidiaries, irrevocable standby letters of credit in a form
customarily used by such Issuing Lender or in such other form as has been
approved by such Issuing Lender (each such standby letter of credit, a "Standby
Letter of Credit") in support of such L/C Supportable Indebtedness and (y) for
the account of the respective Account Party and for the benefit of sellers of
goods to the respective Account Party or any of its or their Subsidiaries in the
ordinary course of business, irrevocable sight trade letters of credit in a form
customarily used by such Issuing Lender or in such other form as has been
approved by such Issuing Lender (each such trade letter of credit, a "Trade
Letter of Credit", and each such Standby Letter of Credit and Trade Letter of
Credit, a "Letter of Credit" and collectively, the "Letters of Credit"). All
Letters of Credit shall be issued on a sight basis only. Each Letter of Credit
shall be deemed to constitute a utilization of the Multicurrency Facility
Revolving Loan Commitments and shall, subject to the provisions of Section 1.14
if a Sharing Event occurs, be participated in (as more fully described in
following Section 2.04(a)) by the Multicurrency Facility RL Lenders in
accordance with their respective Multicurrency Facility RL Percentages. All
Letters of Credit shall be denominated in Dollars or Euros and shall be issued
for the account of the U.S. Borrower or the European Borrower. Each Letter of
Credit shall constitute either a U.S. Borrower Letter of Credit or a European
Borrower Letter of Credit. Subject to any requirement to provide a Subsidiaries
Guaranty pursuant to Section 8.12, the

                                      -28-
<PAGE>

European Borrower shall have no liability under this Agreement with respect to
any U.S. Borrower Letter of Credit which may be issued to the U.S. Borrower.

            (b) Subject to and upon the terms and conditions set forth herein,
each Issuing Lender hereby agrees that it will, at any time and from time to
time on and after the Initial Borrowing Date and prior to the fifth Business Day
(or the 30th day in the case of Trade Letters of Credit) preceding the Revolving
Loan Maturity Date, following its receipt of the respective Letter of Credit
Request, issue for the account of the respective Account Party one or more
Letters of Credit, (x) in the case of Trade Letters of Credit, in support of
trade obligations of the respective Account Party or any of its or their
Subsidiaries that arise in the ordinary course of business or (y) in the case of
Standby Letters of Credit, in support of such L/C Supportable Indebtedness as is
permitted to remain outstanding without giving rise to a Default or Event of
Default hereunder; provided that the respective Issuing Lender shall be under no
obligation to issue any Letter of Credit if at the time of such issuance:

            (i) any order, judgment or decree of any governmental authority or
      arbitrator shall purport by its terms to enjoin or restrain such Issuing
      Lender from issuing such Letter of Credit or any requirement of law
      applicable to such Issuing Lender or any request or directive (whether or
      not having the force of law) from any governmental authority with
      jurisdiction over such Issuing Lender shall prohibit, or request that such
      Issuing Lender refrain from, the issuance of letters of credit generally
      or such Letter of Credit in particular or shall impose upon such Issuing
      Lender with respect to such Letter of Credit any restriction or reserve or
      capital requirement (for which such Issuing Lender is not otherwise
      compensated) not in effect on the date hereof, or any unreimbursed loss,
      cost or expense which was not applicable, in effect or known to such
      Issuing Lender as of the date hereof and which such Issuing Lender in good
      faith deems material to it;

            (ii) such Issuing Lender shall have received written notice from
      either Borrower or the Required Lenders prior to the issuance of such
      Letter of Credit of the type described in clause (vi) of Section 2.01(c)
      or the last sentence of Section 2.03(b); or

            (iii) a Lender Default exists with respect to any Multicurrency
      Facility RL Lender, unless the Issuing Lender has entered into
      arrangements satisfactory to it and the respective Account Party to
      eliminate such Issuing Lender's risk with respect to the Lender which is
      the subject of the Lender Default, including by cash collateralizing (in
      Dollars or Euros, as appropriate) such Lender's Multicurrency Facility RL
      Percentage of the Letter of Credit Outstandings.

            (c) Notwithstanding the foregoing, (i) no Letter of Credit shall be
issued the Stated Amount of which, when added to the Letter of Credit
Outstandings (exclusive of Unpaid Drawings which are repaid on the date of, and
prior to the issuance of, the respective Letter of Credit) at such time, would
exceed $40,000,000, (ii) no Letter of Credit shall be issued at any time when
the Aggregate Multicurrency Facility RL Exposure exceeds (or would after giving
effect to such issuance exceed) the Total Multicurrency Facility Revolving Loan
Commitment at such time, (iii) (x) each Standby Letter of Credit shall by its
terms terminate on or before the date which occurs 12 months after the date of
the issuance thereof (although any such Standby Letter of Credit may be
extendable for successive periods of up to 12 months, but not beyond the fifth

                                      -29-
<PAGE>

Business Day preceding the Revolving Loan Maturity Date, on terms acceptable to
the Issuing Lender thereof) and (y) each Trade Letter of Credit shall by its
terms terminate on or before the date occurring not later than 180 days after
such Trade Letter of Credit's date of issuance, (iv) (x) no Standby Letter of
Credit shall have an expiry date occurring later than the fifth Business Day
preceding the Revolving Loan Maturity Date and (y) no Trade Letter of Credit
shall have an expiry date occurring later than 30 days prior to the Revolving
Loan Maturity Date, (v) each Letter of Credit shall be denominated in Euros or
Dollars and (vi) no Issuing Lender will issue any Letter of Credit after it has
received written notice from either Borrower or the Required Lenders stating
that a Default or an Event of Default exists until such time as such Issuing
Lender shall have received a written notice of (x) rescission of such notice
from the party or parties originally delivering the same or (y) a waiver of such
Default or Event of Default by the Required Lenders.

            2.02 Minimum Stated Amount. The Stated Amount of each Letter of
Credit upon issuance shall be not less than (x) in the case of a Dollar
Denominated Letter of Credit, $250,000 and (y) in the case of a Euro Denominated
Letter of Credit, (euro)250,000, or in each case such lesser amount as is
reasonably acceptable to the respective Issuing Lender.

            2.03 Letter of Credit Requests. (a) Whenever an Account Party
desires that a Letter of Credit be issued for its account, such Account Party
shall give the Administrative Agent (at the appropriate Notice Office) and the
respective Issuing Lender at least 3 days' (or such shorter period as is
acceptable to such Issuing Lender in any given case) written notice (including
by way of facsimile) prior to the proposed date of issuance (which shall be a
Business Day). Each notice shall be in the form of Exhibit C (each, a "Letter of
Credit Request"), including, without limitation, by specifying whether the
requested Letter of Credit shall constitute a U.S. Borrower Letter of Credit or
a European Borrower Letter of Credit and the Available Currency in which the
requested Letter of Credit is to be denominated. Each Letter of Credit Request
shall include any other documents as such Issuing Lender customarily requires in
connection therewith.

            (b) The making of each Letter of Credit Request shall be deemed to
be a representation and warranty by the U.S. Borrower or the European Borrower,
as the case may be, that such Letter of Credit may be issued in accordance with,
and will not violate the requirements of, Section 2.01(c). Unless the respective
Issuing Lender has received notice from the Required Lenders before it issues a
Letter of Credit that one or more of the applicable conditions specified in
Section 5 or 6, as the case may be, are not then satisfied, or that the issuance
of such Letter of Credit would violate Section 2.01(c), then such Issuing Lender
may issue the requested Letter of Credit for the account of the respective
Account Party in accordance with such Issuing Lender's usual and customary
practices.

            2.04 Letter of Credit Participations. (a) Immediately upon the
issuance by any Issuing Lender of any Letter of Credit, such Issuing Lender
shall be deemed to have sold and transferred to each Multicurrency Facility RL
Lender (each such Lender with respect to any Letter of Credit, in its capacity
under this Section 2.04, a "L/C Participant"), and each such L/C Participant
shall be deemed irrevocably and unconditionally to have purchased and received
from such Issuing Lender, without recourse or warranty, an undivided interest
and participation, in a percentage equal to such L/C Participant's Multicurrency
Facility RL Percentage, in such

                                      -30-
<PAGE>

Letter of Credit, each Drawing made thereunder and the obligations of the
respective Borrower under this Agreement with respect thereto (although Letter
of Credit Fees shall be payable directly to the Administrative Agent for the
account of the Multicurrency Facility RL Lenders, as provided in Section 3.01(b)
and the L/C Participants shall have no right to receive any portion of any
Facing Fees with respect to any such Letters of Credit) and any security
therefor or guaranty pertaining thereto. Upon any change in the Multicurrency
Facility Revolving Loan Commitments and, as a result thereof the Multicurrency
Facility RL Percentages, of the Multicurrency Facility RL Lenders pursuant to
Section 1.13 or 13.04, it is hereby agreed that, with respect to all outstanding
Letters of Credit and Unpaid Drawings relating thereto, there shall be an
automatic adjustment to the participations pursuant to this Section 2.04 to
reflect the new Multicurrency Facility RL Percentages of the Multicurrency
Facility RL Lenders. With respect to each Letter of Credit from time to time
outstanding, the percentage participations therein of the various Multicurrency
Facility RL Lenders calculated as provided above in this Section 2.04(a) are
herein called the "L/C Participation Percentages" of the various Multicurrency
Facility RL Lenders in such Letters of Credit. All calculations of the L/C
Participation Percentages shall be made from time to time by the Administrative
Agent, which calculations shall be conclusive absent manifest error.
Furthermore, upon the occurrence of a Sharing Event and as more fully set forth
in Section 1.14, additional sub-participations may be required to be granted by
the various Multicurrency Facility RL Lenders in their participations in
outstanding Letters of Credit, in each case in accordance with, and subject to
the provisions of, Section 1.14.

            (b) In determining whether to pay under any Letter of Credit, the
respective Issuing Lender shall have no obligation relative to the other Lenders
other than to confirm that any documents required to be delivered under such
Letter of Credit appear to have been delivered and that they appear to
substantially comply on their face with the requirements of such Letter of
Credit. Any action taken or omitted to be taken by any Issuing Lender under or
in connection with any Letter of Credit issued by it if taken or omitted in the
absence of gross negligence or willful misconduct (as determined by a court of
competent jurisdiction in a final and non-appealable decision), shall not create
for such Issuing Lender any resulting liability to any Account Party or any
Lender.

            (c) In the event that any Issuing Lender makes any payment or
disbursement under any Letter of Credit issued by it and the respective Account
Party shall not have reimbursed such amount in full to such Issuing Lender
pursuant to Section 2.05(a), such Issuing Lender shall promptly notify the
Administrative Agent, which shall promptly notify each L/C Participant therein
of such failure, and each L/C Participant therein shall promptly and
unconditionally pay to the Administrative Agent for the account of such Issuing
Lender the amount of such L/C Participant's L/C Participation Percentage (as
relates to the respective Letter of Credit) of the respective Unpaid Drawing
(with the amount thereof and the currency in which same is owing to be
calculated in accordance with the provisions of Section 2.05(a)) in Dollars (or,
to the extent the respective Unpaid Drawing is, in accordance with Section
2.05(a), to be reimbursed by the respective Account Party in Euros, in Euros)
and in same day funds. If the Administrative Agent so notifies, prior to 11:00
A.M. (New York time) on any Business Day, any L/C Participant required to fund
an Unpaid Drawing under a Letter of Credit, such L/C Participant shall make
available to the Administrative Agent at the Payment Office for the account of
the respective Issuing Lender, in Dollars (or in Euros to the extent the
respective Unpaid Drawing is required to be paid by the respective Account Party
in Euros pursuant to the

                                      -31-
<PAGE>

provisions of Section 2.05(a)), such L/C Participant's L/C Participation
Percentage (as relates to the respective Letter of Credit) of the amount of such
payment on such Business Day in same day funds. If and to the extent that, for
any reason, such L/C Participant shall not have made its L/C Participation
Percentage of the amount of such payment available to the Administrative Agent
for the account of the respective Issuing Lender, such L/C Participant agrees to
pay to the Administrative Agent for the account of such Issuing Lender,
forthwith on demand such amount, together with interest thereon, for each day
from the date the respective Unpaid Drawing occurred until the date such amount
is paid to the Administrative Agent for the account of such Issuing Lender at
the overnight Federal Funds Rate (or, in the case of amounts owed in Euros, at
the Overnight Euro Rate), provided that if any L/C Participant does not make
available to the Administrative Agent any amounts required to be made available
by it as described above within 2 Business Days after the respective L/C
Participant has been notified by the Administrative Agent or the respective
Issuing Lender to make such amounts available, then the respective L/C
Participant shall pay interest on the amounts demanded of it at the same rates
payable from time to time by the respective Account Party on the respective
Unpaid Drawings pursuant to Section 2.05(a). The failure of any L/C Participant
to make available to the Administrative Agent for the account of the respective
Issuing Lender its relevant L/C Participation Percentage of any payment under
any Letter of Credit issued by it shall not relieve any other L/C Participant in
the respective Letter of Credit of its obligation hereunder to make available to
the Administrative Agent for the account of such Issuing Lender its relevant L/C
Participation Percentage of any such Letter of Credit on the date required, as
specified above, but no L/C Participant shall be responsible for the failure of
any other L/C Participant to make available to the Administrative Agent for the
account of such Issuing Lender such other L/C Participant's relevant L/C
Participation Percentage of any such payment.

            (d) Whenever any Issuing Lender receives a payment of a
reimbursement obligation as to which the Administrative Agent has received for
the account of such Issuing Lender any payments from the L/C Participants
pursuant to clause (c) above, such Issuing Lender shall pay to the
Administrative Agent and the Administrative Agent shall promptly pay each L/C
Participant which has paid its relevant L/C Participation Percentage thereof, in
Dollars (or in Euros in the case of payments to be made in Euros pursuant to
Section 2.05(a)) and in same day funds, an amount equal to such L/C
Participant's share (based on the proportionate aggregate amount funded by such
L/C Participant to the aggregate amount funded by all L/C Participants) of the
principal amount of such reimbursement obligation and interest thereon accruing
after the purchase of the respective participations.

            (e) Each Issuing Lender shall, promptly after the issuance of, or
amendment or modification to, a Standby Letter of Credit, give the
Administrative Agent and the respective Account Party written notice of such
issuance, amendment or modification, as the case may be, and such notice shall
be accompanied by a copy of such Standby Letter of Credit, such amendment or
such modification, as the case may be. Promptly upon receipt of such notice, the
Administrative Agent shall notify each L/C Participant, in writing, of such
issuance, amendment or modification and if any L/C Participant shall so request,
the Administrative Agent shall furnish said L/C Participant with a copy of such
Standby Letter of Credit, such amendment or such modification, as the case may
be.

                                      -32-
<PAGE>

            (f) Each Issuing Lender shall deliver to the Administrative Agent,
promptly on the first Business Day of each week, by facsimile transmission, the
aggregate daily Stated Amount available to be drawn under the outstanding Trade
Letters of Credit issued by such Issuing Lender for the previous week.

            (g) The obligations of the L/C Participants to make payments to the
Administrative Agent for the account of the respective Issuing Lender with
respect to Letters of Credit issued by it shall be irrevocable and not subject
to counterclaim, set-off or other defense or any other qualification or
exception whatsoever and shall be made in accordance with the terms and
conditions of this Agreement under all circumstances, including, without
limitation, any of the following circumstances:

            (i) any lack of validity or enforceability of this Agreement or any
      of the Credit Documents;

            (ii) the existence of any claim, setoff, defense or other right
      which any Credit Party or any of its Subsidiaries may have at any time
      against a beneficiary named in a Letter of Credit, any transferee of any
      Letter of Credit (or any Person for whom any such transferee may be
      acting), any Agent, any Lender, any Issuing Lender, any L/C Participant,
      or any other Person, whether in connection with this Agreement, any Letter
      of Credit, the transactions contemplated herein or any unrelated
      transactions (including any underlying transaction between any Credit
      Party or any of its Subsidiaries and the beneficiary named in any such
      Letter of Credit);

            (iii) any draft, certificate or any other document presented under
      any Letter of Credit proving to be forged, fraudulent, invalid or
      insufficient in any respect or any statement therein being untrue or
      inaccurate in any respect;

            (iv) the surrender or impairment of any security for the performance
      or observance of any of the terms of any of the Credit Documents; or

            (v) the occurrence of any Default or Event of Default;

provided that the L/C Participants shall not be obligated to reimburse such
Issuing Lender for any wrongful payment made by such Issuing Lender under a
Letter of Credit issued by it as a result of deliberate acts or omissions
constituting willful misconduct or gross negligence on the part of such Issuing
Lender (as determined by a court of competent jurisdiction in a final and
non-appealable decision). Any action taken or omitted to be taken by any Issuing
Lender under or in connection with any Letter of Credit shall not create for
such Issuing Lender any resulting liability to the L/C Participants or any other
Person unless such action is taken or omitted to be taken with gross negligence
or willful misconduct (as determined by a court of competent jurisdiction in a
final and non-appealable decision).

            2.05 Agreement to Repay Letter of Credit Drawings. (a) The U.S.
Borrower hereby agrees (in the case of U.S. Borrower Letters of Credit), and the
European Borrower hereby agrees (in the case of European Borrower Letters of
Credit), to reimburse the respective Issuing Lender, by making payment in
Dollars (in the case of all Dollar Denominated Letters of Credit or, after a
Sharing Event, all Letters of Credit) or Euros (in the case of Euro Denominated

                                      -33-
<PAGE>

Letters of Credit at any time prior to a Sharing Event) to the Administrative
Agent in immediately available funds at the Payment Office (or by making the
payment directly to such Issuing Lender at such location as may otherwise have
been agreed upon by the respective Account Party and such Issuing Lender), for
any payment or disbursement (in the case of any such payment or disbursement
under any Euro Denominated Letter of Credit which is unpaid on the date of the
occurrence of a Sharing Event, or which payments or disbursements are made
thereafter, taking the Dollar Equivalent of the amount of the respective payment
or disbursement made in Euros as such Dollar Equivalent is determined on the
first date upon which the respective Sharing Event occurs or, if later, the date
upon which the respective payment or disbursement is made) made by such Issuing
Lender under any Letter of Credit issued by it (each such amount so paid until
reimbursed, an "Unpaid Drawing"), not later than the third Business Day after
the Administrative Agent or the Issuing Lender notifies the respective Borrower
of such payment or disbursement, with interest on the amount so paid or
disbursed by such Issuing Lender, to the extent not reimbursed prior to 1:00
P.M. (New York time), on the date of such payment or disbursement, from and
including the date paid or disbursed to but excluding the date such Issuing
Lender is reimbursed by the U.S. Borrower or the European Borrower, as the case
may be, therefor at a rate per annum which shall be (x) in the case of Dollar
Denominated Letters of Credit and other amounts owing in Dollars after the
occurrence of a Sharing Event, the Base Rate in effect from time to time plus
the Applicable Margin for Multicurrency Facility Revolving Loans maintained as
Base Rate Loans, as in effect from time to time and (y) in the case of Euro
Denominated Letters of Credit for periods occurring prior to the occurrence of a
Sharing Event, the Overnight Euro Rate in effect from time to time plus the
Applicable Margin for Euro Denominated Revolving Loans as in effect from time to
time plus any Mandatory Costs, provided, however, to the extent such amounts are
not reimbursed prior to 1:00 P.M. (New York time) on the third Business Day
following notice to the respective Account Party by the Administrative Agent or
the respective Issuing Lender of such payment or disbursement, interest shall
thereafter accrue on the amounts so paid or disbursed by such Issuing Lender
(and until reimbursed by the respective Account Party) at a rate per annum which
shall be (x) in the case of Dollar Denominated Letters of Credit and other
amounts owing in Dollars after the occurrence of a Sharing Event, the Base Rate
in effect from time to time plus the Applicable Margin for Multicurrency
Facility Revolving Loans maintained as Base Rate Loans, as in effect from time
to time plus 2% and (y) in the case of Euro Denominated Letters of Credit for
periods occurring prior to the occurrence of a Sharing Event, the Overnight Euro
Rate in effect from time to time plus the Applicable Margin for Euro Denominated
Revolving Loans as in effect from time to time plus any Mandatory Costs plus 2%,
in each such case, with interest to be payable on demand, provided further, that
it is understood and agreed, however, that the notices referred to above in this
clause (a) and in the immediately preceding proviso shall not be required to be
given if a Default or an Event of Default under Section 10.05 shall have
occurred and be continuing (in which case the Unpaid Drawings shall be due and
payable immediately without presentment, demand, protest or notice of any kind
(all of which are hereby waived by each Credit Party) and shall bear interest at
the rate provided in the foregoing proviso on and after the third Business Day
following the respective Drawing). The respective Issuing Lender shall give the
respective Account Party prompt notice of each Drawing under any Letter of
Credit, provided that the failure to give, or any delay in giving, any such
notice shall in no way affect, impair or diminish the respective Account Party's
obligations under this Agreement.

                                      -34-
<PAGE>

            (b) The obligations of the U.S. Borrower (with respect to U.S.
Borrower Letters of Credit) and the obligations of the European Borrower (with
respect to European Borrower Letters of Credit) under this Section 2.05 to
reimburse the respective Issuing Lender with respect to Unpaid Drawings
(including, in each case, interest thereon) shall be absolute and unconditional
under any and all circumstances and irrespective of any setoff, counterclaim or
defense to payment which the respective Account Party may have or have had
against any Lender (including in its capacity as Issuing Lender or as L/C
Participant), including, without limitation, any defense based upon the failure
of any drawing under a Letter of Credit (each, a "Drawing") to conform to the
terms of such Letter of Credit or any nonapplication or misapplication by the
beneficiary of the proceeds of such Drawing, the respective Issuing Lender's
only obligation to the respective Account Party being to confirm that any
documents required to be delivered under such Letter of Credit appear to have
been delivered and that they appear to substantially comply on their face with
requirements of such Letter of Credit; provided, however, that no Account Party
shall be obligated to reimburse any Issuing Lender for any wrongful payment made
by such Issuing Lender under a Letter of Credit issued by it as a result of
deliberate acts or omissions constituting willful misconduct or gross negligence
on the part of such Issuing Lender (as determined by a court of competent
jurisdiction in a final and non-appealable decision). Any action taken or
omitted to be taken by any Issuing Lender under or in connection with any Letter
of Credit shall not create for such Issuing Lender any resulting liability to
any Account Party unless such action is taken or admitted to be taken with gross
negligence or willful misconduct (as determined by a court of competent
jurisdiction in a final and non-appealable decision).

            2.06 Increased Costs. If after the Effective Date, any Issuing
Lender or any L/C Participant determines in good faith that the adoption or
effectiveness after the Effective Date of any applicable law, rule or
regulation, order, guideline or request or any change therein, or any change
after the Effective Date in the interpretation or administration thereof by any
governmental authority, central bank or comparable agency charged with the
interpretation or administration thereof, or compliance by any Issuing Lender or
any L/C Participant with any request or directive (whether or not having the
force of law) by any such authority, central bank or comparable agency shall
either (i) impose, modify or make applicable any reserve, deposit, capital
adequacy or similar requirement against Letters of Credit issued by such Issuing
Lender or such L/C Participant's participation therein, or (ii) impose on any
Issuing Lender or any L/C Participant any other conditions directly or
indirectly affecting this Agreement, any Letter of Credit or such L/C
Participant's participation therein; and the result of any of the foregoing is
to increase the cost to such Issuing Lender or such L/C Participant of issuing,
maintaining or participating in any Letter of Credit, or to reduce the amount of
any sum received or receivable by such Issuing Lender or such L/C Participant
hereunder or reduce the rate of return on its capital with respect to Letters of
Credit, then, upon written demand to the U.S. Borrower or the European Borrower,
as the case may be, by such Issuing Lender or such L/C Participant (a copy of
which notice shall be sent by such Issuing Lender or such L/C Participant to the
Administrative Agent), accompanied by the certificate described in the last
sentence of this Section 2.06, the U.S. Borrower or the European Borrower, as
the case may be, shall, subject to the provisions of Section 13.23, pay to such
Issuing Lender or such L/C Participant the amount necessary to cover such
increased cost or reduction. A certificate submitted to the relevant Borrower by
such Issuing Lender or such L/C Participant, as the case may be (a copy of which
certificate shall be sent by such Issuing Lender or such L/C Participant to the
Administrative

                                      -35-
<PAGE>

Agent), setting forth in reasonable detail the basis for the determination of
such additional amount or amounts necessary to compensate such Issuing Lender or
such L/C Participant as aforesaid shall be final and conclusive and binding on
such Borrower absent manifest error, although the failure to deliver any such
certificate shall not release or diminish such Borrower's obligations to pay
additional amounts pursuant to this Section 2.06 upon subsequent receipt of such
certificate.

            SECTION 3. Fees; Commitments.

            3.01 Fees. (a) The Borrowers jointly and severally agree to pay to
the Administrative Agent for distribution to each Non-Defaulting Lender with a
Multicurrency Facility Revolving Loan Commitment a commitment commission, in
Dollars, for the period from the Effective Date to but excluding the Revolving
Loan Maturity Date (or such earlier date as the Total Multicurrency Facility
Revolving Loan Commitment shall have been terminated), computed at a rate equal
to the Applicable Multicurrency Facility Commitment Fee Percentage per annum on
the daily average Unutilized Multicurrency Facility Revolving Loan Commitment of
such Non-Defaulting Lender as in effect from time to time (with the commitment
commission payable as described in this clause (a) being herein referred to as
"RL Commitment Commission"). Accrued RL Commitment Commission shall be due and
payable, in Dollars, quarterly in arrears on each Quarterly Payment Date and on
the Revolving Loan Maturity Date or such earlier date upon which the Total
Multicurrency Facility Revolving Loan Commitment is terminated.

            (b) (x) The U.S. Borrower agrees to pay to the Administrative Agent
for distribution to each Multicurrency Facility RL Lender (based on their
respective L/C Participation Percentages as from time to time in effect) in
Dollars, a fee in respect of each U.S. Borrower Letter of Credit issued
hereunder and (y) the European Borrower agrees to pay to the Administrative
Agent for distribution to each Multicurrency Facility RL Lender (based on their
respective L/C Participation Percentages as from time to time in effect) in
Dollars, a fee in respect of each European Borrower Letter of Credit issued
hereunder (with all fees payable as described in this clause (b) being herein
referred to as "Letter of Credit Fees"), in each case, for the period from and
including the date of issuance of such Letter of Credit through the termination
of such Letter of Credit, computed at a rate per annum equal to the Applicable
Margin for Multicurrency Facility Revolving Loans maintained as Euro Rate Loans,
as in effect from time to time, on the Stated Amount of such Letter of Credit.
Accrued Letter of Credit Fees shall be due and payable quarterly in arrears on
each Quarterly Payment Date and, in the case of Letter of Credit Fees owing
pursuant to preceding clause (x), on the first day on or after the termination
of the Total Multicurrency Facility Revolving Loan Commitment upon which no
Letters of Credit remain outstanding.

            (c) Each Account Party agrees to pay to the respective Issuing
Lender, for its own account, in Dollars, a facing fee in respect of each Letter
of Credit issued to it hereunder (the "Facing Fee") for the period from and
including the date of issuance of such Letter of Credit to and including the
termination or expiration of such Letter of Credit, computed at a rate equal to
1/4 of 1% per annum of the daily Stated Amount of such Letter of Credit,
provided that in no event shall the annual Facing Fee with respect to any Letter
of Credit be less than the Minimum Applicable Facing Fee; it being agreed that
(i) on the date of issuance of any Letter of Credit and

                                      -36-
<PAGE>

on each anniversary thereof prior to the termination of such Letter of Credit,
if the Minimum Applicable Facing Fee will exceed the amount of Facing Fees that
will accrue with respect to such Letter of Credit for the immediately succeeding
12-month period, the full Minimum Applicable Facing Fee shall be payable on the
date of issuance of such Letter of Credit and on each such anniversary thereof
prior to the termination of such Letter of Credit and (ii) if on the date of the
termination of any Letter of Credit, the Minimum Applicable Facing Fee actually
exceeds the amount of Facing Fees paid or payable with respect to such Letter of
Credit for the period beginning on the date of the issuance thereof (or, if the
respective Letter of Credit has been outstanding for more than one year, the
date of the last anniversary of the issuance thereof occurring prior to the
termination of such Letter of Credit) and ending on the date of the termination
thereof, an amount equal to such excess shall be paid as additional Facing Fees
with respect to such Letter of Credit on the next date upon which Facing Fees
are payable in accordance with the immediately succeeding sentence. Except as
provided in the immediately preceding sentence, accrued Facing Fees shall be due
and payable quarterly in arrears on each Quarterly Payment Date and upon the
first day on or after the termination of the Total Multicurrency Facility
Revolving Loan Commitment upon which no Letters of Credit remain outstanding.

            (d) The respective Account Party agrees to pay to the respective
Issuing Lender, in Dollars, for its own account, upon each payment under,
issuance of, or amendment to, any Letter of Credit, such amount as shall at the
time of such event be the administrative charge which such Issuing Lender is
customarily charging for issuances of, payments under or amendments of, Letters
of Credit issued by it.

            (e) All voluntary prepayments of principal of U.S. Borrower Term
Loans or European Borrower Term Loans (other than any such voluntary prepayments
made with (x) internally generated funds or (y) the Net Sales Proceeds retained
by either Borrower pursuant to Section 4.02(c)), all mandatory prepayments of
principal of U.S. Borrower Term Loans and European Borrower Term Loans required
pursuant to Section 4.02(c) in connection with the sale of all or substantially
all of the assets of the U.S. Borrower and its Subsidiaries or of the European
Borrower and its Subsidiaries, all mandatory prepayments of principal of U.S.
Borrower Term Loans and European Borrower Term Loans required pursuant to
Section 4.02(d) (except as expressly otherwise provided in the last proviso
thereto) and all mandatory prepayments of principal of U.S. Borrower Term Loans
and European Borrower Term Loans required pursuant to Section 4.02(g)(iii), in
each case prior to the first anniversary of the Initial Borrowing Date, will be
subject to payment to the Administrative Agent, for the ratable account of each
Lender with outstanding U.S. Borrower Term Loans and/or European Borrower Term
Loans, of a fee (payable in U.S. Dollars) in an amount equal to 1.0% of the
aggregate principal amount (taking the Dollar Equivalent of any amounts
denominated in Euros) of such prepayment. Such prepayment fees shall be due and
payable upon the date of any such prepayment.

            (f) Each Borrower agrees to pay to each Agent, for its own account,
such other fees as have been agreed to in writing by such Borrower and the
Administrative Agent.

            (g) All computations of Fees shall be made in accordance with
Section 13.07(b).

                                      -37-
<PAGE>

            3.02 Voluntary Termination or Reduction of Multicurrency Facility
Revolving Loan Commitments and Adjustments of Multicurrency Facility Revolving
Loan Commitments. (a) Upon at least three Business Days' prior notice from an
Authorized Officer of the U.S. Borrower to the Administrative Agent at its
Notice Office (which notice the Administrative Agent shall promptly transmit to
each of the Lenders), the U.S. Borrower shall have the right, at any time or
from time to time, without premium or penalty, to terminate the Total Unutilized
Multicurrency Facility Revolving Loan Commitment at such time, in whole or in
part, in aggregate minimum amounts of at least $1,000,000 in the case of partial
reductions, provided that no such reduction shall be permitted to be made
pursuant to this Section 3.02(a) if the effect thereof is to cause the Aggregate
Multicurrency Facility RL Exposure to exceed the Total Multicurrency Facility
Revolving Loan Commitment after giving effect to the reduction thereto pursuant
to this Section 3.02(a). Each reduction to the Total Multicurrency Facility
Revolving Loan Commitment pursuant to this Section 3.02(a) shall apply to
proportionately and permanently reduce the Multicurrency Facility Revolving Loan
Commitment of each Multicurrency Facility RL Lender (based on their respective
Multicurrency Facility RL Percentages).

            (b) In the event of certain refusals by a Lender as provided in
Section 4.01 or 13.12(b) to consent to certain proposed changes, waivers,
discharges or terminations with respect to this Agreement which have been
approved by the Required Lenders, the U.S. Borrower may, subject to the
applicable requirements of said Sections 4.01 and/or 13.12(b), upon five
Business Days' prior written notice to the Administrative Agent at its Notice
Office (which notice the Administrative Agent shall promptly transmit to each of
the Lenders) terminate the Multicurrency Facility Revolving Loan Commitment, if
any, of such Lender, so long as (x) all Loans, together with accrued and unpaid
interest, Fees and all other amounts, owing to such Lender (excluding amounts
owing in respect of Loans of any Tranche maintained by such Lender which are not
being repaid pursuant to Section 13.12(b)) are repaid concurrently with the
effectiveness of such termination (at which time Schedule I shall be deemed
modified to reflect such changed amounts) and (y) after giving effect to such
termination (and the adjustments to the Multicurrency Facility RL Percentages
and/or related L/C Participation Percentages of the remaining Lenders as
contemplated below), the Individual Multicurrency Facility RL Exposure of any
remaining Lender shall not exceed its Multicurrency Facility Revolving Loan
Commitment. After giving effect to the termination of the Commitments of any
Lender pursuant to the provisions of this Section 3.02(b), unless the respective
Lender continues to have outstanding Term Loans or other Commitments (if any)
hereunder, such Lender shall no longer constitute a "Lender" for purposes of
this Agreement, except with respect to indemnifications under this Agreement
(including, without limitation, Sections 1.10, 1.11, 2.06, 4.04, 13.01 and
13.06), which shall survive as to such repaid Lender. In cases where the
Multicurrency Facility Revolving Loan Commitment of any Lender is terminated
pursuant to this Section 3.02(b), except in cases where the respective
Commitments are replaced in full, after giving effect to the termination of any
such Commitments of a given Lender pursuant to this Section 3.02(b), there shall
occur automatic adjustments (as determined by the Administrative Agent) in the
Multicurrency Facility RL Percentages (and as a result thereof in the related
L/C Participation Percentages) of the remaining Multicurrency Facility RL
Lenders.

            (c) In connection with any reduction or termination of the Total
Unutilized Multicurrency Revolving Loan Commitment and/or the Multicurrency
Facility Revolving Loan

                                      -38-
<PAGE>

Commitment of any Lender pursuant to this Section 3.02 and Section 3.03, as the
case may be, the European Borrower hereby irrevocably authorizes the U.S.
Borrower to take all necessary action, in the name of the European Borrower as
described in this Section 3.02 or Section 3.03 in order to effect the reduction
or termination of the Total Unutilized Multicurrency Facility Revolving Loan
Commitment and/or the Multicurrency Facility Revolving Loan Commitment of such
Lender in accordance with the provisions of this Section 3.02 or Section 3.03,
as the case may be.

            3.03 Mandatory Reduction of Commitments. (a) The Total Commitment
(and the U.S. Borrower Term Loan Commitment, the European Borrower Dollar Term
Loan Commitment, the European Borrower Euro Term Loan Commitment and the
Multicurrency Facility Revolving Loan Commitment of each Lender with such a
Commitment) shall terminate in its entirety on May 15, 2004 unless the Initial
Borrowing Date has occurred on or before such date.

            (b) In addition to any other mandatory commitment reductions
pursuant to this Section 3.03, the Total U.S. Borrower Term Loan Commitment (and
the U.S. Borrower Term Loan Commitment of each Lender with such a Commitment)
shall terminate in its entirety on the Initial Borrowing Date (after giving
effect to the making of U.S. Borrower Term Loans on such date).

            (c) In addition to any other mandatory commitment reductions
pursuant to this Section 3.03, the Total European Borrower Dollar Term Loan
Commitment (and the European Borrower Dollar Term Loan Commitment of each Lender
with such a Commitment) shall terminate in its entirety on the Initial Borrowing
Date (after giving effect to the making of European Borrower Dollar Term Loans
on such date).

            (d) In addition to any other mandatory commitment reductions
pursuant to this Section 3.03, the Total European Borrower Euro Term Loan
Commitment (and the European Borrower Euro Term Loan Commitment of each Lender
with such a Commitment) shall terminate in its entirety on the Initial Borrowing
Date (after giving effect to the making of European Borrower Euro Term Loans on
such date).

            (e) In addition to any other mandatory commitment reductions
pursuant to this Section 3.03, the Total Multicurrency Facility Revolving Loan
Commitment (and the Multicurrency Facility Revolving Loan Commitment of each
Lender with such a Commitment) shall terminate in its entirety on the earlier to
occur of (i) the Revolving Loan Maturity Date and (ii) unless the Required
Lenders shall otherwise consent in writing in their sole discretion, a Change of
Control.

            (f) In addition to any other mandatory commitment reductions
pursuant to this Section 3.03, the Total Multicurrency Facility Revolving Loan
Commitment shall be permanently reduced from time to time to the extent required
by Section 4.02.

            (g) Each reduction to the Total U.S. Borrower Term Loan Commitment,
the Total European Borrower Dollar Term Loan Commitment, the Total European
Borrower Euro Term Loan Commitment and the Total Multicurrency Facility
Revolving Loan Commitment

                                      -39-
<PAGE>

pursuant to this Section 3.03 as provided above (or pursuant to Section 4.02)
shall be applied proportionately to reduce the U.S. Borrower Term Loan
Commitment, the European Borrower Dollar Term Loan Commitment, the European
Borrower Euro Term Loan Commitment or the Multicurrency Facility Revolving Loan
Commitment, as the case may be, of each Lender with such a Commitment.

            SECTION 4. Prepayments; Repayments; Taxes.

            4.01 Voluntary Prepayments. Each Borrower shall have the right to
prepay the Loans made to such Borrower, without premium or penalty except as
otherwise provided in this Agreement, and the right to allocate such prepayments
to Term Loans, Multicurrency Facility Revolving Loans and/or Swingline Loans as
such Borrower elects, in whole or in part, at any time and from time to time on,
and subject to, the following terms and conditions:

            (i) an Authorized Officer of such Borrower shall give the
      Administrative Agent at its Notice Office written notice (or telephonic
      notice promptly confirmed in writing) of its intent to prepay the Loans,
      whether such Loans are U.S. Borrower Term Loans, European Borrower Dollar
      Term Loans, European Borrower Euro Term Loans, U.S. Borrower Multicurrency
      Facility Revolving Loans, European Borrower Multicurrency Facility
      Revolving Loans, U.S. Borrower Swingline Loans and/or European Borrower
      Swingline Loans, the amount and currency (or currencies) of the Loans to
      be prepaid, the Types of Loans to be repaid and, in the case of Euro Rate
      Loans (other than Swingline Loans), the specific Borrowing or Borrowings
      pursuant to which made, which notice shall be given by the Authorized
      Officer of such Borrower (x) prior to 2:00 P.M. (New York time) at least
      one Business Day prior to the date of such prepayment in the case of Loans
      maintained as Base Rate Loans, (y) the date of such prepayment in the case
      of Swingline Loans, provided such notice is given prior to 10:00 A.M. (New
      York time) and (z) prior to 10:00 A.M. (New York time) at least three
      Business Days prior to the date of such prepayment in the case of Euro
      Rate Loans (other than Euro Denominated Swingline Loans) and shall, except
      in the case of Swingline Loans, be promptly transmitted by the
      Administrative Agent to each of the Lenders;

            (ii) each partial prepayment applied to any Tranche of Loans shall
      be in an aggregate principal amount of at least $1,000,000 (taking the
      Dollar Equivalent of any amounts to be prepaid in Euros) (or the
      applicable Minimum Borrowing Amount in the case of Swingline Loans),
      provided that (x) if any partial prepayment of Eurodollar Loans made
      pursuant to any Borrowing shall reduce the outstanding Eurodollar Loans
      made pursuant to such Borrowing to an amount less than the Minimum
      Borrowing Amount applicable thereto, then such Borrowing may not be
      continued as a Borrowing of Eurodollar Loans beyond the Interest Period
      applicable thereto and any election of an Interest Period with respect
      thereto given by such Borrower shall have no force or effect and (y) in
      the case of partial prepayments of any Borrowing of Euro Rate Loans (other
      than Euro Denominated Swingline Loans) denominated in currencies other
      than Dollars, such Borrower shall use reasonable efforts to allocate such
      prepayments in a manner so that Borrowings do not remain outstanding in
      amounts less than the Minimum Borrowing Amount applicable thereto (and, to
      the extent such Borrowings would remain outstanding in amounts which are
      less than the Minimum Borrowing Amount applicable thereto, in

                                      -40-
<PAGE>

      the case of Multicurrency Facility Revolving Loans, such Borrower shall
      repay any Borrowings which are less than the Minimum Borrowing Amount
      applicable thereto at the end of the then current Interest Period);

            (iii) at the time of any prepayment of Euro Rate Loans (other than
      Euro Denominated Swingline Loans) pursuant to this Section 4.01 on any
      date other than the last day of the Interest Period applicable thereto,
      such Borrower shall pay the amounts required pursuant to Section 1.11;

            (iv) except as provided in clause (vi) below, each prepayment in
      respect of any Loans made pursuant to a Borrowing shall be applied pro
      rata among such Loans made pursuant to such Borrowing, provided, that at
      such Borrower's election in connection with any prepayment of
      Multicurrency Facility Revolving Loans pursuant to this Section 4.01, such
      prepayment shall not be applied to the prepayment of the respective
      Multicurrency Facility Revolving Loans of a Defaulting Lender;

            (v) (A) each prepayment of principal of any Term Loans pursuant to
      this Section 4.01 shall be applied pro rata (based on the TL Repayment
      Percentages of the various Tranches of Term Loans) to the prepayment of
      each Tranche of then outstanding Term Loans, provided that (I)(x) at the
      election of the U.S. Borrower, any prepayment of principal of outstanding
      Term Loans by the U.S. Borrower pursuant to this Section 4.01 shall be
      applied, (i) first, to repay U.S. Borrower Term Loans, and (ii) second, to
      the extent no U.S. Borrower Term Loans are then outstanding, to repay
      European Borrower Dollar Term Loans and European Borrower Euro Term Loans
      on a pro rata basis (taking the Dollar Equivalent of any amounts
      denominated in Euros) and (y) at the election of the European Borrower,
      any prepayment of principal of outstanding Term Loans by the European
      Borrower pursuant to this Section 4.01 shall be applied, (i) first, to
      repay European Borrower Euro Term Loans and European Borrower Dollar Term
      Loans on a pro rata basis (taking the Dollar Equivalent of any amounts
      denominated in Euros), and (ii) second, to the extent no European Borrower
      Term Loans are then outstanding, to repay U.S. Borrower Term Loans, and
      (II) at the election of the respective Borrower, (x) any prepayment of
      principal of outstanding U.S. Borrower Term Loans may, in lieu of the
      applications otherwise provided herein, be applied to pay, in direct order
      of maturity, Scheduled Repayments of U.S. Borrower Term Loans which will
      be due within 12 months after the date of the respective voluntary
      prepayment pursuant to this Section 4.01 and (y) any prepayment of
      principal of outstanding European Borrower Term Loans may, in lieu of the
      applications otherwise provided herein, be applied to pay in direct order
      of maturity, Scheduled Repayments of European Borrower Term Loans which
      will be due within 12 months after the date of the respective voluntary
      prepayment pursuant to this Section 4.01 (which payments shall, in direct
      order, apply to repay in full all Scheduled Repayments of all European
      Borrower Term Loans due on any Scheduled Repayment Date with respect to
      which any principal of European Borrower Term Loans is being prepaid or,
      if the prepayment is insufficient to make such prepayments in full, pro
      rata to the European Borrower Term Loans based on the relative amounts
      (taking the Dollar Equivalent of amounts expressed in Euros) of the
      Scheduled Repayments which will be due on the respective Scheduled
      Repayment Date), and in each case with any excess amount of any such
      prepayment to be applied as provided in the immediately succeeding

                                      -41-
<PAGE>

      subclause (B), and (B) each prepayment of principal of U.S. Borrower Term
      Loans, European Borrower Dollar Term Loans and European Borrower Euro Term
      Loans pursuant to this Section 4.01 shall be applied to reduce the then
      remaining Scheduled Repayments of the respective Tranche of Term Loans,
      pro rata based on the relative amounts of each then remaining Scheduled
      Repayment applicable to the respective Tranche of Loans, provided that
      voluntary repayments of principal of U.S. Borrower Term Loans, European
      Borrower Dollar Term Loans and European Borrower Euro Term Loans made
      pursuant to subclause (II) to the proviso to preceding clause (A) shall
      instead be applied to reduce the Scheduled Repayments of the respective
      Tranche in direct order of maturity;

            (vi) in the event of certain refusals by a Lender as provided in
      Section 13.12(b) to consent to certain proposed changes, waivers,
      discharges or terminations with respect to this Agreement which have been
      approved by the Required Lenders, such Borrower may, upon five Business
      Days' written notice by an Authorized Officer of such Borrower to the
      Administrative Agent at its Notice Office (which notice the Administrative
      Agent shall promptly transmit to each of the Lenders), repay all Loans and
      pay all accrued and unpaid interest, Fees, and other amounts, in each case
      owing to such Lender (or owing to such Lender with respect to each Tranche
      which gave rise to the need to obtain such Lender's individual consent) in
      accordance with, and subject to the requirements of, said Section 13.12(b)
      so long as (A) in the case of the repayment of Multicurrency Facility
      Revolving Loans of any Lender pursuant to this clause (vi), the
      Multicurrency Facility Revolving Loan Commitment of such Lender is
      terminated concurrently with such repayment (at which time Schedule I
      shall be deemed modified to reflect the changed Multicurrency Facility
      Revolving Loan Commitments) and (B) the consents required by Section
      13.12(b) in connection with the repayment pursuant to this clause (vi)
      have been obtained; and

            (vii) each prepayment of Term Loans pursuant to this Section 4.01
      (other than any such prepayment made with (x) internally generated funds
      or (y) the Net Sales Proceeds retained by either Borrower pursuant to
      Section 4.02(c)) made prior to the first anniversary of the Initial
      Borrowing Date shall be subject to the payment of the fee described in
      Section 3.01(e).

            4.02 Mandatory Repayments and Commitment Reductions. (a) If on any
date the Aggregate Multicurrency Facility RL Exposure exceeds the Total
Multicurrency Facility Revolving Loan Commitment as then in effect, the U.S.
Borrower shall prepay on such date the principal of outstanding U.S. Borrower
Multicurrency Facility Revolving Loans and/or U.S. Borrower Swingline Loans,
and/or the European Borrower shall prepay on such date the principal of
outstanding European Borrower Multicurrency Facility Revolving Loans and/or
European Borrower Swingline Loans, in an amount (in the case of payments made
with respect to Euro Denominated Loans, taking the Dollar Equivalent of the
amounts paid in Euros in which payments on such Loans are owing) equal to such
excess (with such repayment of Multicurrency Facility Revolving Loans and
Swingline Loans to be allocated among U.S. Borrower Multicurrency Facility
Revolving Loans, U.S. Borrower Swingline Loans, European Borrower Multicurrency
Facility Revolving Loans and European Borrower Swingline Loans as the Borrowers
may elect). If, after giving effect to the prepayment of all outstanding
Swingline

                                      -42-
<PAGE>

Loans and Multicurrency Facility Revolving Loans, the aggregate amount of the
Letter of Credit Outstandings exceeds the Total Multicurrency Facility Revolving
Loan Commitment as then in effect, the U.S. Borrower agrees (as to U.S. Borrower
Letters of Credit), and the European Borrower agrees (as to European Borrower
Letters of Credit), to pay to the Administrative Agent at the Payment Office on
such date an amount of cash or Cash Equivalents (in Dollars or in the respective
currencies in which the Letter of Credit Outstandings are denominated) equal to
the amount of such excess (up to a maximum amount equal to (x) in the case of
the U.S. Borrower, the Letter of Credit Outstandings with respect to U.S.
Borrower Letters of Credit at such time and (y) in the case of the European
Borrower, the Letter of Credit Outstandings with respect to European Borrower
Letters of Credit at such time), such cash or Cash Equivalents to be held as
security for all obligations of the U.S. Borrower or the European Borrower, as
the case may be, hereunder in a cash collateral account to be established by the
Administrative Agent.

            (b) (i) In addition to any other mandatory repayments or commitment
reductions pursuant to this Section 4.02, on each date set forth below, the U.S.
Borrower shall be required to repay that principal amount of U.S. Borrower Term
Loans, to the extent then outstanding, as is set forth opposite such date (each
such repayment, as the same may be reduced as provided in Sections 4.01 and
4.02(h), a "U.S. Borrower Term Loan Scheduled Repayment"):

<TABLE>
<CAPTION>
U.S. Borrower Term Loan
Scheduled Repayment Date                                 Amount
------------------------                              ------------
<S>                                                   <C>
September 30, 2005                                    $ 2,156,250
December 31, 2005                                     $ 2,156,250
March 31, 2006                                        $ 2,156,250

June 30, 2006                                         $ 2,156,250
September 30, 2006                                    $ 4,312,500
December 31, 2006                                     $ 4,312,500
March 31, 2007                                        $ 4,312,500

June 30, 2007                                         $ 4,312,500
September 30, 2007                                    $ 4,312,500
December 31, 2007                                     $ 4,312,500
March 31, 2008                                        $ 4,312,500

June 30, 2008                                         $ 4,312,500
September 30, 2008                                    $ 6,468,750
December 31, 2008                                     $ 6,468,750
March 31, 2009                                        $ 6,468,750

June 30, 2009                                         $ 6,468,750
September 30, 2009                                    $ 6,468,750
December 31, 2009                                     $48,515,625

Term Loan Maturity Date                               $48,515,625
</TABLE>

                                      -43-
<PAGE>

            (ii) In addition to any other mandatory repayments or commitment
reductions pursuant to this Section 4.02, on each date set forth below, the
European Borrower shall be required to repay that principal amount of European
Borrower Dollar Term Loans, to the extent then outstanding, as is set forth
opposite such date (each such repayment, as the same may be reduced as provided
in Sections 4.01 and 4.02(h), a "European Borrower Dollar Term Loan Scheduled
Repayment"):

<TABLE>
<CAPTION>
European Borrower Dollar Term Loan
    Scheduled Repayment Date                            Amount
-----------------------------------                  -----------
<S>                                                  <C>
September 30, 2005                                   $ 2,156,250
December 31, 2005                                    $ 2,156,250
March 31, 2006                                       $ 2,156,250

June 30, 2006                                        $ 2,156,250
September 30, 2006                                   $ 4,312,500
December 31, 2006                                    $ 4,312,500
March 31, 2007                                       $ 4,312,500

June 30, 2007                                        $ 4,312,500
September 30, 2007                                   $ 4,312,500
December 31, 2007                                    $ 4,312,500
March 31, 2008                                       $ 4,312,500

June 30, 2008                                        $ 4,312,500
September 30, 2008                                   $ 6,468,750
December 31, 2008                                    $ 6,468,750
March 31, 2009                                       $ 6,468,750

June 30, 2009                                        $ 6,468,750
September 30, 2009                                   $ 6,468,750
December 31, 2009                                    $48,515,625

Term Loan Maturity Date                              $48,515,625
</TABLE>

            (iii) In addition to any other mandatory repayments or commitment
reductions pursuant to this Section 4.02, on each date set forth below, the
European Borrower shall be required to repay that principal amount of European
Borrower Euro Term Loans, to the extent then outstanding, as is set forth
opposite such date (each such repayment, as the same may be reduced as provided
in Sections 4.01 and 4.02(h), a "European Borrower Euro Term Loan Scheduled
Repayment"):

                                      -44-
<PAGE>

<TABLE>
<CAPTION>
European Borrower Euro Term Loan
    Scheduled Repayment Date                         Amount
--------------------------------                ----------------
<S>                                             <C>
September 30, 2005                              (euro) 1,625,000
December 31, 2005                               (euro) 1,625,000
March 31, 2006                                  (euro) 1,625,000

June 30, 2006                                   (euro) 1,625,000
September 30, 2006                              (euro) 3,250,000
December 31, 2006                               (euro) 3,250,000
March 31, 2007                                  (euro) 3,250,000

June 30, 2007                                   (euro) 3,250,000
September 30, 2007                              (euro) 3,250,000
December 31, 2007                               (euro) 3,250,000
March 31, 2008                                  (euro) 3,250,000

June 30, 2008                                   (euro) 3,250,000
September 30, 2008                              (euro) 4,875,000
December 31, 2008                               (euro) 4,875,000
March 31, 2009                                  (euro) 4,875,000

June 30, 2009                                   (euro) 4,875,000
September 30, 2009                              (euro) 4,875,000
December 31, 2009                               (euro)36,562,500

Term Loan Maturity Date                         (euro)36,562,500
</TABLE>

            (c) In addition to any other mandatory repayments or commitment
reductions pursuant to this Section 4.02, on each date on or after the Effective
Date upon which the U.S. Borrower or any of its Subsidiaries receives Net Sale
Proceeds from any Asset Sale (excluding any Asset Sale pursuant to clauses
(xvii) and/or (xviii) of Section 9.02), an amount equal to 100% of the Net Sale
Proceeds from such Asset Sale shall be applied as a mandatory repayment and/or
commitment reduction in accordance with the requirements of Sections 4.02(h) and
(i); provided that (x) no mandatory repayment or commitment reduction shall be
required pursuant to this Section 4.02(c) with respect to an aggregate amount
not to exceed $30,000,000 of Net Sale Proceeds received by the U.S. Borrower or
any of its Subsidiaries from the Asset Sales listed in Part B of Schedule XVII
hereto (including any such Net Sale Proceeds from such Asset Sales held in
escrow for the account of the U.S. Borrower or any of its Subsidiaries on or
prior to the Initial Borrowing Date) and (y) with respect to up to 50% of the
aggregate Net Sale Proceeds received by the U.S. Borrower and its Subsidiaries
after the Initial Borrowing Date from Asset Sales which would otherwise be
required to be applied as provided in this Section 4.02(c) (after giving effect
to the parenthetical contained above and to clause (x) of this proviso) (it
being understood and agreed that at no time after the Initial Borrowing Date may
greater than 50% of the aggregate of such Net Sale Proceeds of all Asset Sales
theretofore effected after the Initial

                                      -45-
<PAGE>

Borrowing Date be excluded pursuant to this proviso), such Net Sale Proceeds (or
the relevant portion thereof) shall not give rise to a mandatory repayment
and/or commitment reduction on such date as otherwise required above until such
time as $50,000,000 in the aggregate of Net Sale Proceeds shall have been
retained by the U.S. Borrower and its Subsidiaries (at which time this proviso
shall no longer apply), so long as no Default and no Event of Default exists at
the time such Net Sale Proceeds are received and an Authorized Officer of the
U.S. Borrower has delivered a certificate to the Administrative Agent on or
prior to such date stating that such Net Sale Proceeds shall be used (or
contractually committed to be used) for Capital Expenditures used or to be used
in a Permitted Business within 360 days following the date of receipt of such
Net Sale Proceeds from such Asset Sale (which certificate shall set forth the
estimates of the proceeds to be so expended); provided, further, that (A) at no
time may the certification described in clause (y) of the preceding proviso be
given for more than (x) 50% of aggregate Net Sale Proceeds received by the U.S.
Borrower from all Asset Sales (excluding Asset Sales pursuant to clauses (xvii)
and/or (xviii) of Section 9.02, and excluding Net Sale Proceeds excluded from
application pursuant to this Section 4.02(c) pursuant to clause (x) of the
immediately preceding proviso) effected after the Initial Borrowing Date or, if
less, (y) $50,000,000 and (B) (I) if all or any portion of such Net Sale
Proceeds are not so used within such 360-day period (or contractually committed
within such period to be used), such remaining portion shall be applied on the
last day of such period as a mandatory repayment as provided above (without
giving effect to the immediately preceding proviso) and (II) if all or any
portion of such Net Sale Proceeds are not required to be applied on the last day
of such 360-day period referred to in clause (I) of this proviso because such
amount is contractually committed within such period to be used and then either
(A) subsequent to such date such contract is terminated or expires without such
portion being so used or (B) such contractually committed portion is not so used
within six months after the last day of such 360-day period referred to in
clause (I) of this proviso, such remaining portion, in the case of either of the
preceding clauses (A) or (B), shall be applied as a mandatory repayment as
provided above (without giving effect to the immediately preceding proviso).
Notwithstanding the foregoing provisions of this Section 4.02(c), if the amount
required to be applied as a mandatory repayment and/or commitment reduction on
any date is less than $5,000,000, and so long as no Default or Event of Default
shall have occurred and be continuing, the Borrowers may defer any mandatory
repayments and/or commitment reduction required pursuant to this Section 4.02(c)
until the first date on which the aggregate Net Sale Proceeds from all Asset
Sales required to be applied pursuant to this Section 4.02(c) equals or exceeds
$5,000,000 (at which time all theretofore unapplied amounts shall be required to
be applied). Mandatory repayments of Term Loans required to be made pursuant to
this clause (c) in connection with a sale of all or substantially all of the
assets of the U.S. Borrower and its Subsidiaries or the European Borrower and
its Subsidiaries prior to the first anniversary of the Initial Borrowing Date
shall be subject to the payment of the fee described in Section 3.01(e).

            (d) In addition to any other mandatory repayments or commitment
reductions pursuant to this Section 4.02, on each date on or after the Effective
Date on which the U.S. Borrower or any of its Subsidiaries receives any cash
proceeds from (i) any incurrence of Indebtedness (other than Indebtedness
permitted to be incurred pursuant to Section 9.04 as in effect on the Effective
Date), (ii) any issuance of Equity Interests by the U.S. Borrower (excluding (x)
proceeds received from the sale or issuance by the U.S. Borrower of shares of
its common stock (including as a result of the exercise of options or warrants
with regard thereto) or options or warrants to purchase shares of its common
stock, to any employee, officer or director

                                      -46-
<PAGE>

of the U.S. Borrower or any its subsidiaries in an aggregate amount (for all
such sales and issuances) not to exceed $1,000,000 in any Fiscal Year of the
U.S. Borrower and (y) proceeds received from the sale or issuance by the U.S.
Borrower of shares of its common stock which are used concurrently with such
issuance as consideration for a Permitted Acquisition) or (iii) any issuance of
capital stock or other Equity Interests by, or cash capital contributions to,
any Subsidiary of the U.S. Borrower (other than (x) issuances of Equity
Interests to the U.S. Borrower or any other Subsidiary of the U.S. Borrower by
any Subsidiary of the U.S. Borrower, and (y) cash capital contributions to any
Subsidiary of the U.S. Borrower by the U.S. Borrower or any Subsidiary of the
U.S. Borrower), an amount equal to 100% of the Net Cash Proceeds of the
respective incurrence of Indebtedness, issuance of Equity Interests or cash
capital contribution shall be applied as a mandatory repayment and/or commitment
reduction in accordance with the requirements of Sections 4.02(h) and (i);
provided that any Net Cash Proceeds received by the U.S. Borrower from the
exercise of Plan Warrants, the aggregate amount of which does not exceed
$1,000,000 in any Fiscal Year of the U.S. Borrower, shall not be required to be
applied as a mandatory repayment (and/or commitment reduction, as the case may
be) pursuant to this Section 4.02(d); and provided further, that on each date on
which the U.S. Borrower receives Net Cash Proceeds from the exercise of Plan
Warrants in excess of $1,000,000 during any Fiscal Year of the U.S. Borrower, so
long as (x) no Default or Event of Default is then in existence and (y) the
Leverage Ratio then in effect is less than 2.25:1.00 (determined after giving
effect to any payment required on such date pursuant to this Section 4.02(d)
after giving effect to this proviso), then only 50% of such Net Cash Proceeds
shall be required to be applied as a mandatory repayment (and/or commitment
reduction, as the case may be) pursuant to this Section 4.02(d). Mandatory
repayments of Term Loans required pursuant to this Section 4.02(d) prior to the
first anniversary of the Initial Borrowing Date shall be subject to the payment
of the fee described in Section 3.01(e); provided that such mandatory
repayments, to the extent made with Net Cash Proceeds received by the U.S.
Borrower from the exercise of Plan Warrants, shall not be subject to the payment
of the fee described in Section 3.01(e).

            (e) In addition to any other mandatory repayments or commitment
reductions pursuant to this Section 4.02, within 10 days following each date on
or after the Effective Date on which the U.S. Borrower or any of its
Subsidiaries receives any proceeds from any Recovery Event (other than proceeds
from Recovery Events in an amount less than $1,000,000 per Recovery Event), an
amount equal to 100% of the proceeds of such Recovery Event (net of reasonable
costs (including, without limitation, legal costs and expenses) and taxes
incurred in connection with such Recovery Event and the amount of such proceeds
required to be used to repay any Indebtedness (other than Indebtedness of the
Lenders pursuant to this Agreement) which is secured by the respective assets
subject to such Recovery Event) shall be applied as a mandatory repayment and/or
commitment reduction in accordance with the requirements of Sections 4.02(h) and
(i); provided that so long as no Default and no Event of Default then exists and
such proceeds do not exceed $5,000,000, such proceeds shall not be required to
be so applied on such date to the extent that an Authorized Officer of the U.S.
Borrower has delivered a certificate to the Administrative Agent on or prior to
such date stating that such proceeds shall be used (or contractually committed
to be used) within 360 days following the date of receipt of such proceeds from
such Recovery Event to replace or restore any properties or assets in respect of
which such proceeds were paid (which certificate shall set forth the estimates
of the proceeds to be so expended), and provided, further, that (I) if all or
any portion of such proceeds are not so used (or contractually committed to be
used) within such 360-day period, such remaining portion

                                      -47-
<PAGE>

shall be applied as a mandatory repayment and/or commitment reduction as
provided above (without giving effect to the immediately preceding proviso) and
(II) if all or any portion of such proceeds are not required to be applied on
the last day of such 360-day period referred to in clause (I) of this proviso
because such amount is contractually committed to be used and then either (A)
subsequent to such date such contract is terminated or expires without such
portion being so used or (B) such contractually committed portion is not so used
within six months after the last day of such 360-day period referred to in
clause (I) of this proviso, such remaining portion, in the case of either of the
preceding clauses (A) or (B), shall be applied as a mandatory repayment and/or
commitment reduction as provided above (without giving effect to the immediately
preceding proviso).

            (f) In addition to any other mandatory repayments or commitment
reductions pursuant to this Section 4.02, on each Excess Cash Payment Date, an
amount equal to the Applicable Prepayment Percentage of the Excess Cash Flow for
the relevant Excess Cash Flow Payment Period shall be applied as a mandatory
repayment and/or commitment reduction in accordance with the requirements of
Sections 4.02(h) and (i).

            (g) Notwithstanding anything to the contrary contained elsewhere in
this Agreement, (i) all then outstanding Swingline Loans shall be repaid in full
on the Swingline Expiry Date, (ii) all other then outstanding Loans shall be
repaid in full on the respective Maturity Date for such Loans and (iii) unless
the Required Lenders shall otherwise agree in writing in their sole discretion,
all outstanding Loans shall be repaid in full upon the occurrence of a Change of
Control. Mandatory repayments of Term Loans required pursuant to subclause (iii)
of this Section 4.02(g) prior to the first anniversary of the Initial Borrowing
Date shall be subject to the payment of the fee described in Section 3.01(e).

            (h) (I) Each amount required to be applied pursuant to Sections
4.02(c), (d), (e) and (f) in accordance with this Section 4.02(h) shall, subject
to Section 4.02(j), be applied (i) first, to repay the outstanding principal
amount of Term Loans and (ii) second, to the extent in excess of the amounts
required to be applied pursuant to preceding clause (i), to permanently reduce
the Total Multicurrency Facility Revolving Loan Commitment.

            (II) Each amount required to be applied to repay outstanding Term
Loans pursuant to this Section 4.02(h) shall, subject to the immediately
succeeding proviso, be applied pro rata to each Tranche of Term Loans (based
upon the TL Repayment Percentages of the various Tranches of Term Loans and the
then outstanding principal amounts of the respective Tranches of Term Loans);
provided that (i) the Net Sale Proceeds from any Asset Sale effected by the U.S.
Borrower or any of its Domestic Subsidiaries and required to be applied to the
repayment of Term Loans pursuant to clause (I) of this Section 4.02(h), shall be
applied (x) first, to repay principal of outstanding U.S. Borrower Term Loans
and (y) second, after the repayment in full of all outstanding U.S. Borrower
Term Loans, to repay principal of outstanding European Borrower Dollar Term
Loans and European Borrower Euro Term Loans, on a pro rata basis (based on the
then outstanding relative principal amounts thereof, taking the Dollar
Equivalent of any amounts expressed in Euros), and (ii) the Net Sale Proceeds
from any Asset Sale effected by any Foreign Subsidiary of the U.S. Borrower and
required to be applied to the repayment of Term Loans pursuant to clause (I) of
this Section 4.02(h), shall be applied (x) first, to repay principal of
outstanding European Borrower Dollar Term Loans and European Borrower Euro

                                      -48-
<PAGE>

Term Loans, on a pro rata basis (based on the then outstanding relative
principal amounts thereof, taking the Dollar Equivalent of any amounts in
Euros), and (y) second, after the repayment in full of all outstanding European
Borrower Dollar Term Loans and European Borrower Euro Term Loans, to repay
principal of outstanding U.S. Borrower Term Loans.

            (III) (x) The amount of any reduction to the Multicurrency Facility
Revolving Loan Commitments as provided in subclause (I)(ii) of this Section
4.02(h) above shall be deemed to be an application of proceeds for purposes of
this Section 4.02(h) even though cash may not be required to actually be
applied, (y) in connection with any reduction to the Total Multicurrency
Facility Revolving Loan Commitment, any cash received by the U.S. Borrower or
any Subsidiary of the U.S. Borrower in connection with the event giving rise to
such reduction will be retained by such Person, except to the extent that such
cash is otherwise required to be applied as provided in Section 4.02(a) as a
result of any such reduction to the Total Multicurrency Facility Revolving Loan
Commitment and (z) each reduction to the Total Multicurrency Facility Revolving
Loan Commitment shall apply to reduce the respective underlying Commitments of
the Lenders on a pro rata basis as provided in Section 3.03(f).

            (IV) All repayments of outstanding Term Loans pursuant to Section
4.02(c), (d), (e) or (f) shall be applied to reduce the then remaining Scheduled
Repayments of the respective Tranche of Term Loans on a pro rata basis (based
upon the then remaining principal amounts of the Scheduled Repayments of such
Tranche of Term Loans after giving effect to all prior reductions thereto).

            (i) With respect to each repayment of Loans required by this Section
4.02, the respective Borrower may (subject to the requirements of preceding
clause (h)) designate the Types of Loans of the respective Tranche which are to
be repaid and, in the case of Euro Rate Loans (other than Swingline Loans), the
specific Borrowing or Borrowings of the respective Tranche pursuant to which
made, provided that: (i) in the case of repayments of Euro Rate Loans (other
than Swingline Loans), repayments of such Loans pursuant to this Section 4.02 on
any day other than the last day of an Interest Period applicable thereto shall
be accompanied by payment by the respective Borrower of all amounts owing in
connection therewith pursuant to Section 1.11; (ii) if any repayment of Euro
Rate Loans (other than Swingline Loans) made pursuant to a single Borrowing
shall reduce the outstanding Euro Rate Loans made pursuant to such Borrowing to
an amount less than the Minimum Borrowing Amount applicable to the respective
Euro Rate Loans, such Borrowing (x) in the case of Eurodollar Loans, shall be
converted at the end of the then current Interest Period into a Borrowing of
Base Rate Loans and (y) in the case of Euro Denominated Revolving Loans, shall
be repaid in full at the end of the then current Interest Period; and (iii) each
repayment of any Tranche of Loans made pursuant to a Borrowing shall be applied
pro rata among such Tranche of Loans. In the absence of a designation by the
respective Borrower as described in the preceding sentence, the Administrative
Agent shall, subject to the above, make such designation in its sole discretion
with a view, but no obligation, to minimize breakage costs owing under Section
1.11.

            (j) Notwithstanding anything to the contrary contained above, all
payments owing with respect to each Tranche pursuant to this Section 4.02 shall
be made in the respective currency or currencies in which the respective
obligations are owing in accordance with the terms of this Agreement. For
purposes of making calculations pursuant to this Section 4.02, the

                                      -49-
<PAGE>

Administrative Agent shall be entitled to use the Dollar Equivalent or Euro
Equivalent, as the case may be, of any such amounts required to be converted
into other currencies for purposes of making determinations pursuant to this
Section 4.02.

            4.03 Method and Place of Payment. Except as otherwise specifically
provided herein, all payments under this Agreement or any Note shall be made to
the Administrative Agent for the account of the Lender or Lenders entitled
thereto not later than 2:00 P.M. (New York time) on the date when due and shall
be made in (x) Dollars in immediately available funds at the Payment Office of
the Administrative Agent in respect of any obligation of the Borrowers under
this Agreement except as otherwise provided in the immediately following clause
(y) and (y) Euros in immediately available funds at the Payment Office of the
Administrative Agent, if such payment is made in respect of (i) principal of or
interest on Euro Denominated Loans, (ii) Letter of Credit Fees, Facing Fees and
Unpaid Drawings (and interest thereon) in respect of Euro Denominated Letters of
Credit at any time prior to the occurrence of a Sharing Event or (iii) any
increased costs, indemnities or other amounts owing with respect to Euro
Denominated Loans (or Commitments relating thereto) or Euro Denominated Letters
of Credit at any time prior to the occurrence of a Sharing Event. The
Administrative Agent will thereafter cause to be distributed on the same day (if
payment was actually received by the Administrative Agent prior to 2:00 P.M.
(New York time) like funds relating to the payment of principal, interest or
Fees ratably to the Lenders entitled thereto. Any payments under this Agreement
which are made later than 2:00 P.M. (New York time) shall be deemed to have been
made on the next succeeding Business Day. Whenever any payment to be made
hereunder or under any Note shall be stated to be due on a day which is not a
Business Day, the due date thereof shall be extended to the next succeeding
Business Day and, with respect to payments of principal, interest shall be
payable at the applicable rate during such extension.

            4.04 Net Payments. (a) All payments made by any Credit Party under
any Credit Document (including, in the case of the U.S. Borrower, in its
capacity as a guarantor pursuant to Section 14) or under any Note will be made
without setoff, counterclaim or other defense. Except as provided in Section
4.04(b), all such payments will be made free and clear of, and without deduction
or withholding for, any present or future taxes, levies, imposts, duties, fees,
assessments or other charges of whatever nature now or hereafter imposed by any
jurisdiction or by any political subdivision or taxing authority thereof or
therein with respect to such payments (but excluding, except as provided in the
second succeeding sentence, any tax imposed on or measured by the net income of
a Lender pursuant to the laws of the jurisdiction in which it is organized or
the jurisdiction in which the principal office or applicable lending office of
such Lender is located or any subdivision thereof or therein) and all interest,
penalties or similar liabilities with respect thereto (all such non-excluded
taxes, levies, imposts, duties, fees, assessments or other charges being
referred to collectively as "Taxes"). If any Taxes are so levied or imposed, the
respective Borrower (and any other Credit Party making the payment) agrees to
pay the full amount of such Taxes, and such additional amounts as may be
necessary so that every payment of all amounts due under this Agreement or under
any Note, after withholding or deduction for or on account of any Taxes, will
not be less than the amount provided for herein or in such Note. If any amounts
are payable in respect of Taxes pursuant to the preceding sentence, then the
respective Borrower (and any other Credit Party making the payment) shall be
obligated to reimburse each Lender, upon the written request of such Lender, for
the net additional taxes (after taking into account available credits with
respect to such

                                      -50-
<PAGE>

withholding taxes) imposed on or measured by the net income of such Lender
pursuant to the laws of the jurisdiction in which such Lender is organized or in
which the principal office or applicable lending office of such Lender is
located or under the laws of any political subdivision or taxing authority of
any such jurisdiction in which such Lender is organized or in which the
principal office or applicable lending office of such Lender is located and for
any withholding of taxes as such Lender shall determine are payable by, or
withheld from, such Lender in respect of such amounts so paid to or on behalf of
such Lender pursuant to the preceding sentence and in respect of any amounts
paid to or on behalf of such Lender pursuant to this sentence, the respective
Borrower (or Credit Party) will furnish to the Administrative Agent within 45
days after the date of the payment of any Taxes due pursuant to applicable law
certified copies of tax receipts evidencing such payment by such Borrower (or
the respective other Credit Party). The Credit Agreement Parties jointly and
severally agree (and each Subsidiary Guarantor pursuant to its respective
Subsidiary Guaranty, and the incorporation by reference therein of the
provisions of this Section 4.04, shall agree) to indemnify and hold harmless
each Lender, and reimburse such Lender upon its written request, for the amount
of any Taxes so levied or imposed and paid by such Lender.

            (b) Each Lender that is not a United States person (as such term is
defined in Section 7701(a)(30) of the Code) agrees to deliver to the U.S.
Borrower and the Administrative Agent on or prior to the Effective Date, or in
the case of a Lender that is an assignee or transferee of an interest under this
Agreement pursuant to Section 1.13 or 13.04 (unless the respective Lender was
already a Lender hereunder immediately prior to such assignment or transfer), on
the date of such assignment or transfer to such Lender, (i) two accurate and
complete original signed copies of Internal Revenue Service Form W-8ECI or Form
W-8BEN (with respect to a complete exemption under an income tax treaty) (or
successor forms) certifying to such Lender's entitlement as of such date to a
complete exemption from United States withholding tax with respect to payments
to be made under this Agreement and under any Note, or (ii) if the Lender is not
a "bank" within the meaning of Section 881(c)(3)(A) of the Code and cannot
deliver either Internal Revenue Service Form W-8ECI or Form W-8BEN (with respect
to a complete exemption under an income tax treaty) pursuant to clause (i)
above, (x) a certificate substantially in the form of Exhibit D (any such
certificate, a "Section 4.04(b)(ii) Certificate") and (y) two accurate and
complete original signed copies of Internal Revenue Service Form W-8BEN (with
respect to the portfolio interest exemption) (or successor form) certifying to
such Lender's entitlement as of such date to a complete exemption from United
States withholding tax with respect to payments of interest to be made under
this Agreement and under any Note. In addition, each Lender agrees that from
time to time after the Effective Date, when a lapse in time or change in
circumstances renders the previous certification obsolete or inaccurate in any
material respect, it will deliver to the U.S. Borrower and the Administrative
Agent two new accurate and complete original signed copies of Internal Revenue
Service Form W-8ECI, Form W-8BEN (with respect to the benefits of any income tax
treaty), or Form W-8BEN (with respect to the portfolio interest exemption) and a
Section 4.04(b)(ii) Certificate, as the case may be, and such other forms as may
be required in order to confirm or establish the entitlement of such Lender to a
continued exemption from or reduction in United States withholding tax with
respect to payments under this Agreement and any Note, or it shall immediately
notify the U.S. Borrower and the Administrative Agent of its inability to
deliver any such Form or Certificate, in which case such Lender shall not be
required to deliver any such Form or Certificate pursuant to this Section
4.04(b). Notwithstanding anything to the contrary contained in Section 4.04(a),
but subject to Section

                                      -51-
<PAGE>

13.04(b) and Section 4.04(d), (x) the U.S. Borrower shall be entitled, to the
extent it is required to do so by law, to deduct or withhold income or similar
taxes imposed by the United States (or any political subdivision or taxing
authority thereof or therein) from interest, fees or other amounts payable by
the U.S. Borrower hereunder for the account of any Lender which is not a United
States person (as such term is defined in Section 7701(a)(30) of the Code) for
U.S. Federal income tax purposes to the extent that such Lender has not provided
to the U.S. Borrower U.S. Internal Revenue Service Forms that establish a
complete exemption from such deduction or withholding and (y) the U.S. Borrower
shall not be obligated pursuant to Section 4.04(a) hereof to gross-up payments
to be made to a Lender in respect of income or similar taxes imposed by the
United States if (I) such Lender has not provided to the U.S. Borrower the
Internal Revenue Service Forms required to be provided to the U.S. Borrower
pursuant to this Section 4.04(b) or (II) in the case of a payment, other than
interest, to a Lender described in clause (ii) above, to the extent that such
forms do not establish a complete exemption from withholding of such taxes.

            (c) Each Lender agrees, to the extent it is legally entitled to do
so, to deliver to the European Borrower and the Administrative Agent on or prior
to the Effective Date, or in the case of a Lender that is an assignee or
transferee of an interest under this Agreement pursuant to Section 1.13, 1.14 or
13.04 (unless the respective Lender was already a Lender hereunder immediately
prior to such assignment or transfer), to the extent such Lender is legally
entitled to do so, on the date of such assignment or transfer to such Lender two
accurate and complete original signed copies of any forms or certificates that
the European Borrower shall request such Lender to deliver to it and the
Administrative Agent, to the extent such forms or certificates are necessary to
claim exemption from or reduction in withholding taxes imposed by the
Netherlands with respect to payments under this Agreement (the "Netherlands
Forms"). In addition, each Lender agrees that from time to time after the
Effective Date, when a lapse in time or change in circumstances renders the
previous forms or certificates obsolete or inaccurate in any material respect,
it will (in the case of a lapse in time that renders the previous forms or
certificates obsolete or inaccurate, only upon request from the European
Borrower), to the extent it is legally entitled to do so, deliver to the
European Borrower and the Administrative Agent two new accurate and complete
original signed copies of the Netherlands Forms and such other forms or
certificates as may be required in order to confirm or establish the entitlement
of such Lender to a continued exemption from or reduction in Netherlands
withholding tax with respect to payments under this Agreement and any Note, or
it shall notify the European Borrower and the Administrative Agent of its
inability to deliver the Netherlands Forms or such other forms or certificates
requested by the European Borrower, in which case such Lender shall not be
required to deliver any such Netherlands Forms or other forms or certificates
pursuant to this Section 4.04(c). Notwithstanding anything to the contrary
contained in Section 4.04(a), but subject to Section 13.04(b) and Section
4.04(d), (x) the European Borrower shall be entitled, to the extent it is
required to do so by law, to deduct or withhold income or similar taxes imposed
by the Netherlands (or any political subdivision or taxing authority thereof or
therein) from interest, fees or other amounts payable by the European Borrower
hereunder for the account of any Lender to the extent that such Lender has not
provided to the European Borrower any requested Netherlands Forms that establish
a complete exemption from such deduction or withholding and (y) the European
Borrower shall not be obligated pursuant to Section 4.04(a) hereof to gross-up
payments to be made to a Lender in respect of income or similar taxes imposed by
the Netherlands if such Lender has not provided to the European Borrower any
requested

                                      -52-
<PAGE>

Netherlands Forms that establish a complete exemption from Netherlands
withholding tax pursuant to this Section 4.04(c).

            (d) Notwithstanding anything to the contrary contained elsewhere in
this Section 4.04 and except as set forth in Section 13.04(b), each Borrower
agrees to pay additional amounts and to indemnify each Lender in the manner set
forth in Section 4.04(a) (without regard to the identity of the jurisdiction
requiring the deduction or withholding) in respect of any amounts deducted or
withheld by it as described in Sections 4.02(b) and (c) (x) as a result of any
changes after the Effective Date (or, if later, the date such Lender became
party to this Agreement) in any applicable law, treaty, governmental rule,
regulation, guideline or order, or in the interpretation thereof, relating to
the deducting or withholding of income or similar taxes or (y) with respect to
any Lender that is not legally entitled to provide to the European Borrower any
requested Netherlands Forms or such other forms or certificates as may be
required in order to confirm or establish the entitlement of such Lender to an
exemption from or reduction in Netherlands withholding tax pursuant to Section
4.04(c), as a result of the purchase of a participation by such Lender as
required by Section 1.14 following the occurrence of a Sharing Event.

            SECTION 5. Conditions Precedent to Credit Events on the Initial
Borrowing Date. The obligation of each Lender to make each Loan hereunder and
the obligation of each Issuing Lender to issue each Letter of Credit hereunder,
in any case on the Initial Borrowing Date, is subject, at the time of the making
of such Loans and the issuance of such Letters of Credit to the satisfaction of
the following conditions:

            5.01 Execution of Agreement; Notes. On or prior to the Initial
Borrowing Date, (i) the Effective Date shall have occurred and (ii) there shall
have been delivered to the Administrative Agent for the account of each Lender
which has requested the same the appropriate U.S. Borrower Term Note, European
Borrower Dollar Term Note, European Borrower Euro Term Note, European Borrower
Multicurrency Facility Revolving Note and/or U.S. Borrower Multicurrency
Facility Revolving Note, and to the Swingline Lender, if so requested by it, the
European Borrower Swingline Note and the U.S. Borrower Swingline Note, in each
case executed by the relevant Borrower and in the amount, maturity and as
otherwise provided herein.

            5.02 Officer's Certificate. On the Initial Borrowing Date, the
Administrative Agent shall have received a certificate from the U.S. Borrower,
dated such date and signed by an Authorized Officer of the U.S. Borrower,
certifying that all of the applicable conditions set forth in Sections 5.05
through 5.08, inclusive, and Section 6.01 (other than such conditions that are
expressly subject to the satisfaction of the Administrative Agent and/or the
Required Lenders), have been satisfied on such date.

            5.03 Opinions of Counsel. On the Initial Borrowing Date, the
Administrative Agent shall have received (i) from Kirkland & Ellis LLP, special
counsel to the Credit Parties, an opinion addressed to each Agent and each of
the Lenders and dated the Initial Borrowing Date substantially in the form of
Exhibit E-1, (ii) from AKD Prinsen Van Wijmen, special Dutch counsel to the
Credit Parties organized under the laws of The Netherlands, an opinion addressed
to each Agent and each of the Lenders and dated the Initial Borrowing Date
substantially in the

                                      -53-
<PAGE>

form of Exhibit E-2, (iii) from foreign counsel to the Credit Parties and/or the
Agents in each Qualified Non-U.S. Jurisdiction, in each case reasonably
satisfactory to the Administrative Agent, opinions which shall (x) be addressed
to each Agent and each of the Lenders and be dated the Initial Borrowing Date,
(y) cover various matters regarding the execution, delivery and performance of
the Credit Documents to which Subsidiaries of the U.S. Borrower organized in the
relevant such jurisdiction are party, the perfection and priority of security
interests and/or liens granted by Credit Parties organized in such jurisdiction
or granted in respect of entities organized in such jurisdiction, and/or such
other matters incident to the transactions contemplated herein as the
Administrative Agent may reasonably request and (z) be in form, scope and
substance reasonably satisfactory to the Administrative Agent, (iv) from local
counsel to the U.S. Credit Parties and/or the Administrative Agent reasonably
satisfactory to the Administrative Agent practicing in those jurisdictions in
which U.S. Mortgaged Properties are located and/or U.S. Subsidiary Guarantors
are organized, such opinions as the Administrative Agent may reasonably request,
which opinions (x) shall be addressed to each Agent and each of the Lenders and
be dated the Initial Borrowing Date, (y) shall cover the perfection of the
security interests and/or liens granted pursuant to the relevant Security
Documents and such other matters incident to the transactions contemplated
herein as the Administrative Agent may reasonably request and (z) shall be in
form and substance reasonably satisfactory to the Administrative Agent, and (v)
reliance letters addressed to each Agent and each of the Lenders and dated the
Initial Borrowing Date with respect to such legal opinions delivered in
connection with the Acquisition, as may have been requested by the
Administrative Agent or the Required Lenders, which reliance letters and
opinions shall cover such matters as the Administrative Agent may reasonably
request and be in form, scope and substance reasonably satisfactory to the
Administrative Agent.

            5.04 Company Documents; Proceedings. (a) On the Initial Borrowing
Date, the Administrative Agent shall have received from each Borrower and each
U.S. Subsidiary Guarantor a certificate, dated the Initial Borrowing Date,
signed by the chairman, a vice-chairman, the president or any vice-president of
such Credit Party, and attested to by the secretary, any assistant secretary or
other senior officer of such Credit Party, in the form of Exhibit F with
appropriate insertions, together with copies of the certificate of
incorporation, by-laws or equivalent organizational documents of such Credit
Party and the resolutions of such Credit Party referred to in such certificate
(and, in the case of the certificate from the U.S. Borrower, together with
copies of the certificates of incorporation, by-laws or equivalent
organizational documents of each Foreign Subsidiary of the U.S. Borrower (x)
which is a Subsidiary Guarantor or (y) in respect of which security interests
are being granted by a Subsidiary Guarantor), and all of the foregoing
(including each such certificate of incorporation, by-laws or other
organizational document) shall be reasonably satisfactory to the Administrative
Agent.

            (b) On the Initial Borrowing Date, all instruments and agreements in
connection with the transactions contemplated by this Agreement and the other
Documents shall be reasonably satisfactory in form and substance to the
Administrative Agent, and the Administrative Agent shall have received all
information and copies of all certificates, documents and papers, including good
standing certificates, bring-down certificates and any other records of Company
proceedings and governmental approvals, if any, which the Administrative Agent
reasonably may have requested in connection therewith, such documents and
papers, where appropriate, to be certified by proper Company or governmental
authorities.

                                      -54-
<PAGE>

            (c) On the Initial Borrowing Date and after giving effect to the
Transaction, the capital structure (including, without limitation, the terms of
any capital stock, options, warrants or other securities issued by the U.S.
Borrower and its Subsidiaries) and the plans for the retention of the senior
management of the U.S. Borrower and its Subsidiaries shall be in form and
substance reasonably satisfactory to the Administrative Agent.

            5.05 Adverse Change, etc. On the Initial Borrowing Date, nothing
shall have occurred since March 31, 2003 (and the Administrative Agent and
Lenders shall have become aware of no facts, conditions or other information not
previously known) which the Administrative Agent or the Required Lenders shall
reasonably determine has had, or could reasonably be likely to have, (i) a
Material Adverse Effect or (ii) material adverse effect on the Transaction.

            5.06 Litigation. On the Initial Borrowing Date, there shall be no
actions, suits, proceedings or investigations pending or threatened (a) with
respect to the Transaction or any documentation executed in connection therewith
(including any Credit Document) or the transactions contemplated hereby and
thereby, (b) with respect to any Scheduled Existing Indebtedness or (c) which
the Administrative Agent or the Required Lenders shall reasonably determine has
had, or could reasonably be expected to have (i) a Material Adverse Effect or
(ii) a material adverse effect on the Transaction.

            5.07 Approvals. On or prior to the Initial Borrowing Date, (i) all
necessary governmental (domestic and foreign), regulatory and third party
approvals and/or consents in connection with any Scheduled Existing Indebtedness
or the Transaction and otherwise referred to herein or therein shall have been
obtained and remain in full force and effect and evidence thereof shall have
been provided to the Administrative Agent, and (ii) all applicable waiting
periods shall have expired without any action being taken by any competent
authority which restrains, prevents or imposes materially adverse conditions
upon the consummation of the Transaction, the making of the Loans and the
transactions contemplated by the Documents or otherwise referred to herein or
therein. Additionally, on the Initial Borrowing Date, there shall not exist any
judgment, order, injunction or other restraint issued or filed or a hearing
seeking injunctive relief or other restraint pending or notified prohibiting or
imposing materially adverse conditions upon, or materially delaying, or making
economically unfeasible, the consummation of the Transaction or the making of
the Loans or the other transactions contemplated by the Documents or otherwise
referred to herein or therein.

            5.08 Consummation of the Transaction. (a) On or prior to the Initial
Borrowing Date, (i) there shall have been delivered to the Administrative Agent
true and correct copies of (x) the Plan of Reorganization, the Disclosure
Statement and the Reorganization Documents, which Plan of Reorganization,
Disclosure Statement and Reorganization Documents shall, in each case, be in
form and substance reasonably satisfactory to the Administrative Agent and the
Required Lenders, (ii) a Notice of Confirmation, in form and substance
satisfactory to the Administrative Agent and the Required Lenders, shall have
been entered into and same shall not have been stayed and shall have become
final and non-appealable and (iii) all conditions precedent to the effective
date of the Plan of Reorganization shall have been satisfied (and not waived
without the consent of the Administrative Agent and the Required Lenders) to the
reasonable satisfaction of the Administrative Agent and the Required Lenders.

                                      -55-
<PAGE>

            (b) On the Initial Borrowing Date and prior to or concurrently with
the incurrence of the Loans hereunder, each element of the Transaction shall
have been consummated in accordance with the Plan of Reorganization and the
applicable Documents therefor. Pursuant to the Reorganization and the
Refinancing:

            (i) the total commitments in respect of the Indebtedness to be
      Refinanced shall have been terminated, all letters of credit issued
      thereunder shall have been terminated or supported by a back-stop Letter
      of Credit issued hereunder, and all loans, interest and other amounts
      owing pursuant to the Indebtedness to be Refinanced shall have been repaid
      or otherwise satisfied in full, in each case in accordance with the terms
      of the Plan of Reorganization, and all documents in respect of the
      Indebtedness to be Refinanced and all guarantees with respect thereto
      shall have been terminated and be of no further force and effect;

            (ii) the Administrative Agent shall have received (x) releases of
      security interests in and Liens on the assets owned by the U.S. Borrower
      and its Subsidiaries from the creditors in respect of the Indebtedness to
      be Refinanced (including, without limitation, (I) proper termination
      statements (Form UCC-3 or the appropriate equivalent) for filing under the
      UCC of each jurisdiction where a financing statement (Form UCC-1 or the
      appropriate equivalent) was filed with respect to the U.S. Borrower or any
      of its Subsidiaries in connection with the security interests created with
      respect to the Indebtedness to be Refinanced and the documentation related
      thereto, (II) termination or reassignment of any security interest in, or
      Lien on, any patents, trademarks, copyrights, or similar interests of the
      U.S. Borrower or any of its Subsidiaries on which filings have been made
      and (III) terminations of all mortgages, leasehold mortgages, deeds of
      trust and leasehold deeds of trust created with respect to property of the
      U.S. Borrower or any of its Subsidiaries, in each case, to secure the
      obligations in respect of the Indebtedness to be Refinanced), all of which
      shall be in form, scope and substance reasonably satisfactory to the
      Administrative Agent, and (y) all collateral owned by the U.S. Borrower or
      any of its Subsidiaries in the possession of any of the creditors in
      respect of the Indebtedness to be Refinanced or any collateral agent or
      trustee under any related security document;

            (iii) U.S. Borrower Common Stock, representing approximately 90% of
      the aggregate equity value of the U.S. Borrower (prior to giving effect to
      any employee equity compensation plan), shall have been issued, in each
      case, to the lenders under the Existing Pre-Petition Credit Agreement on
      the terms specified in the Plan of Reorganization;

            (iv) the holders of General Unsecured Claims (including, without
      limitation, the holders of the Existing Senior Notes) shall have been
      issued (or the U.S. Borrower shall have reserved for issuance to them upon
      resolution of Disputed Claims) shares of U.S. Borrower Common Stock
      representing approximately 10% of the aggregate equity value of the U.S.
      Borrower (prior to giving effect to any employee equity compensation plan)
      on the terms specified in the Plan of Reorganization;

            (v) with respect to any Pre-Petition Foreign Secured Claims which
      are not discharged pursuant to the Plan of Reorganization, (A) the
      Administrative Agent shall

                                      -56-
<PAGE>

      have received an amendment to the Existing Pre-Petition Credit Agreement
      in form and substance reasonably satisfactory to the Administrative Agent
      and the Required Lenders, which amendment shall (i) remove all affirmative
      and negative covenants contained in the Existing Pre-Petition Credit
      Agreement, (ii) release all security interests in and Liens on the assets
      owned by Holdings and its Subsidiaries from the creditors in respect of
      the Existing Pre-Petition Credit Agreement and (iii) have become effective
      in accordance with its terms and (B) there shall be no more than
      $17,500,000 of Indebtedness outstanding under the Existing Pre-Petition
      Credit Agreement with respect to Pre-Petition Foreign Secured Claims;

            (vi) on the Initial Borrowing Date, the European Borrower shall
      (subject to Section 7.05(a)) have utilized all or a portion of the
      proceeds of the European Borrower Dollar Term Loans and European Borrower
      Euro Term Loans to make secured intercompany loans and/or capital
      contributions to its Subsidiaries in amounts and on terms (including
      without limitation as to any security therefor and guarantees thereof)
      satisfactory to the Administrative Agent and the Lenders (the
      "Intercompany Loans"); and

            (vii) the Administrative Agent shall have received evidence in form,
      scope and substance reasonably satisfactory to it that the matters set
      forth in this Section 5.08(b) have been satisfied on such date.

            (c) On the Initial Borrowing Date and after giving effect to the
Transaction and the Loans incurred on the Initial Borrowing Date, neither the
U.S. Borrower nor any of its Subsidiaries shall have any Preferred Equity or any
Indebtedness outstanding, except for (i) the Obligations, (ii) the Assumed
Liabilities and (iii) the other Scheduled Existing Indebtedness. On and as of
the Initial Borrowing Date, all of the Scheduled Existing Indebtedness and all
material contractual Assumed Liabilities shall remain outstanding after giving
effect to the Transaction and the other transactions contemplated hereby without
any default or events of default existing thereunder or arising as a result of
the Transaction and the other transactions contemplated hereby (except to the
extent amended or waived by the parties thereto on terms and conditions
reasonably satisfactory to the Administrative Agent and the Required Lenders).
On and as of the Initial Borrowing Date, the Administrative Agent and the
Required Lenders shall be satisfied with the amount of and the terms and
conditions of all Scheduled Existing Indebtedness and Assumed Liabilities.

            (d) On or prior to the Initial Borrowing Date, (i) there shall have
been delivered to the Administrative Agent true and correct copies of all
Documents (other than the Credit Documents), (ii) all such Documents, and all
terms and conditions thereof, shall be in form and substance reasonably
satisfactory to the Administrative Agent and the Required Lenders and (iii) all
such Documents shall be in full force and effect.

            (e) On or prior to the Initial Borrowing Date, the Administrative
Agent shall have received evidence in form, scope and substance reasonably
satisfactory to it that (x) all commitments to purchase receivables under the
European Receivables Facility have been terminated as of the Initial Borrowing
Date, (y) no receivables shall be sold pursuant to the European Receivables
Facility on or after the Initial Borrowing Date and (z) that the European

                                      -57-
<PAGE>

Receivables Facility (and all agreements relating thereto (other than agreements
pursuant to which Batteries Funding Limited (x) is administered, (y) collects
payments on receivables owned by the U.S. Borrower and its Subsidiaries on their
behalf and (z) transfers or arranges for the transfer of all such collected
funds to the U.S. Borrower and its Subsidiaries)) shall be terminated within 30
days after the Initial Borrowing Date.

            5.09 Subsidiaries Guaranties; Intercompany Subordination Agreement.
(a) On the Initial Borrowing Date, each U.S. Subsidiary Guarantor shall have
duly authorized, executed and delivered the U.S. Subsidiaries Guaranty in the
form of Exhibit G-1 (as amended, modified, restated and/or supplemented from
time to time, the "U.S. Subsidiaries Guaranty"), guaranteeing all of the
obligations of each of the Borrowers as more fully provided therein, and the
U.S. Subsidiaries Guaranty shall be in full force and effect.

            (b) On the Initial Borrowing Date, each Wholly-Owned Foreign
Subsidiary of the U.S. Borrower (other than the European Borrower and the
Non-Guarantor Subsidiaries at such time) shall have duly authorized, executed
and delivered the Guaranty in the form of Exhibit G-2 with such modifications or
in such other form as may be necessary or advisable under local law (as
determined by the Administrative Agent and its local counsel) (each such
guaranty as amended, modified, restated and/or supplemented from time to time, a
"Foreign Subsidiaries Guaranty" and, collectively, the "Foreign Subsidiaries
Guaranties")), guaranteeing all of the obligations of the European Borrower as
more fully provided therein (subject to such limits under local law as may be
necessary or advisable, as agreed by the Administrative Agent and its local
counsel), and each Foreign Subsidiaries Guaranty shall be in full force and
effect.

            (c) On the Initial Borrowing Date, each Credit Party and each other
Subsidiary of the U.S. Borrower which is an obligee or obligor with respect to
any Intercompany Debt (other than those Non-Wholly Owned Subsidiaries listed on
Part D of Schedule XI) shall have duly authorized, executed and delivered the
Intercompany Subordination Agreement in the form of Exhibit O hereto (as
amended, modified, restated and/or supplemented from time to time, the
"Intercompany Subordination Agreement"), and the Intercompany Subordination
Agreement shall be in full force and effect.

            5.10 Pledge Agreements. (a) On the Initial Borrowing Date, each U.S.
Credit Party shall have duly authorized, executed and delivered the U.S. Pledge
Agreement in the form of Exhibit H (as amended, modified, restated and/or
supplemented from time to time, the "U.S. Pledge Agreement") and shall have
delivered to the Collateral Agent, as Pledgee thereunder, all of the U.S. Pledge
Agreement Collateral, if any, referred to therein and then owned by such U.S.
Credit Party, (x) endorsed in blank in the case of promissory notes constituting
U.S. Pledge Agreement Collateral and (y) together with executed and undated
transfer powers in the case of certificated Equity Interests constituting U.S.
Pledge Agreement Collateral, and the U.S. Pledge Agreement shall be in full
force and effect.

            (b) On the Initial Borrowing Date, (i) each of the Foreign Credit
Parties listed on Part A of Schedule XI shall have duly authorized, executed and
delivered a pledge agreement or pledge agreements governed by the laws of the
jurisdiction in which the issuer of the Equity Interests pledged thereby is
organized (subject to certain exceptions as are necessary or advisable based on
the advice of local counsel), which pledge agreements shall (x) be prepared by
local

                                      -58-
<PAGE>

counsel reasonably satisfactory to the Administrative Agent, (y) be in form and
substance reasonably satisfactory to the Administrative Agent and (z) be in full
force and effect (each such pledge agreement, as amended, modified, restated
and/or supplemented from time to time, a "Foreign Credit Party Pledge Agreement"
and, collectively, the "Foreign Credit Party Pledge Agreements") and (ii) such
Foreign Credit Parties shall have taken such actions as may be necessary (or
reasonably requested by the Administrative Agent or its counsel) under local law
(as advised by local counsel) to create, maintain, effect, perfect, preserve,
maintain and protect the security interests granted (or purported to be granted)
by each such Foreign Credit Party Pledge Agreement. Part A of Schedule XI sets
forth a list of all Foreign Credit Party Pledge Agreements to be executed and
delivered on the Initial Borrowing Date.

            (c) On the Initial Borrowing Date, with respect to any Credit Party
(whether organized under the laws of the United States or a non-U.S.
jurisdiction) which is pledging promissory notes or Equity Interests in one or
more Persons organized under the laws of a different jurisdiction from the
jurisdiction of organization of the respective Credit Party, if the
Administrative Agent determines (based on advice of local counsel and to the
extent legally permitted by the relevant applicable foreign law) that it would
be in the interests of the Lenders that the respective Credit Party authorize,
execute and deliver one or more additional pledge agreements governed by the
laws of the jurisdiction or jurisdictions in which the Person or Persons whose
promissory notes or Equity Interests are being pledged is (or are) organized,
then the respective Credit Party shall, subject to local law limitations, (i) so
authorize, execute and deliver one or more such additional pledge agreements
(each, as amended, modified, restated and/or supplemented from time to time, a
"Local Law Pledge Agreement" and, collectively, the "Local Law Pledge
Agreements" and together with the Foreign Credit Party Pledge Agreements, the
"Foreign Pledge Agreements") and (ii) take such actions as may be necessary or
desirable under local law (as advised by local counsel) to create, maintain,
effect, perfect, preserve, maintain and protect the security interests granted
(or purported to be granted) by each such Local Law Pledge Agreement. Each Local
Law Pledge Agreement shall (i) be prepared by local counsel reasonably
satisfactory to the Administrative Agent, (ii) be in form and substance
reasonably satisfactory to the Administrative Agent and (iii) be in full force
and effect on the Initial Borrowing Date, it being understood and agreed,
however, in the case of any Local Law Pledge Agreement entered into by the U.S.
Borrower or any of its Domestic Subsidiaries, the respective Credit Party shall
not be required to pledge more than 65% of the total combined voting power of
all classes of Equity Interests entitled to vote of any Foreign Subsidiary that
is a corporation (or treated as such for U.S. federal tax purposes) in support
of its obligations (x) as a Borrower under the Credit Agreement (in the case of
the U.S. Borrower) or (y) under its Guaranty in respect of the Obligations of
the U.S. Borrower (in the case of the other U.S. Credit Parties) (although 100%
of the non-voting Equity Interests, if any, of each such Foreign Subsidiary
shall be required to be pledged in support of such obligations). Part B of
Schedule XI sets forth a list of all Local Law Pledge Agreements to be executed
and delivered on the Initial Borrowing Date.

            5.11 U.S. Security Agreement. On the Initial Borrowing Date, each
U.S. Credit Party shall have duly authorized, executed and delivered the
Security Agreement in the form of Exhibit I (as amended, modified, restated
and/or supplemented from time to time, the "U.S. Security Agreement") covering
all of such U.S. Credit Party's present and future Security Agreement Collateral
referred to therein, together with:

                                      -59-
<PAGE>

            (i) proper financing statements (Form UCC-1 or the equivalent) fully
      executed (where required) for filing under the UCC or other appropriate
      filing offices of each jurisdiction as may be necessary or, in the
      reasonable opinion of the Collateral Agent, desirable to perfect the
      security interests purported to be created by the U.S. Security Agreement;

            (ii) certified copies of Requests for Information or Copies (Form
      UCC-11), or equivalent reports, each of a recent date, listing all
      effective financing statements that name any U.S. Credit Party or any of
      its Subsidiaries as debtor and that are filed in the jurisdictions
      referred to in clause (i) above, together with copies of such other
      financing statements that name any U.S. Credit Party or any of its
      Subsidiaries as debtor (none of which shall cover any of the Collateral,
      except to the extent evidencing Permitted Liens or in respect of which the
      Collateral Agent shall have received termination statements (Form UCC-3)
      or such other termination statements as shall be required by local law
      fully executed (where required) for filing);

            (iii) evidence of the completion of all other recordings and filings
      of, or with respect to, the U.S. Security Agreement as may be necessary
      or, in the reasonable opinion of the Collateral Agent, desirable to
      perfect the security interests intended to be created by the U.S. Security
      Agreement; and

            (iv) evidence that all other actions necessary or, in the reasonable
      opinion of the Collateral Agent, desirable to create, maintain, effect,
      perfect, preserve, maintain and protect the security interests purported
      to be created by the U.S. Security Agreement have been taken;

and the U.S. Security Agreement and such other documents shall be in full force
and effect.

            5.12 Foreign Security Agreements. On the Initial Borrowing Date,
each Foreign Credit Party shall have duly authorized, executed and delivered
such security agreements, documents and instruments as may be required by the
Administrative Agent (based on advice of local counsel), with the intent being
that the Lenders receive, with respect to all Obligations of the European
Borrower and all other obligations of the European Borrower that are guaranteed
pursuant to the Foreign Subsidiaries Guaranties, valid and enforceable first
priority, perfected security interests in all or substantially all of the assets
(including all tangible and intangible assets, including receivables (to the
extent possible under local law), contract rights, securities, inventory (to the
extent possible under local law), equipment, real estate, leasehold interests,
insurances, and material patents, trademarks and other intellectual property
owned by each Foreign Credit Party in which it is practicable (in accordance
with and subject to requirements of local law and taking into account such cost
and practicality considerations as may be agreed by the Administrative Agent) to
obtain such security interests (as determined by the Administrative Agent, based
on advice of local counsel). All security documentation to be executed and
delivered by the Foreign Credit Parties pursuant to the immediately preceding
sentence (each, as amended, modified, restated and/or supplemented from time to
time, a "Foreign Security Agreement" and, collectively, the "Foreign Security
Agreements") shall (i) be prepared by local counsel reasonably satisfactory to
the Administrative Agent, (ii) be in form and substance reasonably satisfactory
to the Administrative Agent and (iii) be in full force and effect on the

                                      -60-
<PAGE>

Initial Borrowing Date. In connection with the execution and delivery of the
Foreign Security Agreements, the respective Foreign Credit Parties shall take
such actions as may be necessary or desirable under local law (as advised by
local counsel) to create, maintain, effect, perfect, preserve and protect the
security interests granted (or purported to be granted) thereby (including,
without limitation, taking actions analogous to those described in Section 5.11
with respect to the Security Agreement Collateral described in the U.S. Security
Agreement and in Section 5.13 with respect to the Mortgages covering U.S.
Mortgaged Properties), in each case to the extent customary in connection with
secured transactions under the laws of the respective jurisdiction or deemed
necessary or desirable by the Administrative Agent based on advice of local
counsel. Part C of Schedule XI sets forth all Foreign Security Agreements to be
executed and delivered on the Initial Borrowing Date.

            5.13 Mortgages; Title Insurance; Surveys; etc. (a) On the Initial
Borrowing Date, the Collateral Agent shall have received:

            (i) fully executed counterparts of Mortgages in form and substance
      reasonably satisfactory to the Collateral Agent, which Mortgages shall
      cover such of the Real Property (located in the United States or any State
      or territory thereof) owned or leased by the U.S. Borrower or any of its
      Subsidiaries (after giving effect to the Transaction) as are designated on
      Part A of Schedule III as a U.S. Mortgaged Property, together with
      evidence that counterparts of the Mortgages have been delivered to the
      title insurance company insuring the lien of such Mortgage for recording
      in all places to the extent necessary or, in the reasonable opinion of the
      Collateral Agent, desirable to effectively create a valid and enforceable
      first priority mortgage lien on each U.S. Mortgaged Property in favor of
      the Collateral Agent (or such other trustee as may be required or desired
      under local law) for the benefit of the Secured Creditors, subject to
      Permitted Encumbrances, the Permitted Liens described in Sections 9.03(i),
      (ii), (vii), and (viii) hereof (collectively referred to herein as the
      "Permitted Exceptions");

            (ii) Mortgage Policies on the U.S. Mortgaged Properties issued by
      such title insurers reasonably satisfactory to the Collateral Agent in
      amounts reasonably satisfactory to the Administrative Agent and the
      Required Lenders assuring the Collateral Agent that the Mortgages on such
      U.S. Mortgaged Properties are valid and enforceable first priority
      mortgage liens on the respective U.S. Mortgaged Properties, free and clear
      of all defects and encumbrances except Permitted Exceptions and such
      Mortgage Policies shall otherwise be in form and substance reasonably
      satisfactory to the Administrative Agent and the Required Lenders and
      shall include, as appropriate, an endorsement for future advances under
      this Agreement and the Notes and for any other matter that the Collateral
      Agent may reasonably request, shall not include an exception for
      mechanics' liens or creditors' rights, and shall provide for affirmative
      insurance and such reinsurance (including direct access agreements) as the
      Collateral Agent may reasonably request; and

            (iii) surveys, in form and substance reasonably satisfactory to the
      Collateral Agent, of each U.S. Mortgaged Property designated as a
      "surveyed property" on Part A of Schedule III, dated a recent date
      reasonably acceptable to the Collateral Agent (provided, however, that
      with respect to surveys that are not dated a recent date, the U.S.
      Borrower shall have the right to deliver an affidavit of no new
      improvements reasonably

                                      -61-
<PAGE>

      acceptable to the Collateral Agent, so long as the title insurer shall
      accept such surveys and agree to issue the Mortgage Policies and
      endorsements described above, excluding the standard survey exception, but
      including the survey dependent endorsements) and certified in a manner
      reasonably satisfactory to the Collateral Agent by a licensed professional
      surveyor reasonably satisfactory to the Collateral Agent.

            (b) On the Initial Borrowing Date, with respect to each Real
Property (located outside the United States and the States and territories
thereof) owned by the U.S. Borrower or any of its Subsidiaries (after giving
effect to the Transaction) and designated on Part B of Schedule III as a Foreign
Mortgaged Property, the respective Credit Party owning same shall have executed
such Foreign Security Agreements as may be necessary or desirable (in accordance
with the requirements of Section 5.12) to create a valid and enforceable first
priority, perfected security interest (or the equivalent under local law) in the
respective Foreign Mortgaged Property to secure (as nearly as possible) its
obligations under this Agreement or its Guaranty, as applicable, and shall have
taken such other actions under local law as are customary in connection with the
granting of security interests in Real Property in such jurisdictions for
transactions of this type. All actions required pursuant to this clause (b)
shall be required to comply with the requirements of Section 5.12 and shall be
taken to the satisfaction of the Administrative Agent.

            5.14 Employee Benefit Plans; Shareholders' Agreements; Management
Agreements; Collective Bargaining Agreements; Existing Indebtedness Agreements;
Tax Allocation Agreements. On or prior to the Initial Borrowing Date, there
shall have been made available to the Administrative Agent by the U.S. Borrower
true and correct copies of the following documents, certified as such by the
U.S. Borrower (in the case of the agreements referred to in clause (ii), (iii)
and (vi) below):

            (i) all written Plans (and for each Plan that is required to file an
      annual report on Internal Revenue Service Form 5500-series, a copy of the
      most recent such report (including, to the extent required, the related
      financial and actuarial statements and opinions and other supporting
      statements, certifications, schedules and information), and for each
      written Plan that is a "single-employer plan", as defined in Section
      4001(a)(15) of ERISA, the most recently prepared actuarial valuation
      therefor) and any other written "employee benefit plans", as defined in
      Section 3(3) of ERISA, and any other material written agreements, plans or
      arrangements, with or for the benefit of current or former employees of
      the U.S. Borrower or any of its Subsidiaries or any ERISA Affiliate
      (provided that the foregoing shall apply in the case of any Multiemployer
      Plan, only to the extent that any document described therein is in the
      possession of the U.S. Borrower or any Subsidiary of the U.S. Borrower or
      any ERISA Affiliate or reasonably available thereto from the sponsor or
      trustee of any such plan) (collectively, the "Employee Benefit Plans");

            (ii) all written agreements (including, without limitation,
      shareholders' agreements, subscription agreements and registration rights
      agreements) entered into by the U.S. Borrower or any of its Subsidiaries
      governing the terms and relative rights of its capital stock or other
      Equity Interests and any agreements entered into by shareholders

                                      -62-
<PAGE>

      relating to any such entity with respect to its capital stock or other
      Equity Interests (collectively, the "Shareholders' Agreements");

            (iii) all material written agreements which require payment by the
      U.S. Borrower or any of its subsidiaries of consideration in excess of
      $1,000,000 over the term of such agreement (including employment
      agreements but limited to those of executive management and division
      presidents), entered into by the U.S. Borrower or any of its Subsidiaries
      with respect to the management of the U.S. Borrower or any of its
      Subsidiaries after giving effect to the Transaction (including consulting
      agreements and other management advisory agreements) (collectively, the
      "Management Agreements");

            (iv) all collective bargaining agreements applying or relating to
      any employee of the U.S. Borrower or any of its Subsidiaries after giving
      effect to the Transaction (collectively, the "Collective Bargaining
      Agreements");

            (v) all agreements evidencing or relating to any Scheduled Existing
      Indebtedness of the U.S. Borrower or any of its Subsidiaries
      (collectively, the "Existing Indebtedness Agreements"); and

            (vi) any tax sharing or tax allocation agreements entered into by
      the U.S. Borrower or any of its Subsidiaries (collectively, the "Tax
      Allocation Agreements");

all of which Employee Benefit Plans, Shareholders' Agreements, Management
Agreements, Collective Bargaining Agreements, Existing Indebtedness Agreements
and Tax Allocation Agreements shall be in form and substance reasonably
satisfactory to the Administrative Agent and shall be in full force and effect
on the Initial Borrowing Date.

            5.15 Solvency Certificate; Insurance Certificates; etc. On or before
the Initial Borrowing Date, the Administrative Agent shall have received:

            (a) a solvency certificate in the form of Exhibit J from the acting
      chief financial officer of the U.S. Borrower, dated the Initial Borrowing
      Date, and supporting the conclusion that, after giving effect to the
      Transaction and the incurrence of all financings contemplated herein, each
      Borrower (on a stand-alone basis), the U.S. Borrower and its Subsidiaries
      (on a consolidated basis), and the European Borrower and its Subsidiaries
      (on a consolidated basis), in each case, are not insolvent and will not be
      rendered insolvent by the indebtedness incurred in connection herewith,
      will not be left with unreasonably small capital with which to engage in
      its or their respective businesses and will not have incurred debts beyond
      its or their ability to pay such debts as they mature and become due; and

            (b) evidence of insurance complying with the requirements of Section
      8.03 for the business and properties of the U.S. Borrower and its
      Subsidiaries, in scope, form and substance reasonably satisfactory to the
      Administrative Agent and the Required Lenders and naming the Collateral
      Agent as an additional insured and/or loss payee, and stating that such
      insurance shall not be canceled or materially revised without at least 30
      days' prior written notice by the insurer to the Collateral Agent.

                                      -63-
<PAGE>

            5.16 Financial Statements; Pro Forma Financial Statements;
Projections. (a) On or prior to the Initial Borrowing Date, there shall have
been delivered to the Administrative Agent (i) true and correct copies of the
financial statements referred to in Section 7.10(b)(i), (ii) an unaudited pro
forma (calculated as if the Transaction had occurred on such date) consolidated
balance sheet of the U.S. Borrower and its Consolidated Subsidiaries as of March
31, 2003 and the related pro forma (calculated as if the Transaction had
occurred on the first day of the period covered thereby) statement of income for
the twelve-month period ended as of such date, after giving effect to the
Transaction and the incurrence of all Indebtedness (including the Loans)
contemplated herein (the "Pro Forma Financial Statements"), which Pro Forma
financial statements shall demonstrate, to the Administrative Agent's and the
Required Lenders' reasonable satisfaction that Consolidated EBITDA for the U.S.
Borrower and its Subsidiaries for the latest twelve months ended at least 30
days prior to the Initial Borrowing Date was at least $175,000,000, together
with a related funds flow statement and (iii) interim consolidated financial
statements (including income statements and balance sheets) of the U.S. Borrower
for each internal accounting period ended after June 30, 2003, which financial
statements, Pro Forma Financial Statements, funds flow statement and interim
financial statements shall be reasonably satisfactory to the Administrative
Agent and the Required Lenders.

            (b) On or prior to the Initial Borrowing Date, there shall have been
delivered to the Administrative Agent detailed projected consolidated financial
statements of the U.S. Borrower and its Consolidated Subsidiaries certified by
the Chief Financial Officer of the U.S. Borrower for the five Fiscal Years ended
after the Initial Borrowing Date (including, with respect to the Fiscal Year of
the U.S. Borrower ended nearest March 31, 2004, for each fiscal quarter
comprising such Fiscal Year) (the "Projections"), which Projections (x) shall
reflect the forecasted consolidated financial conditions and income and expenses
of the U.S. Borrower and its Consolidated Subsidiaries after giving effect to
the Transaction and the related financing thereof and the other transactions
contemplated hereby and (y) shall be reasonably satisfactory in form and
substance to the Administrative Agent and the Required Lenders.

            5.17 Payment of Fees. On the Initial Borrowing Date, all costs, fees
and expenses, and all other compensation due to the Administrative Agent and the
Lenders (including, without limitation, legal fees and expenses) shall have been
paid to the extent then due.

            5.18 Consent Letter. On the Initial Borrowing Date, the
Administrative Agent shall have received a letter from CT Corporation System,
presently located at 111 Eighth Avenue, New York, New York, 10011, substantially
in the form of Exhibit N, indicating its consent to its appointment by each
Credit Party as its agent to receive service of process as specified in Section
13.08, the U.S. Subsidiaries Guaranty or the relevant Foreign Subsidiaries
Guaranty, as the case may be.

                                      -64-
<PAGE>

            SECTION 6. Conditions Precedent to All Credit Events. The obligation
of each Lender to make Loans (including Loans made on the Initial Borrowing
Date, but excluding Mandatory Borrowings made after the Initial Borrowing Date,
which shall be made as provided in Sections 1.01(f)) and the obligation of an
Issuing Lender to issue any Letter of Credit, is subject, at the time of each
such Credit Event (except as hereinafter indicated), to the satisfaction of the
following conditions:

            6.01 No Default; Representations and Warranties. At the time of each
such Credit Event and immediately after giving effect thereto (i) there shall
exist no Default or Event of Default and (ii) all representations and warranties
contained herein or in any other Credit Document shall be true and correct in
all material respects with the same effect as though such representations and
warranties had been made on the date of such Credit Event (it being understood
and agreed that any representation or warranty which by its terms is made as of
a specified date shall be required to be true and correct in all material
respects only as of such specified date).

            6.02 Notice of Borrowing; Letter of Credit Request; etc. (a) Prior
to the making of each Loan (excluding Swingline Loans and Mandatory Borrowings),
the Administrative Agent shall have received a Notice of Borrowing meeting the
requirements of Section 1.03(a). Prior to the making of any Swingline Loan, the
Swingline Lender shall have received the notice required by Section 1.03(b)(i).

            (b) Prior to the issuance of each Letter of Credit, the
Administrative Agent and the respective Issuing Lender shall have received a
Letter of Credit Request meeting the requirements of Section 2.03(a).

            The occurrence of the Initial Borrowing Date and the acceptance of
the benefits or proceeds of each Credit Event shall constitute a representation
and warranty by each Borrower to each Agent and each of the Lenders that all the
conditions specified in Section 5 (with respect to Credit Events occurring on
the Initial Borrowing Date) and Section 6 (with respect to Credit Events on and
after the Initial Borrowing Date) and applicable to such Credit Event (other
than such conditions that are expressly subject to the satisfaction of the
Administrative Agent and/or the Required Lenders) exist as of that time. All of
the Notes, certificates, legal opinions and other documents and papers referred
to in Sections 5 and 6, unless otherwise specified, shall be delivered to the
Administrative Agent at the Notice Office for the account of each of the Lenders
and, except for the Notes, with as many counterparts or copies as the
Administrative Agent may reasonably request and shall be in form and substance
reasonably satisfactory to the Lenders (as evidenced by their execution and
delivery of this Agreement).

            SECTION 7. Representations and Warranties. In order to induce the
Lenders to enter into this Agreement, to make the Loans and issue and/or
participate in the Letters of Credit as provided for herein, each Borrower makes
the following representations, warranties and agreements with the Lenders, in
each case after giving effect to the Transaction, all of which shall survive the
execution and delivery of this Agreement, the making of the Loans and the
issuance of the Letters of Credit (with the occurrence of the Initial Borrowing
Date and each Credit Event on or after the Initial Borrowing Date being deemed
to constitute a representation and warranty that the matters specified in this
Section 7 are true and correct in all material

                                      -65-
<PAGE>

respects on and as of the Initial Borrowing Date and on and as of the date of
each such Credit Event, unless stated to relate to a specific earlier date in
which case such representations and warranties shall be true and correct in all
material respects as of such earlier date):

            7.01 Company Status. Each of the U.S. Borrower and each of its
Subsidiaries (i) is a duly organized and validly existing Company in good
standing (or its equivalent) under the laws of the jurisdiction of its
organization, (ii) has the Company power and authority to own its property and
assets and to transact the business in which it is engaged and presently
proposes to engage and (iii) is duly qualified and is authorized to do business
and is in good standing (or its equivalent) in all jurisdictions where it is
required to be so qualified (or its equivalent) and where the failure to be so
qualified has had, or could reasonably be expected to have, a Material Adverse
Effect.

            7.02 Company Power and Authority. Each Credit Party and each
Subsidiary thereof has the Company power and authority to execute, deliver and
carry out the terms and provisions of the Documents to which it is a party and
has taken all necessary Company action to authorize the execution, delivery and
performance of the Documents to which it is a party. Each Credit Party and each
Subsidiary thereof has duly executed and delivered each Document to which it is
a party and each such Document constitutes the legal, valid and binding
obligation of such Credit Party enforceable in accordance with its terms, except
to the extent that the enforceability thereof may be limited by applicable
bankruptcy, insolvency, reorganization, moratorium or similar laws generally
affecting creditors' rights and by equitable principles (regardless of whether
enforcement is sought in equity or at law).

            7.03 No Violation. Neither the execution, delivery or performance by
any Credit Party or any Subsidiary thereof of the Documents to which it is a
party, nor compliance by any Credit Party or any such Subsidiary with the terms
and provisions thereof, nor the consummation of the transactions contemplated
herein or therein, (i) will contravene any material provision of any applicable
law, statute, rule or regulation, or any order, writ, injunction or decree of
any court or governmental instrumentality, (ii) will conflict or be inconsistent
with or result in any breach of, any of the terms, covenants, conditions or
provisions of, or constitute a default under, or (other than pursuant to the
Security Documents) result in the creation or imposition of (or the obligation
to create or impose) any Lien upon any of the material property or assets of the
U.S. Borrower or any of its Subsidiaries pursuant to the terms of any indenture,
mortgage, deed of trust, loan agreement, credit agreement or any other material
agreement, contract or instrument to which the U.S. Borrower or any of its
Subsidiaries is a party or by which it or any of its material property or assets
are bound or to which it may be subject (including, without limitation, the
Existing Indebtedness Agreements) or (iii) will violate any provision of the
certificate of incorporation, by-laws, certificate of partnership, partnership
agreement, certificate of limited liability company, limited liability company
agreement or equivalent organizational document, as the case may be, of the U.S.
Borrower or any of its Subsidiaries.

            7.04 Litigation. There are no actions, suits, proceedings or
investigations pending or, to the knowledge of either Borrower, threatened (i)
with respect to any Credit Document, (ii) with respect to the Transaction or any
other Document or (iii) that have had, or could reasonably be expected to have,
a Material Adverse Effect. Additionally, there does not

                                      -66-
<PAGE>

exist any judgment, order or injunction prohibiting or imposing material adverse
conditions upon the occurrence of any Credit Event.

            7.05 Use of Proceeds; Margin Regulations. (a) The proceeds of all
Term Loans incurred on the Initial Borrowing Date shall be utilized as described
in the Plan of Reorganization, to finance the Refinancing (including through the
Intercompany Loans, dividends, capital contributions and intercompany stock and
asset purchases the proceeds of which will be used to effect the Refinancing)
and to pay fees and expenses in connection with the Transaction; provided that
no portion of the proceeds of the European Borrower Dollar Term Loans shall be
utilized to purchase the capital stock of Exide Technologies Nederland B.V.

            (b) All proceeds of Multicurrency Facility Revolving Loans and
Swingline Loans shall be used for the Borrowers' and their respective
Subsidiaries' ongoing working capital requirements, for Capital Expenditures and
general corporate purposes (including to effect Permitted Acquisitions (to the
extent permitted by this Agreement) but excluding payments in connection with
the Transaction (except as provided in the proviso below)); provided, however,
that proceeds of Multicurrency Facility Revolving Loans (for this purpose using
the Dollar Equivalent of the principal amount of all Euro Denominated Revolving
Loans incurred on the Initial Borrowing date) in an aggregate amount not to
exceed $15,000,000 may be utilized by the Borrowers for the purposes described
in Section 7.05(a) above.

            (c) No part of any Credit Event (or the proceeds thereof) will be
used to purchase or carry any Margin Stock or to extend credit for the purpose
of purchasing or carrying any Margin Stock. Neither the making of any Loan nor
the use of the proceeds thereof nor the occurrence of any other Credit Event
will violate or be inconsistent with the provisions of Regulation T, Regulation
U or Regulation X.

            7.06 Governmental Approvals. Except as may have been obtained or
made on or prior to the Initial Borrowing Date (and which remain in full force
and effect on the Initial Borrowing Date), no order, consent, approval, license,
authorization or validation of, or filing, recording or registration with, or
exemption by, any foreign or domestic governmental or public body or authority,
or any subdivision thereof, is required to authorize or is required in
connection with (i) the execution, delivery and performance of any Document or
(ii) the legality, validity, binding effect or enforceability of any Document.

            7.07 Investment Company Act. Neither the U.S. Borrower nor any of
its Subsidiaries is an "investment company" or a company "controlled" by an
"investment company", within the meaning of the Investment Company Act of 1940,
as amended.

            7.08 Public Utility Holding Company Act. Neither the U.S. Borrower
nor any of its Subsidiaries is a "holding company", or a "subsidiary company" of
a "holding company", or an "affiliate" of a "holding company" or of a
"subsidiary company" of a "holding company", within the meaning of the Public
Utility Holding Company Act of 1935, as amended.

            7.09 True and Complete Disclosure. All factual information (taken as
a whole) furnished by or on behalf of the U.S. Borrower or any of its
Subsidiaries in writing to any Agent or any Lender (including, without
limitation, all information contained in the Documents) for

                                      -67-
<PAGE>

purposes of or in connection with this Agreement, the other Documents or any
transaction contemplated herein or therein is true and accurate in all material
respects on the date as of which such information is dated or certified and not
incomplete by omitting to state any material fact necessary to make such
information (taken as a whole) not misleading in any material respect at such
time in light of the circumstances under which such information was provided.

            7.10 Financial Condition; Financial Statements. (a) On and as of the
Initial Borrowing Date, on a pro forma basis after giving effect to the
Transaction and to all Indebtedness (including the Loans) incurred, and to be
incurred, and Liens created, and to be created, by each Credit Party in
connection therewith, with respect to each Borrower (on a stand-alone basis) and
each Borrower and its Subsidiaries (on a consolidated basis) (x) the sum of the
assets, at a fair valuation, of each Borrower (on a stand-alone basis) and each
Borrower and its Subsidiaries (on a consolidated basis) will exceed its or their
debts, (y) it has or they have not incurred nor intended to, nor believes or
believe that it or they will, incur debts beyond its or their ability to pay
such debts as such debts mature and (z) it or they will have sufficient capital
with which to conduct its or their business. For purposes of this Section
7.10(a), "debt" means any liability on a claim, and "claim" means (i) right to
payment, whether or not such a right is reduced to judgment, liquidated,
unliquidated, fixed, contingent, matured, unmatured, disputed, undisputed,
legal, equitable, secured or unsecured or (ii) right to an equitable remedy for
breach of performance if such breach gives rise to a payment, whether or not
such right to an equitable remedy is reduced to judgment, fixed, contingent,
matured, unmatured, disputed, undisputed, secured or unsecured. The amount of
contingent liabilities at any time shall be computed as the amount that, in the
light of all facts and circumstances existing at such time, represents the
amount that can reasonably be expected to become an actual or matured liability.

            (b) (i) The audited consolidated statements of financial condition
of Old Exide and its Consolidated Subsidiaries at March 31, 2003 and the related
consolidated statements of income and cash flows and changes in shareholders'
equity of Old Exide and its Consolidated Subsidiaries for the fiscal years of
Old Exide ended on such dates, in each case furnished to the Lenders prior to
the Initial Borrowing Date, present fairly in all material respects the
consolidated financial position of Old Exide and its Consolidated Subsidiaries
at the date of said financial statements and the results for the respective
periods covered thereby and (ii) the Pro Forma Financial Statements present a
good faith estimate of the consolidated pro forma financial condition of the
U.S. Borrower and its Consolidated Subsidiaries and the pro forma results of
operations of the U.S. Borrower and its Consolidated Subsidiaries for the
respective periods covered thereby (after giving effect to the Transaction at
the date thereof or for the period covered thereby). All of the financial
statements referred to in clause (i) of the immediately preceding sentence have
been prepared in accordance with U.S. GAAP consistently applied except to the
extent provided in the notes to said financial statements.

            (c) Since March 31, 2003 (but after giving effect to the Transaction
as if same had occurred immediately prior thereto), nothing has occurred that
has had, or could reasonably be expected to have, a Material Adverse Effect.

            (d) Except as reflected or disclosed in the financial statements
described in Section 7.10(b) and as otherwise permitted by Section 9.04, there
were as of the Initial Borrowing Date (and after giving effect to any Loans made
on such date), no liabilities or

                                      -68-
<PAGE>

obligations with respect to the U.S. Borrower or any of its Subsidiaries of any
nature whatsoever (whether absolute, accrued, contingent or otherwise and
whether or not due) which, either individually or in the aggregate, could
reasonably be expected to be material to the U.S. Borrower and its Subsidiaries
taken as a whole.

            (e) The Projections have been prepared on a basis consistent with
the financial statements referred to in Section 7.10(b) and are based on
reasonable good faith estimates and assumptions made by the management of the
U.S. Borrower, and on the Initial Borrowing Date, the Borrowers believe that the
Projections are reasonable and attainable, it being recognized by the Lenders
that such projections of future events are not to be viewed as facts and that
actual results during the period or periods covered by any such Projections may
differ from the projected results contained therein.

            7.11 Security Interests. On and after the Initial Borrowing Date,
each of the Security Documents creates (or after the execution, delivery and
recordation (if applicable) thereof will create), as security for the
Obligations covered thereby, a valid and enforceable perfected security interest
in and Lien on all of the Collateral subject thereto, without prejudice to any
statutory priority rights, superior to and prior to the rights of all third
Persons, and subject to no other Liens (except that (i) the Security Agreement
Collateral may be subject to Permitted Liens, (ii) the Pledge Agreement
Collateral may be subject to the Liens described in clauses (i) and (v) of
Section 9.03 and (iii) the security interest and mortgage lien created on any
Mortgaged Property may be subject to the Permitted Exceptions related thereto),
in favor of the Collateral Agent (or such other trustee or sub-agent or any
other third party as may be required or desired under local law or, if required
by local law, the Secured Creditors). No filings or recordings or other
formalities are required in order to perfect and/or render enforceable as
against third parties the security interests created under any Security Document
except for filings or recordings required in connection with any such Security
Document which shall have been made or, with respect to any Foreign Security
Document, presented to the relevant governmental authority with respect to any
such filing, recordation or other formality, to the satisfaction of the
Collateral Agent, on or prior to the Initial Borrowing Date or on or prior to
the execution and delivery thereof as contemplated by Sections 8.11 (but (x) in
the case of an Additional Mortgage, immediately following the execution and
delivery thereof and (y) in the case of any Foreign Security Document,
substantially concurrently with Initial Borrowing Date or the execution and
delivery thereof, as the case may be), 8.12, 8.15 and 9.16.

            7.12 Compliance with ERISA. (a) Schedule V sets forth, as of the
Initial Borrowing Date, each Plan and each Multiemployer Plan. Each Plan (and
each related trust, insurance contract or fund) is in compliance in all respects
with its terms and in all respects with all applicable laws, including, without
limitation, ERISA and the Code, except to the extent that any such
noncompliances, individually or in the aggregate, would not result in a Material
Adverse Effect. Except as, individually or in the aggregate, would not
reasonably be expected to result in a Material Adverse Effect: (1) each Plan
(and each related trust, if any) which is intended to be qualified under Section
401(a) of the Code has received a determination letter from the Internal Revenue
Service to the effect that it meets the requirements of Sections 401(a) and
501(a) of the Code (or the sponsor has applied for such determination letter
within the remedial amendment period); (2) except as disclosed on Schedule V, no
Reportable Event has occurred with respect to a Plan (other than a Reportable
Event related to the filing of a petition

                                      -69-
<PAGE>

under Chapter 11 of the Bankruptcy Code); (3) no Multiemployer Plan is insolvent
or in reorganization; (4) except as disclosed on Schedule V, no Plan has an
Unfunded Current Liability; (5) no Plan which is subject to Section 412 of the
Code or Section 302 of ERISA has an accumulated funding deficiency, within the
meaning of such sections of the Code or ERISA, or, except as disclosed on
Schedule V, has applied for or received a waiver of an accumulated funding
deficiency or an extension of any amortization period, within the meaning of
Section 412 of the Code or Section 303 or 304 of ERISA; (6) all required
contributions with respect to a Plan and a Multiemployer Plan have been made;
(7) neither the U.S. Borrower nor any Subsidiary of the U.S. Borrower nor any
ERISA Affiliate has incurred any outstanding material liability (including any
indirect, contingent or secondary liability) to or on account of a Plan or a
Multiemployer Plan pursuant to Section 409, 502(i), 502(l), 515, 4062, 4063,
4064, 4069, 4201, 4204 or 4212 of ERISA or Section 401(a)(29), 4971 or 4975 of
the Code or expects to incur any such material liability under any of the
foregoing sections with respect to any Plan or a Multiemployer Plan; (8) to the
knowledge of either Borrower, no condition exists which presents a material risk
to the U.S. Borrower or any Subsidiary of the U.S. Borrower or any ERISA
Affiliate of incurring a material liability to or on account of a Plan or a
Multiemployer Plan pursuant to the foregoing provisions of ERISA and the Code;
(9) no involuntary proceedings have been instituted to terminate or appoint a
trustee to administer any Plan which is subject to Title IV of ERISA; (10) no
action, suit, proceeding, hearing, audit or investigation with respect to the
administration, operation or the investment of assets of any Plan (other than
routine claims for benefits) is pending, expected or threatened; (11) using
actuarial assumptions and computation methods consistent with Part 1 of subtitle
E of Title IV of ERISA, the aggregate liabilities of the U.S. Borrower and its
Subsidiaries and ERISA Affiliates to any Multiemployer Plans in the event of a
withdrawal therefrom, as of the close of the most recent fiscal year of each
such Multiemployer Plan ended prior to the date of the most recent Credit Event
would not result in a material liability to the U.S. Borrower, any Subsidiary of
the U.S. Borrower or an ERISA Affiliate; (12) each group health plan (as defined
in Section 607(1) of ERISA or Section 4980B(g)(2) of the Code) which covers or
has covered employees or former employees of the U.S. Borrower, any Subsidiary
of the U.S. Borrower, or any ERISA Affiliate has at all times been operated in
compliance with the provisions of Part 6 of subtitle B of Title I of ERISA and
Section 4980B of the Code; (13) no lien imposed under the Code or ERISA on the
assets of the U.S. Borrower or any Subsidiary of the U.S. Borrower or any ERISA
Affiliate exists, or, to the knowledge of either Borrower, is likely to arise on
account of any Plan or any Multiemployer Plan; and (14) except as disclosed on
Schedule V, neither the U.S. Borrower nor any Subsidiary of the U.S. Borrower
maintains or contributes to (a) any group health plan (as defined in Section
5000(b)(1) of the Code) which provides benefits to retired employees and/or
other former employees (other than as required by Section 601 of ERISA) or (b)
any Plan, the obligations with respect to which could reasonably be expected to
have a Material Adverse Effect.

            (b) Except as, individually or in the aggregate, would not
reasonably be expected to result in a Material Adverse Effect: (1) each Foreign
Pension Plan has been maintained in substantial compliance with its terms and
with the requirements of any and all applicable laws, statutes, rules,
regulations and orders and has been maintained, where required, in good standing
with applicable regulatory authorities, (2) all required contributions with
respect to a Foreign Pension Plan have been made, (3) neither the U.S. Borrower
nor any of its Subsidiaries has incurred any material outstanding obligation in
connection with the termination of or withdrawal from any Foreign Pension Plan,
and (4) the present value of the accrued benefit

                                      -70-
<PAGE>

liabilities (whether or not vested) under each Foreign Pension Plan, determined
as of the end of the U.S. Borrower's most recently ended fiscal year on the
basis of actuarial assumptions, each of which is reasonable, did not exceed the
current value of the assets of such Foreign Pension Plan allocable to such
benefit liabilities or alternatively, the Foreign Pension Plan is funded in
compliance with applicable law in all respects and the U.S. Borrower and its
Subsidiaries have established adequate reserves for the present value of such
accrued benefit liabilities under such Foreign Pension Plan in the financial
statements delivered pursuant to Section 8.01(b) and (c).

            7.13 Capitalization. (a) On the Initial Borrowing Date and after
giving effect to the Transaction, the authorized capital stock of the U.S.
Borrower shall consist of (i) 61,500,000 shares of common stock, $0.01 par value
per share (such authorized shares of common stock, together with any
subsequently authorized shares of common stock of the U.S. Borrower, the "U.S.
Borrower Common Stock"), of which 24,193,573 shares shall be issued and
outstanding and (ii) 1,000,000 shares of preferred stock, none of which shares
shall be issued and outstanding. All such outstanding shares have been duly and
validly issued, are fully paid and nonassessable and free of preemptive rights.
As of the Initial Borrowing Date, except as set forth on Part A of Schedule X
hereto, the U.S. Borrower does not have outstanding any securities convertible
into or exchangeable for its capital stock or outstanding any rights to
subscribe for or to purchase, or any options for the purchase of, or any
agreement providing for the issuance (contingent or otherwise) of, or any calls,
commitments or claims of any character relating to, its capital stock or any
stock appreciation or similar rights.

            (b) On the Initial Borrowing Date and after giving effect to the
Transaction, the outstanding Equity Interests of the European Borrower shall
consist of a 99.99% interest in the European Borrower owned by the U.S. Borrower
and a 0.01% interest in the European Borrower owned by EH International, LLC. To
the extent relevant, all such outstanding interests have been duly and validly
issued, are fully paid and nonassessable and free of preemptive rights. The
European Borrower does not have outstanding any securities convertible into or
exchangeable for its Equity Interests or outstanding any rights to subscribe for
or to purchase, or any options for the purchase of, or any agreement providing
for the issuance (contingent or otherwise) of, or any calls, commitments or
claims of any character relating to, its Equity Interests.

            7.14 Subsidiaries. On and as of the Initial Borrowing Date and after
giving effect to the Transaction, the U.S. Borrower has no Subsidiaries other
than those Subsidiaries listed on Schedule VII. Schedule VII correctly sets
forth, as of the Initial Borrowing Date and after giving effect to the
Transaction, (i) the percentage ownership (direct and indirect) of the U.S.
Borrower in each class of capital stock or other Equity Interests of each of its
Subsidiaries and also identifies the direct owner thereof and (ii) the
jurisdiction of organization of each such Subsidiary. All outstanding shares of
capital stock or other Equity Interests of each Subsidiary of the U.S. Borrower
have been duly and validly issued, are fully paid and non-assessable (to the
extent applicable in the jurisdiction of organization of such Subsidiary) and,
in the case of Non-Wholly Owned Subsidiaries of the U.S. Borrower, have been
issued free of preemptive rights. Except as set forth on Part B of Schedule X
attached hereto, no Subsidiary of the U.S. Borrower has outstanding any
securities convertible into or exchangeable for its capital stock or other
Equity Interests or outstanding any right to subscribe for or to purchase, or
any options or warrants for the purchase of, or any agreement providing for the
issuance (contingent or

                                      -71-
<PAGE>

otherwise) of or any calls, commitments or claims of any character relating to,
its capital stock or other Equity Interests or any stock appreciation or similar
rights. Except for the existing investments described on Schedule VI, as of the
Initial Borrowing Date, neither the U.S. Borrower nor any of its Subsidiaries
owns or holds, directly or indirectly, any capital stock or equity security of,
or any other Equity Interests in, any Person other than its Subsidiaries
indicated on Schedule VII.

            7.15 Intellectual Property, etc. The U.S. Borrower and each of its
Subsidiaries owns or has the right to use all domestic and foreign patents,
trademarks, permits, domain names, service marks, trade names, copyrights,
licenses, franchises, inventions, trade secrets, proprietary information and
know-how of any type, whether or not written (including, but not limited to,
rights in computer programs and databases) and formulas, or other rights with
respect to the foregoing, and has obtained assignments of all leases, licenses
and other rights of whatever nature, in each case necessary for the conduct of
its business, without any known conflict with the rights of others which, or the
failure to obtain which, as the case may be, individually or in the aggregate,
has had, or could reasonably be expected to have, a Material Adverse Effect.

            7.16 Compliance with Statutes; Agreements, etc. The U.S. Borrower
and each of its Subsidiaries is in compliance with (i) all applicable statutes,
regulations, rules and orders of, and all applicable restrictions imposed by,
all governmental bodies, domestic or foreign, in respect of the conduct of its
business and the ownership of its property and (ii) all contracts and agreements
to which it is a party, except such non-compliances as have not had, and could
not reasonably be expected to have, individually or in the aggregate, a Material
Adverse Effect.

            7.17 Environmental Matters. (a) The U.S. Borrower and each of its
Subsidiaries has complied with, and on the date of each Credit Event is in
compliance with, all applicable Environmental Laws and the requirements of any
permits issued under such Environmental Laws and neither the U.S. Borrower nor
any of its Subsidiaries is liable for any material penalties, fines or
forfeitures for failure to comply with any of the foregoing. There are no
pending or past or, to the knowledge of either Borrower, threatened
Environmental Claims against the U.S. Borrower or any of its Subsidiaries or any
Real Property owned, leased or operated by the U.S. Borrower or any of its
Subsidiaries (including, to the knowledge of either Borrower, any such claim
arising out of the ownership, lease or operation by the U.S. Borrower or any of
its Subsidiaries of any Real Property formerly owned, leased or operated by the
U.S. Borrower or any of its Subsidiaries but no longer owned, leased or operated
by the U.S. Borrower or any of its Subsidiaries). There are no facts,
circumstances, conditions or occurrences on any Real Property owned, leased or
operated by the U.S. Borrower or any of its Subsidiaries (including, to the
knowledge of either Borrower, any Real Property formerly owned, leased or
operated by the U.S. Borrower or any of its Subsidiaries but no longer owned,
leased or operated by the U.S. Borrower or any of its Subsidiaries) or, to the
knowledge of either Borrower, on any property adjoining or in the vicinity of
any such Real Property that would reasonably be expected (i) to form the basis
of an Environmental Claim against the U.S. Borrower or any of its Subsidiaries
or any such Real Property or (ii) to cause any such Real Property to be subject
to any restrictions on the ownership, occupancy, use or transferability of such
Real Property by the U.S. Borrower or any of its Subsidiaries under any
applicable Environmental Law.

                                      -72-
<PAGE>

            (b) Notwithstanding anything to the contrary in this Section 7.17,
the representations made in this Section 7.17 shall only be untrue if the
aggregate effect of all conditions, failures, noncompliances, Environmental
Claims, Hazardous Materials, Releases and presence of underground storage tanks,
in each case of the types described above, has had, or could reasonably be
expected to have, a Material Adverse Effect. The representations of the Credit
Agreement Parties under this Section 7.17 shall be the sole and exclusive
representations of the Credit Agreement Parties regarding environmental health
and safety matters, including all matters arising under Environmental Law.

            7.18 Properties. All Real Property owned by the U.S. Borrower or any
of its Subsidiaries (other than non-material Real Property owned by Foreign
Subsidiaries of the U.S. Borrower), and all material Leaseholds leased by the
U.S. Borrower or any of its Subsidiaries, in each case as of the Initial
Borrowing Date and after giving effect to the Transaction, and the nature of the
interest therein, is correctly set forth in Schedule III. Each of the U.S.
Borrower and each of its Subsidiaries has good and marketable title to, or a
validly subsisting leasehold interest in, all material properties owned or
leased by it, including all Real Property reflected in Schedule III and in the
financial statements referred to in Section 7.10(b), free and clear of all
Liens, other than Permitted Liens.

            7.19 Labor Relations. Neither the U.S. Borrower nor any of its
Subsidiaries is engaged in any unfair labor practice that has had, or could
reasonably be expected to have, either individually or in the aggregate, a
Material Adverse Effect. There is (i) no unfair labor practice complaint pending
against the U.S. Borrower or any of its Subsidiaries or, to the knowledge of
either Borrower, threatened against any of them, before the National Labor
Relations Board or any similar foreign tribunal or agency, and no grievance or
arbitration proceeding arising out of or under any collective bargaining
agreement is so pending against the U.S. Borrower or any of its Subsidiaries or,
to the knowledge of either Borrower, threatened against any of them, (ii) no
strike, labor dispute, slowdown or stoppage pending against the U.S. Borrower or
any of its Subsidiaries or, to the knowledge of either Borrower, threatened
against the U.S. Borrower or any of its Subsidiaries and (iii) no union
representation question existing with respect to the employees of the U.S.
Borrower or any of its Subsidiaries and no union organizing activities are
taking place, except (with respect to any matter specified in clause (i), (ii)
or (iii) above, either individually or in the aggregate) such as has not had, or
could reasonably be expected to have, a Material Adverse Effect.

            7.20 Tax Returns and Payments. The U.S. Borrower and each of its
Subsidiaries has timely filed (including applicable extensions) with the
appropriate taxing authority, all material returns, statements, forms and
reports for taxes (the "Returns") required to be filed by or with respect to the
income, properties or operations of the U.S. Borrower and each of its
Subsidiaries. The Returns accurately reflect in all material respects all
liability for taxes of the U.S. Borrower and each of its Subsidiaries as a whole
for the periods covered thereby. The U.S. Borrower and each of its Subsidiaries
have paid all material taxes payable by them other than those contested in good
faith and adequately disclosed and for which adequate reserves have been
established in accordance with U.S. GAAP. Except as set forth on Schedule XIV
hereto, there is no action, suit, proceeding, investigation, audit, or claim now
pending or, to the knowledge of either Borrower, threatened by any authority
regarding any taxes relating to the U.S. Borrower and each of its Subsidiaries.
Except as set forth on Schedule XIV hereto, neither

                                      -73-
<PAGE>

the U.S. Borrower nor any of its Subsidiaries has entered into an agreement or
waiver or been requested to enter into an agreement or waiver extending any
statute of limitations relating to the payment or collection of taxes of the
U.S. Borrower or any of its Subsidiaries, or is aware of any circumstances that
would cause the taxable years or other taxable periods of the U.S. Borrower or
any of its Subsidiaries not to be subject to the normally applicable statute of
limitations.

            7.21 Scheduled Existing Indebtedness. (a) Schedule IV sets forth a
true and complete list of all Indebtedness of the U.S. Borrower and its
Subsidiaries as of the Initial Borrowing Date and which is to remain outstanding
after giving effect to the Transaction and the incurrence of Loans on such date
(exclusive of Indebtedness pursuant to this Agreement and the other Credit
Documents), in each case showing the aggregate principal amount thereof (and the
aggregate amount of any undrawn commitments with respect thereto) and the name
of the respective borrower and any other entity which directly or indirectly
guarantees such debt. Part A of Schedule IV lists all Indebtedness as described
in the immediately preceding sentence which is owed to Persons other than the
U.S. Borrower or any of its Subsidiaries (after giving effect to the
consummation of the Transaction) (with all of such Indebtedness being herein
called "Third Party Scheduled Existing Indebtedness") and Part B of Schedule IV
lists all Indebtedness as described in the immediately preceding sentence which
is owed to the U.S. Borrower and its Subsidiaries (after giving effect to the
Transaction) (with all of such Indebtedness being herein called "Intercompany
Scheduled Existing Indebtedness").

            (b) Part C of Schedule IV sets forth a true and complete list of all
Indebtedness to be Refinanced, in each case showing the aggregate principal
amount thereof, the name of the respective borrower and any other entity which
directly or indirectly guaranteed such Indebtedness and the outstanding amount
thereof on the Initial Borrowing Date (before giving effect to the Transaction).

            7.22 Insurance. Set forth on Schedule VIII hereto is a true, correct
and complete summary of all insurance maintained by the U.S. Borrower and its
Subsidiaries (other than local insurance policies maintained by Foreign
Subsidiaries of the U.S. Borrower that are not material) on and as of the
Initial Borrowing Date, with the amounts insured (and any deductibles) set forth
therein.

            SECTION 8. Affirmative Covenants. Each Borrower hereby covenants and
agrees that as of the Effective Date and thereafter for so long as this
Agreement is in effect and until the Total Commitment and all Letters of Credit
have been terminated, and the Loans, Notes and Unpaid Drawings, together with
interest, Fees and all other Obligations (other than any indemnities described
in Section 13.13 which are not then due and payable) incurred hereunder, are
paid in full:

            8.01 Information Covenants. The U.S. Borrower will furnish, or will
cause to be furnished, to the Administrative Agent (who shall furnish to each
Lender):

            (a) Monthly Reports. Within 45 days after the close of each fiscal
      month of the U.S. Borrower (commencing with the fiscal month ending May
      31, 2004), the consolidated balance sheet of the U.S. Borrower and its
      Subsidiaries as at the end of the relevant month and the related
      consolidated statements of income and retained earnings

                                      -74-
<PAGE>

      and of cash flows for such month and for the elapsed portion of the fiscal
      year ended with the last day of such month, setting forth comparative
      figures for the corresponding month in the prior fiscal year, all of which
      shall be certified by the chief financial officer or other Authorized
      Officer of the U.S. Borrower, subject to normal year-end audit
      adjustments.

            (b) Quarterly Financial Statements. Within 50 days after the close
      of the first three quarterly accounting periods in each Fiscal Year of the
      U.S. Borrower (commencing with the fiscal quarter ending closest to June
      30, 2004), (i) (A) the consolidated balance sheet of the U.S. Borrower and
      its Consolidated Subsidiaries as at the end of such quarterly accounting
      period and the related consolidated statements of income and of cash flows
      for such quarterly accounting period and for the elapsed portion of the
      Fiscal Year ended with the last day of such quarterly accounting period
      setting forth comparative figures for the corresponding quarterly
      accounting period in the prior Fiscal Year and the budgeted figures for
      such quarterly period as set forth in the respective financial projections
      theretofore delivered pursuant to Section 8.01(d) (unless such quarterly
      period occurs prior to the delivery (or required delivery) of the first
      financial projections pursuant to Section 8.01(d) which include such
      quarterly accounting period), and (B) consolidating statements of income
      and of cash flows of the U.S. Borrower and its Consolidated Subsidiaries
      by (x) business segment (i.e., industrial and transportation) and (y)
      geographical region (i.e., the United States, Europe and Asia), in each
      case certified by the senior financial officer or other Authorized Officer
      of the U.S. Borrower that they fairly present in all material respects in
      accordance with U.S. GAAP the financial condition of the U.S. Borrower and
      its Consolidated Subsidiaries as of the dates indicated and the results of
      their operations and/or changes in their cash flows for the periods
      indicated, subject to normal year-end audit adjustments and the absence of
      footnotes and (ii) management's discussion and analysis of the important
      operational and financial developments during such quarterly accounting
      period.

            (c) Annual Financial Statements. Within 90 days after the close of
      each Fiscal Year of the U.S. Borrower, (i) (A) the consolidated balance
      sheet of the U.S. Borrower and its Consolidated Subsidiaries as at the end
      of such Fiscal Year and the related consolidated statements of income and
      stockholders' equity and of cash flows for such Fiscal Year and setting
      forth comparative consolidated figures for the preceding Fiscal Year and
      comparable budgeted figures for such Fiscal Year as set forth in the
      respective financial projections delivered pursuant to Section 8.01(d) and
      (B) consolidating statements of income and of cash flows of the U.S.
      Borrower and its Consolidated Subsidiaries by (x) business segment (i.e.,
      industrial and transportation) and (y) geographical region (i.e., the
      United States, Europe and Asia), (ii) in the case of the consolidated
      financial statements referred to in subclause (i) (A) above (except for
      such comparable budgeted figures), together with a certification by
      Pricewaterhouse Coopers LLP or such other independent certified public
      accountants of recognized national standing as shall be reasonably
      acceptable to the Administrative Agent, in each case to the effect that
      (I) such statements fairly present in all material respects the financial
      condition of the U.S. Borrower and its Consolidated Subsidiaries as of the
      dates indicated and the results of their operations and changes in
      financial position for the periods indicated in conformity with U.S. GAAP
      applied on a basis consistent with prior years

                                      -75-

<PAGE>

      except as disclosed therein (i.e., fresh-start accounting) and (II) in the
      course of its regular audit of the business of the U.S. Borrower and its
      Consolidated Subsidiaries, which audit was conducted in accordance with
      U.S. GAAS (and made without qualification or expression of uncertainty, in
      each case as to going concern), no Default or Event of Default which has
      occurred and is continuing has come to their attention or, if such a
      Default or an Event of Default has come to their attention, a statement as
      to the nature thereof, and (iii) management's discussion and analysis of
      the important operational and financial developments during such Fiscal
      Year.

            (d) Financial Projections, etc. Not more than 45 days after the
      commencement of each Fiscal Year of the U.S. Borrower, financial
      projections in form reasonably satisfactory to the Administrative Agent
      (including projected statements of income, sources and uses of cash and
      balance sheets) prepared by the U.S. Borrower (i) for each of the four
      Fiscal Quarters of such Fiscal Year prepared in detail and (ii) for each
      of the immediately succeeding two Fiscal Years prepared in summary form,
      in each case, on a consolidated basis, for the U.S. Borrower and its
      Consolidated Subsidiaries and setting forth, with appropriate discussion,
      the principal assumptions upon which such financial projections are based.

            (e) Officer's Certificates. At the time of the delivery of the
      financial statements provided for in Sections 8.01(a), (b) and (c), a
      certificate of the Chief Financial Officer or other Authorized Officer of
      the U.S. Borrower to the effect that no Default or Event of Default exists
      or, if any Default or Event of Default does exist, specifying the nature
      and extent thereof, which certificate shall (i) if delivered in connection
      with the financial statements required by Section 8.01(b) or (c), set
      forth (x) in reasonable detail the calculations required to establish
      whether the U.S. Borrower and its Subsidiaries were in compliance with the
      provisions of Sections 3.03, 4.02, 9.02, 9.04, 9.05, 9.06 and 9.08 through
      and including 9.12 as at the end of such fiscal quarter or Fiscal Year, as
      the case may be, and (y) the calculation of the Leverage Ratio as at the
      last day of the respective fiscal quarter or Fiscal Year of the U.S.
      Borrower, as the case may be, (ii) if delivered with the financial
      statements required by Section 8.01(c), set forth in reasonable detail the
      amount of (and the calculations required to establish the amount of)
      Excess Cash Flow for the respective Excess Cash Flow Payment Period and
      (iii) certify that there have been no changes to Annexes A through G of
      the U.S. Security Agreement, Annexes A through G of the U.S. Pledge
      Agreement and the annexes or schedules to any other Security Document, in
      each case since the Initial Borrowing Date or, if later, since the date of
      the most recent certificate delivered pursuant to this Section 8.01(e), or
      if there have been any such changes, a list in reasonable detail of such
      changes (but, in each case with respect to this clause (iii), only to the
      extent that such changes are required to be reported to the Collateral
      Agent pursuant to the terms of such Security Documents) and whether the
      Credit Agreement Parties and the other Credit Parties have otherwise taken
      all actions required to be taken by them pursuant to such Security
      Documents in connection with any such changes.

            (f) Notice of Default or Litigation. Promptly, and in any event
      within five Business Days after any Senior Officer of either Borrower
      obtains knowledge thereof, notice of (i) the occurrence of any event which
      constitutes a Default or an Event of

                                      -76-

<PAGE>

      Default, which notice shall specify the nature and period of existence
      thereof and what action the U.S. Borrower or such Subsidiary proposes to
      take with respect thereto, (ii) any litigation or proceeding pending or
      threatened against the U.S. Borrower or any of its Subsidiaries which has
      had, or could reasonably be expected to have, a Material Adverse Effect,
      (iii) any material governmental investigation pending or threatened
      against the U.S. Borrower or any of its Subsidiaries and (iv) any other
      event, change or circumstance which has had, or could reasonably be
      expected to have, a Material Adverse Effect.

            (g) Management Letters. Promptly upon receipt thereof, a copy of any
      "management letter" submitted to the U.S. Borrower or any of its
      Subsidiaries by its independent accountants in connection with any annual,
      interim or special audit made by them of the financial statements of the
      U.S. Borrower or any of its Subsidiaries and management's responses
      thereto.

            (h) Environmental Matters. Within ten Business Days after either
      Borrower obtains knowledge of any of the following (but only to the extent
      that any of the following, either individually or in the aggregate, has
      had, or could reasonably be expected to have, (a) a Material Adverse
      Effect or (b) a remedial cost to the U.S. Borrower or any of its
      Subsidiaries in excess of $2,500,000), written notice of:

                  (i) any pending or threatened Environmental Claim against the
            U.S. Borrower or any of its Subsidiaries or any Real Property owned,
            leased or operated by the U.S. Borrower or any of its Subsidiaries;

                  (ii) any condition or occurrence on any Real Property owned,
            leased or operated by the U.S. Borrower or any of its Subsidiaries
            that (x) results in noncompliance by the U.S. Borrower or any of its
            Subsidiaries with any applicable Environmental Law or (y) could
            reasonably be anticipated to form the basis of an Environmental
            Claim against the U.S. Borrower or any of its Subsidiaries or any
            such Real Property;

                  (iii) any condition or occurrence on any Real Property owned,
            leased or operated by the U.S. Borrower or any of its Subsidiaries
            that could reasonably be anticipated to cause such Real Property to
            be subject to any restrictions on the ownership, lease, occupancy,
            use or transferability by the U.S. Borrower or such Subsidiary, as
            the case may be, of its interest in such Real Property under any
            Environmental Law; and

                  (iv) the taking of any removal or remedial action in response
            to the actual or alleged presence of any Hazardous Material on any
            Real Property owned, leased or operated by the U.S. Borrower or any
            of its Subsidiaries.

      All such notices shall describe in reasonable detail the nature of the
      claim, investigation, condition, occurrence or removal or remedial action
      and the U.S. Borrower's response or proposed response thereto. In
      addition, the U.S Borrower agrees to provide the Lenders (by delivery to
      the Administrative Agent) with copies of such detailed reports relating to

                                      -77-

<PAGE>

      the subject matter of any of the matters set forth in clauses (i)-(iv)
      above as may reasonably be requested by the Administrative Agent or any
      Lender.

            (i) Reports. Within 3 Business Days following transmission thereof,
      copies of any filings and registrations with, and reports to, the SEC by
      the U.S. Borrower or any of its Subsidiaries and copies of all financial
      statements, proxy statements, notices and reports as the U.S. Borrower or
      any of its Subsidiaries shall send generally to the holders of
      Indebtedness or (following the public issuance of Equity Interests of the
      U.S. Borrower or any of its Subsidiaries) their Equity Interests in their
      capacity as such holders (to the extent not theretofore delivered to the
      Lenders pursuant to this Agreement).

            (j) New Subsidiaries; etc. Within 45 days after the close of each of
      the first three fiscal quarters of each Fiscal Year of the U.S. Borrower
      and within 90 days after the close of each Fiscal Year of the U.S.
      Borrower, (w) a list showing each Material Foreign Subsidiary of the U.S.
      Borrower which has not theretofore become party to a Foreign Subsidiaries
      Guaranty or any Security Document, (x) a list showing each Subsidiary of
      the U.S. Borrower established, created or acquired during the respective
      fiscal quarter or Fiscal Year (and specifying whether such Subsidiary is a
      Material Foreign Subsidiary), and each Subsidiary which has had any Equity
      Interests transferred during the respective fiscal quarter or Fiscal Year
      (in each case describing in reasonable detail the respective transfer of
      Equity Interests), in each case naming the direct owner of all Equity
      Interests in such Subsidiary and describing such Equity Interests in
      reasonable detail, and certifying that each such Subsidiary, and each
      Credit Party which owns any Equity Interests therein, has taken all
      actions, if any, required pursuant to Sections 8.11 and 9.16 and the
      relevant Security Documents and certifying the U.S. Borrower's compliance
      with the provisions of Section 8.18, (y) a list of each Domestic
      Subsidiary of the U.S. Borrower, if any, which has not been transferred to
      the U.S. Borrower or one or more Qualified U.S. Obligors pursuant to the
      requirements of Section 8.18(a) (by virtue of the first proviso to said
      Section 8.18(a)), and specifically stating the reasons therefor, and (z) a
      list of each Foreign Subsidiary organized under any Qualified Non-U.S.
      Jurisdiction, if any, which has not been transferred to one or more
      Qualified Non-U.S. Obligors pursuant to the requirements of Section
      8.18(b) (by reason of the first proviso to said Section 8.18(b)), and
      specifically stating the reasons therefor.

            (k) Annual Meetings with Lenders. At the request of the
      Administrative Agent, the U.S. Borrower shall, within 120 days after the
      close of each Fiscal Year of the U.S. Borrower (beginning with the Fiscal
      Year ended nearest to March 31, 2004), hold a meeting (which may be by
      conference call or teleconference), at a time and place selected by the
      U.S. Borrower and reasonably acceptable to the Administrative Agent, with
      all of the Lenders that choose to participate, to review the financial
      results of the previous Fiscal Year and the financial condition of the
      U.S. Borrower and its Subsidiaries and the budgets presented for the
      current Fiscal Year of the U.S. Borrower and its Subsidiaries.

            (l) Notice of Commitment Reductions and Mandatory Repayments. On or
      prior to the date of any reduction to Commitments or any mandatory
      repayment of outstanding Term Loans pursuant to Sections 4.02(c) through
      (g), inclusive, the U.S.

                                      -78-

<PAGE>

      Borrower shall provide written notice to the Administrative Agent of the
      amount of the respective reduction or repayment, as the case may be, to
      the Commitments or the outstanding Term Loans, as applicable, and the
      calculations therefor (in reasonable detail).

            (m) Hedging Arrangements. At the time of the delivery of the
      financial statements provided for in Sections 8.01(b) and (c), a schedule
      of all Interest Rate Protection Agreements, Other Hedging Agreements and
      Commodity Agreements entered into by the U.S. Borrower or any of its
      Subsidiaries with any Lender and/or, to the best knowledge of the U.S.
      Borrower, any affiliates of any Lender.

            (n) Other Information. From time to time, such other information or
      documents (financial or otherwise) with respect to the U.S. Borrower or
      its Subsidiaries as the Administrative Agent or any Lender may reasonably
      request.

            8.02 Books, Records and Inspections. Each Borrower will, and will
cause each of its Subsidiaries to, keep proper books of record and accounts in
which full, true and correct entries which permit the preparation of financial
statements in accordance with U.S. GAAP and which conform to all requirements of
law, shall be made of all dealings and transactions in relation to its business
and activities. Each Borrower will, and will cause each of its Subsidiaries to,
permit officers and designated representatives of any Agent or, if any Default
or any Event of Default then exists, any Lender, to visit and inspect, under
guidance of officers of such Borrower or such Subsidiary, any of the properties
of such Borrower or such Subsidiary, and to examine the books of account of such
Borrower or such Subsidiary and discuss the affairs, finances and accounts of
such Borrower or such Subsidiary with, and be advised as to the same by, its and
their officers and independent accountants, all upon reasonable prior notice and
at such reasonable times and intervals and to such reasonable extent as such
Agent or such Lender may reasonably request.

            8.03 Insurance. (a) Each Borrower will, and will cause each of its
Subsidiaries to, (i) maintain, with financially sound and reputable insurance
companies, insurance on all its property in at least such amounts and against at
least such risks as is consistent and in accordance with industry practice and
(ii) furnish to the Administrative Agent, upon request by the Administrative
Agent or any Lender, full information as to the insurance carried. Such
insurance shall in any event include physical damage insurance on all real and
personal property (whether now owned or hereafter acquired) on an all risk basis
and business interruption insurance.

            (b) Each Borrower will, and will cause each of its Subsidiaries to,
at all times keep the respective property of such Borrower and its Subsidiaries
insured in favor of the Collateral Agent, and all policies or certificates with
respect to such insurance (and any other insurance maintained by, or on behalf
of, either Borrower or any of its Subsidiaries other than local insurance
policies maintained by Foreign Subsidiaries of the U.S. Borrower that are not
material) (i) shall be endorsed to the Collateral Agent's reasonable
satisfaction for the benefit of the Collateral Agent (including, without
limitation, by naming the Collateral Agent as certificate holder, mortgagee and
loss payee with respect to real property, certificate holder and loss payee with
respect to personal property, additional insured with respect to general
liability and umbrella liability coverage and certificate holder with respect to
workers' compensation insur-

                                      -79-

<PAGE>

ance), (ii) shall state that such insurance policies shall not be canceled or
materially changed without at least 30 days' prior written notice thereof by the
respective insurer to the Collateral Agent and (iii) shall be deposited with the
Collateral Agent; provided that any payments made to the Collateral Agent
pursuant to such insurance policies shall be subject to applicable local law
requirements (if any).

            (c) If either Borrower or any of its Subsidiaries shall fail to
maintain all insurance in accordance with this Section 8.03, or if either
Borrower or any of its Subsidiaries shall fail to so name the Collateral Agent
as an additional insured, mortgagee or loss payee, as the case may be, or so
deposit all certificates with respect thereto, the Administrative Agent and/or
the Collateral Agent shall have the right (but shall be under no obligation),
upon ten Business Days' notice to the U.S. Borrower, to procure such insurance,
and the Credit Agreement Parties agree jointly and severally to reimburse the
Administrative Agent or the Collateral Agent, as the case may be, for all costs
and expenses of procuring such insurance.

            8.04 Payment of Taxes. Each Borrower will pay and discharge, and
will cause each of its Subsidiaries to pay and discharge, all taxes, assessments
and governmental charges or levies imposed upon it or upon its income or
profits, or upon any properties belonging to it, in each case on a timely basis,
and all lawful claims which, if unpaid, might become a lien or charge upon any
properties of the Borrowers or any of their Subsidiaries not otherwise permitted
under Section 9.03(i); provided that neither any Borrower nor any of its
Subsidiaries shall be required to pay any such tax, assessment, charge, levy or
claim which is being contested in good faith and by proper proceedings if it has
maintained adequate reserves with respect thereto in accordance with U.S. GAAP.

            8.05 Existence; Franchises. Each Borrower will do, and will cause
each of its Subsidiaries to do, or cause to be done, all things necessary to
preserve and keep in full force and effect its existence and its material
rights, franchises, authorities to do business, licenses, certifications,
accreditations and patents; provided, however, that nothing in this Section 8.05
shall prevent (i) sales of assets and other transactions by the U.S. Borrower or
any of its Subsidiaries in accordance with Section 9.02 or (ii) the withdrawal
by the U.S. Borrower or any of its Subsidiaries of its qualification as a
foreign corporation, partnership or limited liability company, as the case may
be, in any jurisdiction where such withdrawal could not, either individually or
in the aggregate, reasonably be expected to have a Material Adverse Effect.

            8.06 Compliance with Statutes; etc. (a) Each Borrower will, and will
cause each of its Subsidiaries to, comply with all applicable statutes,
regulations and orders of, and all applicable restrictions imposed by, all
governmental bodies, domestic or foreign, in respect of the conduct of its
business and the ownership of its property, except for such noncompliances as,
individually or in the aggregate, have not had, and could not reasonably be
expected to have, a Material Adverse Effect.

            (b) Within 5 Business Days after each Borrower is required by
applicable law, statute, rule or regulation, such Borrower shall file (or cause
to be filed) with the SEC all reports, financial information and certifications
required by applicable law, statute, rule or regulation.

                                      -80-

<PAGE>

            8.07 Compliance with Environmental Laws. (a) (i) Each Borrower will
comply, and will cause each of its Subsidiaries to comply, in all material
respects with all Environmental Laws applicable to the ownership or use of its
Real Property now or hereafter owned, leased or operated by such Borrower or any
of its Subsidiaries, will promptly pay or cause to be paid all costs and
expenses incurred in connection with such compliance, and will keep or cause to
be kept all such Real Property free and clear of any Liens imposed pursuant to
such Environmental Laws and (ii) neither any Borrower nor any of its
Subsidiaries will generate, use, treat, store, Release or dispose of, or permit
the generation, use, treatment, storage, Release or disposal of, Hazardous
Materials on any Real Property owned, leased or operated by such Borrower or any
of its Subsidiaries, or transport or permit the transportation of Hazardous
Materials to or from any such Real Property, except as required in the ordinary
course of business of the U.S. Borrower and its Subsidiaries as conducted on the
Effective Date and as allowed by (and in compliance with) applicable law or
regulation, provided, however, that neither Borrower shall be deemed to have
breached this Section 8.07 to the extent that any failures to comply with the
requirements specified in clause (i) or (ii) above, either individually or in
the aggregate, have not had, and could not reasonably be expected to have, a
Material Adverse Effect. If the U.S. Borrower or any of its Subsidiaries, or any
tenant or occupant of any Real Property owned, leased or operated by the U.S.
Borrower or any of its Subsidiaries, causes or permits any intentional or
unintentional act or omission resulting in the presence or Release of any
Hazardous Material (except in compliance with applicable Environmental Laws),
each Borrower agrees to undertake, and/or to cause any of its Subsidiaries,
tenants or occupants to undertake, at their sole expense, any clean up, removal,
remedial or other action required pursuant to Environmental Laws to remove and
clean up any Hazardous Materials from any Real Property except where the failure
to do so has not had, and could not reasonably be expected to have, a Material
Adverse Effect.

            (b) At the written request of the Administrative Agent or the
Required Lenders, which request shall specify in reasonable detail the basis
therefor, at any time after the occurrence of an Event of Default, a breach by
any Borrower of an environmental provision of this Agreement, or any other
matter that requires the giving of notice under Section 8.01(h), the Borrowers
will provide, at their sole cost and expense, an environmental site assessment
report concerning any Real Property now or hereafter owned, leased or operated
by the U.S. Borrower or any of its Subsidiaries, prepared by an environmental
consulting firm reasonably approved by the Administrative Agent, addressing the
matters which gave rise to such request and estimating the potential costs of
any removal, remedial or other corrective action in connection with any such
matter. If either Borrower fails to provide the same within 45 days after such
request was made, the Administrative Agent may order the same, and the Borrowers
shall grant and hereby do grant, to the Administrative Agent and the Lenders and
their agents, access to such Real Property and specifically grant the
Administrative Agent and the Lenders and their agents an irrevocable
non-exclusive license, subject to the right of tenants, to undertake such an
assessment, all at the Borrowers' joint and several expense.

            8.08 ERISA. As soon as possible and, in any event, within twenty
(20) Business Days after the U.S. Borrower, any Subsidiary of the U.S. Borrower
or any ERISA Affiliate knows or has reason to know of the occurrence of any of
the following, the U.S. Borrower will deliver to the Administrative Agent
written notice of the chief financial officer, vice president of human resources
or other Authorized Officer of the U.S. Borrower setting forth, to the extent
known, and in reasonable detail, such occurrence and the action, if any, that
the U.S. Borrower,

                                      -81-

<PAGE>

such Subsidiary or such ERISA Affiliate is required or proposes to take,
together with any notices required or proposed to be given to or filed by the
U.S. Borrower, such Subsidiary, the Plan administrator or such ERISA Affiliate
to or with, the PBGC or any other governmental agency, or a Plan or
Multiemployer Plan participant, and any notices received by the U.S. Borrower,
such Subsidiary or ERISA Affiliate from the PBGC or other governmental agency or
a Plan or Multiemployer Plan participant or the Plan administrator with respect
thereto: (1) that a Reportable Event has occurred (except to the extent that the
U.S. Borrower has previously delivered to the Administrative Agent a notice
concerning such event pursuant to clause (2) hereof); (2) that a contributing
sponsor (as defined in Section 4001(a)(13) of ERISA) of a Plan subject to Title
IV of ERISA is subject to the advance reporting requirement of PBGC Regulation
Section 4043.61 (without regard to subparagraph (b)(1) thereof), and an event
described in subsection .62, .63, .64, .65, .66, .67 or .68 of PBGC Regulation
Section 4043 is reasonably expected to occur with respect to such Plan within
the following 30 days; (3) that an accumulated funding deficiency, within the
meaning of Section 412 of the Code or Section 302 of ERISA, has been incurred or
(except to the extent that the U.S. Borrower has previously delivered to the
Administrative Agent a notice concerning such event pursuant to clause (2)
hereof) an application has been, or is reasonably expected to be, made for a
waiver or modification of the minimum funding standard (including any required
installment payments) or an extension of any amortization period under Section
412 of the Code or Section 303 or 304 of ERISA with respect to a Plan; (4) that
any contribution required to be made with respect to a Plan or Multiemployer
Plan or Foreign Pension Plan has been made more than sixty (60) days late; (5)
that a Plan or Multiemployer Plan has been or will be involuntarily terminated,
reorganized, partitioned or declared insolvent under Title IV of ERISA; (6) that
a Plan has an Unfunded Current Liability which, when added to the aggregate
amount of Unfunded Current Liabilities with respect to all other Plans as of
such date, exceeds the aggregate amount of the Unfunded Current Liability that
existed on the Initial Borrowing Date by $10,000,000; (7) that involuntary
proceedings have been or will be instituted to terminate or appoint a trustee to
administer a Plan which is subject to Title IV of ERISA; (8) that an involuntary
proceeding has been instituted pursuant to Section 515 of ERISA to collect a
delinquent contribution to a Plan or Multiemployer Plan; (9) that, except as
otherwise disclosed on Schedule V, the U.S. Borrower, any Subsidiary of the U.S.
Borrower or any ERISA Affiliate will incur or is reasonably expected to incur
any material liability (including any indirect, contingent, or secondary
liability) to or on account of the termination of or withdrawal from a Plan or
Multiemployer Plan under Section 4062, 4063, 4064, 4069, 4201, 4204 or 4212 of
ERISA or with respect to a Plan or Multiemployer Plan under Section 401(a)(29),
4971, 4975 or 4980 of the Code or Section 409 or 502(i) or 502(l) of ERISA or
with respect to a group health plan (as defined in Section 607(1) of ERISA or
Section 4980B(g)(2) of the Code) under Section 4980B of the Code; (10) that the
U.S. Borrower or any Subsidiary of the U.S. Borrower will incur any liability
pursuant to any group health plan (as defined in Section 5000(b)(1) of the Code)
that provides benefits to retired employees or other former employees (other
than as required by Section 601 of ERISA) which arises from the extension of
such group health plan to any retirees or former employees who were not eligible
for coverage under such group health plan on the Initial Borrowing Date, except
to the extent that any such liability would not be material to the U.S. Borrower
or any Subsidiary of the U.S. Borrower; or (11) the U.S. Borrower or any
Subsidiary of the U.S. Borrower will incur any liability not otherwise described
in this Section 8.08 pursuant to any Plan or Foreign Pension Plan which, when
added to the aggregate amount of such liabilities with

                                      -82-

<PAGE>

respect to all other Plans and/or Foreign Pension Plans as of such date, exceeds
the aggregate amount of such liabilities that existed on the Initial Borrowing
Date by $10,000,000. To the extent that the financial statements set forth a
liability for which notice would otherwise be required to be given hereunder, a
separate notice thereof shall not be required hereunder. At the request of the
Administrative Agent, the U.S. Borrower will deliver to the Administrative Agent
copies of any records, documents or other information that must be furnished to
the PBGC with respect to any Plan pursuant to Section 4010 of ERISA. The U.S.
Borrower will also deliver upon written request to the Administrative Agent a
complete copy of the annual report (on Internal Revenue Service Form
5500-series) of each Plan (including, to the extent required, the related
financial and actuarial statements and opinions and other supporting statements,
certifications, schedules and information) required to be filed with the
Internal Revenue Service. In addition to any notices delivered to the
Administrative Agent pursuant to the first sentence hereof, copies of annual
reports and any records, documents or other information required to be furnished
to the PBGC or any other government agency, and any material notices received by
the U.S. Borrower, any Subsidiary of the U.S. Borrower or any ERISA Affiliate
with respect to any Plan or Foreign Pension Plan or received from any government
agency or plan administrator or sponsor or trustee with respect to any
Multiemployer Plan, shall, upon request of the Administrative Agent, be
delivered to the Administrative Agent no later than twenty (20) Business Days
after the date of such request. The U.S. Borrower and each of its applicable
Subsidiaries shall ensure that all Foreign Pension Plans administered by it or
into which it makes payments obtain or retain (as applicable) registered status
under and as required by applicable law and is administered in a timely manner
in all respects in compliance with all applicable laws except where the failure
to do any of the foregoing has not had, and could not reasonably be expected to
have, a Material Adverse Effect.

            8.09 Good Repair. Each Borrower will, and will cause each of its
Subsidiaries to, ensure that its material properties and equipment required to
be used in its business are kept in reasonably good repair, working order and
condition, ordinary wear and tear, casualty and condemnation excepted, and that
from time to time there are made in such properties and equipment all necessary
and proper repairs, renewals, replacements, extensions, additions, betterments
and improvements thereto, to the extent and in the manner useful or customary
for companies in similar businesses.

            8.10 End of Fiscal Years; Fiscal Quarters. Each Borrower will cause
(i) each of its fiscal years to end on March 31 of each calendar year and (ii)
each of its fiscal quarters to end on June 30, September 30, December 31 and
March 31 of each year.

            8.11 Additional Security. Additional Guaranties; Actions with
Respect to Non-Guarantor Subsidiaries; Further Assurances. (a) To the extent
permitted under applicable law, each Borrower will, and will cause its
Subsidiaries which are Subsidiary Guarantors to, grant to the Collateral Agent
(or such other trustee, sub-agent or other third party as may be required or
desired under local law) security interests and mortgages (each, an "Additional
Mortgage") in: (i) such fee-owned (or the equivalent) Real Property acquired by
such Person after the Initial Borrowing Date and having a value (for such
purpose, using the initial purchase price paid by such Person for such Real
Property) in excess of $1,000,000 which is not covered by the original Mortgages
or Foreign Security Agreements, as appropriate, and (ii) such material
Leaseholds to which a respective landlord has granted its consent to the
delivery of a Mortgage over such

                                      -83-

<PAGE>

Leaseholds (each such Real Property, an "Additional Mortgaged Property"). All
such Additional Mortgages shall be granted pursuant to documentation
substantially in the form of a relevant existing Mortgage or, in the case of
Additional Mortgaged Properties located in a jurisdiction outside the United
States, the relevant Foreign Security Agreement covering Real Property located
in such jurisdiction (if any) delivered to the Administrative Agent on the
Initial Borrowing Date or in such other form as is reasonably satisfactory to
the Administrative Agent and shall constitute valid and enforceable first
priority perfected Liens, superior to and prior to the rights of all third
Persons and subject to no other Liens (except as are permitted by Section 9.03),
in favor of the Collateral Agent (or such other trustee, sub-agent or other
third party as may be required or desired under local law). The Additional
Mortgages or instruments related thereto shall be duly recorded or filed in such
manner and in such places as are required by law to create, maintain, effect,
perfect, preserve and protect the Liens in favor of the Collateral Agent (or
such other trustee, sub-agent or other third-party as may be required or desired
under local law) required to be granted pursuant to the Additional Mortgages and
all taxes, fees and other charges payable in connection therewith shall be paid
in full.

            (b) Each Borrower will, and will cause each of its Subsidiaries to,
at its own expense, make, execute, endorse, acknowledge, file and/or deliver to
the Collateral Agent from time to time such vouchers, invoices, schedules,
confirmatory assignments, confirmatory conveyances, financing statements,
transfer endorsements, confirmatory powers of attorney, certificates, reports
and other assurances or confirmatory instruments and take such further steps
relating to the Collateral covered by any of the Security Documents as the
Collateral Agent may reasonably require pursuant to this Section 8.11.
Furthermore, each Borrower will cause to be delivered to the Collateral Agent
such opinions of counsel and other related documents as may be reasonably
requested by the Collateral Agent to assure itself that this Section 8.11 has
been complied with.

            (c) Subject to the provisions of following clauses (g) and (h), if
(x) at any time any Domestic Subsidiary of the U.S. Borrower is created,
established or acquired, such Subsidiary shall be required to execute and
deliver (i) a Joinder Agreement substantially in the form of Exhibit P hereto
and (ii) counterparts of the U.S. Subsidiaries Guaranty, the Intercompany
Subordination Agreement and such Security Documents as would have been entered
into by the respective Subsidiary if same had been a U.S. Subsidiary Guarantor
on the Initial Borrowing Date and in each case shall take all action in
connection therewith as would otherwise have been required to be taken pursuant
to Section 5 if such Subsidiary had been a U.S. Subsidiary Guarantor on the
Initial Borrowing Date, (y) at any time any Subsidiary of the U.S. Borrower
organized under the laws of any Qualified Non-U.S. Jurisdiction is created,
established or acquired, such Subsidiary shall be required to execute and
deliver (i) a Joinder Agreement substantially in the form of Exhibit P hereto
and (ii) counterparts of a Foreign Subsidiaries Guaranty (or if requested by the
Administrative Agent upon the advice of local counsel, a new Foreign
Subsidiaries Guaranty), the Intercompany Subordination Agreement and such
Security Documents as would have been entered into by the respective Subsidiary
if same had been a Foreign Subsidiary Guarantor on the Initial Borrowing Date
(determined in accordance with the criteria described in Sections 5.10, 5.12 and
5.13(b)), and in each case shall take all action in connection therewith as
would otherwise have been required to be taken pursuant to Section 5 if such
Subsidiary had been a Foreign Subsidiary Guarantor on the Initial Borrowing Date
and (z) if at any time after the Initial Borrowing Date any jurisdiction is
added

                                      -84-

<PAGE>

to the list of Qualified Jurisdictions in accordance with the definition thereof
contained herein, then at the time of such designation each Foreign Subsidiary
of the U.S. Borrower organized under the laws of such Qualified Jurisdiction
(with such exceptions as may be satisfactory to the Administrative Agent or the
Required Lenders) shall be required to become a Foreign Subsidiary Guarantor and
take all actions specified in preceding clause (y). Furthermore, subject to the
provisions of the following clause (h), the Administrative Agent or the Required
Lenders may at any time request that one or more Subsidiaries of the U.S.
Borrower organized under the laws of one or more jurisdictions which are not
Qualified Jurisdictions become Foreign Subsidiary Guarantors, in which case the
Borrowers shall cause each such Subsidiary which has been specifically requested
to become a Foreign Subsidiary Guarantor to take all actions as are specified in
clause (y) of the immediately preceding sentence, provided that no Subsidiary of
the U.S. Borrower shall be required to take such actions if, and to the extent
that, based upon written advice of local counsel reasonably satisfactory to the
Administrative Agent, the U.S. Borrower and/or such Subsidiary concludes that
the taking of such actions would violate the laws of the jurisdiction in which
the respective Subsidiary is organized, provided further, that if steps (such as
limiting the amount guaranteed) can be taken so that such violation would not
exist, then if requested by the Administrative Agent or the Required Lenders,
the respective Subsidiary shall enter into a modified Foreign Subsidiaries
Guaranty which provides, to the maximum extent permissible under applicable law,
as many of the benefits as are provided pursuant to the Foreign Subsidiaries
Guaranties executed and delivered on the Initial Borrowing Date as is possible.

            (d) In addition to the requirements contained in the Pledge
Agreements, each Borrower agrees to pledge and deliver, or cause to be pledged
and delivered, all of the Equity Interests owned by any Credit Party of each new
Subsidiary of the U.S. Borrower established or created after the Initial
Borrowing Date to the Collateral Agent (or such other trustee, sub-agent or
other third-party as may be required or desired under local law) for the benefit
of the Secured Creditors pursuant to the Pledge Agreements, provided that,
subject to the provisions of Section 8.12, in the case of any Foreign Subsidiary
that is a corporation (or treated as such for U.S. tax purposes) which is owned
by a U.S. Credit Party, not more than 65% of the total outstanding voting Equity
Interests of such Person shall be required to be pledged in support of such U.S.
Credit Party's obligations (x) as a Borrower under the Credit Agreement (in the
case of the U.S. Borrower) or (y) under its Guaranty in respect of the
Obligations of the U.S. Borrower (in the case of the other U.S. Credit Parties).

            (e) Following any request by the Administrative Agent or the
Required Lenders (which request shall be made after taking into account cost and
practicality considerations), the U.S. Borrower or any of its Subsidiaries,
shall, to the maximum extent permitted by applicable law (but subject to the
proviso to the preceding clause (d), to the extent applicable), (x) grant
security interests in such of their Property as may be requested by the
Administrative Agent or the Required Lenders, as the case may be, in which
perfected security interests do not already exist pursuant to the Security
Documents theretofore executed and delivered and, in connection therewith, the
Borrowers shall, or shall cause the relevant Subsidiaries of the U.S. Borrower
to, execute and deliver counterparts of (and thereby become parties to) the
applicable Security Documents and/or Additional Security Documents, in each case
in form and substance reasonably satisfactory to the Administrative Agent and/or
(y) with respect to pledges of Equity Interests of, or promissory notes issued
by, Persons described in Section 13.19, take such action (including, without
limitation, the execution of Additional

                                      -85-

<PAGE>

Security Documents, the making of filings, etc.) under the local law of the
Person whose Equity Interests or promissory notes are pledged as may be
requested in order to create, preserve, protect or perfect security interests in
such Equity Interests and/or promissory notes. Subject to the provisions of
following Section 8.12, any security granted as required above shall secure
Obligations in a manner consistent with the methodology employed on the
Effective Date (i.e., collateral owned by Foreign Credit Parties shall not
secure obligations of the U.S. Borrower).

            (f) The security interests required to be granted pursuant to
Sections 8.11(c), (d) and (e) shall be granted pursuant to the respective
Security Documents already executed and delivered by the Credit Parties (or
other security documentation substantially similar to such Security Documents or
otherwise reasonably satisfactory in form and substance to the Collateral Agent)
and shall constitute valid and enforceable first priority perfected security
interests prior to the rights of all third Persons and subject to no other Liens
(other than Permitted Liens). The Borrowers shall (or shall cause their
respective Subsidiaries), (i) at their own expense, to (x) execute, acknowledge
and deliver, or cause the execution, acknowledgment and delivery of, and
thereafter register, file or record in any appropriate governmental office, any
document or instrument reasonably deemed by the Collateral Agent to be necessary
or desirable for the creation, perfection, maintenance, preservation and
protection of the Liens on its assets intended to be created pursuant to the
relevant Security Documents and (y) take all other actions reasonably requested
by the Collateral Agent (including, without limitation, the furnishing of legal
opinions) in connection with the granting of the security interests required
pursuant to Sections 8.11(c), (d) and (e) and (ii) pay in full all taxes, fees
and other charges payable in connection with the granting of the security
interests required pursuant to Sections 8.11(c), (d) and (e).

            (g) Each Borrower agrees that each action required above by Section
8.11(a) or (b) shall be completed as soon as possible, but in no event later
than 60 days (or, in the case of actions relating to assets located outside the
United States, such greater number of days (not to exceed 90 days) as the
Administrative Agent shall agree to in its sole and absolute discretion in any
given case) after such action is requested to be taken by the Administrative
Agent or the Required Lenders. Each Borrower further agrees that (x) each action
required above by Section 8.11(c), (d) and (f) with respect to a newly formed,
created or acquired Subsidiary, or with respect to any Subsidiary which is
located in a jurisdiction newly-designated as a Qualified Jurisdiction or which
becomes a Subsidiary, shall be completed contemporaneously with the formation,
creation or acquisition of such Subsidiary, the date of the addition of the
respective jurisdiction to the list of Qualified Jurisdictions or the date such
Subsidiary becomes a Subsidiary, as the case may be, and (y) all actions
required to be taken pursuant to the last sentence of Section 8.11(c) and
Section 8.11(e) shall be taken as promptly as practicable, and in any event
within 45 days, after the U.S. Borrower receives the respective request from the
Administrative Agent or the Required Lenders.

            (h) Notwithstanding anything to the contrary contained in clauses
(c) through (g) above, to the extent the taking of any action as described above
by a new Subsidiary acquired pursuant to a Permitted Acquisition, which is
subject to Permitted Acquired Debt which at such time remains in existence as
permitted by Section 9.04(vi), then to the extent that the terms of the
respective Permitted Acquired Debt prohibit the taking of any actions which
would otherwise be required of such Subsidiary by this Section 8.11, then the
time for taking the respective actions (to the extent prohibited by the terms of
the respective Permitted Acquired Debt) shall be

                                      -86-

<PAGE>

extended until 10 Business Days after the earlier of (i) the date of repayment
of such Permitted Acquired Debt and (ii) the first date on which the taking of
such actions would not violate the terms of the respective issue of Permitted
Acquired Debt. To the extent the terms of any Permitted Acquired Debt prohibits
the taking of actions otherwise required by this Section 8.11, upon the request
of the Administrative Agent or the Required Lenders, each Borrower shall, or
shall cause the respective Subsidiaries of the U.S. Borrower to, (x) prepay any
such Permitted Acquired Debt which is permitted to be prepaid and/or (y) use
reasonable efforts to obtain such consents or approvals as are needed so that
the taking of the actions otherwise specified in this Section 8.11 would not
violate the terms of the respective issue of Permitted Acquired Debt.
Furthermore, to the extent any Subsidiary which is not a Wholly-Owned Subsidiary
is acquired pursuant to a Permitted Acquisition (in accordance with the
limitations contained in the definition thereof) or as a result of Investments
made pursuant to Section 9.05(xv), then for so long as such Subsidiary is not a
Wholly-Owned Subsidiary, to the extent the U.S. Borrower in good faith
determines that the respective Subsidiary is not able, under applicable
requirements of law (whether because of fiduciary duties under applicable law or
other requirements of applicable law) to execute and deliver a Subsidiaries
Guaranty or one or more Security Documents, the respective such Subsidiary shall
not be required to become a Subsidiary Guarantor or execute and deliver such
Security Documents as otherwise required above.

            (i) In the event that the Administrative Agent or the Required
Lenders at any time after the Initial Borrowing Date determine in their
reasonable discretion (whether as a result of a position taken by an applicable
bank regulatory agency or official, or otherwise) that real estate appraisals
satisfying the requirements set forth in 12 C.F.R., Part 34-Subpart C, or any
successor or similar statute, role, regulation, guideline or order (any such
appraisal, a "Required Appraisal") are or were required to be obtained, or
should be obtained, in connection with any U.S. Mortgaged Property or U.S.
Mortgaged Properties, then, within 90 days after receiving written notice
thereof from the Administrative Agent or the Required Lenders, as the case may
be, the U.S. Borrower shall cause such Required Appraisal to be delivered, at
the expense of the U.S. Borrower, to the Administrative Agent, which Required
Appraisal, and the respective appraiser, shall be reasonably satisfactory to the
Administrative Agent.

            8.12 Foreign Subsidiaries Security. If following a change in the
relevant sections of the Code or the regulations, rules, rulings, notices or
other official pronouncements issued or promulgated thereunder, counsel for the
U.S. Borrower reasonably acceptable to the Administrative Agent and the Required
Lenders does not within 30 days after a request from the Administrative Agent or
the Required Lenders deliver evidence, in form and substance reasonably
satisfactory to the Administrative Agent and the Required Lenders, that (i) a
pledge of 66-2/3% or more of the total combined voting power of all classes of
Equity Interests entitled to vote of any Foreign Subsidiary owned by a U.S.
Credit Party which has not already had all of its Equity Interests pledged
pursuant to the U.S. Pledge Agreement or a Local Law Pledge Agreement, as
applicable, to secure all of the Obligations (as defined in the respective such
Security Document), (ii) the entering into by a Foreign Subsidiary Guarantor of
a pledge agreement in substantially the form of the U.S. Pledge Agreement, (iii)
the entering into by a Foreign Subsidiary Guarantor of a security agreement in
substantially the form of the U.S. Security Agreement and (iv) the entering into
by a Foreign Subsidiary Guarantor of a guaranty in substantially the form of the
U.S. Subsidiaries Guaranty, in any such case would cause the undistributed
earnings of such Foreign Subsidiary as determined for Federal income tax
purposes to be treated

                                      -87-

<PAGE>

as a deemed dividend to such Foreign Subsidiary's United States parent or a
deemed disposition of the shares of stock of such Foreign Subsidiary for Federal
income tax purposes, then (I) in the case of a failure to deliver the evidence
described in clause (i) above, that portion of such Foreign Subsidiary's
outstanding Equity Interests owned or held by a U.S. Credit Party and not
theretofore pledged pursuant to the U.S. Pledge Agreement or a Local Law Pledge
Agreement, as applicable, to secure all of the Obligations (as defined in the
respective such Security Document) shall be pledged to the Collateral Agent (or
such other trustee, sub-agent or other third-party as may be required or desired
under local law) for the benefit of the Secured Creditors pursuant to the U.S.
Pledge Agreement or the relevant Local Law Pledge Agreement (or another pledge
agreement in substantially similar form, if needed), (II) in the case of a
failure to deliver the evidence described in clause (ii) above, such Foreign
Subsidiary Guarantor shall execute and deliver the U.S. Pledge Agreement (or
another pledge agreement in substantially similar form, if needed), granting to
the Collateral Agent for the benefit of the Secured Creditors a security
interest in all of the capital stock, other Equity Interests and promissory
notes owned by such Foreign Subsidiary (other than Excluded Collateral) and
securing the Obligations of the U.S. Borrower under the Credit Documents and
under any Interest Rate Protection Agreement or Other Hedging Agreement and, in
the event the U.S. Subsidiaries Guaranty shall have been executed by such
Foreign Subsidiary Guarantor, the obligations of such Foreign Subsidiary
Guarantor thereunder, (III) in the case of a failure to deliver the evidence
described in clause (iii) above, such Foreign Subsidiary Guarantor shall execute
and deliver the U.S. Security Agreement (or another security agreement in
substantially similar form, if needed) granting to the Collateral Agent for the
benefit of the Secured Creditors a security interest in all of such Foreign
Subsidiary Guarantor's assets (other than the capital stock, other Equity
Interests and promissory notes owned by such Foreign Subsidiary) and securing
the obligations of the U.S. Borrower under the Credit Documents and under any
Interest Rate Protection Agreement or Other Hedging Agreement and, in the event
the U.S. Subsidiaries Guaranty shall have been executed by such Foreign
Subsidiary Guarantor, the obligations of such Foreign Subsidiary Guarantor
thereunder, and (IV) in the case of a failure to deliver the evidence described
in clause (iv) above, such Foreign Subsidiary Guarantor shall execute and
deliver the U.S. Subsidiaries Guaranty (or another guaranty in substantially
similar form, if needed), guaranteeing the Obligations of the U.S. Borrower
under the Credit Documents and under any Interest Rate Protection Agreement or
Other Hedging Agreement, in each case to the extent that the entering into of
the U.S. Pledge Agreement, the U.S. Security Agreement or the U.S. Subsidiaries
Guaranty (or similar such agreement or guaranty) is permitted by the laws of the
respective foreign jurisdiction and with all documents delivered pursuant to
this Section 8.12 to be in form and substance reasonably satisfactory to the
Administrative Agent and/or the Required Lenders.

            8.13 Use of Proceeds. The U.S. Borrower will, and will cause each of
its Subsidiaries to, use the proceeds of the Loans for the purposes specified in
Section 7.05. Neither Borrower will, nor will it permit any of its Subsidiaries
to, use any of the proceeds of the Loans or any Letter of Credit to finance the
acquisition of any Person that has not been approved and recommended by the
board of directors (or functional equivalent thereof) or the requisite
shareholders of such Person.

            8.14 Ownership of Subsidiaries. (a) Notwithstanding anything to the
contrary contained in this Agreement, (x) the U.S. Borrower shall at all times
own directly or indirectly (through a Wholly-Owned Domestic Subsidiary) 100% of
the Equity Interests of the European

                                      -88-

<PAGE>

Borrower and (y) subject to the proviso to the first sentence of Section
8.18(a), the U.S. Borrower shall at all times own directly or indirectly
(through one or more Wholly-Owned Domestic Subsidiaries (as opposed to through
Foreign Subsidiaries)) all of the capital stock or other Equity Interests (to
the extent owned by the U.S. Borrower or any of its Subsidiaries) of each
Domestic Subsidiary of the U.S. Borrower.

            (b) The U.S. Borrower shall at all times own, directly or
indirectly, 100% of the Equity Interests of its Subsidiaries (except to the
extent (v) with respect to Foreign Subsidiaries, directors' qualifying shares
and other nominal amounts of shares required by applicable law to be held by
Persons (other than directors) are issued from time to time (so long as the
respective Subsidiary continues to constitute a Wholly-Owned Subsidiary of the
U.S. Borrower), (w) 100% of the capital stock or other Equity Interests of any
such Subsidiary are sold, transferred or otherwise disposed of pursuant to a
transaction permitted by Section 9.02, (x) less than 100% of the capital stock
or other Equity Interests are acquired in the respective Subsidiary pursuant to
a Permitted Acquisition which meets the criteria specified in the definition of
Permitted Acquisition contained herein, (y) such capital stock or other Equity
Interests are acquired pursuant to an Investment permitted by Sections 9.05(xiv)
and (xvi) or (z) set forth on Schedule VII).

            8.15 Permitted Acquisitions. (a) Subject to the provisions of this
Section 8.15 and the requirements contained in the definition of Permitted
Acquisition, the U.S. Borrower and any of its Wholly-Owned Subsidiaries may from
time to time effect Permitted Acquisitions, so long as (in each case except to
the extent the Required Lenders otherwise specifically agree in writing in the
case of a specific Permitted Acquisition): (i) no Default or Event of Default
shall be in existence at the time of the consummation of the proposed Permitted
Acquisition or immediately after giving effect thereto; (ii) the U.S. Borrower
shall have given the Administrative Agent (on behalf of the Lenders) at least 5
Business Days' prior written notice of the proposed Permitted Acquisition; (iii)
calculations are made by the U.S. Borrower of compliance with the covenants
contained in Sections 9.08, 9.09 and 9.10 for the respective Calculation Period
on a Pro Forma Basis as if the respective Permitted Acquisition (as well as all
other Permitted Acquisitions and Significant Asset Sales theretofore consummated
after the first day of such Calculation Period) had occurred on the first day of
such Calculation Period, and such calculations shall show that such financial
covenants would have been complied with if the Permitted Acquisition had
occurred on the first day of such Calculation Period (for this purpose, if the
first day of the respective Calculation Period occurs prior to the Initial
Borrowing Date, calculated as if the covenants contained in said Sections 9.08,
9.09 and 9.10 had been applicable from the first day of the Calculation Period),
(iv) based on good faith projections prepared by the U.S. Borrower for the
period from the date of the consummation of the respective Permitted Acquisition
to the date which is one year thereafter, the level of financial performance
measured by the financial covenants set forth in Sections 9.08, 9.09 and 9.10
shall be better than or equal to such level as would be required to comply with
such financial covenants through the date which is one year from the date of the
consummation of the respective Permitted Acquisition; (v) all representations
and warranties contained herein and in the other Credit Documents shall be true
and correct in all material respects with the same effect as though such
representations and warranties had been made on and as of the date of such
Permitted Acquisition (both before and after giving effect thereto), unless
stated to relate to a specific earlier date, in which case such representations
and warranties shall be true and correct in all material respects as of such
earlier

                                      -89-

<PAGE>

date; (vi) the U.S. Borrower provides to the Administrative Agent (on behalf of
the Lenders) as soon as available but not later than 5 Business Days after the
execution thereof, a copy of any executed purchase agreement or similar
agreement with respect to such Permitted Acquisition; (vii) the Maximum
Permitted Consideration payable in connection with the proposed Permitted
Acquisition (for such purpose, treating any related Permitted Acquisitions
theretofore effected as a single Permitted Acquisition) does not exceed
$20,000,000; (viii) the Maximum Permitted Consideration payable in connection
with the proposed Permitted Acquisition, when aggregated with the Maximum
Permitted Consideration payable in connection with all other Permitted
Acquisitions consummated after the Effective Date, does not exceed $50,000,000;
(ix) after giving effect to such Permitted Acquisition and the payment of all
post-closing purchase price adjustments required (in the good faith
determination of the U.S. Borrower) in connection with such Permitted
Acquisition (and all other Permitted Acquisitions for which such purchase price
adjustments may be required to be made) and all Capital Expenditures (and the
financing thereof) reasonably anticipated by the U.S. Borrower to be made in the
business acquired pursuant to such Permitted Acquisition within the 180-day
period (such period for any Permitted Acquisition, a "Post-Closing Period")
following such Permitted Acquisition (and in the businesses acquired pursuant to
all other Permitted Acquisitions with Post-Closing Periods ended during the
Post-Closing Period of such Permitted Acquisition), the Total Unutilized
Multicurrency Facility Revolving Loan Commitment shall equal or exceed
$35,000,000; (x) such proposed Permitted Acquisition shall be effected in
accordance with the relevant requirements of Section 8.18; (xi) the U.S.
Borrower determines in good faith that the U.S. Borrower and its Subsidiaries
taken as a whole are not likely to assume or become liable for material
increased contingent liabilities as a result of such proposed Permitted
Acquisition (excluding, however, Indebtedness permitted to be incurred pursuant
to Section 9.04 in connection therewith); (xii) substantially all of the
Acquired Entity or Business acquired pursuant to the respective Permitted
Acquisition is in a Qualified Jurisdiction, provided, however, the respective
proposed Permitted Acquisition shall not be required to meet the requirements
set forth above in this clause (xii) if the Maximum Permitted Consideration
payable in connection with such Permitted Acquisition, when aggregated with the
Maximum Permitted Consideration payable in connection with all other Permitted
Acquisitions consummated after the Effective Date in which all or substantially
all of the Acquired Entity or Business so acquired were not in Qualified
Jurisdictions, does not exceed $5,000,000; and (xiii) the U.S. Borrower shall
have delivered to the Administrative Agent on the date of the consummation of
such proposed Permitted Acquisition, an officer's certificate executed by an
Authorized Officer of the U.S. Borrower, certifying to the best of his
knowledge, compliance with the requirements of preceding clauses (i) through
(v), inclusive, and clauses (vii) through (xii), inclusive, and containing the
calculations required by the preceding clauses (iii), (iv), (vii), (viii) and
(ix).

            (b) At the time of each Permitted Acquisition involving the creation
or acquisition of a Subsidiary, or the acquisition of capital stock or other
Equity Interests of any Person, all capital stock or other Equity Interests
thereof created or acquired in connection with such Permitted Acquisition shall
be pledged for the benefit of the Secured Creditors as, and to the extent
required by, Section 8.11 and the relevant Security Documents.

            (c) Each Borrower shall cause each Subsidiary that is formed to
effect, or is acquired pursuant to, a Permitted Acquisition to comply with, and
to execute and deliver, all of

                                      -90-

<PAGE>

the documentation required by, Sections 8.11 and 9.16, to the satisfaction of
the Administrative Agent.

            (d) The consummation of each Permitted Acquisition shall be deemed
to be a representation and warranty by each Borrower that the certifications by
each Borrower (or by one or more of its respective Authorized Officers) pursuant
to Section 8.15 are true and correct and that all conditions thereto have been
satisfied and that same is permitted in accordance with the terms of this
Agreement, which representation and warranty shall be deemed to be a
representation and warranty for all purposes hereunder, including, without
limitation, Sections 6 and 10.

            8.16 Maintenance of Company Separateness. Each Borrower will, and
will cause each of its Subsidiaries to, satisfy in all material respects
customary Company formalities, including the holding of regular board of
directors' and shareholders' meetings or action by directors or shareholders
without a meeting and the maintenance of Company records. Neither the U.S.
Borrower nor any other Credit Party shall make any material payment to a
creditor of any Non-Guarantor Subsidiary in respect of any liability of any
Non-Guarantor Subsidiary, and no bank account of any Non-Guarantor Subsidiary
shall be commingled with any bank account of the U.S. Borrower or any other
Credit Party. Any financial statements distributed to any creditors of any
Non-Guarantor Subsidiary shall clearly establish or indicate the corporate
separateness of such Non-Guarantor Subsidiary from the U.S. Borrower and its
other Subsidiaries. Finally, neither the U.S. Borrower nor any of its
Subsidiaries shall take any action, or conduct its affairs in a manner, which is
likely to result in the Company existence of either Borrower, any other Credit
Party or any Non-Guarantor Subsidiaries being ignored, or in the assets and
liabilities of the U.S. Borrower or any other Credit Party being substantively
consolidated with those of any other such Person or any Non-Guarantor Subsidiary
in a bankruptcy, reorganization or other insolvency proceeding.

            8.17 Performance of Obligations. Each Borrower will, and will cause
each of its Subsidiaries to, perform all of its obligations under the terms of
each mortgage, deed of trust, indenture, loan agreement or credit agreement and
each other material agreement, contract or instrument by which it is bound,
except such non-performances as, individually or in the aggregate, have not
caused, and could not reasonably be expected to cause, a Default or Event of
Default hereunder or a Material Adverse Effect.

            8.18 Conduct of Business. (a) The Borrowers shall take all actions
so that, at all times from and after the Initial Borrowing Date, all the assets
of the U.S. Borrower and its Subsidiaries located within the United States, all
Equity Interests in all Domestic Subsidiaries or other U.S. Persons and all or
substantially all of the business of the U.S. Borrower and its Subsidiaries
conducted in the United States, are, in each case, owned or conducted, as the
case may be, by the U.S. Borrower and one or more Qualified U.S. Obligors which
are not direct or indirect Subsidiaries of any Subsidiary of the U.S. Borrower
which is a Foreign Subsidiary, provided that if a Foreign Subsidiary (not itself
created or established in contemplation of a Permitted Acquisition) is acquired
pursuant to a Permitted Acquisition which Foreign Subsidiary has (either
directly or through one or more Domestic Subsidiaries) assets or operations in
the United States, the U.S. Borrower shall have a reasonable period of time (not
to exceed 60 days) to effect the transfer of U.S. assets and operations
(including all Equity Interests in any Domestic

                                      -91-

<PAGE>

Subsidiaries or other U.S. Persons held by it) of the respective Foreign
Subsidiary to one or more Qualified U.S. Obligors, provided further, that the
respective transfer shall not be required to be made if the U.S. Borrower in
good faith determines that such transfer would give rise to adverse tax
consequences to the U.S. Borrower and its Subsidiaries or would give rise to any
material breach or violation of law or contract (in which case, the U.S.
Borrower and its Subsidiaries shall transfer such assets and operations at such
time, if any, as such adverse tax consequences or breach or violation would not
exist and, until such time, shall use good faith efforts so that any growth in
the assets or operations of the entity so acquired, to the extent located in the
United States, are made within one or more Qualified U.S. Obligors).

            (b) In addition to the foregoing requirements, the Borrowers shall
take all actions so that, at all times from and after the Initial Borrowing
Date, all the assets of the U.S. Borrower's Subsidiaries located within all
Qualified Non-U.S. Jurisdictions, all Equity Interests in all Persons organized
under any Qualified Non-U.S. Jurisdiction and all or substantially all of the
business of the U.S. Borrower's Subsidiaries conducted in all Qualified Non-U.S.
Jurisdictions, are, in each case, owned or conducted, as the case may be, by one
or more Qualified Non-U.S. Obligors which are not direct or indirect
Subsidiaries of any Subsidiary of the U.S. Borrower other than Qualified
Obligors, provided that if a Subsidiary of the U.S. Borrower organized under the
laws of a jurisdiction other than any Qualified Non-U.S. Jurisdiction (not
itself created or established in contemplation of the respective Permitted
Acquisition) is acquired pursuant to a Permitted Acquisition which Subsidiary
has (either directly or through one or more Subsidiaries) assets or operations
outside Qualified Non-U.S. Jurisdictions, the U.S. Borrower shall have a
reasonable period of time (not to exceed 60 days) to effect the transfer of all
assets and operations outside Qualified Non-U.S. Jurisdictions (including all
Equity Interests in any Persons held by it which are organized under the laws of
one or more Qualified Non-U.S. Jurisdiction) of the respective Subsidiary to one
or more Qualified Non-U.S. Obligors which are not themselves direct or indirect
Subsidiaries of any Subsidiary of the U.S. Borrower other than Qualified
Obligors, provided further, that the respective transfer shall not be required
to be made if the U.S. Borrower in good faith determines that such transfer
would give rise to adverse tax consequences to the U.S. Borrower and its
Subsidiaries or would give rise to any material breach or violation of law or
contract (in which case, the U.S. Borrower and its Subsidiaries shall transfer
such assets and operations at such time, if any, as such adverse tax
consequences or breach or violation would not exist, and until such time shall
use good faith efforts so that any growth in the assets or operations of the
entity so acquired, to the extent located in the Qualified Non-U.S.
Jurisdictions, are made within one or more Qualified Non-U.S. Obligors which are
not themselves direct or indirect Subsidiaries of any Subsidiary of the U.S.
Borrower other than Qualified Obligors).

            (c) The Borrowers shall take all actions so that all Foreign
Subsidiaries that are not Qualified Non-U.S. Obligors are directly or indirectly
owned by one or more Qualified Non-U.S. Obligors.

            (d) For the avoidance of doubt, it is understood and agreed that the
foregoing provisions of this Section 8.18 shall not prohibit the acquisition of,
or Investments in, Non-Wholly-Owned Subsidiaries as contemplated by Section
9.16(b), provided that the Equity Interest owned by the U.S. Borrower or any of
its Subsidiaries in such Non-Wholly-Owned

                                      -92-

<PAGE>

Subsidiaries, to the extent organized under the laws of any Qualified
Jurisdiction, shall be subject to the requirements of preceding clauses (a), (b)
and (c).

            8.19 European Receivables Facility. The European Receivables
Facility (and all agreements relating thereto (other than agreements pursuant to
which Batteries Funding Limited (x) is administered, (y) collects payments on
receivables owned by the U.S. Borrower and its Subsidiaries on their behalf and
(z) transfers or arranges for the transfer of all such collected funds to the
U.S. Borrower and its Subsidiaries)) shall be terminated within 30 days after
the Initial Borrowing Date.

            SECTION 9. Negative Covenants. Each Borrower hereby covenants and
agrees that as of the Effective Date and thereafter for so long as this
Agreement is in effect and until the Total Commitment has terminated, no Letters
of Credit or Notes are outstanding and the Loans, together with interest, Fees
and all other Obligations (other than any indemnities described in Section 13.13
which are not then due and payable) incurred hereunder, are paid in full:

            9.01 Changes in Business; etc. (a) The U.S. Borrower and its
Subsidiaries will not engage in any business other than a Permitted Business.

            (b) Notwithstanding anything to the contrary contained above in this
Section or elsewhere in this Agreement, at no time shall the U.S. Borrower or
any Subsidiary of the U.S. Borrower be an obligor or an obligee with respect to
any Intercompany Debt, unless each obligor (including each Person which is a
guarantor thereof) and each obligee with respect thereto are party to the
Intercompany Subordination Agreement; provided, however, that the provisions
hereof shall not apply to those Non-Wholly Owned Subsidiaries listed on Part D
of Schedule XI.

            9.02 Consolidation; Merger; Sale or Purchase of Assets; etc. Neither
Borrower will, nor will permit any of its respective Subsidiaries to, wind up,
liquidate or dissolve its affairs or enter into any transaction of merger or
consolidation, or convey, sell, lease or otherwise dispose of all or any part of
its property or assets (other than repayments in cash of Indebtedness
(including, without limitation, Intercompany Debt) and other obligations not
otherwise prohibited under this Agreement), or enter into any sale-leaseback
transactions, or purchase or otherwise acquire (in one or a series of related
transactions) any part of the property or assets (other than purchases or other
acquisitions of inventory, materials and equipment in the ordinary course of
business) of any Person or agree to do any of the foregoing at any future time,
except that the following shall be permitted:

            (i) the U.S. Borrower and its Subsidiaries may lease (as lessee) or
      license (as licensee) real or personal property (including intellectual
      property), and may terminate such leases or licenses, all in the ordinary
      course of business (so long as any such lease or license does not create a
      Capitalized Lease Obligation, except to the extent permitted by Section
      9.04(iv));

            (ii) Capital Expenditures by the U.S. Borrower and its Subsidiaries
      to the extent not in violation of Section 9.12;

            (iii) Investments permitted pursuant to Section 9.05;

                                      -93-

<PAGE>

            (iv) the U.S. Borrower and its Subsidiaries may, in the ordinary
      course of business, sell or otherwise dispose of assets (excluding capital
      stock of, or other Equity Interests in, Subsidiaries and joint ventures)
      which, in the reasonable opinion of such Person, are obsolete, uneconomic
      or worn-out;

            (v) the U.S. Borrower and its Subsidiaries may sell assets (other
      than the capital stock or other Equity Interests of any Wholly-Owned
      Subsidiary unless all of the capital stock or other Equity Interests of
      such Wholly-Owned Subsidiary are sold in accordance with this clause (v)),
      so long as (v) no Default or Event of Default then exists or would result
      therefrom, (w) each such sale is in an arm's-length transaction and the
      U.S. Borrower or the respective Subsidiary receives at least Fair Market
      Value, (x) except for customary post-closing adjustments (to be paid in
      cash within 180 days following the closing of the respective sale or
      disposition), at least 75% of the total consideration received by the U.S.
      Borrower or such Subsidiary is paid in cash at the time of the closing of
      such sale or disposition, (y) the Net Sale Proceeds therefrom are applied
      and/or reinvested as (and to the extent) required by Section 4.02(c) and
      (z) the aggregate amount of the proceeds (taking the amount of cash and
      Cash Equivalents, and the Fair Market Value, as determined in good faith
      by the U.S. Borrower, of all other consideration) received from all assets
      sold pursuant to this clause (v) shall not exceed $10,000,000 in any
      Fiscal Year of the U.S. Borrower;

            (vi) each of the U.S. Borrower and its Subsidiaries may sell or
      discount, in each case without recourse and in the ordinary course of
      business, overdue accounts receivable arising in the ordinary course of
      business, but only in connection with the compromise or collection thereof
      and not as part of any financing transaction;

            (vii) each of the U.S. Borrower and its Subsidiaries may grant
      licenses, sublicenses, leases or subleases to other Persons not materially
      interfering with the conduct of the business of the U.S. Borrower or any
      of its Subsidiaries, in each case so long as no such grant otherwise
      affects the Collateral Agent's security interest in the asset or property
      subject thereto;

            (viii) transfers of assets (v) among the Qualified U.S. Obligors,
      (w) among the Qualified Non-U.S. Obligors, (x) by any Subsidiary of the
      U.S. Borrower to any Qualified U.S. Obligor, (y) by any Foreign Subsidiary
      of the U.S. Borrower to any Qualified Non-U.S. Obligor and (z) by any
      Foreign Subsidiary of the U.S. Borrower (other than a Qualified Non-U.S.
      Obligor) to any Wholly-Owned Foreign Subsidiary of the U.S. Borrower, in
      the case of any such transfer, so long as (I) no Default and no Event of
      Default then exists or would exist immediately after giving effect to the
      respective transfer, (II) any security interests granted to the Collateral
      Agent for the benefit of the Secured Creditors pursuant to the relevant
      Security Documents in the assets so transferred shall remain in full force
      and effect and perfected and enforceable (to at least the same extent as
      in effect immediately prior to such transfer) and (III) if the respective
      transferor is party to a Guaranty, the nature and scope of the obligations
      of such transferor under its Guaranty are substantially identical to the
      nature and scope of the obligations of the respective transferee under its
      Guaranty;

                                      -94-

<PAGE>

            (ix) (x) any Domestic Subsidiary of the U.S. Borrower may be merged,
      consolidated or liquidated with or into the U.S. Borrower (so long as the
      U.S. Borrower is the surviving corporation of such merger, consolidation
      or liquidation) or any U.S. Subsidiary Guarantor (so long as a U.S.
      Subsidiary Guarantor is the surviving corporation of such merger,
      consolidation or liquidation), (y) any Qualified Non-U.S. Obligor may be
      merged, consolidated or liquidated with or into any other Qualified
      Non-U.S. Obligor and (z) any Foreign Subsidiary of the U.S. Borrower
      (other than a Qualified Non-U.S. Obligor) may be merged, consolidated or
      liquidated with or into any Wholly-Owned Foreign Subsidiary of the U.S.
      Borrower, so long as such Wholly-Owned Foreign Subsidiary is the surviving
      corporation of such merger, consolidation or liquidation; provided that
      any such merger, consolidation or liquidation shall only be permitted
      pursuant to this clause (ix), so long as (I) no Default and no Event of
      Default then exists or would exist immediately after giving effect
      thereto, (II) any security interests granted to the Collateral Agent for
      the benefit of the Secured Creditors in the assets (and Equity Interests)
      of any such Person subject to any such transaction shall remain in full
      force and effect and perfected and enforceable (to at least the same
      extent as in effect immediately prior to such merger, consolidation or
      liquidation) and (III) if the Person to be merged, consolidated or
      liquidated into another Person as contemplated above is party to a
      Guaranty, the nature and scope of the obligations of such Person under its
      Guaranty are substantially identical to the nature and scope of the
      obligations of such other Person under its Guaranty;

            (x) the U.S. Borrower and its Subsidiaries may transfer inventory in
      a cash transfer to Wholly-Owned Subsidiaries of the U.S. Borrower that are
      not Qualified Obligors, in each case so long as (I) any such transfer is
      made in the ordinary course of its business and consistent with past
      practice of the U.S. Borrower and its Subsidiaries as in effect on the
      Effective Date, (II) if the respective transfer is being made to any
      Credit Party, all actions needed to maintain the perfection, priority and
      enforceability of the security interests, if any, of the Collateral Agent
      in the assets so transferred are taken at the time of the respective
      transfer, (III) the U.S. Borrower reasonably determines that the transfer
      is not reasonably likely to be adverse to the interests of the Lenders in
      any material respect and (IV) no Default and no Event of Default then
      exists or would exist immediately after giving effect to the respective
      transfer;

            (xi) so long as no Default and no Event of Default exists at the
      time of the respective transfer or immediately after giving effect
      thereto, Qualified Obligors shall be permitted to transfer additional
      assets (other than inventory, cash, Cash Equivalents and Equity Interests
      in any Credit Party) to other Subsidiaries of the U.S. Borrower, so long
      as cash in an amount at least equal to the Fair Market Value of the assets
      so transferred is received by the respective transferor;

            (xii) the U.S. Borrower and its Subsidiaries may sell or exchange
      specific items of equipment, so long as the purpose of each such sale or
      exchange is to acquire (and results within 90 days of such sale or
      exchange in the acquisition of) replacement items of equipment which are
      useful in a Permitted Business;

                                      -95-

<PAGE>

            (xiii) each of the Borrowers and the Subsidiary Guarantors shall be
      permitted to make Permitted Acquisitions, so long as such Permitted
      Acquisitions are effected in accordance with the requirements of Section
      8.15;

            (xiv) each of the U.S. Borrower and its Subsidiaries may sell or
      liquidate Cash Equivalents, in each case for cash at fair market value (as
      reasonably determined by the U.S. Borrower or the respective Subsidiary);

            (xv) the U.S. Borrower and its Subsidiaries may sell inventory to
      their respective customers in the ordinary course of business;

            (xvi) the U.S. Borrower and its Subsidiaries may consummate the
      asset sales described on Part A of Schedule XVII hereto, so long as (v) no
      Default or Event of Default then exists or would result therefrom, (w)
      each such sale (other than the Maple Ontario Property Sale) is in an
      arm's-length transaction and the U.S. Borrower or the respective
      Subsidiary receives at least Fair Market Value, (x) except for customary
      post-closing adjustments (to be paid in cash within 180 days following the
      closing of the respective sale or disposition), immediately after giving
      effect to each such sale or disposition, at least 75% of the total
      consideration received by the U.S. Borrower or such Subsidiary for all
      sales or dispositions consummated pursuant to this Section 9.02(xvi) shall
      have been cash paid at the time of the closing of such sales or
      dispositions, (y) the Net Sale Proceeds therefrom are applied and/or
      reinvested as (and to the extent) required by Section 4.02(c) and (z) the
      aggregate amount of the proceeds (taking the amount of cash and Cash
      Equivalents, and the Fair Market Value, as determined in good faith by the
      U.S. Borrower, of all other consideration) received from all assets sold
      pursuant to this clause (xvi) shall not exceed $130,000,000;

            (xvii) Exide Italia may sell receivables in accordance with past
      practices pursuant to the Fiat Factoring Agreement, so long as (x) each
      such sale is in an arm's-length transaction and Exide Italia receives at
      least 95% of the face amount of the receivables sold, (y) Exide Italia
      receives 100% cash consideration at the time of each sale, and (z) the
      aggregate amount of uncollected receivables that have been sold pursuant
      to such agreement shall not exceed $20,000,000 at any time; and

            (xviii) the U.S. Borrower and/or any of its Domestic Subsidiaries
      party to an Additional Factoring Agreement may sell receivables pursuant
      to such Additional Factoring Agreement (after the execution thereof), so
      long as (x) each such sale is in an arm's-length transaction and the U.S.
      Borrower and/or any of its Domestic Subsidiaries party to the Additional
      Factoring Agreement receives (I) at least 95% of the face amount of the
      receivables sold and (II) 100% cash consideration at the time of each
      sale, and (y) the aggregate amount of uncollected receivables that have
      been sold pursuant to all Additional Factoring Agreements shall not exceed
      $15,000,000 at any time.

Notwithstanding anything to the contrary contained above in this Section 9.02,
in no event shall the U.S. Borrower or any of its Subsidiaries (x) enter into
any sale-leaseback transactions or (y) at any time after the Initial Borrowing
Date, sell any receivables pursuant to the European Receivables Facility. The
foregoing provisions of this Section 9.02 are subject to continued

                                      -96-

<PAGE>

compliance by the Borrowers and their Subsidiaries with the requirements of
Sections 8.18, 9.01 and 9.16. To the extent the Required Lenders waive the
provisions of this Section 9.02 with respect to the sale or other disposition of
any Collateral, or any Collateral is sold or otherwise disposed of as permitted
by this Section 9.02, such Collateral (unless transferred to the U.S. Borrower
or a Subsidiary thereof) shall be sold or otherwise disposed of free and clear
of the Liens created by the Security Documents and the Administrative Agent
shall take such actions (including, without limitation, directing the Collateral
Agent to take such actions) as are appropriate in connection therewith.

            9.03 Liens. Neither Borrower will, nor will permit any of its
Subsidiaries to, create, incur, assume or suffer to exist any Lien upon or with
respect to any property or assets of any kind (real or personal, tangible or
intangible) of the U.S. Borrower or any of its Subsidiaries, whether now owned
or hereafter acquired, or sell any such property or assets subject to an
understanding or agreement, contingent or otherwise, to repurchase such property
or assets (including sales of accounts receivable or notes with recourse to the
U.S. Borrower or any of its Subsidiaries) or assign any right to receive income
or permit the filing of any financing statement under the UCC or any other
similar notice of Lien under any similar recording or notice statute; provided
that the provisions of this Section 9.03 shall not prevent the creation,
incurrence, assumption or existence of the following (Liens described below are
herein referred to as "Permitted Liens"):

            (i) inchoate Liens for taxes, assessments or governmental charges or
      levies not yet due and payable or Liens for taxes, assessments or
      governmental charges or levies being contested in good faith and by
      appropriate proceedings for which adequate reserves have been established
      in accordance with U.S. GAAP;

            (ii) Liens in respect of property or assets of the U.S. Borrower or
      any of its Subsidiaries imposed by law which were incurred in the ordinary
      course of business and which have not arisen to secure Indebtedness for
      borrowed money, such as carriers', warehousemen's and mechanics' Liens,
      statutory landlord's Liens and other similar Liens arising in the ordinary
      course of business, and which either (x) do not in the aggregate
      materially detract from the value of such property or assets or materially
      impair the use thereof in the operation of the business of the U.S.
      Borrower or any of its Subsidiaries or (y) are being contested in good
      faith by appropriate proceedings, which proceedings have the effect of
      preventing the forfeiture or sale of the property or asset subject to such
      Lien;

            (iii) Liens created by or pursuant to this Agreement and the
      Security Documents;

            (iv) Liens in existence on the Initial Borrowing Date which are
      listed, and the property subject thereto described, in Schedule IX, but
      only to the respective date, if any, set forth in such Schedule IX for the
      removal, replacement and termination of any such Liens, plus renewals,
      replacements and extensions of such Liens, provided that (x) the aggregate
      principal amount of the Indebtedness, if any, secured by such Liens does
      not increase from that amount outstanding at the time of any such renewal,
      replacement or extension and (y) any such renewal, replacement or
      extension does not encumber any additional assets or properties of the
      U.S. Borrower or any of its Subsidiaries;

                                      -97-

<PAGE>

            (v) Liens (x) arising from judgments, decrees or attachments in
      circumstances not constituting an Event of Default under Section 10.09,
      (y) arising in connection with the deposit or payment of cash or other
      Property with or to any court or other governmental authority in
      connection with any pending claim or litigation and (z) arising in
      connection with the deposit of cash or other Property in connection with
      the issuance of stay and appeal bonds, provided that the Fair Market Value
      of all Property (including cash) pledged, paid and/or deposited by the
      U.S. Borrower or any of its Subsidiaries pursuant to this clause (v) shall
      not exceed $25,000,000 at any time;

            (vi) Liens (other than any Lien imposed by ERISA) (x) incurred or
      deposits made in the ordinary course of business of the U.S. Borrower and
      its Subsidiaries in connection with workers' compensation, unemployment
      insurance and other types of social security, (y) to secure the
      performance by the U.S. Borrower and its Subsidiaries of tenders,
      statutory obligations (other than excise taxes not described in Section
      9.03(i)), surety and customs bonds, statutory bonds, bids, leases,
      government contracts, trade contracts, performance bonds and other similar
      obligations incurred in the ordinary course of business (exclusive of (I)
      obligations for the payment of Indebtedness and (II) stay and appeal bonds
      and other obligations in respect of litigation, arbitration or similar
      claims or otherwise of the types described in Section 9.03(v) above) or
      (z) to secure the performance by the U.S. Borrower and its Subsidiaries of
      leases of Real Property, to the extent incurred or made in the ordinary
      course of business consistent with past practices;

            (vii) licenses, sublicenses, leases or subleases granted to third
      Persons in the ordinary course of business not interfering in any material
      respect with the business of the U.S. Borrower or any of its Subsidiaries;

            (viii) (x) Permitted Encumbrances and (y) easements, rights-of-way,
      restrictions, encroachments, municipal and zoning ordinances and other
      similar charges or encumbrances, and minor title deficiencies, in each
      case not securing Indebtedness and not materially interfering with the
      conduct of the business of the U.S. Borrower or any of its Subsidiaries;

            (ix) Liens arising from or related to precautionary UCC or like
      personal property security financing statements regarding operating leases
      (if any) entered into by the U.S. Borrower and its Subsidiaries in the
      ordinary course of business;

            (x) Liens upon assets of the U.S. Borrower or any of its
      Subsidiaries subject to Capitalized Lease Obligations permitted pursuant
      to Section 9.04(iv), provided that (x) such Liens only serve to secure the
      payment of Indebtedness arising under such Capitalized Lease Obligation
      and (y) the Lien encumbering the asset giving rise to the Capitalized
      Lease Obligation does not encumber any other asset of the U.S. Borrower or
      any of its Subsidiaries;

            (xi) Liens arising pursuant to purchase money mortgages or security
      interests securing Indebtedness representing the purchase price (or
      financing of the purchase price within 30 days after the respective
      purchase) of assets acquired after the Initial Borrowing Date by the U.S.
      Borrower and its Subsidiaries, provided that (x) any such Liens

                                      -98-

<PAGE>

      attach only to the assets so purchased, (y) the Indebtedness secured by
      any such Lien does not exceed 100% of the Fair Market Value or the
      purchase price of the property being purchased at the time of the
      incurrence of such Indebtedness and (z) the Indebtedness secured thereby
      is permitted to be incurred pursuant to Section 9.04(iv);

            (xii) Liens on property or assets acquired pursuant to a Permitted
      Acquisition, or on property or assets of a Subsidiary of the U.S. Borrower
      in existence at the time such Subsidiary is acquired pursuant to a
      Permitted Acquisition, provided that (i) any Indebtedness that is secured
      by such Liens is permitted to exist under Section 9.04(vi), and (ii) such
      Liens are not incurred in connection with, or in contemplation or
      anticipation of, such Permitted Acquisition and do not attach to any other
      asset of the U.S. Borrower or any of its Subsidiaries;

            (xiii) restrictions imposed in the ordinary course of business and
      consistent with past practices on the sale or distribution of designated
      inventory pursuant to agreements with customers under which such inventory
      is consigned by the customer or such inventory is designated for sale to
      one or more customers;

            (xiv) Liens in favor of customs or revenue authorities arising as a
      matter of law to secure payment of customs duties in connection with the
      importation of goods;

            (xv) Liens securing Permitted Refinancing Indebtedness permitted
      pursuant to Section 9.04(vii) to the extent such Liens comply with clause
      (b)(ii) of the definition of Permitted Refinancing Indebtedness;

            (xvi) Liens on the assets of a Designated Foreign Subsidiary
      securing Indebtedness incurred by such Designated Foreign Subsidiary in
      accordance with the terms of Section 9.04(viii), so long as any such Liens
      only attach to the assets of the relevant Designated Foreign Subsidiary
      incurring such Indebtedness;

            (xvii) other Liens of the U.S. Borrower or any Subsidiary of the
      U.S. Borrower that (x) were not incurred in connection with borrowed
      money, (y) do not encumber any Property of the U.S. Borrower or any of its
      Subsidiaries the Fair Market Value of which exceeds the amount of the
      Indebtedness or other obligations secured by such Property or materially
      impair the use of such Property in the operation of the business of the
      U.S. Borrower or such Subsidiary and (z) do not secure obligations in
      excess of $10,000,000 in the aggregate for all such Liens;

            (xviii) Liens on assets of any Subsidiary of the U.S. Borrower
      acquired as a result of a Permitted Acquisition and securing only
      Permitted Acquired Debt of such Subsidiary, so long as such Liens apply
      only to assets of the Subsidiary so acquired (and so long as additional
      assets of such Subsidiary are not granted as security following, or in
      contemplation of, the respective Permitted Acquisition);

            (xix) sales of accounts receivables by (x) Exide Italia pursuant to
      the Fiat Factoring Agreement and (y) the U.S. Borrower and/or any of its
      Domestic Subsidiaries party to an Additional Factoring Agreement pursuant
      to such Additional Factoring Agreement (after the execution thereof);

                                      -99-

<PAGE>

            (xx) if, and only to the extent agreed to by the Administrative
      Agent in its sole discretion, second-priority Liens, expressly subordinate
      to the Liens granted in favor of the Secured Creditors pursuant to the
      Security Documents, on assets of the U.S. Borrower and/or any of its
      Domestic Subsidiaries granted in favor of a Plan enforceable by the PBGC
      in connection with the U.S. Borrower's requested waiver of the minimum
      funding requirements under ERISA, as described on Schedule V; and

            (xxi) Liens arising under the general business conditions of a
      German credit institution with which a Credit Party or any of its
      Subsidiaries maintains a banking relationship in the ordinary course of
      business.

In connection with the granting of Liens of the type described in clauses (iv),
(x), (xi), (xii), (xvi) and (xvii) of this Section 9.03 by the U.S. Borrower or
any of its Subsidiaries, the Administrative Agent and the Collateral Agent shall
be authorized, at the request of either Borrower, to take any actions deemed
appropriate by it in connection therewith (including, without limitation, by
executing appropriate lien releases or lien subordination agreements in favor of
the holder or holders of such Liens, in either case solely with respect to the
assets subject to such Liens).

            9.04 Indebtedness. Neither Borrower will, nor will permit any of its
Subsidiaries to, contract, create, incur, assume or suffer to exist any
Indebtedness, except:

            (i) Indebtedness incurred pursuant to this Agreement and the other
      Credit Documents;

            (ii) Scheduled Existing Indebtedness (but not of Designated Foreign
      Subsidiaries) outstanding on the Initial Borrowing Date and listed on
      Schedule IV, without giving effect to any subsequent extension, renewal or
      refinancing thereof, except that Scheduled Existing Indebtedness may be
      refinanced through one or more issuances of Permitted Refinancing
      Indebtedness in accordance with Section 9.04(vii) below;

            (iii) Indebtedness of the Borrowers under Interest Rate Protection
      Agreements entered into to protect them against fluctuations in interest
      rates in respect of Indebtedness otherwise permitted under this Agreement,
      so long as the entering into of such Interest Rate Protection Agreements
      are bona fide hedging activities and are not for speculative purposes;

            (iv) Capitalized Lease Obligations and Indebtedness of the U.S.
      Borrower and its Subsidiaries representing purchase money Indebtedness
      secured by Liens permitted pursuant to Section 9.03(xi), provided that (i)
      all such Capitalized Lease Obligations are permitted under Section 9.12
      and (ii) the sum of (x) the aggregate Capitalized Lease Obligations
      outstanding at any time pursuant to this clause 9.04(iv) plus (y) the
      aggregate principal amount of such purchase money Indebtedness outstanding
      at any time shall not exceed $25,000,000;

            (v) intercompany Indebtedness of the U.S. Borrower and its
      Subsidiaries to the extent permitted by Section 9.05(vi);

                                      -100-

<PAGE>

            (vi) Indebtedness of a Subsidiary of the U.S. Borrower acquired
      pursuant to a Permitted Acquisition (or Indebtedness assumed at the time
      of a Permitted Acquisition of an asset securing such Indebtedness),
      provided that (x) such Indebtedness was not incurred in connection with,
      or in anticipation or contemplation of, such Permitted Acquisition and (y)
      the aggregate principal amount of all Indebtedness outstanding pursuant to
      this clause (vi) at any time (such Indebtedness described above in this
      Section 9.04(vi) being called "Permitted Acquired Debt"), when added to
      the aggregate principal amount of Permitted Refinancing Indebtedness
      outstanding pursuant to Section 9.04(vii) at any time (except to the
      extent incurred to refinance Scheduled Existing Indebtedness and
      successive refinancings thereof), shall not exceed $50,000,000;

            (vii) Permitted Refinancing Indebtedness, so long as (x) no Default
      or Event of Default is in existence at the time of the incurrence of such
      Permitted Refinancing Indebtedness and immediately after giving effect
      thereto and (y) the aggregate principal amount of Permitted Refinancing
      Indebtedness outstanding pursuant to this clause (vii) at any time (except
      to the extent incurred to refinance Scheduled Existing Indebtedness and
      successive refinancings thereof), when added to the aggregate principal
      amount of Permitted Acquired Debt outstanding pursuant to Section 9.04(vi)
      at any time, shall not exceed $50,000,000;

            (viii) Indebtedness of Designated Foreign Subsidiaries of the U.S.
      Borrower under lines of credit to any such Designated Foreign Subsidiary
      from Persons other than the U.S. Borrower or any of its Subsidiaries, the
      proceeds of which Indebtedness are used for such Designated Foreign
      Subsidiary's working capital and other general corporate purposes,
      provided that the aggregate principal amount of all such Indebtedness
      outstanding at any time shall not exceed $20,000,000;

            (ix) Indebtedness of the U.S. Borrower under Shareholder
      Subordinated Notes issued pursuant to Section 9.06(ii), so long as the
      aggregate outstanding principal amount of Shareholder Subordinated Notes
      does not at any time exceed $5,000,000;

            (x) additional unsecured Indebtedness of the U.S. Borrower
      consisting of unsecured guarantees by such Borrower of (x) obligations
      (which guaranteed obligations do not themselves constitute Indebtedness)
      of one or more Wholly-Owned Subsidiaries of the U.S. Borrower, (y) leases
      pursuant to which one or more Wholly-Owned Subsidiaries of the U.S.
      Borrower are the respective lessees and (z) Indebtedness of Wholly-Owned
      Subsidiaries of the U.S. Borrower of the type permitted pursuant to
      Section 9.04(xiv);

            (xi) Indebtedness arising from the honoring by a bank or other
      financial institution of a check, draft or similar instrument
      inadvertently (except in the case of daylight overdrafts) drawn against
      insufficient funds in the ordinary course of business, so long as such
      Indebtedness is extinguished within five Business Days of the incurrence
      thereof;

            (xii) Indebtedness in respect of Other Hedging Agreements and
      Commodity Agreements to the extent permitted by Section 9.05(xii);

                                     -101-

<PAGE>

            (xiii) (x) Indebtedness of the U.S. Borrower or any of its
      Subsidiaries evidenced by completion guarantees and performance and surety
      bonds (but excluding (I) such guarantees and bonds issued to support other
      Indebtedness and (II) appeal, performance and other bonds and/or
      guaranties issued in respect of obligations arising in connection with
      litigation, arbitration or similar claims) incurred in the ordinary course
      of business for purposes of insuring the performance of the U.S. Borrower
      or such Subsidiary of its contractual obligations and (y) Indebtedness of
      the U.S. Borrower or any of its Subsidiaries evidenced by appeal,
      performance and other bonds and/or guaranties issued in respect of
      obligations arising in connection with litigation, arbitration or similar
      claims for purposes of insuring the performance of the U.S. Borrower or
      such Subsidiary in an aggregate amount not to exceed $25,000,000 at any
      time outstanding;

            (xiv) Indebtedness of Foreign Subsidiaries of the U.S. Borrower
      under bank guaranties and letters of credit issued by financial
      institutions (on behalf of such Foreign Subsidiaries) and required by
      governmental laws, orders and regulations in an aggregate amount not to
      exceed $15,000,000 at any time;

            (xv) additional unsecured Indebtedness of the U.S. Borrower and its
      Subsidiaries not otherwise permitted hereunder not exceeding $40,000,000
      in aggregate principal amount at any time outstanding, provided that no
      such additional Indebtedness shall be incurred at any time a Default or
      Event of Default then exists or would result therefrom;

            (xvi) Indebtedness of any Wholly-Owned Foreign Subsidiary of the
      U.S. Borrower owed to any Qualified Obligor constituting the purchase
      price in respect of intercompany transfers of goods in the ordinary course
      of business and consistent with past practices, so long as (i) such
      intercompany transfer of goods is permitted by Section 9.02, (ii) any such
      Indebtedness is represented by a promissory note, which is pledged to the
      Collateral Agent pursuant to the relevant Pledge Agreement and (iii) such
      intercompany Indebtedness is permitted by Section 9.05(vi);

            (xvii) Mercolec, so long as same is a Wholly-Owned Subsidiary of
      Exide B.V. and, following the merger of Mercolec with and into Exide B.V.,
      Exide B.V., may be the obligor or obligee with respect to intercompany
      Indebtedness owed (I) by Mercolec or Exide B.V., as the case may be, to
      the Wholly-Owned Foreign Subsidiaries of the U.S. Borrower or (II) to
      Mercolec or Exide B.V., as the case may be, by the Wholly-Owned Foreign
      Subsidiaries of the U.S. Borrower, in each case in connection with the
      cash management arrangements, including, without limitation, cash pooling
      arrangements, in effect with respect to the European Borrower and its
      Wholly-Owned Subsidiaries, so long as (i) with respect to any Wholly-Owned
      Foreign Subsidiary of the U.S. Borrower which is a net debtor of Mercolec
      or Exide B.V., as the case may be (after giving effect to all intercompany
      transfers of funds), any such intercompany Indebtedness is incurred in the
      ordinary course of business to fund ongoing working capital requirements
      of such Wholly-Owned Foreign Subsidiary, (ii) each intercompany advance
      made by Mercolec or Exide B.V., as the case may be, and/or any
      Wholly-Owned Foreign Subsidiary of the U.S. Borrower pursuant to this
      clause (xvii) shall be subject to subordination as, and to the extent,
      required by the Intercompany Subordination Agreement, (iii) to the extent
      a

                                     -102-

<PAGE>

      Wholly-Owned Foreign Subsidiary that is not a Qualified Obligor is the
      obligor with respect to any such intercompany Indebtedness, the aggregate
      amount of all such intercompany Indebtedness owed by all such Wholly-Owned
      Foreign Subsidiaries in excess of $5,000,000 at any time (owed to Mercolec
      or Exide B.V., as the case may be, by such Wholly-Owned Foreign
      Subsidiary) shall be treated as an Investment and shall only be permitted
      if independently justified by Section 9.05 (other than by clause (s) of
      Section 9.05 (vi) and (iv) any intercompany Indebtedness incurred in
      reliance of this clause (xvii) shall cease to be permitted hereunder if
      the obligor or obligee thereunder ceases to constitute a Qualified Obligor
      or a Wholly-Owned Foreign Subsidiary of the U.S. Borrower, as the case may
      be;

            (xviii) up to $20,000,000 of Indebtedness of Exide Italia at any
      time outstanding pursuant to the Fiat Factoring Agreement; and

            (xix) up to an aggregate amount of $15,000,000 of Indebtedness of
      the U.S. Borrower and/or any of its Domestic Subsidiaries party to an
      Additional Factoring Agreement at any time outstanding pursuant to all
      Additional Factoring Agreements (after the execution thereof).

            9.05 Advances; Investments; Loans. Neither Borrower will, nor will
permit any of its Subsidiaries to, directly or indirectly, lend money or extend
credit or make advances to any Person, or purchase or acquire any stock,
obligations or securities of, or any other Equity Interest in, or make any
capital contribution to, any Person, or purchase or own a futures contract or
otherwise become liable for the purchase or sale of currency or other
commodities at a future date in the nature of a futures contract (each of the
foregoing an "Investment" and, collectively, "Investments"), except:

            (i) the U.S. Borrower and its Subsidiaries may acquire and hold Cash
      Equivalents;

            (ii) the U.S. Borrower and its Subsidiaries may acquire and hold
      receivables and chattel paper owing to it, if created or acquired in the
      ordinary course of business and payable or dischargeable in accordance
      with customary trade terms (including the dating of receivables) of the
      U.S. Borrower or such Subsidiary;

            (iii) the U.S. Borrower and its Subsidiaries may acquire and own
      investments (including debt obligations) received in connection with the
      bankruptcy or reorganization of suppliers, trade creditors, licensees,
      licensors and customers and in good faith settlement of delinquent
      obligations of, and other disputes with, suppliers, trade creditors,
      licensees, licensors and customers arising in the ordinary course of
      business;

            (iv) Interest Rate Protection Agreements entered into in compliance
      with Section 9.04(iii) shall be permitted;

            (v) (x) Investments constituting Intercompany Scheduled Existing
      Indebtedness in existence on the Initial Borrowing Date (and any
      refinancings thereof permitted pursuant to Section 9.04(vii) and
      consistent with the definition of Permitted Refinancing Indebtedness) and
      (y) such other Investments in existence on the Initial Borrowing Date

                                     -103-

<PAGE>

      and listed on Schedule VI (without giving effect to any additions thereto
      or replacements thereof); provided that any additional Investments made
      with respect to the Investments described in preceding subclause (y) shall
      be permitted only if independently justified under the other provisions of
      this Section 9.05;

            (vi) (s) intercompany Indebtedness may be incurred pursuant to
      Section 9.04(xvii), (t) Intercompany Loans may be made in accordance with
      the requirements of Section 5.08, (u) Qualified U.S. Obligors may make
      intercompany loans to each other, (v) Qualified Non-U.S. Obligors may make
      intercompany loans to each other, (w) Qualified U.S. Obligors may make
      intercompany loans to any Qualified Non-U.S. Obligor, (x) Qualified
      Obligors may make intercompany loans to any Foreign Subsidiary of the U.S.
      Borrower that is not a Qualified Obligor, (y) any Wholly-Owned Foreign
      Subsidiary of the U.S. Borrower may make intercompany loans to any
      Qualified Obligor and (z) Non-Guarantor Subsidiaries may make intercompany
      loans to each other and to any Foreign Credit Party, provided that (I)
      unless the respective obligor under such intercompany loan reasonably
      determines that the execution, delivery and performance of an Intercompany
      Note is prohibited by, or that such Intercompany Note would not be
      enforceable against such obligor under, applicable local law, any such
      intercompany loan made pursuant to this clause (vi) (other than any such
      loan made to a Non-Wholly Owned Subsidiary) shall be evidenced by an
      Intercompany Note or by such other documentation as may be acceptable to
      the Administrative Agent, (II) at no time shall the aggregate outstanding
      principal amount of all such intercompany loans made pursuant to subclause
      (w) of this clause (vi) above (exclusive of loans made to Qualified
      Non-U.S. Obligors which are promptly on-lent by such Qualified Non-U.S.
      Obligors to Foreign Subsidiaries that are not Qualified Obligors in
      reliance on subclause (x) above), when added to the aggregate amount of
      cash equity contributions made pursuant to (and in reliance on) Section
      9.05(viii)(y), exceed $50,000,000 (determined without regard to
      write-downs or write-offs thereof), (III) at no time shall the aggregate
      outstanding principal amount of all such intercompany loans made pursuant
      to subclause (x) of this clause (vi) above, when added to the aggregate
      amount of cash equity contributions made pursuant to (and in reliance on)
      Section 9.05(viii)(z), exceed $30,000,000 (determined without regard to
      write-downs or write-offs thereof), (IV) no intercompany loans may be made
      pursuant to subclause (w) or (x) of this clause (vi) at any time any
      Default or any Event of Default is in existence (or would be in existence
      after giving effect thereto), (V) each intercompany loan made pursuant to
      this clause (vi) shall be subject to subordination as, and to the extent,
      required by the Intercompany Subordination Agreement and (VI) any
      intercompany loans made pursuant to this clause (vi) shall cease to be
      permitted hereunder if the obligor or obligee thereunder ceases to
      constitute a Qualified Obligor or a Foreign Subsidiary of the U.S.
      Borrower as contemplated above;

            (vii) (x) loans by the U.S. Borrower and its Subsidiaries to
      officers, employees and directors of the U.S. Borrower and its
      Subsidiaries for bona fide business purposes, in each case incurred in the
      ordinary course of business, in an aggregate outstanding principal amount
      not to exceed $2,000,000 at any time outstanding (determined without
      regard to any write-downs or write-offs of such loans and advances) shall
      be permitted and (y) advances of reimbursable expenses by the U.S.
      Borrower and its Subsidiaries to

                                     -104-

<PAGE>

      officers, employees and directors of the U.S. Borrower and its
      Subsidiaries for bona fide purposes, in each case incurred in the ordinary
      course of business;

            (viii) (u) any Wholly-Owned Foreign Subsidiary of the U.S. Borrower
      may make cash common equity contributions to any Qualified Obligor, (v)
      any Qualified U.S. Obligor may make cash common equity contributions to
      any of its direct Wholly-Owned Subsidiaries that is a Qualified U.S.
      Obligor, (w) any Qualified Non-U.S. Obligor may make cash common equity
      contributions to any of its direct Wholly-Owned Subsidiaries that is a
      Qualified Non-U.S. Obligor, (x) any Non-Guarantor Subsidiary may make cash
      common equity contributions to any of its direct Wholly-Owned Subsidiaries
      that is a Non-Guarantor Subsidiary or a Foreign Credit Party, (y) any
      Qualified U.S. Obligor may make cash common equity contributions to any of
      its direct Wholly-Owned Subsidiaries that is Qualified Non-U.S. Obligor,
      and (z) any Qualified Obligor may make cash common equity contributions to
      any of their respective direct Foreign Subsidiaries that is not a
      Qualified Obligor; provided that (I) at no time shall the aggregate amount
      of the cash common equity contributions made pursuant to subclause (y) of
      this clause (viii) (exclusive of (A) cash contributions made to a
      Qualified Non-U.S. Obligor which are promptly contributed, in turn, to a
      Foreign Subsidiary of such Qualified Non-U.S. Obligor that is not a
      Qualified Obligor in reliance on subclause (z) above and (B) cash
      contributions made by the U.S. Borrower to the European Borrower which are
      promptly utilized to make voluntary prepayments of Term Loans), when added
      to the aggregate outstanding principal amount of all intercompany loans
      made pursuant to subclause (w) of clause (vi) above (determined without
      regard to write-downs or write-offs thereof), exceed $50,000,000, (II) at
      no time shall the aggregate amount of the cash common equity contributions
      made pursuant to subclause (z) of this clause (viii), when added to the
      aggregate outstanding principal amount of all intercompany loans made
      pursuant to subclause (x) of clause (vi) above (determined without regard
      to write-downs or write-offs thereof), exceed $30,000,000 and (III) no
      contributions may be made pursuant to subclause (y) or (z) of this clause
      (viii) at any time any Default or any Event of Default is in existence (or
      would be in existence after giving effect thereto);

            (ix) the Borrowers and the Subsidiary Guarantors may make Permitted
      Acquisitions in accordance with the relevant requirements of Section 8.15
      and the component definitions therein;

            (x) the U.S. Borrower and its Subsidiaries may own the capital stock
      of, or other Equity Interests in, their respective Subsidiaries created or
      acquired in accordance with the terms of this Agreement;

            (xi) the U.S. Borrower and its Subsidiaries may acquire and hold
      non-cash consideration issued by the purchaser of assets in connection
      with a sale of such assets to the extent permitted by Sections 9.02(v) and
      (xvi);

            (xii) the U.S. Borrower and its Subsidiaries may enter into (x)
      Other Hedging Agreements in the ordinary course of business providing
      protection against fluctuations in currency values in connection with the
      operations of the U.S. Borrower or any of its Subsidiaries and (y)
      Commodity Agreements in the ordinary course of business having a

                                     -105-

<PAGE>

      tenor of no more than 14 months, providing protection against fluctuations
      in prices of commodities used in the operations of the U.S. Borrower and
      its Subsidiaries, provided that the U.S. Borrower and its Subsidiaries
      shall not enter into a Commodity Agreement with respect to any commodity
      if the amount hedged pursuant to such Commodity Agreement (when aggregated
      with all other Commodity Agreements then in effect with respect to such
      commodity) would exceed 50% of the U.S. Borrower's and its Subsidiaries'
      projected purchases of such commodity from third parties (as determined in
      good faith by the management of the U.S. Borrower or such Subsidiary) for
      the immediately succeeding 14-month period, in each case described in
      clause (x) or (y) above, so long as management of the U.S. Borrower or
      such Subsidiary, as the case may be, has determined in good faith that the
      entering into of such Other Hedging Agreements or Commodity Agreements, as
      the case may be, are bona fide hedging activities and are not for
      speculative purposes;

            (xiii) the U.S. Borrower may acquire and hold obligations of one or
      more officers, directors or other employees of the U.S. Borrower or any of
      its Subsidiaries in connection with such officers', directors' or
      employees' acquisition of shares of capital stock of the U.S. Borrower, so
      long as no cash is paid by the U.S. Borrower or any of its Subsidiaries to
      such officers, directors or employees in connection with the acquisition
      of any such obligations;

            (xiv) Investments constituting guaranties permitted by Section 9.04;
      and

            (xv) so long as no Default or Event of Default then exists or would
      result therefrom, the U.S. Borrower and its Subsidiaries may make
      Investments not otherwise permitted by clauses (i) through (xiv) of this
      Section 9.05 in an aggregate amount not to exceed $30,000,000 (determined
      without regard to any write-downs or write-offs thereof).

            9.06 Restricted Payments; etc. Neither Borrower will, nor will
permit any of its Subsidiaries to, declare or pay any dividends (other than
dividends payable solely in non-redeemable common stock or comparable common
equity interests of the U.S. Borrower or any such Subsidiary, as the case may
be) or return any equity capital to, its stockholders, partners, members or
other equity holders or authorize or make any other distribution, payment or
delivery of property or cash (other than reasonable and customary professional
fees and expenses, and indemnification claims, of directors and/or officers of
the U.S. Borrower paid by the U.S. Borrower) to its stockholders, partners,
members or other equity holders as such, or redeem, retire, purchase or
otherwise acquire, directly or indirectly, for a consideration, any shares of
any class of its capital stock or other Equity Interests, now or hereafter
outstanding (or any warrants for or options or stock appreciation rights in
respect of any of such shares or other Equity Interests), or set aside any funds
for any of the foregoing purposes, and neither Borrower will permit any of its
Subsidiaries to purchase or otherwise acquire for consideration any shares of
any class of the capital stock or other Equity Interests of the U.S. Borrower or
any other Subsidiary, as the case may be, now or hereafter outstanding (or any
options or warrants or stock appreciation rights issued by such Person with
respect to its capital stock or other Equity Interests) (all of the foregoing
"Dividends") or make any payments in respect of any outstanding Shareholder
Subordinated Notes or Intercompany Debt, except that:

                                     -106-

<PAGE>

            (i) (x) any Subsidiary of the U.S. Borrower may pay Dividends to the
      U.S. Borrower or any Wholly-Owned Subsidiary of the U.S. Borrower and (y)
      any non-Wholly-Owned Subsidiary of the U.S. Borrower may pay cash
      Dividends to its shareholders generally so long as the U.S. Borrower or
      its respective Subsidiary which owns the Equity Interest in the Subsidiary
      paying such Dividends receives at least its proportionate share thereof
      (based upon its relative holding of the Equity Interests in the Subsidiary
      paying such Dividends and taking into account the relative preferences, if
      any, of the various classes of Equity Interests of such Subsidiary);
      provided that any Dividend made pursuant to preceding clause (x) to any
      Wholly-Owned Subsidiary that is not a Credit Party may only be made if (A)
      (I) no Default and no Event of Default then exists or would result
      therefrom and (II) such Wholly-Owned Subsidiary promptly distributes
      and/or transfer any Property received pursuant to such Dividend (directly
      or indirectly through other Wholly-Owned Subsidiaries) to a Credit Party
      or (B) the Subsidiary making such Dividend is not a Credit Party;

            (ii) the U.S. Borrower may redeem or purchase shares of U.S.
      Borrower Common Stock or options to purchase U.S. Borrower Common Stock,
      as the case may be, held by former officers or employees of the U.S.
      Borrower or any of its Subsidiaries following the death, disability,
      retirement or termination of employment of such officers or employees,
      provided that (w) the only consideration paid by the U.S. Borrower in
      respect of such redemptions and/or purchases shall be cash and Shareholder
      Subordinated Notes, (x) the sum of (A) the aggregate amount paid by the
      U.S. Borrower in cash in respect of all such redemptions and/or purchases
      plus (B) the aggregate amount of all principal and interest payments made
      on Shareholder Subordinated Notes, shall not exceed $500,000 in any Fiscal
      Year of the U.S. Borrower, and (z) at the time of any redemption or
      purchase pursuant to this Section 9.06(ii), no Default or Event of Default
      shall then exist or result therefrom;

            (iii) the Transaction shall be permitted to be consummated in
      accordance with the relevant requirements of this Agreement;

            (iv) the U.S. Borrower and its Subsidiaries may make payments with
      respect to Intercompany Debt, so long as the respective payment is
      permitted to be made in accordance with the terms of the Intercompany
      Subordination Agreement;

            (v) the U.S. Borrower may make payments of interest and principal on
      the Shareholder Subordinated Notes in accordance with the terms thereof,
      so long as the sum of (A) the aggregate amount paid by the U.S. Borrower
      in cash in respect of all redemptions and/or purchases of U.S. Borrower
      Common Stock pursuant to Section 9.06(ii) plus (B) the aggregate amount of
      all principal and interest payments made on Shareholder Subordinated
      Notes, does not exceed $500,000 in any Fiscal Year of the U.S. Borrower;

            (vi) the U.S. Borrower may pay regularly scheduled Dividends on its
      Qualified Preferred Stock pursuant to the terms thereof solely through the
      issuance of additional shares of such Qualified Preferred Stock rather
      than in cash;

                                     -107-

<PAGE>

            (vii) the U.S. Borrower may redeem or purchase shares of U.S.
      Borrower Common Stock or warrants to purchase U.S. Borrower Common Stock,
      as the case may be, issued to Wholly-Owned Subsidiaries of the U.S.
      Borrower pursuant to the Plan of Reorganization;

            (viii) the U.S. Borrower may issue shares of U.S. Borrower Common
      Stock (A) upon the exercise of Plan Warrants, (B) to satisfy Disputed
      Claims pursuant to the Plan of Reorganization and (C) to holders of
      Prepetition Credit Facility Claims (as defined in the Plan of
      Reorganization) in the event of an Additional Class P4 Distribution (if
      any) pursuant to the Plan of Reorganization; and

            (ix) the U.S. Borrower may issue additional Plan Warrants in the
      event of an Additional Class P4 Distribution (if any) pursuant to the Plan
      of Reorganization.

            9.07 Transactions with Affiliates. Neither Borrower will, nor will
permit any of its Subsidiaries to, enter into any transaction or series of
transactions with any Affiliate of the U.S. Borrower or any of its Subsidiaries
other than in the ordinary course of business and on terms and conditions
substantially as favorable to such Borrower or such Subsidiary as would be
reasonably expected to be obtainable by such Borrower or such Subsidiary at the
time in a comparable arm's-length transaction with a Person other than an
Affiliate; provided that the following shall in any event be permitted: (i) the
Transaction; (ii) intercompany transactions among the U.S. Borrower and its
Subsidiaries to the extent expressly permitted by Sections 9.02, 9.04, 9.05 and
9.06; (iii) the payment of consulting or other fees to the U.S. Borrower by any
of its Subsidiaries in the ordinary course of business; (iv) customary fees to
non-officer directors of the U.S. Borrower and its Subsidiaries; (v) the U.S.
Borrower and its Subsidiaries may enter into employment and severance
arrangements with respect to the procurement of services with their respective
officers and employees in the ordinary course of business; (vi) Dividends may be
paid by the U.S. Borrower to the extent permitted by Section 9.06; (vii) the
payment of customary fees (excluding management fees) to the Agents and their
Affiliates for services rendered (including, without limitation, any
underwriting discounts and commissions); and (viii) transactions between the
U.S. Borrower and/or any of its Subsidiaries and their respective Affiliates
listed on Schedule XIII hereto. In no event shall any management, consulting or
similar fee be paid or payable by the U.S. Borrower or any of its Subsidiaries
to any Affiliate (other than the U.S. Borrower or any other Credit Party),
except as specifically provided in this Section 9.07.

            9.08 Consolidated Interest Coverage Ratio. The U.S. Borrower will
not permit the Consolidated Interest Coverage Ratio for any Test Period ended
after the Initial Borrowing Date to be less than 3.5 to 1.0. For purposes of
making determinations of compliance with this Section 9.08 pursuant to Section
8.15(a) only, the Consolidated Interest Coverage Ratio shall be calculated on a
Pro Forma Basis.

            9.09 Leverage Ratio. The U.S. Borrower will not permit the Leverage
Ratio at any time during a period set forth below to be greater than the ratio
set forth opposite such period below:

                                      -108-

<PAGE>

<TABLE>
<CAPTION>
                   Period                                     Ratio
-----------------------------------------------              --------
<S>                                                          <C>
Initial Borrowing Date to and including the day              3.50:1.0
occurring prior to the last day of the 3rd
Fiscal Quarter of Fiscal Year 2005

Last day of the 3rd Fiscal Quarter of Fiscal                 3.25:1.0
Year 2005 to and including the day occurring
prior to the last day of 3rd Fiscal Quarter of
Fiscal Year 2006

Last day of the 3rd Fiscal Quarter of Fiscal                 3.00:1.0
Year 2006 to and including the day occurring
prior to the last day of 3rd Fiscal Quarter of
Fiscal Year 2007

Last day of 3rd Fiscal Quarter of Fiscal Year                2.50:1.0
2007 and thereafter
</TABLE>

            9.10 Minimum Consolidated EBITDA. The U.S. Borrower will not permit
Consolidated EBITDA for any Test Period ending on the last day of a Fiscal
Quarter of the U.S. Borrower set forth below to be less than the respective
amount set forth opposite such Fiscal Quarter below:

<TABLE>
<CAPTION>
               Fiscal Quarter Ending                                      Amount
---------------------------------------------------                    ------------
<S>                                                                    <C>
Fiscal Quarter ending closest to September 30, 2004                    $165,000,000
Fiscal Quarter ending closest to December 31, 2004                     $165,000,000
Fiscal Quarter ending closest to March 31, 2005                        $165,000,000

Fiscal Quarter ending closest to June 30, 2005                         $170,000,000
Fiscal Quarter ending closest to September 30, 2005                    $170,000,000
Fiscal Quarter ending closest to December 31, 2005                     $175,000,000
Fiscal Quarter ending closest to March 31, 2006                        $180,000,000

Fiscal Quarter ending closest to June 30, 2006                         $185,000,000
Fiscal Quarter ending closest to September 30, 2006                    $185,000,000
Fiscal Quarter ending closest to December 31, 2006                     $190,000,000
Fiscal Quarter ending closest to March 31, 2007                        $195,000,000

Fiscal Quarter ending closest to June 30, 2007                         $200,000,000
Fiscal Quarter ending closest to September 30, 2007                    $200,000,000
Fiscal Quarter ending closest to December 31, 2007                     $205,000,000
Fiscal Quarter ending closest to March 31, 2008                        $210,000,000

Fiscal Quarter ending closest to June 30, 2008                         $210,000,000
</TABLE>

                                     -109-

<PAGE>

<TABLE>
<CAPTION>
               Fiscal Quarter Ending                                      Amount
-----------------------------------------------------------              --------
<S>                                                                    <C>
Fiscal Quarter ending closest to September 30, 2008                    $215,000,000
Fiscal Quarter ending closest to December 31, 2008                     $215,000,000
Fiscal Quarter ending closest to March 31, 2009                        $220,000,000

Fiscal Quarter ending closest to June 30, 2009                         $220,000,000
Fiscal Quarter ending closest to September 30, 2009                    $220,000,000
Fiscal Quarter ending closest to December 31, 2009 and each            $225,000,000
Fiscal Quarter ended thereafter
</TABLE>

            9.11 Minimum Asset Coverage. The U.S. Borrower agrees that it shall
not permit the ratio of (x) Adjusted Consolidated Total Current Assets to (y)
Consolidated Bank Debt at any time during any Fiscal Quarter set forth below to
be less than the ratio set forth opposite such Fiscal Quarter below:

<TABLE>
<CAPTION>
                  Fiscal Quarter                                          Ratio
-----------------------------------------------------------              --------
<S>                                                                      <C>
Fiscal Quarter ending closest to June 30, 2004                           1.65:1.0
Fiscal Quarter ending closest to September 30, 2004                      1.65:1.0
Fiscal Quarter ending closest to December 31, 2004                       1.65:1.0
Fiscal Quarter ending closest to March 31, 2005                          1.70:1.0

Fiscal Quarter ending closest to June 30, 2005                           1.70:1.0
Fiscal Quarter ending closest to September 30, 2005                      1.75:1.0
Fiscal Quarter ending closest to December 31, 2005                       1.75:1.0
Fiscal Quarter ending closest to March 31, 2006                          1.80:1.0

Fiscal Quarter ending closest to June 30, 2006                           1.80:1.0

Fiscal Quarter ending closest to September 30, 2006                      1.85:1.0

Fiscal Quarter ending closest to December 31, 2006 and each              2.00:1.0
Fiscal Quarter ended thereafter
</TABLE>

            9.12 Capital Expenditures. (a) The U.S. Borrower will not, and will
not permit any of its Subsidiaries to, make any Capital Expenditures, except
that during any Fiscal Year of the U.S. Borrower set forth below (taken as one
accounting period), the U.S. Borrower and its Subsidiaries may make Capital
Expenditures so long as the aggregate amount of such Capital Expenditures does
not exceed the amount set forth below opposite such Fiscal Year below:

<TABLE>
<CAPTION>
   Fiscal Year            Amount
----------------       -----------
<S>                    <C>
Fiscal Year 2005       $72,000,000
Fiscal Year 2006       $72,000,000
Fiscal Year 2007       $72,000,000
Fiscal Year 2008       $72,000,000
Fiscal Year 2009       $72,000,000
Fiscal Year 2010       $72,000,000
</TABLE>

                                      -110-

<PAGE>

<TABLE>
<CAPTION>
   Fiscal Year            Amount
----------------       -----------
<S>                    <C>
Fiscal Year 2011       $72,000,000
</TABLE>

            (b) Notwithstanding the foregoing, in the event that the amount of
Capital Expenditures permitted to be made by the U.S. Borrower and its
Subsidiaries pursuant to clause (a) above in any Fiscal Year of the U.S.
Borrower (beginning with Fiscal Year 2005) (before giving effect to any increase
in such permitted Capital Expenditure amount pursuant to this clause (b)) is
greater than the amount of Capital Expenditures actually made by the U.S.
Borrower and its Subsidiaries during such Fiscal Year (but excluding Capital
Expenditures made pursuant to following clauses (c), (d) and (e)), the lesser of
(x) such excess and (y) $25,000,000, may be carried forward and utilized to make
Capital Expenditures in the immediately succeeding Fiscal Year, provided that no
amounts once carried forward pursuant to this Section 9.12(b) may be carried
forward to any subsequent Fiscal Year of the U.S. Borrower thereafter and such
amounts may only be utilized after the U.S. Borrower and its Subsidiaries have
utilized in full the permitted Capital Expenditure amount for such period as set
forth in the table in clause (a) above (without giving effect to any increase in
such amount pursuant to this clause (b)).

            (c) In addition to the foregoing, the U.S. Borrower and its
Subsidiaries may make additional Capital Expenditures (which Capital
Expenditures will not be included in any determination under Section 9.12(a))
with the Net Sale Proceeds of Asset Sales to the extent such Net Sale Proceeds
do not require, or result in, a mandatory repayment of Term Loans and/or a
mandatory reduction to the Total Multicurrency Facility Revolving Loan
Commitment pursuant to Section 4.02(c) and such proceeds are reinvested within
360 days (subject to a six month extension for contractual commitments that are
not completed during such 360-day period) following the date of such Asset Sale
in accordance with the requirements of said Section.

            (d) In addition to the foregoing, the U.S. Borrower and its
Subsidiaries may make additional Capital Expenditures (which Capital
Expenditures will not be included in any determination under Section 9.12(a))
with the insurance proceeds received by the U.S. Borrower or any of its
Subsidiaries from any Recovery Event so long as such Capital Expenditures are to
replace or restore any properties or assets in respect of which such proceeds
were paid within 360 days (subject to a six month extension for contractual
commitments that are not completed during such 360-day period) following the
date of the receipt of such insurance proceeds, in each case to the extent such
insurance proceeds do not require, or result in, a mandatory repayment of Term
Loans and/or a mandatory reduction to the Total Multicurrency Facility Revolving
Loan Commitment pursuant to Section 4.02(f).

            (d) In addition to the foregoing, the Borrowers and the Subsidiary
Guarantors may make additional Capital Expenditures (which Capital Expenditures
will not be included in any determination under Section 9.12(a)) constituting
Permitted Acquisitions effected in accordance with the requirements of Section
8.15.

            9.13 Limitation on Voluntary Payments and Modifications of
Indebtedness; Modifications of Certificate of Incorporation, By-Laws and Certain
Other Agreements; Issuances of Capital Stock; etc. Neither Borrower will, and
neither Borrower will permit any of its Subsidiaries to:

                                      -111-

<PAGE>

            (i) make (or give any notice in respect of) any voluntary or
      optional payment or prepayment on or redemption, repurchase or acquisition
      for value of (including, without limitation, by way of depositing with the
      trustee with respect thereto or any other Person money or securities
      before due for the purpose of paying when due), or any prepayment,
      repurchase, redemption or acquisition for value as a result of any asset
      sale, change of control or similar event of any Third Party Scheduled
      Existing Indebtedness, or, after the incurrence or issuance thereof, any
      Permitted Refinancing Indebtedness, Shareholder Subordinated Notes (except
      to the extent expressly permitted under Section 9.06(v)) or Permitted
      Acquired Debt; provided that so long as no Default and no Event of Default
      then exists or would result therefrom, any Third Party Scheduled Existing
      Indebtedness, any Permitted Acquired Debt and any Permitted Refinancing
      Indebtedness incurred to refinance same may be refinanced with Permitted
      Refinancing Indebtedness in accordance with the requirements of this
      Agreement; or

            (ii) amend, modify or change any Reorganization Document, any Third
      Party Scheduled Existing Indebtedness, any Permitted Acquired Debt, any
      Permitted Refinancing Indebtedness, any Tax Allocation Agreement, any
      Management Agreement, any Qualified Preferred Stock, its certificate of
      incorporation (including, without limitation, by the filing or
      modification of any certificate of designation), by-laws, certificate of
      partnership, partnership agreement, certificate of limited liability
      company, limited liability company agreement (or equivalent organizational
      documents) or any agreement entered into by it, with respect to its
      capital stock or other Equity Interests (including any Shareholders'
      Agreement), or enter into any new Tax Allocation Agreement, Management
      Agreement or agreement with respect to its capital stock or other Equity
      Interests, other than (A) any change to Third Party Scheduled Existing
      Indebtedness, Permitted Acquired Debt or Permitted Refinancing
      Indebtedness as a result of the refinancing thereof as permitted by
      Section 9.13(i), (B) any amendments or modifications to Permitted
      Refinancing Indebtedness or Qualified Preferred Stock consistent with the
      definitions thereof provided herein and (C) any amendments, modifications
      or changes pursuant to this clause (ii) and any such new agreements
      pursuant to this clause (ii), (x) which do not in any way adversely affect
      the interests of the Lenders, (y), in the case of any Management
      Agreement, which does not involve the payment by the U.S. Borrower or any
      of its Subsidiaries of any amount which could give rise to a violation of
      this Agreement and (z) any amendment to such Person's respective
      certificates of incorporation or other organizational documents to
      authorize the issuance of capital stock or other Equity Interests
      otherwise permitted to be issued pursuant to the terms of this Agreement.

            9.14 Limitation on Issuance of Equity Interests. (a) The U.S.
Borrower will not issue (i) any Preferred Equity (or any options, warrants or
rights to purchase Preferred Equity) (other than Qualified Preferred Stock
issued pursuant to clause (c) below) or (ii) any redeemable common stock or
equivalent common Equity Interests.

            (b) The U.S. Borrower shall not permit any of its Subsidiaries to
issue any capital stock or other Equity Interests (including by way of sales of
treasury stock), except (i) for transfers and replacements of then outstanding
shares of capital stock or other Equity Interests, (ii) for stock splits, stock
dividends and additional issuances which do not decrease the aggregate

                                     -112-

<PAGE>

percentage ownership of the U.S. Borrower and its Subsidiaries in any class of
the capital stock or other Equity Interests of such Subsidiaries, (iii) in the
case of Foreign Subsidiaries of the U.S. Borrower, to qualify directors to the
extent required by applicable law, (iv) Subsidiaries formed after the Effective
Date pursuant to Section 9.16 may issue capital stock or other Equity Interests
in accordance with the requirements of Section 9.16 and (v) issuances of Equity
Interests (including Preferred Equity) by any Wholly-Owned Subsidiary of the
U.S. Borrower to one or more other Wholly-Owned Subsidiaries of the U.S.
Borrower. All capital stock or other Equity Interests issued in accordance with
this Section 9.14(b) shall, to the extent required by the relevant Security
Document, be delivered to the Collateral Agent for pledge pursuant to such
Security Document.

            (c) The U.S. Borrower may issue Qualified Preferred Stock so long as
(x) no Default or Event of Default shall exist at the time of any such issuance
or immediately after giving effect thereto, and (y) with respect to each issue
of Qualified Preferred Stock, the gross cash proceeds therefrom (or in the case
of Qualified Preferred Stock directly issued as consideration for a Permitted
Acquisition, the Fair Market Value thereof of the assets received therefor)
shall be at least equal to 100% of the liquidation preference thereof at the
time of issuance.

            9.15 Limitation on Certain Restrictions on Subsidiaries. Neither
Borrower will, nor will permit any of its Subsidiaries to, directly or
indirectly, create or otherwise cause or suffer to exist or become effective,
any encumbrance or restriction on the ability of any such Subsidiary to (x) pay
dividends or make any other distributions on its capital stock or any other
Equity Interests or participation in its profits owned by the U.S. Borrower or
any Subsidiary of the U.S. Borrower, or pay any Indebtedness owed to the U.S.
Borrower or a Subsidiary of the U.S. Borrower, (y) make loans or advances to the
U.S. Borrower or any Subsidiary of the U.S. Borrower or (z) transfer any of its
properties or assets to the U.S. Borrower or any of its Subsidiaries, except for
such encumbrances or restrictions existing under or by reason of (i) applicable
law, (ii) this Agreement and the other Credit Documents, (iii) customary
provisions restricting subletting or assignment of any lease governing a
leasehold interest of the U.S. Borrower or a Subsidiary of the U.S. Borrower,
(iv) customary provisions restricting assignment of any licensing agreement (in
which the U.S. Borrower or any of its Subsidiaries is the licensee) or any other
contract entered into by the U.S. Borrower or any Subsidiary of the U.S.
Borrower in the ordinary course of business, (v) any agreement or instrument
governing Permitted Acquired Debt, which encumbrance or restriction is not
applicable to any Person or the properties or assets of any Person, other than
the Person or the properties or assets of the Person acquired pursuant to the
respective Permitted Acquisition and so long as the respective encumbrances or
restrictions were not created (or made more restrictive) in connection with or
in anticipation of the respective Permitted Acquisition, (vi) restrictions
applicable to any Non-Wholly Owned Subsidiary existing at the time of the
acquisition thereof as a result of an Investment pursuant to Section 9.05 or a
Permitted Acquisition effected in accordance with Section 8.15; provided that
the restrictions applicable to such joint venture are not made more burdensome,
from the perspective of the U.S. Borrower and its Subsidiaries, than those as in
effect immediately before giving effect to the consummation of the respective
Investment or Permitted Acquisition and (vii) any restriction or encumbrance
with respect to assets subject to Liens permitted by Sections 9.03(iv), (v),
(vi), (x), (xi), (xii), (xv) and (xvi).

                                     -113-

<PAGE>

            9.16 Limitation on the Creation of Subsidiaries and Joint Ventures.
(a) Except as otherwise specifically provided in immediately succeeding clause
(b), the U.S. Borrower will not, and will not permit any of its Subsidiaries to,
establish, create or acquire after the Initial Borrowing Date any Subsidiary,
provided that the U.S. Borrower and its Wholly-Owned Subsidiaries shall be
permitted to establish or create Wholly-Owned Subsidiaries so long as (A) at
least 15 Business Days' (or such lesser period as is acceptable to the
Administrative Agent in any given case) prior written notice thereof is given to
the Administrative Agent, (B) subject to Sections 8.11(d) and 8.12, the Equity
Interests of each such new Wholly-Owned Subsidiary are pledged pursuant to, and
to the extent required by, the applicable Pledge Agreements and/or Foreign
Security Agreements and, if such Equity Interests constitute certificated Equity
Interests, the certificates representing such Equity Interests, together with
stock or other powers duly executed in blank, are delivered to the Collateral
Agent for the benefit of the Secured Creditors, (C) to the extent such new
Wholly-Owned Subsidiary is required, in accordance with the applicable
provisions of Section 8.11, to become a U.S. Subsidiary Guarantor, such new
Wholly-Owned Subsidiary executes and delivers (x) a Joinder Agreement
substantially in the form of Exhibit P hereto and (y) counterparts of the U.S.
Subsidiaries Guaranty, the Intercompany Subordination Agreement and such
Security Documents as would have been entered into by the respective Subsidiary
if same had been a U.S. Subsidiary Guarantor on the Initial Borrowing Date, and
takes all action in connection therewith as would otherwise have been required
to be taken pursuant to Section 5 if such new Wholly-Owned Subsidiary had been a
U.S. Credit Party on the Initial Borrowing Date, (D) to the extent such new
Wholly-Owned Subsidiary is organized in a Qualified Non-U.S. Jurisdiction and is
required, in accordance with the applicable provisions of Section 8.11, to
become a Foreign Subsidiary Guarantor, such new Wholly-Owned Subsidiary executes
and delivers (x) a Joinder Agreement substantially in the form of Exhibit P
hereto and (y) counterparts of a Foreign Subsidiaries Guaranty, the Intercompany
Subordination Agreement and such Security Documents as would have been entered
into by the respective Subsidiary if same had been a Foreign Subsidiary
Guarantor on the Initial Borrowing Date (determined in accordance with the
criteria described in Sections 5.10, 5.12 and 5.13(b)), and takes all action in
connection therewith as would otherwise have been required to be taken pursuant
to Section 5 if such new Wholly-Owned Subsidiary had been a Foreign Credit Party
on the Initial Borrowing Date and (E) such new Wholly-Owned Subsidiary, to the
extent requested by the Administrative Agent or the Required Lenders, takes all
other actions required pursuant to Section 8.11 (including, without limitation,
to, at its own expense, execute, acknowledge and deliver, or cause the
execution, acknowledgment and delivery of, and thereafter register, file or
record in any appropriate governmental office, any document or instrument
reasonably deemed by the Collateral Agent to be necessary or desirable for the
creation and perfection of the Liens on its assets intended to be created
pursuant to the applicable Security Documents); provided that in the case of a
newly-formed Wholly-Owned Subsidiary of the U.S. Borrower organized in a
Qualified Non-U.S. Jurisdiction, the actions described in clauses (D) and (E)
and applicable to such Wholly-Owned Subsidiary, shall not be required to be
taken by such Wholly-Owned Subsidiary if the gross book value of its assets
(determined as of the last day of the calendar month then last ended) is less
than $1,000,000, until (and only until) the aggregate gross book value of all
Wholly-Owned Subsidiaries which have not taken the actions described in clauses
(D) and (E) and applicable to such Wholly-Owned Subsidiaries in reliance on this
proviso (determined as of the last day of the calendar month then last ended)
exceeds $1,000,000, at which time all such excluded Wholly-Owned Subsidiaries
(and not just those Wholly-Owned

                                     -114-

<PAGE>

Subsidiaries required to reduce the aggregate gross book value of such excluded
Wholly-Owned Subsidiaries to below $1,000,000) shall take the actions described
in clauses (D) and (E) and applicable to such Wholly-Owned Subsidiaries.

            (b) In addition to Subsidiaries of the U.S. Borrower created
pursuant to preceding clause (a), the U.S. Borrower and its Subsidiaries may
establish, acquire or create, and make Investments in, Non-Wholly Owned
Subsidiaries after the Initial Borrowing Date as a result of Permitted
Acquisitions (subject to the limitations contained in the definition thereof)
and Investments expressly permitted to be made pursuant to Section 9.05,
provided that (x) all Equity Interests of each such Non-Wholly Owned Subsidiary
shall be pledged by any Credit Party which owns same to the extent required by
the Pledge Agreements or relevant Foreign Security Agreements, and (y) any
actions required to be taken pursuant to Section 8.11 in connection with the
establishment of, or Investments in, the respective Subsidiaries are taken in
accordance with the requirements of said Section 8.11.

            SECTION 10. Events of Default. Upon the occurrence of any of the
following specified events (each, an "Event of Default"):

            10.01 Payments. Either Borrower shall (i) default in the payment
when due of any principal of any Loan or Note, (ii) default, and such default
shall continue for three or more Business Days, in the payment when due of any
Unpaid Drawing, any interest on any Loan or Note or any Fees or (iii) default,
and such default shall continue for 10 or more Business Days after notice to
either Borrower by the Administrative Agent or any Lender, in the payment when
due of any other amounts owing hereunder or under any other Credit Document; or

            10.02 Representations, etc. Any representation, warranty or
statement made or deemed made by any Credit Party herein or in any other Credit
Document or in any statement or certificate delivered pursuant hereto or thereto
shall prove to be untrue in any material respect on the date as of which made or
deemed made; or

            10.03 Covenants. The U.S. Borrower or any of its Subsidiaries shall
(a) default in the due performance or observance by it of any term, covenant or
agreement contained in Section 8.01(f)(i), 8.10, 8.11, 8.13, 8.15, 8.18, or 9,
or (b) default in the due performance or observance by it of any term, covenant
or agreement contained in this Agreement (other than those referred to in
Section 10.01, 10.02 or clause (a) of this Section 10.03) and such default shall
continue unremedied for a period of at least 15 days after notice to the
defaulting party by the Administrative Agent or any Lender; or

            10.04 Default Under Other Agreements. (a) The U.S. Borrower or any
of its Subsidiaries shall (i) default in any payment with respect to any
Indebtedness (other than the Obligations) beyond the period of grace, if any,
provided in the instrument or agreement under which such Indebtedness was
created or (ii) default in the observance or performance of any agreement or
condition relating to any such Indebtedness or contained in any instrument or
agreement evidencing, securing or relating thereto, or any other event shall
occur or condition exist, the effect of which default or other event or
condition is to cause, or to permit the holder or holders of such Indebtedness
(or a trustee or agent on behalf of such holder or holders) to cause (determined
without regard to whether any notice is required), any such Indebtedness to
become

                                     -115-

<PAGE>

due prior to its stated maturity; or (b) any Indebtedness (other than the
Obligations) of the U.S. Borrower or any of its Subsidiaries shall be declared
to be (or shall become) due and payable, or shall be required to be prepaid
other than by a regularly scheduled required prepayment, prior to the stated
maturity thereof; provided that it shall not constitute an Event of Default
pursuant to clause (a) or (b) of this Section 10.04 unless the principal amount
of any one issue of such Indebtedness, or the aggregate amount of all such
Indebtedness referred to in clauses (a) and (b) above, equals or exceeds
$10,000,000; or

            10.05 Bankruptcy, etc. The U.S. Borrower or any of its Subsidiaries
shall commence a voluntary case concerning itself under Title 11 of the United
States Code entitled "Bankruptcy", as now or hereafter in effect, or any
successor thereto (the "Bankruptcy Code"); or an involuntary case is commenced
against the U.S. Borrower or any of its Subsidiaries and the petition is not
controverted within 10 days, or is not dismissed within 60 days, after
commencement of the case; or a custodian (as defined in the Bankruptcy Code) is
appointed for, or takes charge of, all or substantially all of the property of
the U.S. Borrower or any of its Subsidiaries; or the U.S. Borrower or any of its
Subsidiaries commences any other proceeding under any reorganization,
arrangement, adjustment of debt, relief of debtors, dissolution, insolvency or
liquidation or similar law of any jurisdiction whether now or hereafter in
effect relating to the U.S. Borrower or any of its Subsidiaries; or there is
commenced against the U.S. Borrower or any of its Subsidiaries any such
proceeding which remains undismissed for a period of 60 days; or the U.S.
Borrower or any of its Subsidiaries is adjudicated insolvent or bankrupt; or any
order of relief or other order approving any such case or proceeding is entered;
or the U.S. Borrower or any of its Subsidiaries suffers any appointment of any
custodian or the like for it or any substantial part of its property to continue
undischarged or unstayed for a period of 60 days; or the U.S. Borrower or any of
its Subsidiaries makes a general assignment for the benefit of creditors; or any
Company action is taken by the U.S. Borrower or any of its Subsidiaries for the
purpose of effecting any of the foregoing; or

            10.06 ERISA. (a) (1) Any Plan shall fail to satisfy the minimum
funding standard required for any plan year or part thereof under Section 412 of
the Code or Section 302 of ERISA or a waiver of such standard or extension of
any amortization period is sought or granted under Section 412 of the Code or
Section 303 or 304 of ERISA, (2) a Reportable Event shall have occurred, (3) a
contributing sponsor (as defined in Section 4001(a)(13) of ERISA) of a Plan
subject to Title IV of ERISA shall be subject to the advance reporting
requirement of PBGC Regulation Section 4043.61 (without regard to subparagraph
(b)(1) thereof) and an event described in subsection .62, .63, .64, .65, .66,
..67 or .68 of PBGC Regulation Section 4043 shall be reasonably expected to occur
with respect to such Plan within the following 30 days which will result in a
Material Adverse Effect, (4) any Plan which is subject to Title IV of ERISA
shall have had or will have a trustee appointed to administer such Plan pursuant
to Section 4042(b) of ERISA, (5) any Plan or Multiemployer Plan which is subject
to Title IV of ERISA is, shall have been or will be involuntarily terminated or
to be the subject of termination proceedings under ERISA, any Plan subject to
Title VI of ERISA shall have an Unfunded Current Liability, (6) a contribution
required to be made with respect to a Plan subject to Title IV of ERISA or
Multiemployer Plan or a Foreign Pension Plan has not been made within 60 days of
when due, (7) the U.S. Borrower or any Subsidiary of the U.S. Borrower or any
ERISA Affiliate has incurred or will incur any liability to or on account of a
Plan subject to Title IV of ERISA or Multiemployer Plan under Section 409,
502(i), 502(l), 515, 4062, 4063, 4064, 4069, 4201, 4204

                                     -116-

<PAGE>

or 4212 of ERISA or Section 401(a)(29), 4971 or 4975 of the Code or on account
of a group health plan (as defined in Section 607(1) of ERISA or Section
4980B(g)(2) of the Code) under Section 4980B of the Code, (8) the U.S. Borrower
or any Subsidiary of the U.S. Borrower has incurred or will incur liabilities
pursuant to one or more group health plans (as defined in Section 5000(b)(1) of
the Code) that provide benefits to retired employees or other former employees
(other than as required by Section 601 of ERISA), (9) a "default" within the
meaning of Section 4219(c)(5) of ERISA, shall occur with respect to any
Multiemployer Plan or (10) the U.S. Borrower or any Subsidiary of the U.S.
Borrower has incurred or will incur liabilities not otherwise described in this
Section 10.06 pursuant to one or more Plans or Foreign Pension Plans; (b) there
shall result from any such event or events described above in this Section 10.06
the imposition of a lien, the granting of a security interest, or a liability or
a material risk of incurring a liability resulting from any event described in
clause (a) above; and (c) such lien, security interest or liability,
individually and/or in the aggregate, in the reasonable opinion of the Required
Lenders, has had, or could reasonably be expected to have, a Material Adverse
Effect; provided that notwithstanding the foregoing, the funding waivers for the
years and amounts set forth on Schedule V and the amount of Unfunded Current
Liability set forth on Schedule V shall not constitute an Event of Default under
this Section 10.06; provided further, an Event of Default shall occur if any
Plan subject to Title IV of ERISA shall have an Unfunded Current Liability,
which when added to the aggregate amount of Unfunded Current Liabilities with
respect to all other Plans, exceeds the aggregate amount of the Unfunded Current
Liabilities that existed on the Initial Borrowing Date by an amount that could
reasonably be expected to have a Material Adverse Effect; or

            10.07 Security Documents. (a) Any Security Document shall cease to
be in full force and effect (except in accordance with the terms thereof), or
shall cease to give the Collateral Agent for the benefit of the Secured
Creditors the Liens, rights, powers and privileges purported to be created
thereby (including, without limitation, a perfected security interest in, and
Lien on, all of the Collateral wherein perfection of a security interest is
required hereunder or under the relevant Security Document), in favor of the
Collateral Agent, superior to and prior to the rights of all third Persons
(except as permitted by Section 9.03), and subject to no other Liens (except as
permitted by Section 9.03), or (b) any Credit Party shall default in the due
performance or observance of any term, covenant or agreement on its part to be
performed or observed pursuant to any such Security Document and such default
shall continue beyond any cure or grace period specifically applicable thereto
pursuant to the terms of any such Security Document; or

            10.08 Guaranties. Any Guaranty or any provision thereof shall cease
to be in full force or effect (except in accordance with the terms thereof) as
to the relevant Guarantor, or any Guarantor or Person acting by or on behalf of
such Guarantor shall deny or disaffirm such Guarantor's obligations under the
relevant Guaranty, or any Guarantor shall default in the due performance or
observance of any term, covenant or agreement on its part to be performed or
observed pursuant to its Guaranty; or

            10.09 Judgments. One or more judgments or decrees shall be entered
against the U.S. Borrower or any of its Subsidiaries involving a liability (to
the extent not paid or covered by a reputable and solvent insurance company
(with any portion of any judgment or decree not so covered to be included in any
determination hereunder)) equal to or in excess of $10,000,000 for

                                     -117-

<PAGE>

all such judgments and decrees and all such judgments or decrees shall either be
final and non-appealable or shall not have been vacated, discharged or stayed or
bonded pending appeal for any period of 60 consecutive days; or

            10.10 Ownership(a) . A Change of Control shall have occurred; or

            10.11 Denial of Liability. (a) Either Borrower shall deny its
obligations under this Agreement, any Note or any other Credit Document, (b) any
law, rule or regulation shall purport to render invalid, or preclude enforcement
of, any material provision of this Agreement or any other Credit Document or
impair performance of any Foreign Credit Party's obligations hereunder or under
any other Credit Document or (c) any dominant authority asserting or exercising
de jure or de facto governmental or police powers shall, by moratorium laws or
otherwise, cancel, suspend or defer the obligation of any Foreign Credit Party
to pay any amount required to be paid hereunder or under any other Credit
Document; or

            10.12 Governmental Action. Any governmental authority shall have
condemned, nationalized, seized, or otherwise expropriated all or any
substantial part of the property, shares of capital stock or other assets of any
Foreign Credit Party or any of its Subsidiaries, or shall have assumed custody
or control of such property or other assets or of the business or operations of
any Foreign Credit Party or any of its Subsidiaries, or shall have taken any
action for the dissolution or disestablishment of any Foreign Credit Party or
any of its Subsidiaries or any action that would prevent any Foreign Credit
Party, any of its Subsidiaries or any of their respective officers from carrying
on the business of such Foreign Credit Party or such Subsidiary or a substantial
part thereof;

then, and in any such event, and at any time thereafter, if any Event of Default
shall then be continuing, the Administrative Agent shall, upon the written
request of the Required Lenders, by written notice to the U.S. Borrower, take
any or all of the following actions, without prejudice to the rights of any
Agent or any Lender to enforce its claims against any Credit Party (provided
that if an Event of Default specified in Section 10.05 shall occur with respect
to either Borrower, the result which would occur upon the giving of written
notice by the Administrative Agent as specified in clauses (i) and (ii) below
shall occur automatically without the giving of any such notice): (i) declare
the Total Commitment terminated, whereupon the Commitment of each Lender shall
forthwith terminate immediately and any RL Commitment Commission and any other
Fees shall forthwith become due and payable without any other notice of any
kind; (ii) declare the principal of and any accrued interest in respect of all
Loans and all Obligations owing hereunder (including Unpaid Drawings) to be,
whereupon the same shall become, forthwith due and payable without presentment,
demand, protest or other notice of any kind, all of which are hereby waived by
the Borrowers; (iii) enforce, as Collateral Agent (or direct the Collateral
Agent to enforce), any or all of the Liens and security interests created
pursuant to the Security Documents; (iv) terminate any Letter of Credit which
may be terminated in accordance with its terms; (v) direct the European Borrower
to pay (and the European Borrower agrees that upon receipt of such notice, or
upon the occurrence of an Event of Default specified in Section 10.05 with
respect to either Borrower, it will pay) to the Administrative Agent at the
Payment Office such additional amount of cash (in the respective currencies in
which such Letters of Credit are denominated), to be held as security by the
Administrative Agent, as is equal to the sum of the aggregate Stated Amount of
all European Borrower Letters of Credit issued for the

                                     -118-

<PAGE>

account of the European Borrower and then outstanding; (vi) direct the U.S.
Borrower to pay (and the U.S. Borrower agrees that upon receipt of such notice,
or upon the occurrence of an Event of Default specified in Section 10.05 with
respect to either Borrower, it will pay) to the Administrative Agent at the
Payment Office such additional amount of cash (in the respective currencies in
which such Letters of Credit are denominated), to be held as security by the
Administrative Agent, as is equal to sum of the aggregate Stated Amount of all
U.S. Borrower Letters of Credit then outstanding; and (vii) apply any cash
collateral held by the Administrative Agent as provided in Section 4.02 to the
repayment of the Obligations.

            SECTION 11. Definitions. As used herein, the following terms shall
have the meanings herein specified unless the context otherwise requires.
Defined terms in this Agreement shall include in the singular number the plural
and in the plural the singular:

            "Account Party" shall mean, with respect to Letters of Credit, the
U.S. Borrower and/or the European Borrower, as the case may be.

            "Acquired Entity or Business" shall mean either (x) the assets
constituting a business, division or product line of any Person not already a
Subsidiary of the U.S. Borrower or (y) 100% of the Equity Interests of any such
Person, which Person shall, as a result of the acquisition of such Equity
Interests, become a Wholly-Owned Subsidiary of the U.S. Borrower (or shall be
merged with and into the U.S. Borrower or a Wholly-Owned Subsidiary of the U.S.
Borrower, with the U.S. Borrower or such Wholly-Owned Subsidiary being the
surviving Person).

            "Additional Class P4 Distribution" shall have the meaning provided
in the Plan of Reorganization.

            "Additional Collateral" shall mean all property (whether real or
personal) in which security interests are granted (or have been purported to be
granted) (and continue to be in effect at the time of determination) pursuant to
Sections 8.11, 8.12 and/or 9.16.

            "Additional Factoring Agreement" shall mean an agreement, in form
and substance satisfactory to the Administrative Agent in its sole discretion,
pursuant to which the U.S. Borrower and/or certain of its Domestic Subsidiaries
shall sell certain receivables to an unrelated third party.

            "Additional Mortgage" shall have the meaning provided in Section
8.11(a).

            "Additional Mortgaged Property" shall have the meaning provided in
Section 8.11(a).

            "Additional Security Documents" shall mean all mortgages, pledge
agreements, security agreements and other security documents entered into from
time to time pursuant to Sections 8.11, 8.12, 8.15 and/or 9.16, as each such
document may be modified, supplemented or amended from time to time in
accordance with the terms hereof and thereof.

            "Adjustable Applicable Margins" shall have the meaning provided in
the definition of Applicable Margin.

                                     -119-

<PAGE>

            "Adjusted Consolidated Total Current Assets" at any time shall mean
the Consolidated Total Current Assets at such time, adjusted by deducting
therefrom all amounts reflected therein attributable to assets of (x) Exide
Holding Pte Limited and its Subsidiaries, (y) any other Subsidiary of the U.S.
Borrower organized in Asia or Australia and any Subsidiary thereof and (z) any
asset of the U.S. Borrower or any of its Subsidiaries located in Asia or
Australia.

            "Administrative Agent" shall have the meaning provided in the first
paragraph of this Agreement and shall include any successor to the
Administrative Agent appointed pursuant to Section 12.10.

            "Affiliate" shall mean, with respect to any Person, any other Person
directly or indirectly controlling (including but not limited to all directors
and officers of such Person), controlled by, or under direct or indirect common
control with such Person. A Person shall be deemed to control another Person if
such Person possesses, directly or indirectly, the power (i) to vote 10% or more
of the securities having ordinary voting power for the election of directors (or
equivalent governing body) of such Person or (ii) to direct or cause the
direction of the management and policies of such other Person, whether through
the ownership of voting securities, by contract or otherwise; provided, however,
that neither any Agent nor any Lender (nor any Affiliate thereof) shall be
considered an Affiliate of the U.S. Borrower or any Subsidiary thereof.

            "Agent" shall mean the Administrative Agent, the Syndication Agents,
the Book Running Managers, the Collateral Agent and shall include any successor
to any such Person appointed pursuant to Section 12.10.

            "Aggregate Multicurrency Facility RL Exposure" at any time shall
mean the sum of (i) the aggregate principal amount of all Multicurrency Facility
Revolving Loans then outstanding (for this purpose, using the Dollar Equivalent
of each Euro Denominated Revolving Loan then outstanding), (ii) the aggregate
amount of all Letter of Credit Outstandings (using the Dollar Equivalent of all
amounts expressed in Euros) at such time and (iii) the aggregate principal
amount of all Swingline Loans (for this purpose, using the Dollar Equivalent of
each Euro Denominated Swingline Loan then outstanding).

            "Agreement" shall mean this Credit Agreement, as modified,
supplemented, amended, restated (including any amendment and restatement
hereof), extended, renewed, refinanced or replaced from time to time.

            "Applicable Currency" shall mean (i) with respect to any Loan, the
Available Currency in which such Loan was incurred and (ii) with respect to any
Letter of Credit, the Available Currency in which such Letter of Credit was
denominated; provided that in the event Loans maintained in, or Unpaid Drawings
owed in, Euros are converted into Loans maintained or Unpaid Drawings owing, as
the case may be, in Dollars under the circumstances contemplated by Section
1.14, the Applicable Currency with respect to such Loans and Unpaid Drawings
shall be Dollars.

            "Applicable Margin" initially shall mean a percentage per annum
equal to (i) in the case of U.S. Borrower Term Loans and European Borrower
Dollar Term Loans maintained

                                     -120-

<PAGE>

as (A) Base Rate Loans, 2.50% and (B) Euro Rate Loans, 3.50%; (ii) in the case
of European Borrower Euro Term Loans, 4.00%; (iii) in the case of Multicurrency
Facility Revolving Loans maintained as (A) Base Rate Loans, 3.00% and (B) Euro
Rate Loans, 4.00%; and (iv) in the case of Swingline Loans maintained as (A)
Base Rate Loans, 3.00% and (B) Euro Rate Loans, 4.00%. From and after each day
of delivery of any certificate delivered in accordance with the first sentence
of the following paragraph indicating an entitlement to a different margin for
any Tranche of Loans (other than U.S. Borrower Term Loans and European Borrower
Dollar Term Loans) than that described in the immediately preceding sentence
(each, a "Start Date") to and including the applicable End Date described below,
the Applicable Margins for such Tranches of Loans (hereinafter, the "Adjustable
Applicable Margins") shall be those set forth below opposite the Leverage Ratio
indicated to have been achieved in any certificate delivered in accordance with
the following sentence:

<TABLE>
<CAPTION>
                                 Multicurrency Facility
                                        Revolving                                           Multicurrency Facility
                                        Loan and                 European Borrower            Revolving Loan, and
                                     Swingline Loans               Euro Term Loan               Swingline Loan
      Leverage Ratio               Euro Rate Margin              Euro Rate Margin             Base Rate Margin
----------------------------     ----------------------          -----------------          ----------------------
<S>                              <C>                             <C>                        <C>
Equal to or greater than 2.0              4.00%                        4.00%                         3.00%
to 1.0

Equal to or greater than 1.5              3.50%                        3.75%                         2.50%
to 1.0 but less than 2.0 to
1.0

Equal to or greater than                  3.00%                        3.75%                         2.00%
1.00 to 1.0 but less than
1.5 to 1.0

Less than 1.0 to 1.0                      2.50%                        3.75%                         1.50%
</TABLE>

            The Leverage Ratio used in a determination of Adjustable Applicable
Margins sha ll be determined based on the delivery of a certificate of the U.S.
Borrower (each, a "Quarterly Pricing Certificate") by an Authorized Officer of
the U.S. Borrower to the Administrative Agent (with a copy to be sent by the
Administrative Agent to each Lender), within 45 days of the last day of any
Fiscal Quarter of the U.S. Borrower, which certificate shall set forth the
calculation of the Leverage Ratio as at the last day of the Test Period ended
immediately prior to the relevant Start Date (but determined on a Pro Forma
Basis solely to give effect to all Permitted Acquisitions (if any) and all
Significant Asset Sales (if any) consummated on or prior to the date of delivery
of such certificate and any Indebtedness incurred, assumed or permanently repaid
in connection therewith) and the Adjustable Applicable Margins which shall be
thereafter applicable (until same are changed or cease to apply in accordance
with the following sentences); provided that at the time of the consummation of
any Permitted Acquisition or Significant Asset Sale, an Authorized Officer of
the U.S. Borrower shall deliver to the Administrative Agent a certificate
setting forth the calculation of the Leverage Ratio on a Pro Forma Basis (solely
to give effect to all Permitted Acquisitions, if any, and all Significant Asset
Sales (if any) consummated on or prior to the date of the delivery of such
certificate and any Indebtedness incurred or assumed in connection therewith) as
of the last day of the last Calculation Period ended prior to the date on which
such Permitted Acquisition or Significant

                                     -121-

<PAGE>

Asset Sale is consummated for which financial statements have been made
available (or were required to be made available) pursuant to Section 8.01(b) or
(c), as the case may be, and the date of such consummation shall be deemed to be
a Start Date and the Adjustable Applicable Margins which shall be thereafter
applicable (until same are changed or cease to apply in accordance with the
following sentences) shall be based upon the Leverage Ratio as so calculated.
The Adjustable Applicable Margins so determined shall apply, except as set forth
in the succeeding sentence, from the relevant Start Date to the earliest of (x)
the date on which the next certificate is delivered to the Administrative Agent,
(y) the date on which the next Permitted Acquisition or Significant Asset Sale
is consummated or (z) the date which is 45 days following the last day of the
Test Period in which the previous Start Date occurred (such earliest date, the
"End Date"), at which time, if no certificate has been delivered to the
Administrative Agent indicating an entitlement to new Adjustable Applicable
Margins (and thus commencing a new Start Date), the Adjustable Applicable
Margins shall be those set forth in the first sentence of this definition (such
Adjustable Applicable Margins as so determined, the "Highest Adjustable
Applicable Margins"). Notwithstanding anything to the contrary contained above
in this definition, the Adjustable Applicable Margins shall be the Highest
Adjustable Applicable Margins (x) at all times during which there shall exist
any Default or any Event of Default and (y) at all times prior to the date of
delivery of the financial statements pursuant to Section 8.01(b) for the Fiscal
Quarter ended June 30, 2004.

            "Applicable Multicurrency Facility Commitment Fee Percentage" shall
mean, for any day, (i) in the event the Total Unutilized Multicurrency Facility
Revolving Loan Commitment in effect on such day is greater than 67% of the Total
Multicurrency Facility Revolving Loan Commitment as in effect on such day,
1.00%, (ii) in the event the Total Unutilized Multicurrency Facility Revolving
Loan Commitment in effect on such day is (x) greater than or equal to 34% of the
Total Multicurrency Facility Revolving Loan Commitment as in effect on such day
and (y) less than or equal to 67% of the Total Multicurrency Facility Revolving
Loan Commitment as in effect on such day, 0.750%, and (iii) in the event the
Total Unutilized Multicurrency Facility Revolving Loan Commitment in effect on
such day is less than or equal to 34% of the Total Multicurrency Facility
Revolving Loan Commitment as in effect on such day, 0.500%. For purposes of this
definition, the Total Unutilized Multicurrency Facility Revolving Loan
Commitment and the Total Multicurrency Facility Revolving Loan Commitment as in
effect on any day shall be determined after the close of business (New York
time) on such day, following adjustments to such amounts for activity on such
day.

            "Applicable Prepayment Percentage" shall mean, at any time, 75%;
provided that, so long as no Default or Event of Default is then in existence,
(i) if at any time the Leverage Ratio is less than 2.00:1.00 (as set forth in an
officer's certificate delivered pursuant to Section 8.01(e) for the Fiscal
Quarter or Fiscal Year of the U.S. Borrower then last ended), the Applicable
Prepayment Percentage shall instead be 50% and (ii) if at any time the Leverage
Ratio is less than 1.50:1.00 (as set forth in an officer's certificate delivered
pursuant to Section 8.01(e) for the Fiscal Quarter or Fiscal Year of the U.S.
Borrower then last ended), the Applicable Prepayment Percentage shall instead be
0%.

            "Asset Sale" shall mean any sale, transfer or other disposition by
the U.S. Borrower or any of its Subsidiaries to any Person other than the U.S.
Borrower or any Wholly-Owned Subsidiary of the U.S. Borrower of any asset or
Property (including, without limitation,

                                     -122-

<PAGE>

any capital stock or other securities of, or other Equity Interests in, another
Person, but excluding the sale by the U.S. Borrower of its own capital stock) of
the U.S. Borrower or such Subsidiary other than (i) sales, transfers or other
dispositions of inventory made in the ordinary course of business, (ii) any
other sale, transfer or disposition (treating any related sales, transfers or
dispositions as a single sale, transfer or disposition) that generates Net Sale
Proceeds of less than $100,000 in the aggregate or (iii) sales or liquidations
of Cash Equivalents, it being understood and agreed that the grant of a Lien by
the U.S. Borrower or any of its Subsidiaries in favor of another Person shall
not in and of itself constitute an "Asset Sale" for purposes of this definition.

            "Assignment and Assumption Agreement" shall mean the Assignment and
Assumption Agreement substantially in the form of Exhibit K (appropriately
completed).

            "Assumed Liabilities" shall mean liabilities of Old Exide and its
Subsidiaries assumed by the U.S. Borrower and its Subsidiaries pursuant to the
Plan of Reorganization.

            "Australian/Asian Subsidiaries" shall mean (x) Exide Holding Pte
Limited and its Subsidiaries and (y) any other Wholly-Owned Foreign Subsidiary
of the U.S. Borrower organized in a jurisdiction located in Australia, New
Zealand or Asia.

            "Austrian Security" shall mean the assets of the U.S. Borrower and
its Subsidiaries which are subject to any Foreign Security Document governed by
the laws of Austria.

            "Authorized Officer" shall mean, with respect to (i) delivering
Notices of Borrowing, Notices of Conversion, Letter of Credit Requests and
similar notices, any person or persons that has or have been authorized by the
board of directors of either Borrower to deliver such notices pursuant to this
Agreement and that has or have appropriate signature cards on file with the
Administrative Agent, the Swingline Lender and the respective Issuing Lender;
(ii) delivering financial information and officer's certificates pursuant to
this Agreement, the chief financial officer, any treasurer or other financial
officer of the U.S. Borrower and (iii) any other matter in connection with this
Agreement or any other Credit Document, any officer (or a person or persons so
designated by any two officers) of the U.S. Borrower.

            "Available Currency" shall mean (i) with respect to U.S. Borrower
Term Loans and European Borrower Dollar Term Loans, Dollars, (ii) with respect
to Multicurrency Facility Revolving Loans, Swingline Loans and Letters of
Credit, Dollars and Euros and (iii) with respect to European Borrower Euro Term
Loans, Euros.

            "Bankruptcy Code" shall have the meaning provided in Section 10.05.

            "Bankruptcy Court" shall mean the United States Bankruptcy Court for
the District of Delaware.

            "Base Rate" at any time shall mean the higher of (x) the rate
which is 1/2 of 1% in excess of the Federal Funds Rate at such time and (y) the
Prime Lending Rate at such time.

            "Base Rate Loan" shall mean (i) each Dollar Denominated Swingline
Loan, (ii) each other Dollar Denominated Loan which is designated or deemed
designated as a Base Rate

                                     -123-

<PAGE>

Loan by the respective Borrower at the time of the incurrence thereof or
conversion thereto and (iii) each outstanding Loan after the conversion thereof
to Dollars pursuant to Section 1.14.

            "Belgian Credit Party" shall mean any Foreign Credit Party organized
under the laws of Belgium.

            "Belgian Pledges on Business Assets" shall have the meaning provided
in Section 12.16.

            "Bonds" shall have the meaning provided in Section 12.15(a).

            "Book Running Managers" shall have the meaning provided in the first
paragraph of this Agreement.

            "Borrowers" shall have the meaning provided in the first paragraph
of this Agreement.

            "Borrowing" shall mean the borrowing of one Type of Loan pursuant to
a single Tranche by the European Borrower or by the U.S. Borrower from all the
Lenders having Commitments with respect to such Tranche (or from the Swingline
Lender, in the case of Swingline Loans) on a given date (or resulting from a
conversion or conversions on such date), having in the case of Euro Rate Loans
(other than Euro Denominated Swingline Loans) the same Interest Period, provided
that Base Rate Loans incurred pursuant to Section 1.10(b) shall be considered
part of the related Borrowing of Eurodollar Loans.

            "Business Day" shall mean (i) for all purposes other than as covered
by clause (ii) below, any day excluding Saturday, Sunday and any day which shall
be in the City of New York (or, with respect to an Issuing Lender not located in
the City of New York, the location of such Issuing Lender) a legal holiday or a
day on which banking institutions are authorized by law or other governmental
actions to close, and (ii) with respect to all notices and determinations in
connection with, and payments of principal, Unpaid Drawings and interest on or
with respect to, Euro Denominated Loans or any Euro Denominated Letters of
Credit, any day which is a Business Day described in clause (i) and which is
also (A) a day for trading by and between banks in the London interbank market
and which shall not be a legal holiday or a day on which banking institutions
are authorized or required by law or other government action to close in London
or New York City and (B) in relation to any payment in Euros, a day on which the
Trans-European Automated Real-Time Gross Settlement Express Transfer (TARGET)
System is open.

            "Calculation Period" shall mean, with respect to any Permitted
Acquisition, any Significant Asset Sale or any other event expressly required to
be calculated on a Pro Forma Basis pursuant to the terms of this Agreement, the
Test Period most recently ended prior to the date of such Permitted Acquisition,
Significant Asset Sale or other event.

            "Capital Expenditures" shall mean, with respect to any Person, for
any period, all expenditures by such Person which should be capitalized in
accordance with U.S. GAAP during such period, including, without duplication,
all such expenditures with respect to fixed or capital assets (including,
without limitation, expenditures for maintenance and repairs which should be

                                     -124-

<PAGE>

capitalized in accordance with U.S. GAAP) and the amount of all Capitalized
Lease Obligations incurred by such Person during such period.

            "Capital Lease", as applied to any Person, shall mean any lease of
any Property by that Person as lessee which, in conformity with U.S. GAAP, is
accounted for as a capital lease on the balance sheet of that Person.

            "Capitalized Lease Obligations" of any Person shall mean all
obligations under Capital Leases of such Person, in each case taken at the
amount thereof accounted for as indebtedness in accordance with U.S. GAAP.

            "Cash Equivalents" means (i) securities issued or directly fully
guaranteed or insured by the governments of the United States and members of the
European Union or any agency or instrumentality thereof (provided that the full
faith and credit of the respective such government is pledged in support
thereof) having maturities of not more than six months from the date of
acquisition, (ii) securities issued by any state of the United States or any
political subdivision of any such state or any public instrumentality thereof
maturing within six months from the date of acquisition thereof and, at the time
of acquisition, having one of the two highest ratings obtainable from either S&P
or Moody's, (iii) certificates of deposit and eurodollar time deposits with
maturities of six months or less from the date of acquisition, bankers'
acceptances with maturities not exceeding six months and overnight bank
deposits, in each case with any domestic commercial bank or commercial bank of a
foreign country recognized by the United States, (x) in the case of a domestic
commercial bank, having capital and surplus in excess of $500,000,000 and
outstanding debt which is rated "A" (or similar equivalent thereof) or higher by
at least one nationally recognized statistical rating organization (as defined
under Rule 436 under the Securities Act) and (y) in the case of a foreign
commercial bank, having capital and surplus in excess of $250,000,000 (or the
foreign currency equivalent thereof), (iv) repurchase obligations with a term of
not more than seven days for underlying securities of the types described in
clauses (i) and (iii) above entered into with any financial institution meeting
the qualifications specified in clause (iii) above, (v) commercial paper having
a rating of at least A-1 from S&P or at least P-1 from Moody's and in each case
maturing within six months after the date of acquisition and (vi) investments in
money market funds which invest substantially all their assets in securities of
the types described in clauses (i) through (v) above. Furthermore, with respect
to Foreign Subsidiaries of the U.S. Borrower that are not organized in one or
more Qualified Jurisdictions, Cash Equivalents shall include bank deposits (and
investments pursuant to operating account agreements) maintained with various
local banks in the ordinary course of business consistent with past practice of
the U.S. Borrower's Foreign Subsidiaries.

            "Change of Control" shall mean (i) the U.S. Borrower shall at any
time cease to own directly or indirectly 100% of the Equity Interests of the
European Borrower, (ii) any "Person" or "Group" (within the meaning of Sections
13(d) and 14(d) under the Exchange Act, as in effect on the Initial Borrowing
Date) (other than the Permitted Holders) is or shall (A) be the "beneficial
owner" (as so defined in Rules 13(d)-3 and 13(d)-5 under the Exchange Act) of
30% or more on a fully diluted basis of the voting and/or economic interest in
the U.S. Borrower's capital stock or other Equity Interests or (B) have obtained
the power (whether or not exercised) to elect a majority of the U.S. Borrower's
directors, (iii) the Board of Directors of the U.S. Borrower shall cease to
consist of a majority of Continuing Directors, or (iv) a "change of

                                     -125-

<PAGE>

control" or similar event shall occur as provided in any Qualified Preferred
Stock (or certificate of designation governing the same).

            "Chapter 11 Cases" shall mean the voluntary petitions for relief
filed by Old Exide and certain of its Subsidiaries on April 15, 2002, under
Chapter 11 of the Bankruptcy Code.

            "Co-Book Running Manager" shall have the meaning provided in the
first paragraph of this Agreement.

            "Code" shall mean the Internal Revenue Code of 1986, as amended from
time to time, and the regulations promulgated and rulings issued thereunder.
Section references to the Code are to the Code, as in effect at the date of this
Agreement and any subsequent provisions of the Code, amendments thereof,
supplemental thereto or substituted therefor.

            "Collateral" shall mean all property (whether real or personal,
movable or immovable) with respect to which any security interests have been
granted (or purported to be granted) pursuant to any Security Document
(including any Additional Security Document), including, without limitation, all
Pledge Agreement Collateral, all Security Agreement Collateral, all Mortgaged
Properties and all cash and Cash Equivalents delivered as collateral pursuant to
Section 4.02 or 10 or any Credit Document and all Additional Collateral, if any.

            "Collateral Agent" shall mean DBAG and any of its Affiliates,
including without limitation DBL, acting as collateral agent for the Secured
Creditors pursuant to the terms of any Credit Document.

            "Collective Bargaining Agreements" shall have the meaning provided
in Section 5.14.

            "Commitment" shall mean any of the commitments of any Lender, i.e.,
whether the U.S. Borrower Term Loan Commitment, the European Borrower Dollar
Term Loan Commitment, the European Borrower Euro Term Loan Commitment or the
Multicurrency Facility Revolving Loan Commitment of such Lender.

            "Commodity Agreements" shall mean commodity agreements, hedging
agreements and other similar agreements or arrangements designed to protect
against price fluctuations of commodities (e.g., lead) used in the business of
the U.S. Borrower and its Subsidiaries.

            "Company" shall mean any corporation, limited liability company,
partnership or other business entity (or the adjectival form thereof, where
appropriate).

            "Consolidated Bank Debt" at any time shall mean the sum of (i) the
aggregate principal amount of all Term Loans outstanding at such time (taking
the Dollar Equivalent of all amounts denominated in Euros), (ii) the aggregate
principal amount of all Multicurrency Facility Revolving Loans then outstanding
(for this purpose, using the Dollar Equivalent of each Euro Denominated
Revolving Loan then outstanding), (iii) the aggregate principal amount of all
Swingline Loans (for this purpose, using the Dollar Equivalent of each Euro
Denominated

                                     -126-

<PAGE>

Swingline Loan then outstanding), (iv) the aggregate amount of all
Unpaid Drawings (taking the Dollar Equivalent of any amounts owed in currencies
other than Dollars) in respect of all Letters of Credit at such time and (v) the
aggregate principal amount of all Indebtedness outstanding pursuant to Section
9.04(viii).

            "Consolidated Debt" shall mean, at any time, the sum of (without
duplication) (i) all Indebtedness of the U.S. Borrower and its Consolidated
Subsidiaries (on a consolidated basis) as would be required to be reflected as
debt or Capital Leases on the liability side of a consolidated balance sheet of
the U.S. Borrower and its Consolidated Subsidiaries in accordance with U.S.
GAAP, (ii) all Indebtedness of the U.S. Borrower and its Consolidated
Subsidiaries of the type described in clauses (ii), (vii) and (viii) of the
definition of Indebtedness and (iii) all Contingent Obligations of the U.S.
Borrower and its Consolidated Subsidiaries in respect of Indebtedness of any
third Person of the type referred to in preceding clauses (i) and (ii); provided
that the sum of (x) the aggregate amount available to be drawn (i.e., unfunded
amounts) under all letters of credit, bankers' acceptances, bank guaranties,
surety bonds and similar obligations issued for the account of the U.S. Borrower
or any of its Consolidated Subsidiaries (but excluding, for avoidance of doubt,
all unpaid drawings or other matured monetary obligations owing in respect of
such letters of credit, bankers' acceptances, bank guaranties, surety bonds and
similar obligations) and (y) the aggregate amount of any Indebtedness of the
U.S. Borrower and its Consolidated Subsidiaries of the type described in
Sections 9.04(xviii) and (xix), shall not be included in any determination of
"Consolidated Debt".

            "Consolidated EBITDA" shall mean, for any period, the Consolidated
Net Income (without giving effect to (x) any extraordinary gains and (y) any
gains or losses from sales of assets other than inventory and equipment sold in
the ordinary course of business) adjusted by (x) adding thereto (in each case to
the extent deducted in determining Consolidated Net Income for such period),
without duplication, the amount of (i) total interest expense (inclusive of
amortization of deferred financing fees and any other original issue discount)
of the U.S. Borrower and its Consolidated Subsidiaries determined on a
consolidated basis for such period, (ii) provision for taxes based on income and
foreign withholding taxes for the U.S. Borrower and its Consolidated
Subsidiaries determined on a consolidated basis for such period, (iii) all
depreciation and amortization expense of the U.S. Borrower and its Consolidated
Subsidiaries determined on a consolidated basis for such period, (iv) any other
non-cash charges incurred in such period to the extent that same were deducted
in arriving at Consolidated Net Income for such period (other than non-cash
charges incurred in connection with the accrual of pension liabilities in
accordance with U.S. GAAP), (v) the amount of all fees and expenses incurred in
connection with the Transaction for such period to the extent same were deducted
in arriving at Consolidated Net Income for such period, (vi) for any Test Period
which includes any portion of any period set forth on Schedule XVI, an amount up
to the amount set forth under the caption "Restructuring Charges" on Schedule
XVI, to the extent such Restructuring Charges were actually recorded or accrued
during such period for the purpose specified on Schedule XVI for such
Restructuring Charges and were deducted in arriving at Consolidated Net Income
for such period and (vii) for any Test Period during which the amount of
Restructuring Charges set forth on Schedule XVI for a prior Test Period which
were not recorded or accrued and deducted in arriving at Consolidated Net Income
during such prior Test Period were actually recorded or accrued for the purpose
specified on Schedule XVI for such Restructuring Charges, the amount of such
Restructuring Charges to the extent so recorded or accrued during such Test
period and

                                     -127-

<PAGE>

deducted in arriving at Consolidated Net Income for such Test Period and (y)
subtracting therefrom, (i) to the extent included in arriving at Consolidated
Net Income for such period, the amount of non-cash gains during such period and
(ii) the aggregate amount of all cash payments made during such period in
connection with non-cash charges incurred in a prior period (other than cash
payments made in such period with respect to pension liabilities accrued in a
prior period in accordance with U.S. GAAP), to the extent such non-cash charges
were added back pursuant to clause (x)(iv) above in a prior period. For the
avoidance of doubt, it is understood and agreed that, to the extent any amounts
are excluded from Consolidated Net Income by virtue of the proviso to the
definition thereof contained herein, any add backs to Consolidated Net Income in
determining Consolidated EBITDA as provided above shall be limited (or denied)
in a fashion consistent with the proviso to the definition of Consolidated Net
Income contained herein. Notwithstanding anything to the contrary contained
above, for purposes of determining the Leverage Ratio, to the extent
Consolidated EBITDA is to be determined for any Test Period which ends prior to
the first anniversary of the Initial Borrowing Date, Consolidated EBITDA for all
portions of such period occurring prior to the Initial Borrowing Date shall be
calculated in accordance with the definition of Test Period contained herein.

            "Consolidated Interest Coverage Ratio" shall mean, for any period,
the ratio of (x) Consolidated EBITDA for such period to (y) Consolidated
Interest Expense for such period.

            "Consolidated Interest Expense" shall mean, for any period, (i) the
total consolidated interest expense of the U.S. Borrower and its Consolidated
Subsidiaries (including, without limitation, all commissions, discounts and
other fees and charges owed with respect to letters of credit and bank
guaranties) for such period (calculated without regard to any limitations on
payment thereof), adjusted to exclude (to the extent same would otherwise be
included in the calculation above in this clause (i)) the amortization of any
deferred financing costs for such period, plus (ii) without duplication, (x)
that portion of Capitalized Lease Obligations of the U.S. Borrower and its
Consolidated Subsidiaries on a consolidated basis representing the interest
factor for such period and (y) the "deemed interest expense" (i.e., the interest
expense which would have been applicable if the respective obligations were
structured as on-balance sheet financing arrangements) with respect to all
Indebtedness of the U.S. Borrower and its Consolidated Subsidiaries of the type
described in clause (viii) of the definition of Indebtedness contained herein
(to the extent same does not arise from a financing arrangement constituting an
operating lease) for such period.

            "Consolidated Net Income" shall mean, for any period, the net income
(or loss) of the U.S. Borrower and its Consolidated Subsidiaries determined on a
consolidated basis for such period (taken as a single accounting period) in
accordance with U.S. GAAP, provided that the following items shall be excluded
in computing Consolidated Net Income (without duplication): (i) the net income
(or loss) of any Person in which the Person or Persons other than the U.S.
Borrower and its Wholly Owned Subsidiaries has an Equity Interest or Equity
Interests to the extent of such Equity Interests held by Persons other than the
U.S. Borrower and its Wholly-Owned Subsidiaries in such Person, (ii) except for
determinations expressly required to be made on a Pro Forma Basis, the net
income (or loss) of any Person accrued prior to the date it becomes a
Consolidated Subsidiary or all or substantially all of the property or assets of
such Person are acquired by a Consolidated Subsidiary and (iii) the net income
of any Consolidated Subsidiary to the extent that the declaration or payment of
dividends or similar distributions by such

                                     -128-

<PAGE>

Consolidated Subsidiary of such net income is not at the time permitted by the
operation of the terms of its charter or any agreement, instrument, judgment,
decree, order, statute, rule or governmental regulation applicable to such
Consolidated Subsidiary.

            "Consolidated Subsidiary" shall mean, with respect to any Person, at
any date, any other Person the Equity Interests of which are owned by such
Person and whose financial results are consolidated in the financial statements
of such Person in accordance with U.S. GAAP (and consistent with the
consolidation practices of the U.S. Borrower as in effect on the Effective
Date), if such statements were prepared as of such date.

            "Consolidated Total Current Assets" shall mean, at any time, the
total current assets of the U.S. Borrower and its Consolidated Subsidiaries as
same would be shown on a consolidated balance sheet of the U.S. Borrower
prepared in accordance with U.S. GAAP.

            "Contingent Obligation" shall mean, as to any Person, any obligation
of such Person as a result of such Person being a general partner of any other
Person, unless the underlying obligation is expressly made non-recourse as to
such general partner, and any obligation of such Person guaranteeing or intended
to guarantee any Indebtedness, leases, dividends or other obligations ("primary
obligations") of any other Person (the "primary obligor") in any manner, whether
directly or indirectly, including, without limitation, any obligation of such
Person, whether or not contingent, (i) to purchase any such primary obligation
or any property constituting direct or indirect security therefor, (ii) to
advance or supply funds (x) for the purchase or payment of any such primary
obligation or (y) to maintain working capital or equity capital of the primary
obligor or otherwise to maintain the net worth or solvency of the primary
obligor, (iii) to purchase property, securities or services primarily for the
purpose of assuring the owner of any such primary obligation of the ability of
the primary obligor to make payment of such primary obligation or (iv) otherwise
to assure or hold harmless the holder of such primary obligation against loss in
respect thereof; provided, however, that the term Contingent Obligation shall
not include endorsements of instruments for deposit or collection in the
ordinary course of business. The amount of any Contingent Obligation shall be
deemed to be an amount equal to the lesser of (x) the stated or determinable
amount of the primary obligation in respect of which such Contingent Obligation
is made or, if not stated or determinable, the maximum reasonably anticipated
liability in respect thereof (assuming such Person is required to perform
thereunder) as determined by such Person in good faith and (y) the stated amount
of such Contingent Obligation.

            "Continuing Directors" shall mean the directors of the U.S. Borrower
on the Initial Borrowing Date and each other director if such director's
election to, or nomination for the election to, the Board of Directors of the
U.S. Borrower is recommended or approved by a majority of then Continuing
Directors.

            "Credit Documents" shall mean this Agreement, the Notes, each
Subsidiaries Guaranty, the Intercompany Subordination Agreement, each Security
Document and any other guarantees or security documents executed and delivered
for the benefit of the Lenders in accordance with the requirements of this
Agreement and any other guaranties, pledge agreements or security documents
executed and delivered in accordance with the requirements of Sections 8.11,
8.12 and/or 9.16.

                                     -129-

<PAGE>

            "Credit Event" shall mean the making of a Loan (other than a
Multicurrency Facility Revolving Loan made pursuant to a Mandatory Borrowing) or
the issuance of a Letter of Credit.

            "Credit Party" shall mean each U.S. Credit Party and each Foreign
Credit Party.

            "CSFB" shall mean Credit Suisse First Boston.

            "DBAG" shall mean Deutsche Bank AG New York Branch, in its
individual capacity, and any successor corporation thereto by merger,
consolidation or otherwise.

            "DBL" shall have the meaning provided in Section 12.16.

            "DBSI" shall mean Deutsche Bank Securities Inc., in its individual
capacity, and any successor corporation thereto by merger, consolidation or
otherwise.

            "Default" shall mean any event, act or condition, which with notice
or lapse of time, or both, would constitute an Event of Default.

            "Defaulting Lender" shall mean any Lender with respect to which a
Lender Default is in effect.

            "Designated Foreign Subsidiaries" shall mean (w) the Nordic
Subsidiaries, (x) the Australian/Asian Subsidiaries, (y) the Polish Subsidiaries
and (z) the Portuguese Subsidiaries.

            "DIP Credit Agreement" shall mean the Secured Super Priority
Debtor-in-Possession Credit Agreement, dated as of April 15, 2002, and amended
and restated as of February 13, 2004, among Old Exide, the subsidiaries of Old
Exide listed on the signature pages thereto as debtors and debtors in possession
as borrowers, the subsidiaries of Old Exide listed on the signature pages
thereto as guarantors, the financial institutions from time to time party
thereto, Citicorp USA, Inc. as collateral agent and escrow agent, and Deutsche
Bank AG New York, as administrative agent and collateral monitoring agent.

            "Disclosure Statement" shall mean the Disclosure Statement, dated
March 11, 2004, issued pursuant to Section 1125 of the Bankruptcy Code relating
to the Plan of Reorganization, as approved by the Bankruptcy Court.

            "Disputed Claims" shall have the meaning provided in the Plan of
Reorganization.

            "Dividend" shall have the meaning provided in Section 9.06.

            "Documents" shall mean and include (i) the Credit Documents, (ii)
the Refinancing Documents and (iii) the Reorganization Documents.

            "Dollar Denominated Letter of Credit" shall mean each Letter of
Credit denominated in Dollars.

                                     -130-

<PAGE>

            "Dollar Denominated Letter of Credit Outstandings" shall mean, at
any time, the sum of (i) the aggregate Stated Amount of all outstanding Dollar
Denominated Letters of Credit at such time and (ii) the aggregate amount of all
Unpaid Drawings with respect to Dollar Denominated Letters of Credit at such
time.

            "Dollar Denominated Loan" shall mean all Loans denominated in
Dollars, which shall include each U.S. Borrower Term Loan, each European
Borrower Dollar Term Loan, each Multicurrency Facility Revolving Loan made in
Dollars and each Swingline Loan made in Dollars, as well as each Loan converted
into Dollars in accordance with the provisions of Section 1.14.

            "Dollar Denominated Revolving Loan" shall mean all Multicurrency
Facility Revolving Loans incurred in Dollars.

            "Dollar Denominated Swingline Loan" shall mean all Swingline Loans
incurred in Dollars.

            "Dollar Equivalent" of an amount denominated in a currency other
than Dollars shall mean, at any time for the determination thereof, the amount
of Dollars which could be purchased with the amount of such currency involved in
such computation at the spot exchange rate therefor as quoted by the
Administrative Agent as of 11:00 A.M. (New York time) on the date two Business
Days prior to the date of any determination thereof for purchase on such date
(or, in the case of (1) any determination pursuant to Section 1.14 or 13.23 or
Section 26 (or any analogous provision) of any Subsidiaries Guaranty or (2) with
respect to Euro Denominated Swingline Loans, on the date of determination);
provided that following the occurrence of a Sharing Event, the Dollar Equivalent
of any Unpaid Drawing or unreimbursed payment under a Letter of Credit expressed
in Euros shall be determined on the later of the time the drawing under the
related Letter of Credit was paid or disbursed by the Issuing Lender or the date
of the occurrence of the Sharing Event, provided further, that for purposes of
(x) determining compliance with Sections 1.01(c), (e) and (g), 2.01(c), 4.02(a)
and 6.01 and (y) calculating Fees pursuant to Section 3.01 (except Fees which
are expressly required to be paid in a currency other than Dollars pursuant to
Section 3.01), the Dollar Equivalent of any amounts denominated in a currency
other than Dollars shall be revalued on a monthly basis using the spot exchange
rates therefor as quoted in the Wall Street Journal (or, if same does not
provide such exchange rates, on such other basis as is reasonably satisfactory
to the Administrative Agent) on the last Business Day of each calendar month,
provided, however, that at any time during a calendar month, if the Aggregate
Multicurrency Facility RL Exposure (for the purposes of the determination
thereof, using the Dollar Equivalent as recalculated based on the spot exchange
rate therefor as quoted in the Wall Street Journal (or, if same does not provide
such exchange rates, on such other basis as is reasonably satisfactory to the
Administrative Agent) on the respective date of determination pursuant to this
exception) would exceed 85% of the Total Multicurrency Facility Revolving Loan
Commitment, then in the sole discretion of the Administrative Agent or at the
request of the Required Lenders, the Dollar Equivalent shall be reset based upon
the spot exchange rates on such date as quoted in the Wall Street Journal (or,
if same does not provide such exchange rates, on such other basis as is
reasonably satisfactory to the Administrative Agent), which rates shall remain
in effect until the last Business Day of such calendar month or such earlier
date, if any, as the rate is reset pursuant to this proviso. Notwithstanding
anything to

                                     -131-

<PAGE>

the contrary contained in this definition, at any time that a Default or an
Event of Default then exists, the Administrative Agent may revalue the Dollar
Equivalent of any amounts outstanding under the Credit Documents in a currency
other than Dollars in its sole discretion.

            "Dollars" and the designation "$" shall mean the currency of the
United States of America.

            "Domestic Subsidiary" shall mean, as to any Person, any Subsidiary
of such Person incorporated or organized in the United States or any State or
territory thereof.

            "Dutch ASCS" shall mean the Act on the Supervision of the Credit
System 1992 (Wet Toezicht Kredietwezen 1992) as amended from time to time.

            "Dutch Exemption Regulation" shall mean the Exemption Regulation
pursuant to the Dutch ASCS (Vrijstellingsregeling Wet Toezicht Kredietwezen
1992) as amended from time to time.

            "Dutch Policy Rules" shall mean the Policy Rule on Key Concepts of
Market Access and Enforcement of the Act on the Supervision of the Credit System
1992 (Beleidsregel kernbegrippen markttoetreding en handhaving WTK 1992) as
amended from time to time.

            "Drawing" shall have the meaning provided in Section 2.05(b).

            "Effective Date" shall have the meaning provided in Section 13.10.

            "Eligible Transferee" shall mean and include a commercial bank, a
mutual fund, an insurance company, a financial institution, a "qualified
institutional buyer" (as defined in Rule 144A of the Securities Act), any fund
that regularly invests in bank loans or any other "accredited investor" (as
defined in Regulation D of the Securities Act), but in any event excluding any
individual and the U.S. Borrower and its Subsidiaries and Affiliates (determined
without regard to the proviso to the definition thereof); provided that any
Person which received U.S. Borrower Common Stock pursuant to Section
5.08(b)(iii) that would otherwise constitute an Eligible Transferee if such
Person did not own such U.S. Borrower Common Stock shall be deemed to be an
Eligible Transferee hereunder (subject to compliance with the following proviso,
to the extent applicable); and provided further, that to be an Eligible
Transferee hereunder, each assignee with respect to any assignment of
Multicurrency Facility Revolving Loan Commitments (and related outstanding
Obligations hereunder), European Borrower Dollar Term Loans and/or European
Borrower Euro Term Loans must, at the time of the respective assignment, also be
(x) a PMP, (y) exempted because it forms a restricted circle (besloten kring)
with the European Borrower or (z) otherwise qualify as a legal assignee
hereunder under the laws of the Netherlands.

            "Employee Benefit Plans" shall have the meaning set forth in
Section 5.14.

            "End Date" shall have the meaning provided in the definition of
Applicable Margin.

                                     -132-

<PAGE>

            "Environmental Claims" shall mean any and all administrative,
regulatory or judicial actions, suits, demands, demand letters, claims, liens,
written notices of non-compliance or violation, investigations or proceedings
relating in any way to any violation (or alleged violation) by the U.S. Borrower
or any of its Subsidiaries under any Environmental Law or any permit issued to
the U.S. Borrower or any of its Subsidiaries under any such law (hereafter
"Claims"), including, without limitation, (a) any and all Claims by governmental
or regulatory authorities for enforcement, cleanup, removal, response, remedial
or other actions or damages pursuant to any applicable Environmental Law, and
(b) any and all Claims by any third party seeking damages, contribution,
indemnification, cost recovery, compensation or injunctive relief resulting from
Hazardous Materials or arising from alleged injury or threat of injury to
health, safety or the environment.

            "Environmental Law" shall mean any federal, state or local policy
having the force and effect of law, statute, law, rule, regulation, ordinance,
code or rule of common law now or hereafter in effect and in each case as
amended, and any judicial or administrative interpretation thereof, including
any legally-binding judicial or administrative order, consent, decree or
judgment (for purposes of this definition (collectively, "Laws")), relating to
pollution or protection of the environment, or Hazardous Materials or health and
safety to the extent such health and safety issues arise under the Occupational
Safety and Health Act of 1970, as amended, or any such similar Laws.

            "Equity Interests" of any Person shall mean any and all shares,
interests, rights to purchase, warrants, options, participation or other
equivalents of or interest in (however designated) equity of such Person,
including any preferred stock, any limited or general partnership interest and
any limited liability company membership interest.

            "ERISA" shall mean the Employee Retirement Income Security Act of
1974, as amended from time to time, and the regulations promulgated and rulings
issued thereunder. Section references to ERISA are to ERISA, as in effect at the
date of this Agreement and any subsequent provisions of ERISA, amendatory
thereof, supplemental thereto or substituted therefor.

            "ERISA Affiliate" shall mean each person (as defined in Section 3(9)
of ERISA) which together with the U.S. Borrower or a Subsidiary of the U.S.
Borrower would be deemed to be a "single employer" (i) within the meaning of
Section 414(b), (c), (m) or (o) of the Code or (ii) as a result of the U.S.
Borrower or a Subsidiary of the U.S. Borrower being or having been a general
partner of such Person.

            "Euro Denominated Letter of Credit" shall mean each Letter of Credit
denominated in Euros.

            "Euro Denominated Letter of Credit Outstandings" shall mean, at any
time, the sum of (i) the aggregate Stated Amount of all outstanding Euro
Denominated Letters of Credit at such time and (ii) the aggregate amount of all
Unpaid Drawings with respect to Euro Denominated Letters of Credit at such time.

                                      -133-

<PAGE>

            "Euro Denominated Loan" shall mean all Loans denominated in Euros,
including all Euro Denominated Term Loans, Euro Denominated Revolving Loans and
all Euro Denominated Swingline Loans.

            "Euro Denominated Revolving Loan" shall mean each Multicurrency
Facility Revolving Loan denominated in Euros at the time of the incurrence
thereof.

            "Euro Denominated Swingline Loan" shall mean each Swingline Loan
denominated in Euros at the time of the incurrence thereof.

            "Euro Denominated Term Loan" shall mean each European Borrower Euro
Term Loans.

            "Eurodollar Loans" shall mean each Dollar Denominated Loan
(excluding Swingline Loans) designated as such by the respective Borrower or
Borrowers at the time of the incurrence thereof or conversion thereto.

            "Eurodollar Rate" shall mean, for any Interest Period, in the case
of any U.S. Dollar Denominated Loan, (i) the arithmetic average (rounded upwards
to the nearest 1/16 of 1%) of the offered quotation to first class banks in the
interbank Eurodollar market by DBAG for U.S. dollar deposits of amounts in
immediately available funds comparable to the principal amount of the applicable
Eurodollar Loan then being made by the Administrative Agent as part of the
relevant Borrowing (or, if the Administrative Agent is not a Lender with respect
thereto, taking the average principal amount of the Eurodollar Loan then being
made by the various Lenders pursuant thereto) for which the Eurodollar Rate is
being determined with maturities comparable to the Interest Period for which
such Eurodollar Rate will apply, as of approximately 10:00 A.M. (New York time)
on the Interest Determination Date divided by (ii) a percentage equal to 100%
minus the then stated maximum rate of all reserve requirements (including,
without limitation, any marginal, emergency, supplemental, special or other
reserves) applicable to any member bank of the Federal Reserve System in respect
of Eurocurrency liabilities as defined in Regulation D (or any successor
category of liabilities under Regulation D). The determination of the Eurodollar
Rate by the Administrative Agent shall be conclusive and binding on the
Borrowers absent demonstrable error.

            "Euro Equivalent" shall mean, at any time for the determination
thereof, the amount of Euros which could be purchased with the amount of Dollars
involved in such computation at the spot rate of exchange therefor as quoted by
the Administrative Agent as of 11:00 A.M. (New York time) on the date two
Business Days prior to the date of any determination thereof for purchase on
such date with respect to Euro Denominated Revolving Loans and on the date of
any determination thereof for purchase on such date with respect to Euro
Denominated Swingline Loans (or, in the case of any determination pursuant to
Section 1.14 or 13.22 of this Agreement or Section 26 (or any analogous
provision) of any Subsidiaries Guaranty, on the date of determination).

            "Euro L/C Stated Amount" of each Euro Denominated Letter of Credit
shall, at any time, mean the maximum amount available to be drawn thereunder
(expressed in Euros) (in

                                     -134-

<PAGE>

each case determined without regard to whether any conditions to drawing could
then be met, but after giving effect to all previous drawings made thereunder).

            "Euro LIBOR" shall mean, with respect to each Borrowing of Euro
Denominated Revolving Loans, (i) the rate per annum for deposits in Euros as
determined by the Administrative Agent for a period corresponding to the
duration of the relevant Interest Period which appears on Reuters Page
EURIBOR-01 (or any successor page) at approximately 11:00 A.M. (Brussels time)
on the date which is two Business Days prior to the commencement of such
Interest Period or (ii) if such rate is not shown on Reuters Page EURIBOR-01 (or
any successor page), the average offered quotation to prime banks in the
Euro-zone interbank market by the Administrative Agent for Euro deposits of
amounts comparable to the principal amount of the Euro Denominated Loan to be
made by the Administrative Agent as part of such Borrowing (or, if the
Administrative Agent is not a Lender with respect thereto, taking the average
principal amount of the Euro Denominated Loan then being made by the various
Lenders) with maturities comparable to the Interest Period to be applicable to
such Loan (rounded upward to the next whole multiple of 1/16 of 1%), determined
as of 11:00 A.M. (Brussels time) on the date which is two Business Days prior to
the commencement of such Interest Period; provided that in the event the
Administrative Agent has made any determination pursuant to Section 1.10(a)(i)
in respect of Loans denominated in Euros, or in the circumstances described in
clause (i) to the proviso to Section 1.10(b) in respect of Loans denominated in
Euros, Euro LIBOR determined pursuant to this definition shall instead be the
rate determined by the Administrative Agent as the all-in-cost of funds for the
Administrative Agent (or such other Lender) to fund a Borrowing of Loans
denominated in Euros with maturities comparable to the Interest Period
applicable thereto.

            "European Borrower" shall have the meaning provided in the first
paragraph of this Agreement.

            "European Borrower Dollar Term Loan" shall mean have the meaning
provided in Section 1.01(b).

            "European Borrower Dollar Term Loan Commitment" shall mean, with
respect to each Lender, the amount set forth opposite such Lender's name in
Schedule I directly below the column entitled "European Borrower Dollar Term
Loan Commitment", as the same may be terminated pursuant to Sections 3.03 and/or
10.

            "European Borrower Dollar Term Loan Scheduled Repayment" shall have
the meaning provided in Section 4.02(b)(ii).

            "European Borrower Dollar Term Note" shall have the meaning provided
in Section 1.05(a).

            "European Borrower Euro Term Loan" shall have the meaning provided
in Section 1.01(c).

            "European Borrower Euro Term Loan Commitment" shall mean, with
respect to each Lender, the amount set forth opposite such Lender's name in
Schedule I directly below the column entitled "European Borrower Euro Term Loan
Commitment", as the same may be terminated pursuant to Sections 3.03 and/or 10.

                                     -135-

<PAGE>

            "European Borrower Euro Term Loan Scheduled Repayment" shall have
the meaning provided in Section 4.02(b)(iii).

            "European Borrower Euro Term Note" shall have the meaning provided
in Section 1.05(a).

            "European Borrower Letter of Credit" shall mean each Letter of
Credit (which may be denominated in Dollars or Euros) issued for the account of
the European Borrower pursuant to Section 2.01 and designated as such by the
European Borrower in the respective Letter of Credit Request.

            "European Borrower Multicurrency Facility Revolving Loan" shall have
the meaning provided in Section 1.01(d).

            "European Borrower Multicurrency Facility Revolving Note" shall have
the meaning provided in Section 1.05(a).

            "European Borrower Swingline Loan" shall have the meaning provided
in Section 1.01(e).

            "European Borrower Swingline Note" shall have the meaning provided
in Section 1.05(a).

            "European Borrower Term Loans" shall mean the European Borrower
Dollar Term Loans and the European Borrower Euro Term Loans.

            "European Receivables Facility" shall mean the facility under which
receivables are sold or pledged pursuant to (i) those certain receivables sale
agreements or receivables securitization deeds, in each case dated as of May 24,
2002, between certain Subsidiaries of Exide Holding Europe S.A., as sellers,
Exide Holding Europe S.A., as offer agent, Batteries Funding Limited, as buyer,
and Citibank, N.A., London Branch, as operating agent; (ii) that certain amended
- receivables subrogation agreement, dated as of May 24, 2002, among CEAC,
Compagnie Europeenne D'Accumulateurs S.A.S., as originator, Exide Holding Europe
S.A., as offer agent, Exide Europe Funding Ltd., as purchaser, and Citibank,
N.A. London Branch, as operating agent; (iii) that certain onward receivables
sale agreement, dated as of May 24, 2002, among Exide Europe Funding Ltd., as
seller, Exide Holding Europe S.A., as offer agent, Batteries Funding Ltd., as
buyer, and Citibank, N.A., London Branch, as operating agent; (iv) that certain
amended and restated receivables sale agreement, dated as of May 24, 2002, by
and among Exide Italia S.r.l., as seller, Archimede Securitisation S.r.l., as
buyer, Exide Holding Europe S.A., as offer agent, and Citibank, N.A., as
operating agent and as allocation agent; (v) that certain onward sale agreement,
dated as of May 24, 2002, among Archimede Securitisation S.r.l., London Branch,
as onward seller, Batteries Funding Limited, as onward buyer, and Citibank,
N.A., London Branch, as operating agent; and (vi) that certain term and
revolving facilities agreement, dated as of May 24, 2002, by and among Batteries
Funding Limited, as borrower, certain financial institutions party thereto, as
lenders, and Citibank, N.A. London Branch, as agent and arranger, in each case
as amended, restated, modified and/or supplemented prior to the date of this
Agreement.

                                     -136-

<PAGE>

            "Euro Rate" shall mean and include each of the Eurodollar Rate, Euro
LIBOR and the Overnight Euro Rate.

            "Euro Rate Loan" shall mean each Eurodollar Loan and each Euro
Denominated Loan.

            "Euros" and the designation (euro) shall mean the currency
introduced on January 1, 1999 at the start of the third stage of European
economic and monetary union pursuant to the Treaty (expressed in euros).

            "Event of Default" shall have the meaning provided in Section 10.

            "Excess Cash Flow" shall mean, for any Excess Cash Flow Payment
Period, the remainder of (a) the sum (without duplication) of (i) the "net cash
provided by operating activities" as shown on the U.S. Borrower's "Consolidated
Statement of Cash Flows" as delivered with its financial statements for the
relevant Excess Cash Flow Payment Period pursuant to Section 8.01(c) and (ii)
any return of capital during such period in respect of Investments previously
made, or deemed made, by the U.S. Borrower and its Subsidiaries in Persons that
are not Subsidiaries of the U.S. Borrower pursuant to Section 9.05(xv), minus
(b) the sum of (i) the amount of Capital Expenditures made by the U.S. Borrower
and its Subsidiaries on a consolidated basis during such period to the extent
otherwise permitted under this Agreement (other than Capital Expenditures to the
extent financed with equity proceeds, Equity Interests, asset sale proceeds,
insurance proceeds or Indebtedness (other than with Multicurrency Facility
Revolving Loans or Swingline Loans)), (ii) the aggregate amount (on a
consolidated basis) of permanent principal payments of Indebtedness for borrowed
money of the U.S. Borrower and its Subsidiaries and the permanent repayment of
the principal component of Capitalized Lease Obligations of the U.S. Borrower
and its Subsidiaries (excluding (1) repayments made pursuant to the Refinancing,
(2) repayments with proceeds of asset sales or insurance, (3) payments with the
proceeds of Indebtedness or equity and (4) payments of Loans or other
Obligations, provided that repayments of Loans shall only be deducted in
determining Excess Cash Flow if such repayments were (x) required as a result of
a Scheduled Repayment under Section 4.02(b) or (y) made as a voluntary
prepayment pursuant to Section 4.01 with internally generated funds (but in the
case of a voluntary prepayment of Multicurrency Facility Revolving Loans or
Swingline Loans, only to the extent accompanied by a voluntary reduction to the
Total Multicurrency Facility Revolving Loan Commitment in an amount equal to
such repayment)) during such period, (iii) cash Investments made during such
period by the U.S. Borrower and its Subsidiaries in Persons that are not
Subsidiaries of the U.S. Borrower pursuant to Section 9.05(xv) and (iv) without
duplication of amounts deducted in the preceding clauses (b)(i), (ii) and (iii),
the amount of cash expended in respect of Permitted Acquisitions during such
period, except to the extent financed with equity proceeds, asset sale proceeds,
insurance proceeds or Indebtedness.

            "Excess Cash Flow Payment Period" shall mean, with respect to any
Excess Cash Payment Date, the immediately preceding Fiscal Year of the U.S.
Borrower.

                                     -137-

<PAGE>

            "Excess Cash Payment Date" shall mean the date occurring 90 days
after the last day of a Fiscal Year of the U.S. Borrower (commencing with the
Fiscal Year of the U.S. Borrower ended closest to March 31, 2005).

            "Exchange Act" shall mean the Securities Exchange Act of 1934, as
amended.

            "Exchange Percentage" shall mean, as to each Lender, a fraction,
expressed as a decimal, in each case determined on the date of occurrence of a
Sharing Event (but before giving effect to any actions to occur on such date
pursuant to Section 1.14) of which (a) the numerator shall be the sum of (i) the
Multicurrency Facility RL Percentage of such Lender of (x) the aggregate
outstanding principal of all Multicurrency Facility Revolving Loans and
Swingline Loans (taking the Dollar Equivalents of any amounts expressed in
currencies other than Dollars on the date of the occurrence of the Sharing
Event) and (y) the aggregate amount of Letter of Credit Outstandings and (ii)
the aggregate principal amount of all outstanding Term Loans of such Lender
(taking the Dollar Equivalent of any amounts expressed in currencies other than
Dollars on the date of the occurrence of the Sharing Event), and (b) the
denominator of which shall be the sum of (i) the sum of (x) the aggregate
outstanding principal of all Multicurrency Facility Revolving Loans and
Swingline Loans (taking the Dollar Equivalents of any amounts expressed in
currencies other than Dollars on the date of the occurrence of the Sharing
Event) and (y) the aggregate amount of Letter of Credit Outstandings, and (ii)
the aggregate principal amount of all outstanding Term Loans of all Lenders
(taking the Dollar Equivalent of any amounts expressed in currencies other than
Dollars on the date of the occurrence of the Sharing Event).

            "Exide B.V." shall mean Exide Holding Netherlands B.V.

            "Exide Italia" shall mean Exide Italia S.R.L.

            "Existing Indebtedness Agreements" shall have the meaning provided
in Section 5.14(v).

            "Existing Letters of Credit" shall have the meaning provided in
Section 2.01(d).

            "Existing Pre-Petition Credit Agreement" shall mean that certain
Amended and Restated Credit Agreement and Guarantee Agreement, dated as of
September 29, 2000, among the U.S. Borrower and various financial institutions,
as in effect on the Initial Borrowing Date.

            "Existing Senior Notes" shall mean the 10% senior notes due 2005
issued by Old Exide.

            "Facing Fee" shall have the meaning provided in Section 3.01(c).

            "Fair Market Value" shall mean, with respect to any asset, the price
at which a willing buyer, not an Affiliate of the seller, and a willing seller
who does not have to sell, would agree to purchase and sell such asset, as
determined in good faith by the board of directors or other governing body or,
pursuant to a specific delegation of authority by such board of directors or
governing body, a designated senior executive officer, of the U.S. Borrower, or
the Subsidiary of the U.S. Borrower selling such asset.

                                     -138-

<PAGE>

            "Federal Funds Rate" shall mean, for any period, a fluctuating
interest rate equal for each day during such period to the weighted average of
the rates on overnight Federal Funds transactions with members of the Federal
Reserve System arranged by Federal Funds brokers, as published for such day (or,
if such day is not a Business Day, for the next preceding Business Day) by the
Federal Reserve Lender of New York, or, if such rate is not so published for any
day which is a Business Day, the average of the quotations for such day on such
transactions received by the Administrative Agent from three Federal Funds
brokers of recognized standing selected by the Administrative Agent.

            "Fees" shall mean all amounts payable pursuant to, or referred to
in, Section 3.01.

            "Fiat Factoring Agreement" shall mean, collectively, those certain
letter agreements, each dated May 7, 1997, between Exide Italia (as successor by
merger to Societa Industriale Accumulatori) and Savafactoring S.p.A. regarding
the sale of receivables by Exide Italia to Savafactoring S.p.A.

            "Fiscal Quarter" means for any Fiscal Year of the U.S. Borrower and
its Subsidiaries, the fiscal quarters ending on, each of June 30, September 30,
December 31 and March 31.

            "Fiscal Year" means the fiscal year of the U.S. Borrower ending on
March 31 of each calendar year. For purposes of this Agreement, any particular
Fiscal Year shall be designated by reference to the calendar year in which such
Fiscal Year ends (e.g., Fiscal Year 2004 shall be the fiscal year of the U.S.
Borrower ended March 31, 2004).

            "Fleet Securities" shall mean Fleet Securities, Inc.

            "Foreign Credit Party" shall mean the European Borrower and each
Foreign Subsidiary Guarantor.

            "Foreign Credit Party Pledge Agreement" shall have the meaning
provided in Section 5.10(b).

            "Foreign Mortgaged Property" shall mean each Real Property located
outside the United States and the States and territories thereof with respect to
which a Mortgage is required to be delivered pursuant to the terms of this
Agreement.

            "Foreign Pension Plan" means any plan, fund (including, without
limitation, any superannuation fund) or other similar program established or
maintained outside the United States of America by the U.S. Borrower or any one
or more of its Subsidiaries primarily for the benefit of employees of the U.S.
Borrower or any of its Subsidiaries residing outside the United States of
America, which plan, fund or other similar program provides, or results in,
retirement income, a deferral of income in contemplation of retirement or
payments to be made upon termination of employment, and which plan is not
subject to ERISA or the Code.

            "Foreign Pledge Agreement" shall have the meaning provided in
Section 5.10(c).

            "Foreign Security Agreement" shall have the meaning provided in
Section 5.12.

                                     -139-

<PAGE>

            "Foreign Security Document" shall mean each Security Document other
than a U.S. Security Document.

            "Foreign Subsidiaries Guaranties" shall have the meaning provided in
Section 5.09(b) and shall include any counterpart thereof and any other similar
guaranty executed and delivered by any Foreign Subsidiary of the U.S. Borrower
pursuant to Section 8.11, 8.12 or 9.16.

            "Foreign Subsidiary" shall mean, as to any Person, any Subsidiary of
such Person that is not a Domestic Subsidiary of such Person.

            "Foreign Subsidiary Guarantor" shall mean each Foreign Subsidiary of
the U.S. Borrower (other than the European Borrower and any Non-Guarantor
Subsidiary) which executes and delivers a Foreign Subsidiaries Guaranty, unless
and until such time as the respective Foreign Subsidiary ceases to constitute a
Foreign Subsidiary or is released from all of its obligations under its Foreign
Subsidiaries Guaranty in accordance with the terms and provisions thereof.

            "French Collateral Documents" shall have the meaning provided in
Section 12.14(a).

            "General Unsecured Claims" shall have the meaning provided in the
Plan of Reorganization.

            "German Security" shall mean the assets of the U.S. Borrower and its
Subsidiaries which are subject to a Foreign Security Document governed by the
laws of Germany.

            "Guaranteed Creditors" shall mean and include each of the Agents,
the Lenders, each Issuing Lender and each Person (other than any Credit Party or
any of its Subsidiaries) party to an Interest Rate Protection Agreement or Other
Hedging Agreement to the extent that such Person constitutes a Secured Creditor
under the Security Documents.

            "Guarantors" shall mean and include the U.S. Borrower, the European
Borrower and each Subsidiary Guarantor.

            "Guaranty" shall mean and include the U.S. Borrower's Guaranty and
each Subsidiaries Guaranty.

            "Hazardous Materials" shall mean (a) any petrochemical or petroleum
products, radioactive materials, asbestos in any form that is or could become
friable, urea formaldehyde foam insulation, transformers or other equipment that
contain dielectric fluid containing levels of polychlorinated biphenyls, and
radon gas; and (b) any chemicals, materials, substances or mixtures defined as
or included in the definition of "hazardous substances", "hazardous wastes",
"hazardous materials", "restricted hazardous materials", "extremely hazardous
substances", "restrictive hazardous wastes", "toxic substances", "toxic
pollutants", "contaminants" or "pollutants", or words of similar meaning and
regulatory effect.

            "Highest Adjustable Applicable Margins" shall have the meaning
provided in the definition of Applicable Margin contained herein.

                                     -140-

<PAGE>

            "Indebtedness" shall mean, as to any Person, without duplication,
(i) all indebtedness of such Person for borrowed money or for the deferred
purchase price of property or services, (ii) the maximum amount available to be
drawn or paid under all letters of credit, bankers' acceptances, bank
guaranties, surety and appeal bonds and similar obligations issued for the
account of such Person and all unpaid drawings and unreimbursed payments in
respect of such letters of credit, bankers' acceptances, bank guaranties, surety
and appeal bonds and similar obligations, (iii) all indebtedness of the types
described in clause (i), (ii), (iv), (v), (vi), (vii) or (viii) of this
definition secured by any Lien on any property owned by such Person, whether or
not such indebtedness has been assumed by such Person (provided that, if the
Person has not assumed or otherwise become liable in respect of such
indebtedness, such indebtedness shall be deemed to be in an amount equal to the
fair market value of the property to which such Lien relates as determined in
good faith by such Person), (iv) the aggregate amount of all Capitalized Lease
Obligations of such Person, (v) all obligations of such Person to pay a
specified purchase price for goods or services, whether or not delivered or
accepted, i.e., take-or-pay and similar obligations, (vi) all Contingent
Obligations of such Person, (vii) all obligations under any Interest Rate
Protection Agreement, any Other Hedging Agreement, Commodity Agreements or under
any similar type of agreement and (viii) all Off-Balance Sheet Liabilities of
such Person. Notwithstanding the foregoing, Indebtedness shall not include trade
payables, accrued expenses and deferred tax and other credits incurred by any
Person in accordance with customary practices and in the ordinary course of
business of such Person.

            "Indebtedness to be Refinanced" shall mean and include (without
duplication) (i) Indebtedness under the DIP Credit Agreement and (ii) all other
Indebtedness of the U.S. Borrower and its Subsidiaries which is to be repaid or
refinanced on the Initial Borrowing Date, including any such Indebtedness which
is not permitted to remain outstanding after the Initial Borrowing Date pursuant
to Section 5.08 or 9.04. Without limiting the foregoing, it is understood and
agreed that the aggregate amount of the "Indebtedness to be Refinanced" shall
not exceed $461,000,000.

            "Individual European Borrower Multicurrency Facility RL Exposure" of
any Multicurrency Facility RL Lender shall mean, at any time, the sum of (I) the
aggregate principal amount of all European Borrower Multicurrency Facility
Revolving Loans made by such Multicurrency Facility RL Lender and then
outstanding (for this purpose, using the Dollar Equivalent of the principal
amount of all Euro Denominated Revolving Loans made to the European Borrower and
then outstanding), (II) such Multicurrency Facility RL Lender's L/C
Participation Percentage in each then outstanding European Borrower Letter of
Credit multiplied by the sum of the Stated Amount of the respective European
Borrower Letter of Credit and any Unpaid Drawings relating thereto (for this
purpose, using the Dollar Equivalent of any amounts expressed in Euros), and
(III) such Multicurrency Facility RL Lender's Multicurrency Facility RL
Percentage multiplied by the aggregate principal amount of outstanding European
Borrower Swingline Loans (for this purpose, using the Dollar Equivalent of the
principal amount of Euro Denominated Swingline Loans made to the European
Borrower and then outstanding).

            "Individual Multicurrency Facility RL Exposure" of any Multicurrency
Facility RL Lender shall mean, at any time, the sum of (I) the aggregate
principal amount of all Multicurrency Facility Revolving Loans made by such
Multicurrency Facility RL Lender and then outstanding (for this purpose, using
the Dollar Equivalent of the principal amount of all

                                     -141-

<PAGE>

Euro Denominated Revolving Loans then outstanding), (II) such Multicurrency
Facility RL Lender's L/C Participation Percentage in each then outstanding
Letter of Credit multiplied by the sum of the Stated Amount of the respective
Letter of Credit and any Unpaid Drawings relating thereto (for this purpose,
using the Dollar Equivalent of any amounts expressed in Euros) and (III) such
Multicurrency Facility RL Lender's Multicurrency Facility RL Percentage
multiplied by the aggregate principal amount of outstanding Swingline Loans (for
this purpose, using the Dollar Equivalent of the principal amount of Euro
Denominated Swingline Loans then outstanding).

            "Individual U.S. Borrower Multicurrency Facility RL Exposure" of any
Multicurrency Facility RL Lender shall mean, at any time, the sum of (I) the
aggregate principal amount of all U.S. Borrower Multicurrency Facility Revolving
Loans made by such Multicurrency Facility RL Lender and then outstanding (for
this purpose, using the Dollar Equivalent of the principal amount of all Euro
Denominated Revolving Loans made to the U.S. Borrower and then outstanding),
(II) such Multicurrency Facility RL Lender's L/C Participation Percentage in
each then outstanding U.S. Borrower Letter of Credit multiplied by the sum of
the Stated Amount of the respective U.S. Borrower Letter of Credit and any
Unpaid Drawings relating thereto (for this purpose, using the Dollar Equivalent
of any amounts expressed in Euros) and (III) such Multicurrency Facility RL
Lender's Multicurrency Facility RL Percentage multiplied by the aggregate
principal amount of outstanding U.S. Borrower Swingline Loans (for this purpose,
using the Dollar Equivalent of the principal amount of Euro Denominated
Swingline Loans made to the U.S. Borrower and then outstanding).

            "Initial Borrowing Date" shall mean the date (which shall occur on
the Effective Date) upon which the initial Borrowing of Loans occurs.

            "Intercompany Debt" shall mean any Indebtedness, payables or other
obligations (including without limitation all the Intercompany Loans), whether
now existing or hereafter incurred, owed by the U.S. Borrower or any Subsidiary
of the U.S. Borrower to the U.S. Borrower or any other Subsidiary of the U.S.
Borrower.

            "Intercompany Loans" shall have the meaning provided in Section
5.08(b).

            "Intercompany Note" shall mean a promissory note evidencing
intercompany loans made pursuant to Section 9.05(vi), in each case duly executed
and delivered substantially in the form of Exhibit L, with blanks completed in
conformity herewith (or such other form as may be approved by the Administrative
Agent or the Required Lenders).

            "Intercompany Scheduled Existing Indebtedness" shall have the
meaning provided in Section 7.21.

            "Intercompany Subordination Agreement" shall have the meaning
provided in Section 5.09(c).

            "Interest Determination Date" shall mean, with respect to any Euro
Rate Loan (other than a Swingline Loan), the second Business Day prior to the
commencement of any Interest Period relating to such Euro Rate Loan.

                                     -142-

<PAGE>

            "Interest Period" with respect to any Euro Rate Loan, shall mean the
interest period applicable thereto, as determined pursuant to Section 1.09.

            "Interest Rate Protection Agreement" shall mean any interest rate
swap agreement, interest rate cap agreement, interest rate collar agreement,
interest rate hedging agreement, interest rate floor agreement or other similar
agreement or arrangement.

            "Investment" shall have the meaning provided in the preamble to
Section 9.05.

            "Issuing Lender" shall mean DBAG (and/or any affiliate of DBAG
designated by it) and any Multicurrency Facility RL Lender (and/or any affiliate
of such Multicurrency Facility RL Lender designated by it) which at the request
of an Account Party and with the consent of the Administrative Agent agrees, in
such Multicurrency Facility RL Lender's (or affiliate's) sole discretion, to
become an Issuing Lender for the purpose of issuing Letters of Credit pursuant
to Section 2.

            "Italian Collateral Documents" shall have the meaning provided in
Section 12.18(a).

            "Judgment Currency" shall have the meaning provided in Section
13.22(a).

            "Judgment Currency Conversion Date" shall have the meaning provided
in Section 13.23(a).

            "L/C Participant" shall have the meaning provided in Section
2.04(a).

            "L/C Participation Percentages" shall have the meaning provided in
Section 2.04(a).

            "L/C Supportable Indebtedness" shall mean (i) obligations of the
U.S. Borrower or its Wholly-Owned Subsidiaries incurred in the ordinary course
of business with respect to insurance obligations and workers' compensation,
surety bonds and other similar statutory obligations, (ii) obligations of the
U.S. Borrower and its Wholly-Owned Subsidiaries under bank guaranties issued by
financial institutions in support of obligations of the U.S. Borrower and its
Wholly-Owned Subsidiaries otherwise permitted to exist pursuant to the terms of
this Agreement and (iii) such other obligations of the U.S. Borrower or any of
its Wholly-Owned Subsidiaries as are reasonably acceptable to the Administrative
Agent and the respective Issuing Lender and otherwise permitted to exist
pursuant to the terms of this Agreement.

            "Leasehold" of any Person shall mean all of the right, title and
interest of such Person as lessee or licensee in, to and under leases or
licenses of land, improvements and/or fixtures.

            "Lender" shall mean and include (i) each financial institution with
a Commitment listed on Schedule I (as amended from time to time), as well as any
Person that becomes a "Lender" hereunder pursuant to Section 1.13 and/or
13.04(b) and (ii) the Swingline Lender. Unless the context otherwise requires,
each reference in this Agreement to a Lender includes

                                     -143-

<PAGE>

each lending office (including any Affiliate of the respective Lender) of the
respective Lender designated from time to time pursuant to Section 1.12.

            "Lender Default" shall mean (i) the wrongful refusal (which has not
been retracted) of a Lender to make available its portion of any Borrowing
(including any Mandatory Borrowing) or to fund its portion of any unreimbursed
payment under Section 2.04 or (ii) a Lender having notified the Administrative
Agent and/or either Borrower that it does not intend to comply with its
obligations under Section 1.01 or 2.03 in circumstances where such
non-compliance would constitute a breach of such Lender's obligations under the
respective Section.

            "Letter of Credit" shall have the meaning provided in Section
2.01(a).

            "Letter of Credit Fees" shall have the meaning provided in Section
3.01(b).

            "Letter of Credit Outstandings" shall mean, at any time, the sum of
(i) the aggregate Stated Amount of all outstanding Letters of Credit which have
not terminated at such time and (ii) the aggregate amount of all Unpaid Drawings
(taking the Dollar Equivalent of any amounts owed in currencies other than
Dollars) in respect of all Letters of Credit at such time.

            "Letter of Credit Request" shall have the meaning provided in
Section 2.03(a).

            "Leverage Ratio" shall mean, on any date of determination, the ratio
of (i) Consolidated Debt on such date to (ii) Consolidated EBITDA for the Test
Period most recently ended on or prior to such date; provided that for all
purposes of this Agreement, (i) Consolidated EBITDA for purposes of the Leverage
Ratio shall be determined on a Pro Forma Basis in accordance with clause (iv) of
the definition of Pro Forma Basis contained herein and (ii) Consolidated Debt
for purposes of the Leverage Ratio as it relates to the definition of
"Applicable Margin" shall be determined on a Pro Forma Basis in accordance with
clause (iii) of the definition of "Pro Forma Basis" contained herein.

            "Lien" shall mean any mortgage, pledge, hypothecation, assignment,
deposit arrangement, security interest, encumbrance, lien (statutory or other),
charge, preference, priority or other security agreement of any kind or nature
whatsoever (including any agreement to give any of the foregoing, any
conditional sale or other title retention agreement, any financing or similar
statement or notice filed under the UCC or any similar recording or notice
statute, and any lease having substantially the same effect as the foregoing).

            "Loan" shall mean each U.S. Borrower Term Loan, each European
Borrower Dollar Term Loan, each European Borrower Euro Term Loan, each
Multicurrency Facility Revolving Loan and each Swingline Loan.

            "Local Law Pledge Agreement" shall have the meaning provided in
Section 5.10(c).

            "Majority Lenders" of any Tranche shall mean those Non-Defaulting
Lenders which would constitute the Required Lenders under, and as defined in,
this Agreement if all outstanding Obligations of the other Tranches under this
Agreement were repaid in full and all Commitments with respect thereto were
terminated.

                                     -144-

<PAGE>

            "Management Agreements" shall have the meaning provided in Section
5.14.

            "Mandatory Borrowing" shall have the meaning provided in Section
1.01(f).

            "Mandatory Cost" means the cost imputed to each Lender of compliance
with any reserve asset requirements of the European Central Bank.

            "Maple Ontario Property Sale" shall mean the sale by Exide Canada,
Inc. to Zafir Holdings Inc. of the real property and buildings located thereon
having the municipal address of 8301 Keele Street, Maple, Ontario L64 1T2,
Canada pursuant to a final judgment issued by the Ontario Superior Court of
Justice, which judgment shall not have been vacated, discharged or stayed or
pursuant to a reasonable settlement agreement between Exide Canada, Inc. and
Zafir Holdings Inc.

            "Margin Stock" shall have the meaning provided in Regulation U.

            "Material Adverse Effect" shall mean (i) a material adverse effect
on the business, properties, assets, nature of assets, operations, liabilities,
financial condition or prospects of the U.S. Borrower and its Subsidiaries taken
as a whole, or (ii) a material adverse effect (x) on the rights or remedies of
the Lenders or any Agent hereunder or under any other Credit Document or (y) on
the ability of any Credit Party to perform its obligations to the Lenders or any
Agent hereunder or under any other Credit Document.

            "Material Foreign Subsidiary" shall mean, at any time, any Foreign
Subsidiary of the U.S. Borrower the net book value of the assets of which equals
or exceeds $5,000,000 at such time.

            "Maturity Date" shall mean (i) with respect to U.S. Borrower Term
Loans and European Borrower Term Loans, the Term Loan Maturity Date, (ii) with
respect to Multicurrency Facility Revolving Loans, the Revolving Loan Maturity
Date and (iii) with respect to Swingline Loans, the Swingline Expiry Date.

            "Maximum Permitted Consideration" shall mean, with respect to any
Permitted Acquisition, the sum (without duplication) of (i) the fair market
value of the U.S. Borrower Common Stock (based on the average closing trading
price of the U.S. Borrower Common Stock for the 20 trading days immediately
prior to the date of such Permitted Acquisition on the stock exchange on which
the U.S. Borrower Common Stock is listed or, if U.S. Borrower Common Stock is
not so listed, the good faith determination of the senior management of the U.S.
Borrower) issued (or to be issued) as consideration in connection with such
Permitted Acquisition (including, without limitation, U.S. Borrower Common Stock
which may be required to be issued as earnout consideration upon the achievement
of certain future performance goals of the respective Acquired Entity or
Business), (ii) the aggregate amount of all cash paid (or to be paid) by the
U.S. Borrower or any of its Subsidiaries in connection with such Permitted
Acquisition (including, without limitation, payments of fees and costs and
expenses in connection therewith) and all contingent cash purchase price or
other earnout obligations of the U.S. Borrower and its Subsidiaries incurred in
connection therewith (as determined in good faith by the U.S. Borrower), (iii)
the aggregate principal amount of all Indebtedness assumed, incurred and/or
issued in connection with such Permitted Acquisition to

                                     -145-

<PAGE>

the extent permitted by Section 9.04 and (iv) the fair market value (determined
in good faith by senior management of the U.S. Borrower) of all other
consideration payable in connection with such Permitted Acquisition.

            "Maximum Swingline Amount" shall mean $25,000,000.

            "Mercolec" shall mean Mercolec Tudor B.V.

            "Minimum Applicable Facing Fee" shall mean, in the case of all
Letters of Credit, $500.

            "Minimum Borrowing Amount" shall mean (i) in the case of Dollar
Denominated Loans (excluding Dollar Denominated Swingline Loans and Dollar
Denominated Revolving Loans maintained as Base Rate Loans), $5,000,000, (ii) in
the case of Multicurrency Facility Revolving Loans maintained from time to time
as Base Rate Loans, $1,000,000, (iii) in the case of Euro Denominated Loans
(other than Euro Denominated Swingline Loans), (euro)1,000,000, (iv) in the case
of Dollar Denominated Swingline Loans, $250,000 and (v) in the case of Euro
Denominated Swingline Loans, (euro)250,000.

            "Moody's" shall mean Moody's Investors Service, Inc.

            "Mortgage" shall mean each mortgage, deed of trust or deed to secure
debt required to be delivered with respect to any Real Property pursuant to the
terms of this Agreement (including, after the execution and delivery thereof,
each Additional Mortgage), together with any assignment of leases and rents to
be executed in connection therewith (as amended, modified or supplemented from
time to time in accordance with the terms hereof and thereof).

            "Mortgage Policy" shall mean each mortgage title insurance policy
(and all endorsements thereto) for each Mortgaged Property required to be
delivered pursuant to this Agreement.

            "Mortgaged Property" shall mean each Real Property owned by the U.S.
Borrower or any of its Subsidiaries and required to be mortgaged pursuant to
this Agreement (including, after the execution and delivery of any Additional
Mortgage, the respective Additional Mortgaged Property).

            "Multicurrency Facility Revolving Loan" shall have the meaning
provided in Section 1.01(d).

            "Multicurrency Facility Revolving Loan Commitment" shall mean, for
each Lender, the amount set forth opposite such Lender's name on Schedule I
hereto directly below the column entitled "Multicurrency Facility Revolving Loan
Commitment", as same may be (x) reduced from time to time and/or terminated
pursuant to Section 3.02, 3.03, 4.02 and/or 10, or (y) adjusted from time to
time as a result of assignments to or from such Lender pursuant to Section 1.13
or 13.04(b).

                                     -146-

<PAGE>

            "Multicurrency Facility RL Lender" shall mean each Lender which has
a Multicurrency Facility Revolving Loan Commitment (without giving effect to any
termination of the Total Multicurrency Facility Revolving Loan Commitment if any
Swingline Loans or Letter of Credit Outstandings remain outstanding) or which
has any outstanding Multicurrency Facility Revolving Loans (or an L/C
Participation Percentage in any then outstanding Letter of Credit Outstandings).

            "Multicurrency Facility RL Percentage" of any Multicurrency Facility
RL Lender at any time shall be that percentage which is equal to a fraction
(expressed as a percentage) the numerator of which is the Multicurrency Facility
Revolving Loan Commitment of such Multicurrency Facility RL Lender at such time
and the denominator of which is the Total Multicurrency Facility Revolving Loan
Commitment at such time, provided that if any such determination is to be made
after the Total Multicurrency Facility Revolving Loan Commitment (and the
related Multicurrency Facility Revolving Loan Commitments of the Lenders) has
(or have) terminated, the determination of such percentages shall be made
immediately before giving effect to such termination.

            "Multiemployer Plan" shall mean (i) any plan, as defined in Section
4001(a)(3) of ERISA, which is maintained or contributed to (or to which there is
an obligation to contribute to) by the U.S. Borrower or a Subsidiary of the U.S.
Borrower or an ERISA Affiliate and that is subject to Title IV of ERISA, and
(ii) each such plan for the five year period immediately following the latest
date on which the U.S. Borrower, a Subsidiary of the U.S. Borrower or an ERISA
Affiliate maintained, contributed to or had an obligation to contribute to such
plan.

            "Net Cash Proceeds" shall mean for any event requiring a reduction
of the Total Multicurrency Facility Revolving Loan Commitment and/or repayment
of Term Loans pursuant to Section 3.03 or 4.02, as the case may be, the gross
cash proceeds (including any cash received by way of deferred payment pursuant
to a promissory note, receivable or otherwise, but only as and when received)
received from such event, net of reasonable transaction costs (including, as
applicable, any underwriting, brokerage or other customary commissions and
reasonable legal, advisory and other fees and expenses associated therewith)
received from any such event.

            "Net Sale Proceeds" shall mean for any sale or other disposition of
assets, the gross cash proceeds (including any cash received by way of deferred
payment pursuant to a promissory note, receivable or otherwise, but only as and
when received), received from such sale or other disposition of assets, net of
(without duplication) (i) reasonable transaction costs (including, without
limitation, any underwriting, brokerage or other customary selling commissions,
reasonable legal, advisory and other fees and expenses (including title and
recording expenses), associated therewith and sales, VAT and transfer taxes
arising therefrom), (ii) payments of unassumed liabilities (other than
Environmental Claims) relating to the assets sold or otherwise disposed of at
the time of, or within 30 days after, the date of such sale or other
disposition, (iii) the amount of such gross cash proceeds required to be used to
permanently repay any Indebtedness (other than amounts owed to pre-petition
creditors pursuant to the Plan of Reorganization and Indebtedness of the Lenders
pursuant to this Agreement) which is secured by the respective assets which were
sold or otherwise disposed of and (iv) the estimated net marginal increase in
income taxes which will be payable by the U.S. Borrower's consolidated group or
any Subsidiary of the U.S. Borrower with respect to the Fiscal Year in which the
sale or

                                     -147-

<PAGE>

other disposition occurs as a result of such sale or other disposition;
provided, however, that such gross proceeds shall not include any portion of
such gross cash proceeds which the U.S. Borrower determines in good faith should
be reserved (x) for post-closing adjustments to occur within 180 days after the
date of the respective sale or disposition or (y) to pay unassumed Environmental
Claims (to the extent not indemnified by the respective purchaser) relating to
the assets sold or otherwise disposed of which are expected to be paid or spent
within 180 days after the date of the respective sale or disposition (in each
case, to the extent the U.S. Borrower delivers to the Lenders a certificate
signed by its chief financial officer or treasurer, controller or chief
accounting officer as to such determination), it being understood and agreed
that (i) in the case of preceding clause (x), on the earlier of the 180th day
after the respective sale or disposition or the day that all such post-closing
adjustments have been determined (which shall not be later than six months
following the date of the respective asset sale), the amount (if any) by which
the reserved amount for post-closing adjustments in respect of such sale or
disposition exceeds the actual post-closing adjustments paid by the U.S.
Borrower and its Subsidiaries shall constitute Net Sale Proceeds on such date
received by the U.S. Borrower and/or any of its Subsidiaries from such sale or
other disposition and (ii) in the case of preceding clause (y), on the earlier
of the 180th day after the date of the respective sale or disposition or the day
that all retained Environmental Claims relating thereto have been paid or
finally determined, the amount (if any) by which the reserved amount in respect
of such Environmental Claims from such sale or disposition exceeds the actual
amounts paid by the U.S. Borrower and its Subsidiaries with respect thereto
shall constitute Net Sale Proceeds on such date received by the U.S. Borrower
and/or any of its Subsidiaries from such sale or disposition.

            "Netherlands Forms" shall have the meaning provided in Section
4.02(c).

            "Non-Defaulting Lender" shall mean each Lender other than a
Defaulting Lender.

            "Non-Guarantor Subsidiaries" shall mean (i) on the Initial Borrowing
Date, each Subsidiary of the U.S. Borrower listed on Part A of Schedule XII and
(ii) after the Initial Borrowing Date, any Subsidiary of the U.S. Borrower that
is not at such time a Subsidiary Guarantor.

            "Non-Wholly Owned Subsidiary" shall mean, as to any Person, each
Subsidiary of such Person which is not a Wholly-Owned Subsidiary of such Person.

            "Nordic Subsidiaries" shall mean, collectively, (i) Exide Sonnak A/S
and its Subsidiaries, (ii) Tudor AB and its Subsidiaries, (iii) Exide OY and its
Subsidiaries, (iv) Exide Batterier AB and its Subsidiaries and (v) any other
Wholly-Owned Foreign Subsidiary of the U.S. Borrower formed under the laws of
Denmark, Finland, Sweden or Norway.

            "Note" shall mean each U.S. Borrower Term Note, each European
Borrower Dollar Term Note, each European Borrower Euro Term Note, each U.S.
Borrower Multicurrency Facility Revolving Note, each European Borrower
Multicurrency Facility Revolving Note, the U.S. Borrower Swingline Note and the
European Borrower Swingline Note.

            "Notice of Borrowing" shall have the meaning provided in Section
1.03(a).

                                     -148-

<PAGE>

            "Notice of Confirmation" shall mean the notice from the Bankruptcy
Court confirming the Plan of Reorganization pursuant to Sections 1128 and 1129
of the Bankruptcy Code entered on April 21, 2004.

            "Notice of Conversion/Continuation" shall have the meaning provided
in Section 1.06.

            "Notice Office" shall mean the office of the Administrative Agent
located at 60 Wall Street, New York, New York 10005 or such other office as the
Administrative Agent may designate to the U.S. Borrower and the Lenders from
time to time.

            "Obligation Currency" shall have the meaning provided in Section
13.22(a).

            "Obligations" shall mean all amounts, direct or indirect,
contingent or absolute, of every type or description, and at any time existing,
owing to any Agent, any Issuing Lender or any Lender pursuant to the terms of
this Agreement or any other Credit Document.

            "Off-Balance Sheet Liabilities" of any Person shall mean (i) any
repurchase obligation or liability of such Person with respect to accounts or
notes receivable sold by such Person, (ii) any liability of such Person under
any sale and leaseback transactions that do not create a liability on the
balance sheet of such Person, (iii) any obligation under a Synthetic Lease or
(iv) any obligation arising with respect to any other transaction which is the
functional equivalent of or takes the place of borrowing but which does not
constitute a liability on the balance sheet of such Person.

            "Old Exide" shall mean Exide Technologies, a Delaware corporation
(as same existed before giving effect to the Plan of Reorganization).

            "Other Hedging Agreements" shall mean any foreign exchange
contracts, currency swap agreements or other similar agreements or arrangements
designed to protect against fluctuations in currency values.

            "Overnight Euro Rate" on any date shall mean the offered quotation
to first-class banks in the Euro-Zone interbank market by the Swingline Lender
for Euro overnight deposits of amounts in immediately available funds comparable
to the outstanding principal amount of the Euro Denominated Swingline Loan of
the Swingline Lender as of 11:00 A.M. (Brussels time) on such date; provided
that in the event the Administrative Agent has made any determination pursuant
to Section 1.10(a)(i) in respect of Euro Denominated Swingline Loans, or in the
circumstances described in clause (i) to the proviso to Section 1.10(b) in
respect of Euro Denominated Swingline Loans, the Overnight Euro Rate determined
pursuant to this definition shall instead be the rate determined by the
Swingline Lender as the all-in-cost of funds for the Swingline Lender to fund
such Euro Denominated Swingline Loan.

            "Payment Office" shall mean the office of the Administrative Agent
located at 60 Wall Street, New York, New York 10005 or such other office as the
Administrative Agent may hereafter designate in writing to the U.S. Borrower and
the Lenders from time.

                                     -149-

<PAGE>

            "PBGC" shall mean the Pension Benefit Guaranty Corporation
established pursuant to Section 4002 of ERISA, or any successor thereto.

            "Permitted Acquired Debt" shall have the meaning set forth in
Section 9.04(vi).

            "Permitted Acquisition" shall mean the acquisition by the U.S.
Borrower or any of its Wholly-Owned Subsidiaries of assets constituting a
business, division or product line of any Person, not already a Subsidiary of
the U.S. Borrower or any of its Wholly-Owned Subsidiaries, or of 100% of the
capital stock or other Equity Interests of any such Person, which Person shall,
as a result of such acquisition, become a Wholly-Owned Subsidiary of the U.S.
Borrower or such Wholly-Owned Subsidiary, provided that (A) the consideration
paid by the U.S. Borrower or such Wholly-Owned Subsidiary consists solely of
cash (including proceeds of Multicurrency Facility Revolving Loans), the
issuance of U.S. Borrower Common Stock, the issuance of Qualified Preferred
Stock, the incurrence of Indebtedness otherwise permitted pursuant to Section
9.04 and the assumption/acquisition of any Permitted Acquired Debt relating to
such business, division, product line or Person which is permitted to remain
outstanding in accordance with the requirements of Section 9.04, (B) in the case
of the acquisition of 100% of the capital stock or other Equity Interests of any
Acquired Entity or Business, such Acquired Entity or Business shall own no
capital stock or other Equity Interests of any other Person unless either (x)
the Acquired Entity or Business owns 100% of the capital stock or other Equity
Interests of such other Person or (y) if the Acquired Entity or Business owns
capital stock or Equity Interests in any other Person which is a Non-Wholly
Owned Subsidiary of the Acquired Entity or Business, (1) the Acquired Entity or
Business shall not have been created or established in contemplation of, or for
purposes of, the respective Permitted Acquisition, (2) such Non-Wholly Owned
Subsidiary of the Acquired Entity or Business shall have been a Non-Wholly Owned
Subsidiary of the Acquired Entity or Business prior to the date of the
respective Permitted Acquisition and not created or established in contemplation
thereof and (3) the Acquired Entity or Business and/or its Wholly-Owned
Subsidiaries own 80% of the consolidated assets of such Person and its
Subsidiaries, (C) the Acquired Entity or Business shall be a Permitted Business
and (D) all applicable requirements of Sections 8.11, 8.15, 9.02, 9.03 and 9.04
applicable to Permitted Acquisitions are satisfied. Notwithstanding anything to
the contrary contained in the immediately preceding sentence, an acquisition
which does not otherwise meet the requirements set forth above in the definition
of "Permitted Acquisition" shall constitute a Permitted Acquisition if, and to
the extent, the Required Lenders agree in writing that such acquisition shall
constitute a Permitted Acquisition for purposes of this Agreement.

            "Permitted Business" shall mean any business which (i) is the same,
similar, ancillary or reasonably related to the business in which the U.S.
Borrower or any of its Subsidiaries is engaged on the Effective Date or (ii) is
conducted by an Acquired Entity or Business acquired pursuant to a Permitted
Acquisition and which does not qualify as a "Permitted Business" pursuant to
preceding clause (i), so long as (x) such business represents an immaterial
portion of the businesses acquired pursuant to such Permitted Acquisition and
(y) such business is sold or otherwise disposed of as soon as reasonably
practicable following the consummation of such Permitted Acquisition (but, in
any event, within one year following such Permitted Acquisition).

                                     -150-
<PAGE>

                  "Permitted Encumbrances" shall mean, with respect to any
Mortgaged Property, such exceptions to title as are set forth in the Mortgage
Policy delivered with respect thereto, all of which exceptions must be
acceptable to the Administrative Agent in its reasonable discretion.

                  "Permitted Exceptions" shall have the meaning provided in
Section 5.13(a)(i).

                  "Permitted Holders" shall mean Angelo Gordon & Co. and its
controlled Affiliates, Black Diamond Capital Management LLC and its controlled
Affiliates, Citadel Investment Group, LLC and its controlled Affiliates, and R2
Investments and its controlled Affiliates.

                  "Permitted Liens" shall have the meaning provided in Section
9.03.

                  "Permitted Refinancing Indebtedness" shall mean any
Indebtedness of the U.S. Borrower and its Subsidiaries issued or given in
exchange for, or the proceeds of which are used to, extend, refinance, renew,
replace or refund any Scheduled Existing Indebtedness, Permitted Acquired Debt
or any Indebtedness issued to so extend, refinance, renew, replace, substitute
or refund any such Indebtedness, so long as (a) such Indebtedness has a weighted
average life to maturity greater than or equal to the weighted average life to
maturity of the Indebtedness being extended, refinanced, renewed, replaced or
refunded, (b) such extension, refinancing, renewal, replacement or refunding
does not (i) increase the amount of such Indebtedness outstanding immediately
prior to such extension, refinancing, renewal, replacement or refunding (other
than by the amount of any prepayment premium or fees owed in connection with the
refinancing of such Indebtedness) or (ii) add guarantors, obligors or security
from that which applied to such Indebtedness being extended, refinanced,
renewed, replacement or refunding, (c) such Indebtedness has substantially the
same (or, from the perspective of the Lenders, more favorable) subordination
provisions, if any, as applied to the Indebtedness being extended, renewed,
refinanced, replaced or refunded, and (d) all other terms of such extension,
refinancing, renewal, replacement or refunding (including, without limitation,
with respect to the amortization schedules, redemption provisions, maturities,
covenants, defaults and remedies) are not less favorable in any material respect
to the respective borrower than those previously existing with respect to the
Indebtedness being extended, refinanced, renewed, replaced or refunded,
provided, however, that any Intercompany Scheduled Existing Indebtedness (and
subsequent extensions, refinancings, renewals, replacements and refundings
thereof as provided above in this definition) may only be extended, refinanced,
renewed, replaced or refunded as provided above in this definition if the
Indebtedness so extended, refinanced, renewed, replaced or refunded has the same
obligors(s) and obligee(s) as the Indebtedness being extended, refinanced,
renewed, replaced or refunded.

                  "Person" shall mean any individual, partnership, joint
venture, firm, corporation, limited liability company, association, trust or
other enterprise or any government or political subdivision or any agency,
department or instrumentality thereof.

                  "Plan" shall mean any pension plan as defined in Section 3(2)
of ERISA (other than a Multiemployer Plan), which is maintained or contributed
to (or to which there is an obligation to contribute to) by the U.S. Borrower or
a Subsidiary of the U.S. Borrower or an ERISA Affiliate, and each such plan for
the five year period immediately following the latest

                                     -151-

<PAGE>

date on which the U.S. Borrower, or a Subsidiary of the U.S. Borrower or an
ERISA Affiliate maintained, contributed to or had an obligation to contribute to
such plan.

                  "Plan of Reorganization" shall mean the Plan of Reorganization
of Old Exide and the other Credit Parties, as in effect on the Effective Date,
but without giving effect to any subsequent modifications thereto unless in form
and substance satisfactory to the Required Lenders.

                  "Plan Warrants" shall mean and include all warrants issued by
the U.S. Borrower with respect to U.S. Borrower Common Stock pursuant to the
Plan of Reorganization.

                  "Pledge Agreement Collateral" shall mean all U.S. Pledge
Agreement Collateral and all other Equity Interests or other property similar to
that pledged pursuant to the U.S. Pledge Agreement which is pledged pursuant to
one or more Foreign Pledge Agreements, Foreign Security Agreements or Additional
Security Documents.

                  "Pledge Agreements" shall mean the U.S. Pledge Agreement and
each Foreign Pledge Agreement.

                  "PMP" shall have the meaning provided in Schedule XIX.

                  "Polish Collateral Documents" shall have the meaning provided
in Section 12.19(a).

                  "Polish Subsidiaries" shall mean, collectively, (i) Centra
Spolka Akcyjna (Centra Sa) and its Subsidiaries and (ii) any other Wholly-Owned
Foreign Subsidiary of the U.S. Borrower organized under laws of Poland.

                  "Portuguese Subsidiaries" shall mean, collectively, (i)
Sociedad Portuguesa do Acumulador Tudor, S.A. and its Subsidiaries, (ii) R.U. -
Renovacao Urbana Lda. and (iii) any other Wholly-Owned Foreign Subsidiary of the
U.S. Borrower organized under the laws of Portugal.

                  "Post-Closing Period" shall have the meaning provided in
Section 8.15(a).

                  "Preferred Equity", as applied to the Equity Interests of any
Person, means Equity Interests of such Person (other than common stock of such
Person) of any class or classes (however designed) that ranks prior, as to the
payment of dividends or as to the distribution of assets upon any voluntary or
involuntary liquidation, dissolution or winding up of such Person, to Equity
Interests of any other class of such Person.

                  "Pre-Petition Foreign Secured Claims" shall have the meaning
provided in the Plan of Reorganization.

                  "Prime Lending Rate" shall mean the rate which DBAG (or
another bank of recognized standing reasonably selected by the Administrative
Agent) announces from time to time as its prime lending rate, the Prime Lending
Rate to change when and as such prime lending rate changes. The Prime Lending
Rate is a reference rate and does not necessarily represent the

                                     -152-

<PAGE>

lowest or best rate actually charged to any customer. DBAG may make commercial
loans or other loans at rates of interest at, above or below the Prime Lending
Rate.

                  "Pro Forma Basis" shall mean, in connection with any
calculation of compliance with any financial covenant or financial term, the
calculation thereof after giving effect on a pro forma basis to (x) any
Permitted Acquisition or Significant Asset Sale then being consummated as well
as any other Permitted Acquisition or Significant Asset Sale consummated after
the first day of the relevant Test Period or Calculation Period, as the case may
be, and on or prior to the date of the respective Permitted Acquisition or
Significant Asset Sale, as the case may be, then being effected, (y) the
incurrence or assumption of any Indebtedness that is incurred or assumed in
connection with, or to finance, one or more Permitted Acquisitions and (z) the
permanent repayment of any Indebtedness in connection with any Significant Asset
Sale; provided that, for purposes of calculations pursuant to Section 8.15, such
calculations shall also give effect on a pro forma basis to (a) the incurrence
of any Indebtedness (other than revolving Indebtedness, except to the extent
same is incurred to refinance other outstanding Indebtedness or to finance a
Permitted Acquisition) after the first day of the relevant Calculation Period as
if such Indebtedness had been incurred (and the proceeds thereof applied) on the
first day of the relevant Calculation Period and (b) the permanent repayment of
any Indebtedness (other than revolving Indebtedness) after the first day of the
relevant Calculation Period as if such Indebtedness had been retired or repaid
on the first day of the relevant Calculation Period, with the following rules to
apply in connection therewith:

                  (i)      for purposes of Section 8.15 only, all Indebtedness
         (x) (other than revolving Indebtedness, except to the extent same is
         incurred to refinance other outstanding Indebtedness or to finance
         Permitted Acquisitions) incurred or issued after the first day of the
         relevant Calculation Period (whether incurred to finance a Permitted
         Acquisition, to refinance Indebtedness or otherwise) shall be deemed to
         have been incurred or issued (and the proceeds thereof applied) on the
         first day of the respective Calculation Period and remain outstanding
         through the date of determination (and thereafter in the case of
         projections pursuant to Section 8.15) and (y) (other than revolving
         Indebtedness) permanently retired or redeemed after the first day of
         the relevant Calculation Period shall be deemed to have been retired or
         redeemed on the first day of the respective Calculation Period and
         remain retired through the date of determination (and thereafter in the
         case of projections pursuant to Section 8.15);

                  (ii)     for purposes of Section 8.15 only, all Indebtedness
         assumed to be outstanding pursuant to preceding clause (i) shall be
         deemed to have borne interest at (x) the rate applicable thereto, in
         the case of fixed rate indebtedness or (y) the rates which would have
         been applicable thereto during the respective period when same was
         deemed outstanding, in the case of floating rate Indebtedness (although
         interest expense with respect to any Indebtedness for periods while
         same was actually outstanding during the respective period shall be
         calculated using the actual rates applicable thereto while same was
         actually outstanding); provided that all Indebtedness (whether actually
         outstanding or deemed outstanding) bearing interest at a floating rate
         of interest shall be tested on the basis of the rates applicable at the
         time the determination is made pursuant to said provisions;

                                     -153-

<PAGE>

                  (iii)    for determinations of the Leverage Ratio for purposes
         of determining the Applicable Margins, Consolidated Debt shall be the
         actual amount thereof as of the last day of the respective Calculation
         Period or Test Period, as the case may be; provided that, (x) to the
         extent any Permitted Acquisition is consummated after the last day of
         the respective Calculation Period or Test Period and on or prior to the
         date of delivery of the Quarterly Pricing Certificate referenced in the
         definition of "Applicable Margin", all Indebtedness incurred or assumed
         in connection with one or more Permitted Acquisitions consummated after
         the last day of the respective Calculation Period or Test Period, as
         the case may be, shall be added to Consolidated Debt and shall be
         deemed to have been outstanding on the last day of the respective
         Calculation Period or Test Period, as the case may be, and (y) to the
         extent any Significant Asset Sale is consummated after the last day of
         the respective Calculation Period or Test Period and on or prior to the
         date of delivery of the Quarterly Pricing Certificate referenced in the
         definition of "Applicable Margin", all Indebtedness permanently repaid
         or retired in connection with one or more Significant Asset Sales
         consummated after the last day of the respective Calculation Period or
         Test Period, as the case may be, shall be deducted from Consolidated
         Debt and shall be deemed not to have been outstanding on the last day
         of the respective Calculation Period or Test Period, as the case may
         be; and

                  (iv)     in making any determination of Consolidated EBITDA on
         a Pro Forma Basis, pro forma effect shall be given to any Permitted
         Acquisition or Significant Asset Sale effected during the respective
         Calculation Period or Test Period (or thereafter to the extent provided
         in the definition of Applicable Margin, for determinations of the
         Applicable Margins, or as provided in Section 8.15, for determinations
         pursuant to Section 8.15 only) as if same had occurred on the first day
         of the respective Calculation Period or Test Period, as the case may
         be, taking into account, in the case of any Permitted Acquisition,
         factually supportable and identifiable cost savings and expenses which
         would otherwise be accounted for as an adjustment pursuant to Article
         11 of Regulation S-X under the Securities Act, as if such cost savings
         or expenses were realized on the first day of the respective period.

                  "Pro Forma Financial Statements" shall have the meaning
provided in Section 5.16(a).

                  "Projections" shall have the meaning provided in Section
5.16(b).

                  "Property" of a Person means any and all property, whether
real, personal, tangible, intangible or mixed, of such Person, or other assets
owned, leased, or operated by such Person.

                  "Qualified Jurisdictions" shall mean and include the United
States, The Netherlands and each other jurisdiction identified on Schedule XV
hereto, in each case including any states, provinces or other similar local
units therein. Furthermore, from time to time after the Initial Borrowing Date,
the U.S. Borrower may request (by written notice to, and following consultation
with, the Administrative Agent) that one or more additional jurisdictions be
added to the list of Qualified Jurisdictions. In such event, such jurisdictions
shall be added to (and thereafter form part of) the list of Qualified
Jurisdictions so long as, in each case, the respective

                                     -154-

<PAGE>

jurisdiction to be added is a jurisdiction in which the U.S. Borrower and/or any
of its Subsidiaries conducts business, the jurisdiction to be added is
satisfactory to the Administrative Agent (including with respect to the amount
and enforceability of Foreign Subsidiaries Guaranties that may be entered into
by entities organized in such jurisdiction, as well as the security interests
(and enforceability thereof) that may be granted with respect to collateral (or
various classes of assets) located in such jurisdiction as well as any political
risk associated with such jurisdiction) and so long as the U.S. Borrower has
furnished opinions of counsel, in each case from counsel, and in form and
substance, reasonably satisfactory to the Administrative Agent, concluding that
Subsidiaries of the U.S. Borrower organized under the laws of such jurisdiction
may execute and deliver a Foreign Subsidiaries Guaranty (unlimited in amount (or
subject to such limits as may be necessary or advisable under local law and
which are satisfactory to the Administrative Agent) and otherwise containing
provisions reasonably consistent with the provisions of the Foreign Subsidiaries
Guaranties executed and delivered on the Initial Borrowing Date), the
Intercompany Subordination Agreement and such Security Documents as may be
satisfactory to the Collateral Agent (generally consistent with the Security
Documents executed and delivered by Qualified Non-U.S. Obligors on the Initial
Borrowing Date, and providing security interests in such asset classes as shall
be satisfactory to the Administrative Agent) and that, in accordance with the
laws of the respective jurisdiction, such Credit Documents shall constitute the
legal, valid and binding obligations, enforceable in accordance with their
terms, and (in the case of the Security Documents) create valid and perfected
security interests under applicable law (in each case subject to such customary
exceptions (not inconsistent with the requirements set forth above) as are
satisfactory to the Administrative Agent). The parties hereto further agree
that, in the discretion of the Administrative Agent, as a condition to the
addition of any jurisdiction to the list of Qualified Jurisdictions, the
Administrative Agent may (but shall not be required to) request the consent of
the Required Lenders to such addition and, in such event, the Administrative
Agent shall be entitled to wait for such consent before adding the respective
jurisdiction to the list of Qualified Jurisdictions.

                  "Qualified Non-U.S. Jurisdictions" shall mean and include each
Qualified Jurisdiction other than the United States (and the States thereof).

                  "Qualified Non-U.S. Obligors" shall mean the European Borrower
and each Foreign Credit Party which (x) is a Wholly-Owned Subsidiary of the U.S.
Borrower organized under the laws of a Qualified Non-U.S. Jurisdiction, (y) has
provided a full and unconditional guaranty (unlimited in amount (or subject to
such limits as may be necessary or advisable under local law as agreed to by the
Administrative Agent in consultation with its local counsel) of all Guaranteed
Obligations (as defined in the Foreign Subsidiaries Guaranties) pursuant to a
Foreign Subsidiaries Guaranty and (z) has executed the relevant Security
Documents in accordance with the requirements of Sections 5 and 8.11 securing
all such Guaranteed Obligations.

                  "Qualified Obligors" shall mean each Qualified U.S. Obligor
and each Qualified Non-U.S. Obligor.

                  "Qualified Preferred Stock" shall mean any Preferred Equity of
the U.S. Borrower, the express terms of which shall provide that dividends
thereon shall not be required to be paid at any time (and to the extent) that
such payment would be prohibited by the terms of this Agreement or any other
agreement of the U.S. Borrower or any of its Subsidiaries relating to

                                     -155-

<PAGE>

outstanding indebtedness and which, by its terms (or by the terms of any
security into which it is convertible or for which it is exchangeable), or upon
the happening of any event (including any change of control event), cannot
mature (excluding any maturity as the result of an optional redemption by the
issuer thereof) and is not mandatorily redeemable, pursuant to a sinking fund
obligation or otherwise, and is not redeemable, or required to be repurchased,
at the sole option of the holder thereof (including, without limitation, upon
the occurrence of an change of control event), in whole or in part, on or prior
to one year following the latest Maturity Date then in effect.

                  "Qualified U.S. Obligors" shall mean and include the U.S.
Borrower and each other U.S. Credit Party which is a Wholly-Owned Subsidiary of
the U.S. Borrower, provided that any Qualified U.S. Obligor that is (or was) a
Subsidiary of the U.S. Borrower shall cease to constitute a Qualified U.S.
Obligor at such time, if any, as such Subsidiary ceases to be a Wholly-Owned
Subsidiary of the U.S. Borrower.

                  "Quarterly Payment Date" shall mean the last Business Day of
each November, February, May and August, it being understood that the first
Quarterly Payment Date shall be the last Business Day of the fiscal month ending
August 2004.

                  "Quarterly Pricing Certificate" shall have the meaning
provided in the definition of Applicable Margin.

                  "Quebec Secured Party" shall have the meaning provided in
Section 12.15(a).

                  "Quebec Security Granting Parties" shall have the meaning
provided in Section 12.15(a).

                  "Real Property" of any Person shall mean all of the right,
title and interest of such Person in and to land, improvements and fixtures,
including Leaseholds.

                  "Recovery Event" shall mean the receipt by the U.S. Borrower
or any of its Subsidiaries of any insurance or condemnation proceeds payable (i)
by reason of theft, physical destruction or damage or any other similar event
with respect to any properties or assets of the U.S. Borrower or any of its
Subsidiaries, (ii) by reason of any condemnation, taking, seizing or similar
event with respect to any properties or assets of the U.S. Borrower or any of
its Subsidiaries or (iii) under any policy of insurance required to be
maintained under Section 8.03.

                  "Refinancing" shall mean the refinancing and repayment or
other satisfaction in full of all amounts outstanding under, and the termination
of all commitments in respect of, all Indebtedness to be Refinanced.

                  "Refinancing Documents" shall mean all of the agreements,
documents and instruments executed or delivered in connection with the
Refinancing.

                  "Register" shall have the meaning provided in Section 13.17.

                                     -156-

<PAGE>

                  "Regulation D" shall mean Regulation D of the Board of
Governors of the Federal Reserve System as from time to time in effect and any
successor to all or a portion thereof establishing reserve requirements.

                  "Regulation T" shall mean Regulation T of the Board of
Governors of the Federal Reserve System as from to time in effect and any
successor to all or any portion thereof.

                  "Regulation U" shall mean Regulation U of the Board of
Governors of the Federal Reserve System as from time to time in effect and any
successor to all or a portion thereof.

                  "Regulation X" shall mean Regulation X of the Board of
Governors of the Federal Reserve System as from time to time in effect and any
successor to all or any portion thereof.

                  "Release" shall have the meaning set forth in the
Comprehensive Environmental Response, Compensation and Liability Act of 1980, as
amended ("CERCLA") (42 U.S.C. Section 9601 et seq.).

                  "Reorganization" shall mean the consummation of the
transactions contemplated by the Plan of Reorganization and the Disclosure
Statement to occur prior to the Initial Borrowing Date.

                  "Reorganization Documents" shall mean each of the agreements,
documents and instruments entered into in connection with the Reorganization
(other than the Credit Documents and the Refinancing Documents).

                  "Replaced Lender" shall have the meaning provided in Section
1.13.

                  "Replacement Lender" shall have the meaning provided in
Section 1.13.

                  "Reportable Event" shall mean an event described in Section
4043(c) of ERISA with respect to a Plan that is subject to Title IV of ERISA
other than those events as to which the 30-day notice period under ERISA has
been waived under subsection .22, .23, .25, .27, or .28 of PBGC Regulation
Section 4043.

                  "Required Appraisal" shall have the meaning provided in
Section 8.11(i).

                  "Required Lenders" shall mean Non-Defaulting Lenders, the sum
of whose outstanding principal (taking the Dollar Equivalent of any outstanding
Euro Denominated Term Loans) of Term Loans (or, if prior to the occurrence of
the Credit Events on the Initial Borrowing Date, whose U.S. Borrower Term Loan
Commitments, European Borrower Dollar Term Loan Commitments and European
Borrower Euro Term Loan Commitments, taking the Dollar Equivalent of any such
European Borrower Euro Term Loan Commitments) and Multicurrency Facility
Revolving Loan Commitments (or after the termination thereof, outstanding
Individual Multicurrency Facility RL Exposures) as of any date of determination
represent greater than 50% of the sum of all outstanding principal (taking the
Dollar Equivalent of any outstanding Euro Denominated Term Loans) of Term Loans
(or, if prior to the occurrence

                                     -157-

<PAGE>

of the Credit Events on the Initial Borrowing Date, the sum of all U.S. Borrower
Term Loan Commitments, European Borrower Dollar Term Loan Commitments and
European Borrower Euro Term Loan Commitments, taking the Dollar Equivalent of
any such European Borrower Euro Term Loan Commitments) of Non-Defaulting Lenders
at such time and the sum of all Multicurrency Facility Revolving Loan
Commitments of all Non-Defaulting Lenders at such time (or, after the
termination thereof, the sum of the then total Individual Multicurrency Facility
RL Exposures of all Non-Defaulting Lenders at such time).

                  "Restructuring Charges" shall mean non-recurring and other
one-time costs incurred by the U.S. Borrower in connection with the
reorganization of its and its Subsidiaries' business, operations and structure
in respect of (i) the implementation of lean manufacturing initiatives, (ii)
plant closures and the consolidation, relocation or elimination of operations,
(iii) related severance costs and other costs incurred in connection with the
termination, relocation and training of employees, and (iv) legal, consulting,
employee retention and other advisor fees incurred in connection with the
Chapter 11 Cases and the related Plan of Reorganization.

                  "Returns" shall have the meaning provided in Section 7.20.

                  "Revolving Loan Maturity Date" shall mean May 5, 2009.

                  "RL Commitment Commission" shall have the meaning provided in
Section 3.01(a).

                  "S&P" shall mean Standard & Poor's Ratings Services, a
division of McGraw Hill, Inc.

                  "Scheduled Existing Indebtedness" shall mean Third Party
Scheduled Existing Indebtedness and Intercompany Scheduled Existing
Indebtedness.

                  "Scheduled Repayment" shall mean any U.S. Borrower Term Loan
Scheduled Repayment, any European Borrower Dollar Term Loans Scheduled Repayment
and/or any European Borrower Euro Term Loan Scheduled Repayment, as applicable.

                  "SEC" shall mean the Securities and Exchange Commission or any
successor thereto.

                  "Section 4.04(b)(ii) Certificate" shall have the meaning
provided in Section 4.04(b)(ii).

                  "Secured Creditors" shall have the meaning provided in the
respective Security Documents.

                  "Securities Act" shall mean the Securities Act of 1933, as
amended, and the rules and regulations promulgated thereunder.

                  "Security Agreement Collateral" shall mean all collateral in
which any security interest is granted pursuant to the Security Agreements.

                                     -158-

<PAGE>

                  "Security Agreements" shall mean the U.S. Security Agreement
and each Foreign Security Agreement.

                  "Security Document" shall mean and include each of the U.S.
Security Agreement, the U.S. Pledge Agreement, each Mortgage, each Foreign
Security Agreement, each Foreign Pledge Agreement and, after the execution and
delivery thereof, each Additional Security Document (including each Additional
Mortgage).

                  "Senior Officer" shall mean (i) senior executive management of
the U.S. Borrower, (ii) the general counsel of the U.S. Borrower and (iii) the
division presidents of the U.S. Borrower and its Subsidiaries.

                  "Shareholder Subordinated Note" shall mean an unsecured junior
subordinated note issued by the U.S. Borrower (and not guaranteed or supported
in any way by the European Borrower or any other Subsidiary of the U.S.
Borrower) in the form of Exhibit M, as the same may be amended, modified and/or
supplemented from time to time in accordance with the terms hereof and thereof.

                  "Shareholders' Agreements" shall have the meaning provided in
Section 5.14.

                  "Sharing Event" shall mean (i) the occurrence of any Event of
Default with respect to either Borrower pursuant to Section 10.05, (ii) the
declaration of the termination of any Multicurrency Facility Revolving Loan
Commitment, or the acceleration of the maturity of any Loans, in each case
pursuant to the last paragraph of Section 10 or (iii) the failure of either
Borrower to pay any principal of, or interest on, Loans of any Tranche or any
Letter of Credit Outstandings on the relevant Maturity Date.

                  "Significant Asset Sale" shall mean each Asset Sale which
generates Net Sale Proceeds of at least $10,000,000.

                  "Sole Lead Arranger" shall mean DBSI, in its capacity as Sole
Lead Arranger and Book Running Manager.

                  "Special Reserve Account" shall have the meaning provided in
Section 1.14(c).

                  "Standby Letter of Credit" shall have the meaning provided in
Section 2.01(a).

                  "Start Date" shall have the meaning provided in the definition
of Applicable Margin.

                  "Stated Amount" of each Letter of Credit shall, at any time,
mean the maximum amount available to be drawn thereunder (in each case
determined without regard to whether any conditions to drawing could then be
met, but after giving effect to all previous drawings made thereunder), provided
that except as such term is used in Section 2.02, the "Stated Amount" of each
Euro Denominated Letter of Credit shall be, on any date of calculation, the
Dollar Equivalent of the maximum amount available to be drawn in Euros
thereunder (determined without regard to whether any conditions to drawing could
then be met but after giving effect to all previous drawings made thereunder).

                                     -159-

<PAGE>

                  "Subsidiaries Guaranty" shall mean and include the U.S.
Subsidiaries Guaranty, each Foreign Subsidiaries Guaranty and any other guaranty
executed and delivered by any Subsidiary of the U.S. Borrower pursuant to any of
Sections 8.11, 8.12 and/or 9.16.

                  "Subsidiary" of any Person shall mean and include (i) any
corporation more than 50% of whose stock of any class or classes having by the
terms thereof ordinary voting power to elect a majority of the directors of such
corporation (irrespective of whether or not at the time stock of any class or
classes of such corporation shall have or might have voting power by reason of
the happening of any contingency) is at the time owned by such Person directly
or indirectly through one or more Subsidiaries of such Person and (ii) any
partnership, association, limited liability company, joint venture or other
entity (other than a corporation) in which such Person directly or indirectly
through one or more Subsidiaries of such Person, has more than a 50% Equity
Interest at the time.

                  "Subsidiary Guarantor" shall mean each Subsidiary of the U.S.
Borrower that executes and delivers any Subsidiaries Guaranty, unless and until
such time as the respective Subsidiary is released from all of its obligations
under any relevant Subsidiaries Guaranty in accordance with the terms and
provisions thereof.

                  "Supermajority Lenders" of any Tranche shall mean those
Non-Defaulting Lenders which would constitute the Required Lenders under, and as
defined in, this Agreement if (x) all outstanding Obligations of the other
Tranches under this Agreement were repaid in full and all Commitments with
respect thereto were terminated and (y) the percentage "50%" contained therein
were changed to "66-2/3%".

                  "Swingline Expiry Date" shall mean the date that is five
Business Days prior to the Revolving Loan Maturity Date.

                  "Swingline Lender" shall mean DBAG, or any Person serving as a
successor Administrative Agent hereunder, in its capacity as a lender of
Swingline Loans.

                  "Swingline Loan" shall have the meaning provided in Section
1.01(e).

                  "Syndication Agents" shall have the meaning provided in the
first paragraph of this Agreement.

                  "Syndication Date" shall mean the earlier of (i) the 90th day
following the Initial Borrowing Date and (ii) the date upon which the
Administrative Agent determines (and notifies the U.S. Borrower and the Lenders)
that the primary syndication (and resultant addition of Persons as Lenders
pursuant to Section 13.04(b)) has been completed.

                  "Synthetic Lease" means a lease transaction under which the
parties intend that (i) the lease will be treated as an "operating lease" by the
lessee and (ii) the lessee will be entitled to various tax and other benefits
ordinarily available to owners (as opposed to lessees) of like property.

                  "Tax Allocation Agreements" shall have the meaning provided in
Section 5.14.

                                     -160-

<PAGE>

                  "Taxes" shall have the meaning provided in Section 4.04(a).

                  "Term Loan Maturity Date" shall mean May 5, 2010.

                  "Term Loans" shall mean and include U.S. Borrower Term Loans
and European Borrower Term Loans.

                  "Test Period" shall mean each period of four consecutive
Fiscal Quarters then last ended, in each case taken as one accounting period;
provided that in the case of any Test Period which includes any Fiscal Quarter
ended on or prior to March 31, 2005, the rules set forth in the immediately
succeeding sentence shall apply; provided further, that in the case of
determinations of the Leverage Ratio pursuant to this Agreement, such further
adjustments (if any) as described in the proviso to the definition of "Leverage
Ratio" contained herein shall be made to the extent applicable. If the
respective Test Period (i) includes the Fiscal Quarter ended September 30, 2003,
(x) Consolidated EBITDA for such Fiscal Quarter shall be deemed to be
$46,700,000 and (y) Consolidated Interest Expense for such Fiscal Quarter shall
be deemed to be $7,200,000, (ii) includes the Fiscal Quarter ended December 31,
2003, (x) Consolidated EBITDA for such Fiscal Quarter shall be deemed to be
$59,000,000, and (y) Consolidated Interest Expense for such Fiscal Quarter shall
be deemed to be $7,200,000, (iii) includes the Fiscal Quarter ended March 31,
2004, (x) Consolidated EBITDA for such Fiscal Quarter shall be deemed to be
$48,100,000 and (y) Consolidated Interest Expense for such Fiscal Quarter shall
be deemed to be $7,200,000, and (iv) includes the Fiscal Quarter ended June 30,
2004, (x) Consolidated EBITDA shall be deemed to be the sum of actual
Consolidated EBITDA for the period from and including the Initial Borrowing Date
to and including the last day of such Fiscal Quarter plus an amount equal to
$30,600,000 multiplied by a fraction the numerator of which is the number of
days in said Fiscal Quarter to but excluding the Initial Borrowing Date and the
denominator of which is the total number of days in such Fiscal Quarter and (y)
Consolidated Interest Expense shall be deemed to be the sum of actual
Consolidated Interest Expense for the period from and including the Initial
Borrowing Date to and including the last day of such Fiscal Quarter plus an
amount equal to $7,200,000 multiplied by a fraction the numerator of which is
the number of days in said Fiscal Quarter to but excluding the Initial Borrowing
Date and the denominator of which is the number of days in said Fiscal Quarter.

                  "Third Party Scheduled Existing Indebtedness" shall have the
meaning provided in Section 7.21.

                  "TL Repayment Percentage" of any Tranche of Term Loans at any
time shall be a fraction (expressed as a percentage) (x) the numerator of which
is the aggregate principal amount of outstanding Term Loans of such Tranche
(using the Dollar Equivalent of any amounts denominated in Euros) and (y) the
denominator of which is the sum of the aggregate principal amount of all
outstanding Term Loans at such time (using the Dollar Equivalent of any amounts
denominated in Euros).

                  "Total Commitment" shall mean, at any time, the sum of the
Total U.S. Borrower Term Loan Commitment, the Total European Borrower Dollar
Term Loan Commitment, the Total European Borrower Euro Term Loan Commitment and
the Total Multicurrency Facility Revolving Loan Commitment.

                                     -161-

<PAGE>

                  "Total European Borrower Dollar Term Loan Commitment" shall
mean, at any time, the sum of the European Borrower Term Loan Commitments of
each of the Lenders with such a Commitment at such time.

                  "Total European Borrower Euro Term Loan Commitment" shall
mean, at any time, the sum of the European Borrower Euro Term Loan Commitments
of each of the Lenders with such a Commitment at such time.

                  "Total Multicurrency Facility Revolving Loan Commitment" shall
mean, at any time, the sum of the Multicurrency Facility Revolving Loan
Commitments of each of the Lenders with such a Commitment at such time.

                  "Total Unutilized Multicurrency Facility Revolving Loan
Commitment" shall mean, at any time, an amount equal to the remainder of (x) the
Total Multicurrency Facility Revolving Loan Commitment as in effect at such time
less (y) the Aggregate Multicurrency Facility RL Exposure at such time; provided
that for purposes of the definition of Applicable Multicurrency Facility
Commitment Fee Percentage (and as the term "Total Unutilized Multicurrency
Facility Revolving Loan Commitment" is used therein) only, "Aggregate
Multicurrency Facility RL Exposure" shall be determined as provided in the
definition thereof but for such purposes excluding the obligations described in
clause (iii) of said definition (and treating same as if they were not
outstandings).

                  "Total U.S. Borrower Term Loan Commitment" shall mean, at any
time, the sum of the U.S. Borrower Term Loan Commitments of each of the Lenders
with such a Commitment at such time.

                  "Trade Letter of Credit" shall have the meaning set forth in
Section 2.01(a).

                  "Tranche" shall mean the respective facilities and commitments
utilized in making Loans hereunder, with there being seven separate Tranches
(i.e., U.S. Borrower Term Loans, European Borrower Dollar Term Loans, European
Borrower Euro Term Loans, U.S. Borrower Multicurrency Facility Revolving Loans,
European Borrower Multicurrency Facility Revolving Loans, U.S. Borrower
Swingline Loans and European Borrower Swingline Loans; provided that for
purposes of the definition of "Supermajority Lenders", "Majority Lenders" and
Section 13.12(a), there shall be deemed to be four separate Tranches (i.e., U.S.
Borrower Term Loans, European Borrower Dollar Term Loans, European Borrower Euro
Term Loans and Multicurrency Facility Revolving Loans).

                  "Transaction" shall mean, collectively, (i) the consummation
of the Reorganization, (ii) the consummation of the Refinancing, (iii) the
entering into of the Credit Documents and the incurrence of all Loans and the
issuance of all Letters of Credit on the Initial Borrowing Date, and (iv) the
payment of fees and expenses in connection with the foregoing.

                  "Treaty" means the Treaty establishing the European Community
being the Treaty of Rome of March 25, 1957, as amended by the Single European
Act 1986, the Maastricht Treaty (which was signed at Maastricht on February 7,
1992) and the Treaty of Amsterdam (which was signed in Amsterdam on October 2,
1997).

                                     -162-

<PAGE>

                  "Type" shall mean the type of Loan determined with regard to
the interest option applicable thereto, i.e., whether a Base Rate Loan, a
Eurodollar Loan, a Euro Denominated Loan (other than a Euro Denominated
Swingline Loan) or a Euro Denominated Swingline Loan.

                  "UCC" shall mean the Uniform Commercial Code as in effect from
time to time in the relevant jurisdiction.

                  "Unfunded Current Liability" shall mean the amount, if any, by
which the actuarial present value of accumulated benefits of any Plan subject to
Title IV of ERISA as of the close of its most recent plan year, determined using
actuarial assumptions at such time consistent with those prescribed by Financial
Account Standards No. 87, exceeds the fair market value of the assets allocable
to such liabilities.

                  "Unpaid Drawing" shall have the meaning provided in Section
2.05(a).

                  "Unutilized Multicurrency Facility Revolving Loan Commitment"
with respect to any Multicurrency Facility RL Lender, at any time, shall mean
such Multicurrency Facility RL Lender's Multicurrency Facility Revolving Loan
Commitment at such time, if any, less the sum of (i) the aggregate outstanding
principal amount of Multicurrency Facility Revolving Loans (taking the Dollar
Equivalent of any such Loans denominated in Euros) made by such Multicurrency
Facility RL Lender and then outstanding and (ii) the sum of such Multicurrency
Facility RL Lender's L/C Participation Percentage of the Stated Amount of each
Letter of Credit and any Unpaid Drawings (taking the Dollar Equivalent of any
amounts expressed in Euros) relating thereto.

                  "U.S." or "United States" shall mean the United States of
America.

                  "U.S. Borrower" shall have the meaning provided in the first
paragraph of this Agreement.

                  "U.S. Borrower Common Stock" shall have the meaning provided
in Section 7.13(a).

                  "U.S. Borrower Guaranteed Obligations" shall mean (i) the
principal and interest on each European Borrower Dollar Term Note, each European
Borrower Euro Term Note, each European Borrower Multicurrency Facility Revolving
Note and the European Borrower Swingline Note issued by the European Borrower to
each Lender, and each European Borrower Dollar Term Loan, each European Borrower
Euro Term Loan, each European Borrower Multicurrency Facility Revolving Loan and
each European Borrower Swingline Loan made, under this Agreement, all
reimbursement obligations and Unpaid Drawings with respect to each Letter of
Credit issued for the account of the European Borrower, together with all the
other obligations (including obligations which, but for the automatic stay under
Section 362(a) of the Bankruptcy Code, would become due) and liabilities
(including, without limitation, indemnities, fees and interest thereon) of the
European Borrower to each Lender, each Agent, each Issuing Lender and the
Collateral Agent now existing or hereafter incurred under, arising out of or in
connection with this Agreement or any other Credit Document and the due
performance and compliance by the European Borrower with all the terms,
conditions and agreements contained in the Credit Documents to which it is a
party and (ii) all obligations (including obligations

                                     -163-

<PAGE>

which, but for the automatic stay under Section 362(a) of the Bankruptcy Code,
would become due) and liabilities of the European Borrower or any other
Subsidiary of the U.S. Borrower owing under any Interest Rate Protection
Agreement or any Other Hedging Agreement entered into by the European Borrower
or any other Subsidiary of the U.S. Borrower with any Lender or any affiliate
thereof (even if such Lender subsequently ceases to be a Lender under this
Agreement for any reason) so long as such Lender or affiliate participates in
such Interest Rate Protection Agreement or Other Hedging Agreement, and their
subsequent assigns, if any, whether now in existence or hereafter arising, and
the due performance and compliance with all terms, conditions and agreements
contained therein.

                  "U.S. Borrower Guaranteed Party" shall mean the European
Borrower and each Subsidiary of the U.S. Borrower party to any Interest Rate
Protection Agreement or Other Hedging Agreement with any Secured Creditor.

                  "U.S. Borrower Letter of Credit" shall mean each Multicurrency
Facility Letter of Credit (which may be denominated in Dollars or Euros) issued
for the account of the U.S. Borrower pursuant to Section 2.01 and designated as
such by the U.S. Borrower in the respective Letter of Credit Request.

                  "U.S. Borrower Letter of Credit Outstandings" shall mean, at
any time, the sum of (i) the aggregate Stated Amount of all outstanding U.S.
Borrower Letters of Credit and (ii) the aggregate amount of all Unpaid Drawings
(taking the Dollar Equivalent of all amounts payable in Euros) in respect of all
U.S. Borrower Letters of Credit.

                  "U.S. Borrower Multicurrency Facility Revolving Loan" shall
have the meaning provided in Section 1.01(d).

                  "U.S. Borrower Multicurrency Facility Revolving Note" shall
have the meaning provided in Section 1.05(a).

                  "U.S. Borrower Swingline Loan" shall have the meaning provided
in Section 1.01(e).

                  "U.S. Borrower Swingline Note" shall have the meaning provided
in Section 1.05(a).

                  "U.S. Borrower Term Loan" shall have the meaning provided in
Section 1.01(a).

                  "U.S. Borrower Term Loan Commitment" shall mean, with respect
to each Lender, the amount set forth opposite such Lender's name in Schedule I
directly below the column entitled "U.S. Borrower Term Loan Commitment", as the
same may be terminated pursuant to Sections 3.03 and/or 10.

                  "U.S. Borrower Term Loan Scheduled Repayment" shall have the
meaning provided in Section 4.02(b)(i).

                  "U.S. Borrower Term Note" shall have the meaning provided in
Section 1.05(a).

                                     -164-
<PAGE>

                  "U.S. Borrower's Guaranty" shall mean the guaranty of the U.S.
Borrower pursuant to Section 14.

                  "U.S. Credit Party" shall mean the U.S. Borrower and each U.S.
Subsidiary Guarantor.

                  "U.S. Dollars", "Dollars" and the sign "$" shall each mean
freely transferable lawful money of the United States of America.

                  "U.S. GAAP" shall mean generally accepted accounting
principles in the United States of America as in effect from time to time;
provided that determinations in accordance with U.S. GAAP for purposes of
Applicable Margins and Sections 4.02, 8.15 and 9, including defined terms as
used therein, and for all purposes of determining the Leverage Ratio, are
subject (to the extent provided therein) to Section 13.07(a).

                  "U.S. GAAS" shall mean generally accepted audit standards in
the United States of America as in effect from time to time.

                  "U.S. Mortgaged Property" shall mean each Real Property
located in the United States or any State or territory thereof with respect to
which a Mortgage is required to be delivered pursuant to the terms of this
Agreement.

                  "U.S. Pledge Agreement" shall have the meaning provided in
Section 5.10(a).

                  "U.S. Pledge Agreement Collateral" shall mean all of the
"Collateral" as defined in the U.S. Pledge Agreement.

                  "U.S. Security Agreement" shall have the meaning provided in
Section 5.11.

                  "U.S. Security Documents" shall mean and include the U.S.
Security Agreement, the U.S. Pledge Agreement, each Mortgage covering a U.S.
Mortgaged Property and each Additional Security Document covering assets of a
U.S. Credit Party situated in the United States.

                  "U.S. Subsidiaries Guaranty" shall have the meaning provided
in Section 5.09(a) and shall include any counterpart thereof and any other
substantially identical guaranty executed and delivered by any Subsidiary of the
U.S. Borrower pursuant to Section 8.11, 8.12 or 9.16.

                  "U.S. Subsidiary Guarantor" shall mean (i) each Wholly-Owned
Domestic Subsidiary of the U.S. Borrower as of the Initial Borrowing Date and
(ii) each other Wholly-Owned Domestic Subsidiary of the U.S. Borrower created,
established or acquired after the Initial Borrowing Date which executes and
delivers a U.S. Subsidiaries Guaranty, unless and until such time as the
respective Domestic Subsidiary ceases to constitute a Domestic Subsidiary or is
released from all of its obligations under its U.S. Subsidiaries Guaranty in
accordance with the terms and provisions thereof.

                  "Wholly-Owned Domestic Subsidiary" shall mean, as to any
Person, any Wholly-Owned Subsidiary of such Person that is a Domestic Subsidiary
of such Person.

                                     -165-

<PAGE>

                  "Wholly-Owned Foreign Subsidiary" shall mean, as to any
Person, any Wholly-Owned Subsidiary of such Person that is not a Domestic
Subsidiary of such Person.

                  "Wholly-Owned Subsidiary" shall mean, as to any Person, (i)
any corporation 100% of whose capital stock (other than director's qualifying
shares and/or other nominal amounts of shares required by applicable law to be
held by Persons other than such Person) is at the time owned by such Person
and/or one or more Wholly-Owned Subsidiaries of such Person and (ii) any
partnership, limited liability company, association, joint venture or other
entity in which such Person and/or one or more Wholly-Owned Subsidiaries of such
Person has a 100% Equity Interest at such time; provided that any Foreign
Subsidiary of such Person at least 90% of whose capital stock or other Equity
Interests are owned by such Person and/or one or more Wholly-Owned Subsidiaries
(determined after giving effect to this proviso) of such Person at such time
shall be deemed to be a Wholly-Owned Subsidiary of such Person.

                  "Written" (whether lower or upper case) or "in writing" shall
mean any form of written communication or a communication by means of telex,
facsimile device, telegraph or cable.

                  SECTION 12. The Agents.

                  12.01 Appointment. (a) Each Lender hereby irrevocably
designates and appoints (x) DBAG as Administrative Agent for such Lender (for
purposes of this Section 12, the term "Administrative Agent" shall mean DBAG in
its capacities as Administrative Agent and as Collateral Agent hereunder and
pursuant to the Security Documents) and (y) CSFB and Fleet Securities as
Syndication Agents for such Lender, each to act as specified herein and in the
other Credit Documents, and each such Lender hereby irrevocably authorizes the
Administrative Agent and each Syndication Agent to take such action on its
behalf under the provisions of this Agreement and the other Credit Documents and
to exercise such powers and perform such duties as are expressly delegated to or
required of the Administrative Agent or such Syndication Agent, as the case may
be, by the terms of this Agreement and the other Credit Documents, together with
such other powers as are reasonably incidental thereto. Each of the Agents may
perform any of their respective duties under this Agreement, the other Credit
Documents and any other instruments and agreements referred to herein or therein
by or through its respective officers, directors, agents, employees or
affiliates (it being understood and agreed, for avoidance of doubt and without
limiting the generality of the foregoing, that the Administrative Agent and/or
Collateral Agent may perform any of its duties under the Security Documents by
or through one or more of its affiliates).

                  (b)      The provisions of this Section 12 are solely for the
benefit of the Agents and the Lenders, and neither the U.S. Borrower nor any of
its Subsidiaries shall have any rights as a third party beneficiary of any of
the provisions hereof. In performing its functions and duties under this
Agreement, each Agent shall act solely as agent for the Lenders, and each Agent
assumes no (and shall not be deemed to have assumed any) obligation or
relationship of agency or trust with or for the U.S. Borrower or any of its
Subsidiaries.

                  (c)      Notwithstanding anything to the contrary contained
herein or in any other Credit Document, its is understood and agreed that (x)
Fleet National Bank shall be deemed to be

                                     -166-

<PAGE>

the Syndication Agent for all purposes hereunder and (y) all references to
"Fleet Securities" or "Fleet Securities, Inc." in this Agreement or any other
Credit Document shall be deemed to be references to Fleet National Bank.

                  12.02 Nature of Duties. (a) No Agent shall have any duties or
responsibilities except those expressly set forth in this Agreement and in the
other Credit Documents. Neither any Agent nor any of its officers, directors,
agents, employees or affiliates shall be liable for any action taken or omitted
by it hereunder or under any other Credit Document or in connection herewith or
therewith, unless caused by its or their gross negligence or willful misconduct
(as determined by a court of competent jurisdiction in a final and
non-appealable decision). The duties of the Agents shall be mechanical and
administrative in nature; no Agent shall have by reason of this Agreement or any
other Credit Document a fiduciary relationship in respect of any Lender or the
holder of any Note and nothing in this Agreement or in any other Credit
Document, expressed or implied, is intended to or shall be so construed as to
impose upon any Agent any obligations in respect of this Agreement or any other
Credit Document except as expressly set forth herein or therein, provided that
the Agents shall be deemed to be a trustee and stand in a fiduciary relationship
with respect to the Lenders and the holders of Notes for purposes of any
Security Document governed by the laws of a jurisdiction located outside the
United States where the Agents shall determine, based on advice of local
counsel, that same is necessary or desirable for purposes of realizing the
benefits intended to be conferred pursuant to such Security Document, and the
Lenders hereby irrevocably designate each of the Agents as their trustee for
such purpose and authorize each of the Agents to at any time and from time to
time take all actions (including, without limitation, making demand for all
amounts then due and payable and the exercise of other remedies) on their behalf
in accordance with the terms of such Security Document without the necessity of
any notice to or further consent from any Lender, and the Lenders hereby agree
to indemnify the Agents (and each of their respective officers, directors,
trustees, employees, representatives and agents) and hold each of them harmless
against any and all liabilities, obligations (including removal or remedial
actions), losses, damages, penalties, claims, actions, judgments, suits, costs,
expenses and disbursements (including reasonable attorneys' and consultants'
fees and disbursements) incurred by, imposed on or assessed against any of them
as a result of, or arising out of, or in any way related to, or by reason of,
the taking of any action or any omission to take action under any such Security
Document unless such action is taken or omitted to be taken with gross
negligence or willful misconduct (as determined by a court of competent
jurisdiction in a final and non-appealable decision).

                  (b)      Notwithstanding any other provision of this Agreement
or any provision of any other Credit Document, each of the Book Running Managers
is named as such for recognition purposes only, and in their respective
capacities as such shall have no powers, duties, responsibilities or liabilities
with respect to this Agreement or the other Credit Documents or the transactions
contemplated hereby and thereby; it being understood and agreed that the Book
Running Managers shall be entitled to all indemnification and reimbursement
rights in favor of "Agents" as, and to the extent, provided for under Sections
12.07 and 13.01. Without limitation of the foregoing, neither of the Book
Running Managers shall, solely by reason of this Agreement or any other Credit
Documents, have any fiduciary relationship in respect of any Lender or any other
Person.

                                     -167-

<PAGE>

                  12.03 Certain Rights of the Agents. The Agents shall have the
right to request instructions from the Required Lenders at any time. If any
Agent shall request instructions from the Required Lenders with respect to any
act or action (including failure to act) in connection with this Agreement or
any other Credit Document, such Agent shall be entitled to refrain from such act
or taking such action unless and until such Agent shall have received
instructions from the Required Lenders; and such Agent shall not incur liability
to any Lender by reason of so refraining. Without limiting the foregoing,
neither any Lender nor the holder of any Note shall have any right of action
whatsoever against any Agent or any of its employees, directors, officers,
agents or affiliates as a result of such Agent or such other person acting or
refraining from acting hereunder or under any other Credit Document in
accordance with the instructions of the Required Lenders.

                  12.04 Reliance by Agents. Each Agent shall be entitled to
rely, and shall be fully protected (and shall have no liability to any Person)
in relying, upon any note, writing, resolution, notice, statement, certificate,
telex, teletype or telecopier message, cablegram, radiogram, order, telephone
message or other document or conversation that such Agent believed, in the
absence of gross negligence or willful misconduct (as determined by a court of
competent jurisdiction in a final and non-appealable decision), to be the proper
Person, and, with respect to all legal matters pertaining to this Agreement and
any other Credit Document and its duties hereunder and thereunder, upon advice
of counsel selected by such Agent (which may be counsel for the Credit Parties)
and, with respect to other matters, upon advice of independent public
accountants or other experts selected by it.

                  12.05 Notice of Default, etc. No Agent shall be deemed to have
knowledge or notice of the occurrence of any Default or Event of Default unless
such Agent has actually received written notice from a Lender or either Borrower
referring to this Agreement, describing such Default or Event of Default and
stating that such notice is a "notice of default". In the event that any Agent
receives such a notice, such Agent shall give prompt notice thereof to the
Lenders. The Agents shall take such action with respect to such Default or Event
of Default as shall be reasonably directed by the Required Lenders; provided
that, unless and until any Agent shall have received such directions, such Agent
may (but shall not be obligated to) take such action, or refrain from taking
such action, with respect to such Default or Event of Default as it shall deem
advisable in the best interests of the Lenders (as determined by such Agent in
its sole discretion).

                  12.06 Nonreliance on Agents and Other Lenders. Independently
and without reliance upon any Agent, each Lender and the holder of each Note, to
the extent it deems appropriate, has made and shall continue to make its own
independent investigation of the financial condition and affairs of the U.S.
Borrower and its Subsidiaries in connection with the making and the continuance
of the Loans and the taking or not taking of any action in connection herewith
and, except as expressly provided in this Agreement, no Agent shall have any
duty or responsibility, either initially or on a continuing basis, to provide
any Lender or the holder of any Note with any credit or other information with
respect thereto, whether coming into its possession before the making of the
Loans or at any time or times thereafter. No Agent or their respective
affiliates nor any of their respective officers, directors, agents or employees
shall be responsible to any Lender or the holder of any Note for, or be required
or have any duty to ascertain, inquire or verify the accuracy of, (i) any
recitals, statements, information,

                                     -168-

<PAGE>

representations or warranties herein or in any document, certificate or other
writing delivered in connection herewith, (ii) the execution, effectiveness,
genuineness, validity, enforceability, perfection, collectibility, priority or
sufficiency of this Agreement or any other Credit Document, (iii) the financial
condition of the U.S. Borrower and any of its Subsidiaries, (iv) the performance
or observance of any of the terms, provisions or conditions of this Agreement or
any other Credit Document, (v) the satisfaction of any of the conditions
precedent set forth in Section 5 or 6, or (vi) the existence or possible
existence of any Default or Event of Default.

                  12.07 Indemnification. (a) To the extent any Agent (or any
affiliate thereof) is not reimbursed and indemnified by the Borrowers, the
Lenders will reimburse and indemnify such Agent (and any affiliate thereof) in
proportion to their respective "percentages" as used in determining the Required
Lenders (determined as if there were no Defaulting Lenders), for and against any
and all liabilities, obligations, losses, damages, penalties, claims, actions,
judgments, costs, expenses or disbursements of whatsoever kind or nature which
may be imposed on, asserted against or incurred by such Agent (or any affiliate
thereof) in performing its respective duties hereunder or under any other Credit
Document or in any way relating to or arising out of this Agreement or any other
Credit Document, provided that no Lender shall be liable for any portion of such
liabilities, obligations, losses, damages, penalties, actions, judgments, suits,
costs, expenses or disbursements resulting from such Agent's gross negligence or
willful misconduct (as determined by a court of competent jurisdiction in a
final and non-appealable decision).

                  (b)      Any Agent shall be fully justified in failing or
refusing to take any action hereunder and under any other Credit Document
(except actions expressly required to be taken by it hereunder or under the
Credit Documents) unless it shall first be indemnified to its satisfaction by
the Lenders pro rata against any and all liability, cost and expense that it may
incur by reason of taking or continuing to take any such action.

                  (c)      The agreements in this Section 12.07 shall survive
the payment of all Obligations.

                  12.08 Agents in their Individual Capacities. With respect to
its obligation to make Loans, or issue or participate in Letters of Credit,
under this Agreement, each Agent shall have the rights and powers specified
herein for a "Lender" and may exercise the same rights and powers as though it
were not performing the duties specified herein; and the term "Lender",
"Required Lenders", "Supermajority Lenders", "Majority Lenders", "holders of
Notes" or any similar terms shall, unless the context clearly otherwise
indicates, include each Agent in its individual capacity. Each Agent and its
affiliates may accept deposits from, lend money to, and generally engage in any
kind of banking, investment banking, trust or other business with, or provide
debt financing, equity capital or other services (including financial advisory
services) to, any Credit Party or any Affiliate of any Credit Party (or any
Person engaged in a similar business with any Credit Party or any Affiliate
thereof) as if they were not performing the duties specified herein, and may
accept fees and other consideration from any Credit Party or any Affiliate of
any Credit Party for services in connection with this Agreement and otherwise
without having to account for the same to the Lenders.

                  12.09 Holders. The Administrative Agent may deem and treat the
payee of any Note as the owner thereof for all purposes hereof unless and until
a written notice of the

                                     -169-

<PAGE>

assignment, transfer or endorsement thereof, as the case may be, shall have been
filed with the Administrative Agent. Any request, authority or consent of any
Person or entity who, at the time of making such request or giving such
authority or consent, is the holder of any Note shall be conclusive and binding
on any subsequent holder, transferee, assignee or endorsee, as the case may be,
of such Note or of any Note or Notes issued in exchange therefor.

                  12.10 Resignation of the Agents. (a) The Administrative Agent
may resign from the performance of all its functions and duties hereunder and/or
under the other Credit Documents (including, without limitation, its functions
and duties as Collateral Agent) at any time by giving 30 Business Days' prior
written notice to the Lenders and, unless a Default or an Event of Default under
Section 10.05 then exists, the U.S. Borrower. Any such resignation by an Agent
hereunder shall also constitute its resignation (if applicable) as an Issuing
Lender and Swingline Lender, in which case the resigning Agent (x) shall not be
required to issue any further Letters of Credit or make any additional Swingline
Loans hereunder and (y) shall maintain all of its rights as Issuing Lender or
Swingline Lender, as the case may be, with respect to any Letter of Credit
issued by it, or Swingline Loans made by it, prior to the date of such
resignation. Such resignation shall take effect upon the appointment of a
successor Administrative Agent pursuant to clauses (b) and (c) below or as
otherwise provided below.

                  (b)      Upon any such notice of resignation by the
Administrative Agent, the Required Lenders shall appoint a successor
Administrative Agent hereunder and/or under the other Credit Documents who shall
be a commercial bank or trust company acceptable to the U.S. Borrower, which
acceptance shall not be unreasonably withheld or delayed (provided that the U.S.
Borrower's approval shall not be required if an Event of Default then exists).

                  (c)      If a successor Administrative Agent shall not have
been so appointed within such 30 Business Day period, the Administrative Agent,
with the consent of the U.S. Borrower (which consent shall not be unreasonably
withheld or delayed, provided that the U.S. Borrower's consent shall not be
required if an Event of Default then exists), shall then appoint a successor
Administrative Agent who shall serve as Administrative Agent hereunder and/or
under the other Credit Documents until such time, if any, as the Required
Lenders appoint a successor Administrative Agent as provided above.

                  (d)      If no successor Administrative Agent has been
appointed pursuant to clause (b) or (c) above by the 30th Business Day after the
date such notice of resignation was given by the Administrative Agent, the
Administrative Agent's resignation shall become effective and the Required
Lenders shall thereafter perform all the duties of the Administrative Agent
hereunder and/or under any other Credit Document until such time, if any, as the
Lenders appoint a successor Administrative Agent as provided above.

                  (e)      Either Syndication Agent may resign from the
performance of all its functions and duties hereunder and/or under the other
Credit Documents at any time by giving five Business Days' prior written notice
to the Lenders. Such resignation shall take effect at the end of such five
Business Day period.

                  (f)      Upon a resignation of any Agent pursuant to this
Section 12.10, such Agent shall remain indemnified to the extent provided in
this Agreement and the other Credit

                                     -170-

<PAGE>

Documents and the provisions of this Section 12 shall continue in effect for the
benefit of such Agent for all of its actions and inactions while serving as such
Agent.

                  12.11 Collateral Matters. (a) Each Lender authorizes and
directs the Collateral Agent to enter into the Security Documents for the
benefit of the Lenders and the other Secured Creditors. Each Lender hereby
agrees, and each holder of any Note or participant in Letters of Credit by the
acceptance thereof will be deemed to agree, that, except as otherwise set forth
herein, any action taken by the Required Lenders in accordance with the
provisions of this Agreement or the Security Documents, and the exercise by the
Required Lenders of the powers set forth herein or therein, together with such
other powers as are reasonably incidental thereto, shall be authorized and
binding upon all of the Lenders. The Collateral Agent is hereby authorized on
behalf of all of the Lenders, without the necessity of any notice to or further
consent from any Lender, from time to time prior to an Event of Default, to take
any action with respect to any Collateral or Security Documents which may be
necessary to perfect and maintain perfected the security interest in and liens
upon the Collateral granted pursuant to the Security Documents.

                  (b)      The Lenders hereby authorize the Collateral Agent, at
its option and in its discretion, to release any Lien granted to or held by the
Collateral Agent upon any Collateral (i) upon termination of the Commitments and
payment and satisfaction of all of the Obligations at any time arising under or
in respect of this Agreement or the Credit Documents or the transactions
contemplated hereby or thereby, (ii) constituting property being sold or
otherwise disposed of (to Persons other than the U.S. Borrower and its
Subsidiaries) upon the sale or other disposition thereof in compliance with
Section 9.02, (iii) if approved, authorized or ratified in writing by the
Required Lenders (or all of the Lenders hereunder, to the extent required by
Section 13.12) or (iv) as otherwise may be expressly provided in the relevant
Security Documents. Upon request by the Administrative Agent at any time, the
Lenders will confirm in writing the Collateral Agent's authority to release
particular types or items of Collateral pursuant to this Section 12.11.

                  (c)      The Collateral Agent shall have no obligation
whatsoever to the Lenders or to any other Person to assure that the Collateral
exists or is owned by either Borrower or any of its Subsidiaries or is cared
for, protected or insured or that the Liens granted to the Collateral Agent
herein or pursuant hereto have been properly or sufficiently or lawfully
created, perfected, protected or enforced or are entitled to any particular
priority, or to exercise or to continue exercising at all or in any manner or
under any duty of care, disclosure or fidelity any of the rights, authorities
and powers granted or available to the Collateral Agent in this Section 12.11 or
in any of the Security Documents, it being understood and agreed that in respect
of the Collateral, or any act, omission or event related thereto, the Collateral
Agent may act in any manner it may deem appropriate, in its sole discretion,
given the Collateral Agent's own interest in the Collateral as one of the
Lenders and that the Collateral Agent shall have no duty or liability whatsoever
to the Lenders, except for its gross negligence or willful misconduct (as
determined by a court of competent jurisdiction in a final and non-appealable
decision).

                  12.12 Delivery of Information. The Administrative Agent shall
not be required to deliver to any Lender originals or copies of any documents,
instruments, notices, communications or other information received by the
Administrative Agent from either

                                     -171-

<PAGE>

Borrower, any Subsidiary, the Required Lenders, any Lender or any other Person
under or in connection with this Agreement or any other Credit Document except
(i) as specifically provided in this Agreement or any other Credit Document and
(ii) as specifically requested from time to time in writing by any Lender with
respect to a specific document, instrument, notice or other written
communication received by and in the possession of the Administrative Agent at
the time of receipt of such request and then only in accordance with such
specific request.

                  12.13 Special Appointment of Collateral Agent (Germany).
(a)Without prejudice to the generality of Section 12.11:

                  (i)      each Lender and each Issuing Lender that is or will
         become party to this Agreement hereby appoints, and each Secured
         Creditor (including each Hedging Creditor (as defined in the Foreign
         Subsidiaries Guaranty) that is not or will not become a party to this
         Agreement) by its acceptance of the benefits of the German Security,
         appoints on the terms set out in this Section 12.13, the Collateral
         Agent as trustee (Treuhaender) and administrator for the purpose of
         holding in trust (Treuhand) and administering, enforcing and releasing
         the German Security for the Secured Creditors;

                  (ii)     the Collateral Agent accepts its appointment as a
         trustee (Treuhaender) and administrator of the German Security on the
         terms and subject to the conditions set out in this Agreement; and

                  (iii)    the Secured Creditors agree that, in relation to the
         German Security, no Secured Creditor shall exercise any independent
         power to enforce any German Security or take any other action in
         relation to the enforcement of the German Security, or make or receive
         any declarations in relation thereto.

                  (b)      The Collateral Agent shall hold and administer any
German Security which is security assigned, transferred or pledged under German
law to it as a trustee (Treuhaender) for the benefit of the Secured Creditors.

                  (c)      Furthermore, each Secured Creditor hereby authorizes
(bevollmaechtigt) the Collateral Agent (with the right of sub-delegation) to
enter into any documents evidencing German Security and to make and accept all
declarations and take all actions as it considers necessary or useful in
connection with any German Security on behalf of such Secured Creditor. The
Collateral Agent shall further be entitled to rescind, release, amend and/or
execute new and different documents securing the German Security. The Collateral
Agent is released from the restrictions arising under section 181 of the German
Civil Code (Buergerliches Gesetzbuch) (restrictions on self-dealing).

                  (d)      The Secured Creditors and the Collateral Agent agree
that all rights and claims to be constituted by an abstract acknowledgement of
indebtedness to be entered into by certain Credit Parties and the Collateral
Agent and all proceeds held by the Collateral Agent pursuant to or in connection
with such abstract acknowledgement of indebtedness are held by the Collateral
Agent with effect from the date of such abstract acknowledgement of indebtedness
on trust (treuhanderisch) for the Secured Creditors and will be administered in
accordance with this Agreement. The Secured Creditors and the Collateral Agent
agree further that the respective

                                     -172-

<PAGE>

Credit Parties' obligations under such abstract acknowledgement of indebtedness
shall not increase the total amount of the Secured Obligations as defined in the
Security Documents relating to German Security and shall not result in any
additional liability of any of the Credit Parties or otherwise prejudice the
rights of any of the Credit Parties under any Credit Document. Accordingly,
payment of the obligations under such abstract acknowledgement of indebtedness
shall, to the same extent, discharge the corresponding Secured Obligations and
vice versa.

                  12.14 Special Appointment of Collateral Agent (France). (a)
Without prejudice to the generality of Section 12.11:

                  (i)      each Lender (including, without limitation, each
         Lender in its capacity as a Hedging Creditor (as defined in the Foreign
         Subsidiaries Guaranty)) and each Issuing Lender (as "mandants" under
         French Law), by executing this Agreement, or in the case of a Hedging
         Creditor, by executing an Accession Notice (as defined in the French
         Collateral Documents (as defined below) relating to pledges over
         shares), irrevocably appoints the Collateral Agent to act as agent
         ("mandataire" under French Law) under and in connection with the
         Foreign Security Documents governed by French law and any documents
         relating thereto (collectively, the "French Collateral Documents") and
         irrevocably authorizes the Collateral Agent (i) to execute on its
         behalf the French Collateral Documents to which it is a party, and (ii)
         to perform the duties and to exercise the rights, powers and
         discretions of the Secured Creditors that are specifically delegated to
         it pursuant to this Agreement or the French Collateral Documents in
         connection with such French Collateral Documents, together with any
         other incidental rights, powers and discretions which are incidental
         thereto and (iii) to give any discharge for any monies payable under
         the French Collateral Documents; and

                  (ii)     each Lender (including, without limitation, each
         Lender which is a Hedging Creditor (as defined in the Foreign
         Subsidiaries Guaranty)) and each Issuing Lender irrevocably authorizes
         the Collateral Agent for and on its behalf to exercise the rights,
         powers and discretions which are specifically delegated to it by the
         terms of the French Collateral Documents and this Agreement, together
         with all rights, powers and discretions which are incidental thereto
         and to give any discharge for any monies payable under the French
         Collateral Documents.

                  (b)      Notwithstanding Section 13.08 hereof, the provisions
of this Section 12.14 shall be governed by the laws of the France.

                  12.15 Special Appointment of Collateral Agent (Quebec). (a)
Without limiting the powers of the Administrative Agent and the Collateral Agent
hereunder and under the Security Documents, each Lender (for its benefit and the
benefit of its affiliates), each Issuing Lender, the Administrative Agent, the
Collateral Agent, each other Agent, the Sole Lead Arranger and each Hedging
Creditor (as defined in the Foreign Subsidiaries Guaranty entered into by the
relevant Quebec Security Granting Parties (as hereinafter defined)) (all such
Lenders (for their benefit and the benefit of their respective affiliates),
Issuing Lenders, Administrative Agent, Collateral Agent, other Agents, Sole Lead
Arranger and Hedging Creditors are collectively called, for purposes of this
Section 12.15, the "Quebec Secured Parties") and the Collateral Agent (in its
sole capacity as the initial holder of the Bonds (as defined below)) hereby

                                     -173-

<PAGE>

acknowledges and agrees that the Collateral Agent shall, for the purposes of
holding any security granted under the Security Documents pursuant to the laws
of the Province of Quebec to secure payment of bonds (or any similar
instruments) issued by 1036058 Ontario Inc., Exide Canada Inc. or any other
Credit Party (collectively, the "Quebec Security Granting Parties") (which bonds
as amended, restated, replaced, modified or supplemented at any time, for
purposes of this Section 12.15, shall be hereinafter referred to as the
"Bonds"), be the holder of an irrevocable power of attorney ("fonde de pouvoir")
(within the meaning of Article 2692 of the Civil Code of Quebec) for all present
and future Quebec Secured Parties and holders of the Bonds. Each of the Quebec
Secured Parties and the Collateral Agent (solely in its capacity as the initial
holder of the Bonds) hereby ratifies the appointment of and constitutes, to the
extent necessary, the Collateral Agent as the holder of such irrevocable power
of attorney ("fonde de pouvoir") in order to hold security granted by any one of
the Quebec Security Granting Parties under the Credit Documents in the Province
of Quebec to secure payment of the Bonds. Each assignee Quebec Secured Party and
each assignee holder of Bonds shall be deemed to have confirmed and ratified the
constitution of the Collateral Agent as the holder of such irrevocable power of
attorney ("fonde de pouvoir") by execution of the relevant agreements relating
to such assignment. The Collateral Agent agrees to act in such capacity.
Furthermore, the Collateral Agent hereby agrees and each of the other Quebec
Secured Parties hereby appoints the Collateral Agent to act in the capacity of
the holder and depositary of the Bonds on its own behalf as Collateral Agent and
for and on behalf and for the benefit of all present and future Quebec Secured
Parties. Each assignee Quebec Secured Party shall be deemed to have confirmed
and ratified the constitution of the Collateral Agent as such holder and
depositary of the Bonds by execution of the relevant agreements relating to such
assignment. To the extent necessary, each Hedging Creditor shall be deemed to
confirm and ratify the appointments made under this Section 12.15 by its
execution of the relevant Interest Rate Protection Agreement or Other Hedging
Agreement.

                  (b)      The parties hereto expressly waive the provisions and
protection of Section 32 of An Act Respecting Special Powers of Legal Persons
(Quebec). The Collateral Agent may acquire and be the holder of the Bonds or
other titles of indebtedness. Each of parties hereto acknowledges and agrees
that the Bonds constitute a title of indebtedness as such term is used in
Article 2692 of the Civil Code of Quebec.

                  (c)      Notwithstanding Section 13.08 hereof, the provisions
of this Section 12.15 shall be governed by the laws of the Province of Quebec
and the federal laws of Canada applicable therein.

                  12.16 Special Appointment of Collateral Agent (Belgium). (a)
Without prejudice to the generality of Section 12.11, each Lender and each
Issuing Lender that is or will become party to this Agreement hereby authorizes
and directs, and each Secured Creditor (including each Hedging Creditor (as
defined in the Foreign Subsidiaries Guaranty) that is not or will not become a
party to this Agreement) by its acceptance of the benefits of the Foreign
Security Agreements over the business assets of any Belgian Credit Party (the
"Belgian Pledges on Business Assets") hereby authorizes and directs, Deutsche
Bank Luxembourg SA ("DBL") to be the collateral agent for the purpose of the
Belgian Pledges on Business Assets. The provisions applicable to the Collateral
Agent shall apply mutatis mutandis to DBL for the purpose of the Belgian Pledges
on Business Assets.

                                     -174-

<PAGE>

                  (b)      Without prejudice to the rights of the Secured
Creditors under the Belgian Pledges on Business Assets, each such Secured
Creditor agrees that DBL shall be the obligee of the Belgian Credit Party with
respect to such Belgian Pledges on Business Assets and shall be entitled in its
own name to claim performance of the Secured Obligations thereunder, and there
shall be a solidarite active/actieve hoofdelijkheid between DBL and the Lenders
in relation thereto.

                  12.17 Special Appointment of Collateral Agent (Austria). (a)
Without prejudice to the generality of Section 12.11:

                  (i)      each Lender and each Issuing Lender that is or will
         become party to this Agreement hereby assigns and transfers, and each
         Secured Creditor (including each Hedging Creditor (as defined in the
         U.S. Security Agreement) that is not or will not become party to the
         Agreement) by its acceptance of the benefits of the Austrian Security
         assigns and transfers on the terms set forth in this Section, to the
         Collateral Agent as nominee ("Treuhaender") for the purpose of holding,
         accepting, administering, enforcing and releasing in its own name but
         for the account ("treuhaendig") of each Lender, each Issuing Lender and
         of each Secured Creditor: (x) all obligations guaranteed by the
         respective Foreign Subsidiary Guarantor by executing the Foreign
         Subsidiaries Guaranty which obligations are secured by the Austrian
         Security and (y) the Austrian Security of the Secured Creditors;

                  (ii)     the Collateral Agent accepts the above assignment and
         transfer and its appointment as a nominee ("Treuhaender") of all
         obligations secured by the Foreign Subsidiaries Guaranty and takes over
         all such obligations and accepts its appointment as a nominee
         ("Treuhaender") of the Austrian Security on the terms and subject to
         the conditions set out in this Agreement; and

                  (iii)    the Secured Creditors agree that, in relation to the
         Austrian Security, no Secured Party may dispose of any obligation which
         is secured by the Foreign Subsidiaries Guaranty or by the Austrian
         Security or take any other action in relation to any obligation which
         is secured by the Foreign Subsidiaries Guaranty or the Austrian
         Security, or make or receive any declarations in relation thereto in
         its own name but only by directing the Collateral Agent as nominee
         ("Treuhaender") to act in the name of the Collateral Agent but for the
         account of the Secured Creditors since the Collateral Agent is holding
         all such obligations secured by the Foreign Subsidiaries Guaranty or
         the Austrian Security in its own name.

                  (b)      The Collateral Agent shall:

                  (i)      hold and administer any obligation which is secured
         by the Austrian Security; and

                  (ii)     hold and administer any Austrian Security which is
         pledged under Austrian law ("verpfaendet") or otherwise transferred
         ("uebertragen") in accordance with Austrian law to any of the Secured
         Parties under an accessory security right ("akzessorische Sicherheit").

                                     -175-

<PAGE>

                  (c)      Each Secured Party hereby authorizes the Collateral
Agent to accept, as its nominee ("Treuhaender"), any Austrian Security created
in favor of such Secured Party.

Furthermore, each Secured Party hereby authorizes the Collateral Agent (with the
right of sub-delegation) to enter in its own name but for the account of
("treuhaendig") the Secured Party into any documents evidencing Austrian
Security and to make and accept all declarations and take all actions as it
considers necessary or useful in connection with any Austrian Security in favor
of such Secured Party. The Collateral Agent shall further be entitled to
rescind, release, amend and/or execute new and different documents securing the
Austrian Security.

                  (d)      The Collateral Agent shall, upon the request of a
Lender, Issuing Lender or a Secured Creditor, as the case may be, re-assign and
re-transfer any obligation which is secured by the Foreign Subsidiaries Guaranty
or the Austrian Security or any claim and/or right or asset or proceeds arising
from the Austrian Security or any accessory security right which is held by the
Collateral Agent on behalf of such Lender, Issuing Lender or Secured Creditor as
nominee ("treuhaendig") upon a respective request of such Lender, Issuing Lender
or Secured Creditor in accordance with the request and the terms and conditions
of this Agreement without undue delay.

                  (e)      Notwithstanding Section 13.08 hereof, the provisions
of this Section 12.17 shall be governed by the laws of Austria.

                  12.18 Special Appointment of Collateral Agent (Italy). (a)
Without prejudice to the generality of Section 12.11:

                  (i)      each Lender (including, without limitation, each
         Lender which is a Hedging Creditor (as defined in the Foreign
         Subsidiaries Guaranty)) (as "mandante" under Italian law), by executing
         this Agreement, irrevocably appoints the Collateral Agent to act as
         agent ("mandatario con rappresentanza" under Italian law) under and in
         connection with the Foreign Security Documents governed by Italian law
         (collectively, the "Italian Collateral Documents") and irrevocably
         authorizes the Collateral Agent (x) to execute on its behalf the
         Italian Collateral Documents, and (y) to perform the duties and to
         exercise the rights, powers and discretions that are specifically
         delegated to it under or in connection with the Italian Collateral
         Documents, together with any other incidental rights, powers and
         discretions; and

                  (ii)     each Lender (including, without limitation, each
         Lender which is a Hedging Creditor (as defined in the Foreign
         Subsidiaries Guaranty)) irrevocably authorizes the Collateral Agent for
         and on its behalf to exercise the rights, powers and discretions which
         are specifically delegated to it by the terms of the Italian Collateral
         Documents and this Agreement, together with all rights, powers and
         discretions which are incidental thereto and to give any discharge for
         any monies payable under the Italian Collateral Documents.

                  (b)      Notwithstanding Section 13.08 hereof, the provisions
of this Section 12.18 shall be governed by Italian law.

                                     -176-

<PAGE>

                  12.19 Special Appointment of Collateral Agent (Poland). (a)
Without prejudice to the generality of Section 12.11:

                  (i)      each Lender and Issuing Lender that is or will become
         party to this Agreement and each Secured Creditor (including each
         Hedging Creditor (as defined in the Foreign Subsidiaries Guaranty) that
         is not or will not become a party to this Agreement) by its acceptance
         of the benefits of the Foreign Subsidiary Guaranty and/or any Foreign
         Security Document governed by Polish law (collectively, the "Polish
         Collateral Documents"), hereby (as "mocodawca" under Polish law)
         irrevocably appoints the Collateral Agent to act as agent (as
         "pe(3)nomocnik" under Polish law) under and in connection with the
         Polish Collateral Documents and irrevocably authorizes the Collateral
         Agent (i) to execute on its behalf the Polish Collateral Documents, and
         (ii) to perform the duties and to exercise the rights, powers and
         discretions that are specifically delegated to it under or in
         connection with the Polish Collateral Documents, together with any
         other incidental rights and powers, including, without limitation, the
         ability to act as the pledge agent ("administrator zastawu") within the
         meaning of Art. 4 of the Polish Law on the registered pledge and pledge
         register dated December 6, 1996; and

                  (ii)     each Lender and Issuing Lender that is or will become
         party to this Agreement and each Secured Creditor (including each
         Hedging Creditor (as defined in the Foreign Subsidiaries Guaranty) that
         is not or will not become a party to this Agreement) by its acceptance
         of the benefits of the Polish Collateral Documents, hereby irrevocably
         authorizes the Collateral Agent for and on its behalf to exercise the
         rights, powers and discretions which are specifically delegated to it
         by the terms of each of the Polish Collateral Documents and this
         Agreement, together with all rights, powers and discretions which are
         incidental thereto and to give any discharge for any monies payable
         under any Polish Collateral Documents.

                  (b)      Notwithstanding Section 13.08 hereof, the provisions
of Section 12.19 shall be governed by the laws of Poland.

                  SECTION 13. Miscellaneous.

                  13.01 Payment of Expenses, etc. The Borrowers jointly and
severally agree to: (i) whether or not the transactions herein contemplated are
consummated, pay all reasonable out-of-pocket costs and expenses of the Agents
(including, without limitation, the reasonable fees and disbursements of White &
Case LLP and local and foreign counsel) in connection with the negotiation,
preparation, execution and delivery of this Agreement and the other Credit
Documents and the documents and instruments referred to herein and therein and
of the Agents in connection with any amendment, waiver or consent relating
hereto or thereto, and of each Agent in connection with its syndication efforts
with respect to this Agreement; (ii) pay all reasonable out-of-pocket costs and
expenses of each Agent, each Issuing Lender and each of the Lenders in
connection with the enforcement of the Credit Documents and the documents and
instruments referred to therein (including, without limitation, the reasonable
fees and disbursements of counsel) and the protection of the rights of each
Agent, each Issuing Lender and each of the Lenders thereunder (including,
without limitation, the reasonable fees and disbursements of counsel (including
in-house counsel) for each Agent, each Issuing Lender and each of the

                                     -177-

<PAGE>

Lenders); (iii) pay and hold each of the Agents, each Issuing Lender and each of
the Lenders harmless from and against any and all present and future stamp,
documentary, transfer, sales and use, value added, excise and other similar
taxes with respect to the foregoing matters, the performance of any obligation
under this Agreement or any other Credit Document or any payment thereunder, and
save each of the Agents, each Issuing Lender and each of the Lenders harmless
from and against any and all liabilities with respect to or resulting from any
delay or omission (other than to the extent attributable to the Agents, such
Issuing Lender or such Lender) to pay such taxes; and (iv) indemnify each Agent,
each Issuing Lender and each Lender, their respective officers, directors,
employees, representatives, trustees and agents from and hold each of them
harmless against any and all liabilities, obligations (including removal or
remedial actions), losses, damages, penalties, claims, actions, costs, expenses
and disbursements incurred by, imposed on or assessed against any of them as a
result of, or arising out of, or in any way related to, or by reason of, (a) any
investigation, litigation or other proceeding (whether or not any Agent, any
Issuing Lender or any Lender is a party thereto and whether or not any such
investigation, litigation or other proceeding is between or among any Agent, any
Issuing Lender, any Lender, any Credit Party or any third Person or otherwise)
related to the entering into and/or performance of this Agreement or any other
Document or the use of any Letter of Credit or the proceeds of any Loans
hereunder or the Transaction or the consummation of any other transactions
contemplated by any Document or the exercise or enforcement of any of their
rights or remedies provided herein or in the other Credit Documents (but
excluding any such liabilities, obligations, losses, damages, penalties, claims,
actions, costs, expenses and disbursements to the extent incurred by reason of
the gross negligence or willful misconduct (as determined by a court of
competent jurisdiction in a final and non-appealable decision) of the Person to
be indemnified), or (b) the actual or alleged presence of Hazardous Materials in
the air, surface water or groundwater or on the surface or subsurface of any
Real Property at any time owned, leased or operated by any Credit Party or any
of its Subsidiaries, the Release, generation, storage, transportation, handling
or disposal of Hazardous Materials at any location, whether or not owned, leased
or operated by any Credit Party or any of its Subsidiaries, the non-compliance
of any Real Property with foreign, federal, state and local laws, regulations,
and ordinances (including applicable permits thereunder) applicable to any Real
Property, or any Environmental Claim in connection with or relating to any
Credit Party, any of its Subsidiaries or any of their operations or activities
or any Real Property at any time owned, leased or operated by any Credit Party
or any of its Subsidiaries, in each case, including, without limitation, the
reasonable fees and disbursements of counsel and independent consultants
incurred in connection with any such investigation, litigation or other
proceeding (but excluding any such liabilities, obligations, losses, damages,
penalties, claims, actions, costs, expenses and disbursements to the extent
incurred by reason of the gross negligence or willful misconduct (as determined
by a court of competent jurisdiction in a final and non-appealable decision) of
the Person to be indemnified)). To the extent that the undertaking to indemnify,
pay or hold harmless any Agent, any Issuing Lender or any Lender set forth in
the preceding sentence may be unenforceable because it is violative of any law
or public policy, the Borrowers hereby agree to make the maximum contribution to
the payment and satisfaction of each of the indemnified liabilities which is
permissible under applicable law.

                  13.02 Right of Setoff. (a) In addition to any rights now or
hereafter granted under applicable law or otherwise, and not by way of
limitation of any such rights, upon the occurrence of an Event of Default, each
Agent, each Issuing Lender and each Lender is hereby

                                     -178-

<PAGE>

authorized at any time or from time to time, without presentment, demand,
protest or other notice of any kind to the U.S. Borrower or any of its
Subsidiaries or to any other Person, any such notice being hereby expressly
waived, to set off and to appropriate and apply any and all deposits (general or
special) and any other Indebtedness at any time held or owing by such Agent,
such Issuing Lender or such Lender (including, without limitation, by
Affiliates, branches and agencies of such Agent, such Issuing Lender or such
Lender wherever located) to or for the credit or the account of the U.S.
Borrower or any of its Subsidiaries against and on account of the Obligations of
the U.S. Borrower or such Subsidiary, as the case may be, to such Agent, such
Issuing Lender or such Lender under this Agreement or under any of the other
Credit Documents, including, without limitation, all interests in Obligations
purchased by such Lender pursuant to Section 13.06(b), all participations by any
Lender in any Swingline Loans or Letters of Credit as required pursuant to the
provisions of this Agreement and all other claims of any nature or description
arising out of or connected with this Agreement or any other Credit Document,
irrespective of whether or not such Agent, such Issuing Lender or such Lender
shall have made any demand hereunder and although said Obligations shall be
contingent or unmatured. Each Borrower agrees that any Lender purchasing
participations in one or more Letters of Credit issued, or Swingline Loans made,
to it as required by the provisions of this Agreement, or purchasing
participations as required by Section 13.06(b), may, to the fullest extent
permitted by law, exercise all rights (including without limitation the right of
setoff) with respect to such participations as fully as if such Lender is a
direct creditor of such Borrower with respect to such participations in the
amount thereof.

                  (b)      NOTWITHSTANDING THE FOREGOING SUBSECTION (a), AT ANY
TIME THAT THE LOANS OR ANY OTHER OBLIGATION SHALL BE SECURED BY REAL PROPERTY
LOCATED IN CALIFORNIA, NO LENDER OR THE ADMINISTRATIVE AGENT SHALL EXERCISE A
RIGHT OF SETOFF, LIEN OR COUNTERCLAIM OR TAKE ANY COURT OR ADMINISTRATIVE ACTION
OR INSTITUTE ANY PROCEEDING TO ENFORCE ANY PROVISION OF THIS AGREEMENT OR ANY
NOTE UNLESS IT IS TAKEN WITH THE CONSENT OF THE REQUIRED LENDERS OR APPROVED IN
WRITING BY THE ADMINISTRATIVE AGENT, IF SUCH SETOFF OR ACTION OR PROCEEDING
WOULD OR MIGHT (PURSUANT TO CALIFORNIA CODE OF CIVIL PROCEDURE SECTIONS 580A,
580B, 580D AND 726 OF THE CALIFORNIA CODE OF CIVIL PROCEDURE OR SECTION 2924 OF
THE CALIFORNIA CIVIL CODE, IF APPLICABLE, OR OTHERWISE) AFFECT OR IMPAIR THE
VALIDITY, PRIORITY OR ENFORCEABILITY OF THE LIENS GRANTED TO THE COLLATERAL
AGENT PURSUANT TO THE SECURITY DOCUMENTS OR THE ENFORCEABILITY OF THE NOTES AND
OTHER OBLIGATIONS HEREUNDER, AND ANY ATTEMPTED EXERCISE BY ANY LENDER OR THE
ADMINISTRATIVE AGENT OF ANY SUCH RIGHT WITHOUT OBTAINING SUCH CONSENT OF THE
REQUIRED LENDERS OR THE ADMINISTRATIVE AGENT SHALL BE NULL AND VOID. THIS
SUBSECTION (b) SHALL BE SOLELY FOR THE BENEFIT OF EACH OF THE LENDERS AND THE
ADMINISTRATIVE AGENT HEREUNDER.

                  13.03 Notices. (a) Except as otherwise expressly provided
herein, all notices and other communications provided for hereunder shall be in
writing (including telegraphic, telex, facsimile or cable communication) and
mailed, telegraphed, telexed, telecopied, cabled or

                                     -179-

<PAGE>

delivered: if to either Borrower, at the address specified opposite its
signature below; if to any Lender, at its address specified for such Lender on
Schedule II; and if to the Administrative Agent, at its Notice Office; or, as to
either Borrower or any of the Agents, at such other address as shall be
designated by such party in a written notice to the other parties hereto and, as
to each Lender, at such other address as shall be designated by such Lender in a
written notice to the U.S. Borrower and the Administrative Agent. All such
notices and communications shall be mailed, telegraphed, telexed, telecopied or
cabled or sent by overnight courier, and shall be effective when received.

                  (b)      Without in any way limiting the obligation of the
U.S. Borrower and its Subsidiaries to confirm in writing any telephonic notice
permitted to be given hereunder, any Agent, the Swingline Lender (in the case of
a Borrowing of Swingline Loans) or any Issuing Lender (in the case of the
issuance of a Letter of Credit), as the case may be, may prior to receipt of
written confirmation act without liability upon the basis of such telephonic
notice, believed by such Agent, the Swingline Lender or such Issuing Lender in
good faith to be from an Authorized Officer. In each such case, each of the
Borrowers hereby waive the right to dispute such Agent's, the Swingline Lender's
or such Issuing Lender's record of the terms of such telephonic notice.

                  13.04 Benefit of Agreement. (a) This Agreement shall be
binding upon and inure to the benefit of and be enforceable by the respective
successors and assigns of the parties hereto; provided, however, neither
Borrower may assign or transfer any of its rights, obligations or interest
hereunder or under any other Credit Document without the prior written consent
of each of the Lenders and, provided further, that, although any Lender may
(without the consent of any Credit Party) transfer, assign or grant
participations in its rights hereunder, such Lender shall remain a "Lender" for
all purposes hereunder (and may not transfer or assign all or any portion of its
Commitments or Loans hereunder except as provided in Section 13.04(b)) and the
transferee, assignee or participant, as the case may be, shall not constitute a
"Lender" hereunder and, provided further, that no Lender shall transfer or grant
any participation under which the participant shall have rights to approve any
amendment to or waiver of this Agreement or any other Credit Document except to
the extent such amendment or waiver would (i) extend the final scheduled
maturity of any Loan, Note, or Letter of Credit (unless such Letter of Credit is
not extended beyond the Revolving Loan Maturity Date) in which such participant
is participating, or reduce the rate or extend the time of payment of interest
or Fees thereon (except in connection with a waiver of applicability of any
post-default increase in interest rates) or reduce the principal amount thereof,
or increase the amount of the participant's participation over the amount
thereof then in effect (it being understood that a waiver of any Default or
Event of Default or of a mandatory reduction in the Total Commitment or of a
mandatory repayment of Loans shall not constitute a change in the terms of such
participation, that an increase in any Commitment or Loan shall be permitted
without the consent of any participant if the participant's participation is not
increased as a result thereof and that any amendment or modification to the
financial definitions in this Agreement (other than a modification of the
percentages set forth in the definition of "Applicable Margin") shall not
constitute a reduction in any rate of interest or fees for purposes of this
clause (i), notwithstanding the fact that such amendment or modification
actually results in such a reduction), (ii) consent to the assignment or
transfer by either Borrower of any of its rights and obligations under this
Agreement or (iii) release all or substantially all of the Collateral under all
of the Security Documents (except as

                                     -180-

<PAGE>

expressly provided in the Security Documents) supporting the Obligations in
which such participant is participating. In the case of any such participation,
the participant shall not have any rights under this Agreement or any of the
other Credit Documents (the participant's rights against such Lender in respect
of such participation to be those set forth in the agreement executed by such
Lender in favor of the participant relating thereto) and all amounts payable by
the Borrowers hereunder shall be determined as if such Lender had not sold such
participation.

                  (b)      Notwithstanding the foregoing, any Lender (or any
Lender together with one or more other Lenders) may (x) assign all or a portion
of its Multicurrency Facility Revolving Loan Commitment (and related outstanding
Obligations hereunder), and/or its outstanding Term Loans to (i) its parent
company and/or any affiliate of such Lender which is at least 50% owned by such
Lender or its parent company, (ii) one or more Lenders or (iii) in the case of
any Lender that is a fund that invests in bank loans, any other fund that
invests in bank loans and is managed by the same investment advisor as a Lender
or by an Affiliate of such investment advisor or (y) assign all, or if less than
all, a portion equal to at least $1,000,000 in the aggregate for the assigning
Lender or assigning Lenders, of such Multicurrency Facility Revolving Loan
Commitments (and related outstanding Obligations hereunder) and/or outstanding
principal amount of Term Loans hereunder to one or more Eligible Transferees
(treating (I) any fund that invests in bank loans and (II) any other fund that
invests in bank loans and is managed by the same investment advisor as such fund
or by an Affiliate of such investment advisor, as a single Eligible Transferee),
each of which assignees shall become a party to this Agreement as a Lender by
execution of an Assignment and Assumption Agreement, provided that (i) at such
time Schedule I shall be deemed modified to reflect the Multicurrency Facility
Revolving Loan Commitments and/or outstanding Term Loans, as the case may be, of
such new Lender and of the existing Lenders, (ii) upon request of assigning or
assignee Lender, and upon surrender of the old Notes (if any) or a lost Note(s)
indemnity in form reasonably satisfactory to the Administrative Agent, new Notes
will be issued, at the Borrowers' expense, to such new Lender and to the
assigning Lender, such new Notes to be in conformity with the requirements of
Section 1.05 (with appropriate modifications) to the extent needed to reflect
the revised Multicurrency Facility Revolving Loan Commitments and/or outstanding
Term Loans, as the case may be, (iii) except in the case of assignments made by
the Agents prior to the Syndication Date and as part of the primary syndication
of the Loans and Commitments, the consent of the Administrative Agent and, so
long as no Default or Event of Default then exists and is continuing, the
Borrowers shall be required in connection with any such assignment pursuant to
clause (y) of this Section 13.04(b) (which consent shall not be unreasonably
withheld or delayed), (iv) the consent of the Swingline Lender and each Issuing
Lender shall be required in connection with any assignment of Multicurrency
Facility Revolving Loan Commitments pursuant to this Section 13.04(b) (which
consent shall not be unreasonably withheld or delayed), and (v) the
Administrative Agent shall receive at the time of each such assignment, from the
assigning or assignee Lender, the payment of a non-refundable assignment fee of
$3,500 and, provided further, that such transfer or assignment will not be
effective until recorded by the Administrative Agent on the Register pursuant to
Section 13.17. To the extent of any assignment pursuant to this Section
13.04(b), the assigning Lender shall be relieved of its obligations hereunder
with respect to its assigned Commitments and/or outstanding Term Loans, as the
case may be. At the time of each assignment pursuant to this Section 13.04(b) to
a Person which is not already a Lender hereunder and which is not a United
States person (as such term is defined in Section 7701(a)(30) of the Code) for
Federal income tax purposes, the respective assignee

                                     -181-

<PAGE>

Lender shall, to the extent legally entitled to do so, provide to the U.S.
Borrower and the Administrative Agent the appropriate Internal Revenue Service
Forms (and, if applicable, a Section 4.04(b)(ii) Certificate) described in
Section 4.04(b)(ii) to the extent such forms would provide a complete exemption
from or reduction in United States withholding tax. At the time of each
assignment pursuant to this Section 13.04(b) to a Person which is not already a
Lender hereunder, the respective assignee Lender shall, to the extent legally
entitled to do so, provide to the European Borrower and the Administrative Agent
the appropriate Netherlands Forms or such other forms or certificates described
in Section 4.04(c) to the extent the European Borrower requests the assigned
Lender to provide such forms or certificates and such forms or certificates
would provide a complete exemption from or reduction in Netherlands withholding
tax. To the extent that an assignment of all or any portion of a Lender's
Commitments and related outstanding Obligations pursuant to Section 1.13 or this
Section 13.04(b) would, at the time of such assignment, result in increased
costs under Section 1.10, 1.11, 2.06 or 4.04 from those being charged by the
respective assigning Lender prior to such assignment, then the Borrowers shall
not be obligated to pay such increased costs (although the Borrowers, in
accordance with and pursuant to the other provisions of this Agreement, shall be
obligated to pay any other increased costs of the type described above resulting
from changes after the date of the respective assignment). Notwithstanding
anything to the contrary contained above, at any time after the termination of
the Total Multicurrency Facility Revolving Loan Commitment, if any Multicurrency
Facility Revolving Loans or Letters of Credit remain outstanding, assignments
may be made as provided above, except that the respective assignment shall be of
a portion of the outstanding Multicurrency Facility Revolving Loans of the
respective Multicurrency Facility RL Lender and its participation in Letters of
Credit and its obligation to make Mandatory Borrowings, although any such
assignment effected after the termination of the Total Multicurrency Facility
Revolving Loan Commitment shall not release the assigning Multicurrency Facility
RL Lender from its obligations as a participant with respect to outstanding
Letters of Credit or to fund its share of any Mandatory Borrowing (although the
respective assignee may agree, as between itself and the respective assigning
Multicurrency Facility RL Lender, that it shall be responsible for such
amounts).

                  (c)      Nothing in this Agreement shall prevent or prohibit
any Lender from pledging its Loans and Notes hereunder to a Federal Reserve Bank
in support of borrowings made by such Lender from such Federal Reserve Bank and,
with prior notification to the Administrative Agent (but without the consent of
the Administrative Agent or either Borrower), any Lender which is a fund may
pledge all or any portion of its Notes or Loans to its trustee or to a
collateral agent or to another creditor providing credit or credit support to
such Lender in support of its obligations to such trustee, such Collateral Agent
or a holder of, or any other representative of a holder of, such obligations, or
such other creditor, as the case may be. No pledge pursuant to this clause (c)
shall release the transferor Lender from any of its obligations hereunder.

                  13.05 No Waiver; Remedies Cumulative. No failure or delay on
the part of any Agent or any Lender in exercising any right, power or privilege
hereunder or under any other Credit Document and no course of dealing between
any Credit Party and any Agent or any Lender shall operate as a waiver thereof,
nor shall any single or partial exercise of any right, power or privilege
hereunder or under any other Credit Document preclude any other or further
exercise thereof or the exercise of any other right, power or privilege
hereunder or thereunder.

                                     -182-

<PAGE>

The rights and remedies herein expressly provided are cumulative and not
exclusive of any rights or remedies which any Agent or any Lender would
otherwise have. No notice to or demand on any Credit Party in any case shall
entitle any Credit Party to any other or further notice or demand in similar or
other circumstances or constitute a waiver of the rights of any Agent or any
Lender to any other or further action in any circumstances without notice or
demand.

                  13.06 Payments Pro Rata. (a) The Administrative Agent agrees
that promptly after its receipt of each payment from or on behalf of any Credit
Party in respect of any Obligations of such Credit Party, it shall, except as
otherwise provided in this Agreement, distribute such payment to the Lenders
(other than any Lender that has consented in writing to waive its pro rata share
of such payment) pro rata based upon their respective shares, if any, of the
Obligations with respect to which such payment was received.

                  (b)      Each of the Lenders agrees that, if it should receive
any amount hereunder (whether by voluntary payment, by realization upon
security, by the exercise of the right of setoff or banker's lien, by
counterclaim or cross action, by the enforcement of any right under the Credit
Documents, or otherwise) which is applicable to the payment of the principal of,
or interest on, the Loans, Unpaid Drawings or Fees, of a sum which with respect
to the related sum or sums received by other Lenders is in a greater proportion
than the total of such Obligation then owed and due to such Lender bears to the
total of such Obligation then owed and due to all of the Lenders immediately
prior to such receipt, then such Lender receiving such excess payment shall
purchase for cash without recourse or warranty from the other Lenders an
interest in the Obligations of the respective Credit Party to such Lenders in
such amount as shall result in a proportional participation by all of the
Lenders in such amount; provided that if all or any portion of such excess
amount is thereafter recovered from such Lender, such purchase shall be
rescinded and the purchase price restored to the extent of such recovery, but
without interest.

                  (c)      Notwithstanding anything to the contrary contained
herein, the provisions of the preceding Sections 13.06(a) and (b) shall be
subject to the express provisions of this Agreement which require, or permit,
differing payments to be made to Non-Defaulting Lenders as opposed to Defaulting
Lenders.

                  13.07 Calculations; Computations. (a) The financial statements
to be furnished to the Lenders pursuant hereto shall be made and prepared in
accordance with U.S. GAAP consistently applied throughout the periods involved
(except as set forth in the notes thereto or as otherwise disclosed in writing
by the U.S. Borrower to the Lenders), provided that (i) except as otherwise
specifically provided herein, all computations determining the Applicable
Margins, Excess Cash Flow, the Leverage Ratio and compliance with Sections 4,
8.15 and 9, including in each case definitions used therein, shall, in each
case, utilize United States accounting principles and policies in effect at the
time of the preparation of, and in conformity with those used to prepare, the
historical consolidated audited financial statements of Old Exide delivered to
the Lenders pursuant to Section 7.10(b) for the fiscal year of the Old Exide
ended March 31, 2003, (ii) to the extent expressly required pursuant to the
provisions of this Agreement, certain calculations shall be made on a Pro Forma
Basis, and (iii) for purposes of determining compliance with any incurrence or
expenditure tests set forth in Sections 8 and/or 9 (excluding Sections 9.08,
9.09 and 9.10), any amounts so incurred or expended (to the extent incurred or
expended in a currency other than Dollars) shall be converted into Dollars on
the basis of the

                                     -183-

<PAGE>

exchange rates (as shown on Reuters ECB page 37 or, if same does not provide
such exchange rates, on such other basis as is reasonably satisfactory to the
Administrative Agent) as in effect on the date of such incurrence or expenditure
under any provision of any such Section that has an aggregate Dollar limitation
provided for therein (and to the extent the respective incurrence or expenditure
test regulates the aggregate amount outstanding at any time and it is expressed
in terms of Dollars, all outstanding amounts originally incurred or spent in
currencies other than Dollars shall be converted into Dollars on the basis of
the exchange rates (as shown on Reuters ECB page 37 or, if same does not provide
such exchange rates, on such other basis as is reasonably satisfactory to the
Administrative Agent) as in effect on the date of any new incurrence or
expenditures made under any provision of any such Section that regulates the
Dollar amount outstanding at any time).

                  (b)      All computations of interest, RL Commitment
Commission and other Fees hereunder shall be made on the basis of a year of 360
days for the actual number of days (including the first day but excluding the
last day) occurring in the period for which such interest, RL Commitment
Commission or Fees are payable.

                  13.08 Governing Law; Submission to Jurisdiction; Venue. (a)
THIS AGREEMENT AND THE OTHER CREDIT DOCUMENTS AND THE RIGHTS AND OBLIGATIONS OF
THE PARTIES HEREUNDER AND THEREUNDER SHALL, EXCEPT AS OTHERWISE PROVIDED IN
CERTAIN OF THE SUBSIDIARIES GUARANTIES AND SECURITY DOCUMENTS, BE CONSTRUED IN
ACCORDANCE WITH AND BE GOVERNED BY THE LAW OF THE STATE OF NEW YORK. Any legal
action or proceeding with respect to this Agreement or any other Credit Document
may be brought in the courts of the State of New York or of the United States
for the Southern District of New York, in each case located within the City of
New York and, by execution and delivery of this Agreement, each Borrower hereby
irrevocably accepts for itself and in respect of its property, generally and
unconditionally, the jurisdiction of the aforesaid courts. Each Borrower hereby
irrevocably designates, appoints and empowers CT Corporation System, with
offices on the date hereof at 111 Eighth Avenue, New York, New York, 10011, as
its authorized designee, appointee and agent to receive, accept and acknowledge
for and on its behalf, and in respect of its property, service of any and all
legal process, summons, notices and documents which may be served in any such
action or proceeding. If for any reason such authorized designee, appointee and
agent shall cease to be available to act as such, each Borrower agrees to
designate a new authorized designee, appointee and agent in New York City on the
terms and for the purposes of this provision reasonably satisfactory to the
Administrative Agent under this Agreement. Each Borrower hereby further
irrevocably waives any claim that any such courts lack jurisdiction over such
Borrower, and agrees not to plead or claim, in any legal action or proceeding
with respect to this Agreement or any other Credit Document brought in any of
the aforesaid courts, that any such court lacks jurisdiction over such Borrower.
Each Borrower further irrevocably consents to the service of process in any such
action or proceeding by the mailing of copies thereof by registered or certified
mail, postage prepaid, to such Borrower, as the case may be, at its address for
notices pursuant to Section 13.03, such service to become effective 30 days
after such mailing. Each Borrower hereby irrevocably waives any objection to
such service of process and further irrevocably waives and agrees not to plead
or claim in any action or proceeding commenced hereunder or under any other
Credit Document that service of process was in any way invalid or ineffective.
Nothing herein shall affect the right of any Agent, any Lender or the

                                     -184-

<PAGE>

holder of any Note to serve process in any other manner permitted by law or to
commence legal proceedings or otherwise proceed against either Borrower in any
other jurisdiction.

                  (b)      EACH BORROWER HEREBY IRREVOCABLY WAIVES ANY OBJECTION
WHICH IT MAY NOW OR HEREAFTER HAVE TO THE LAYING OF VENUE OF ANY OF THE
AFORESAID ACTIONS OR PROCEEDINGS ARISING OUT OF OR IN CONNECTION WITH THIS
AGREEMENT OR ANY OTHER CREDIT DOCUMENT BROUGHT IN THE COURTS REFERRED TO IN
CLAUSE (a) ABOVE AND HEREBY FURTHER IRREVOCABLY WAIVES AND AGREES NOT TO PLEAD
OR CLAIM IN ANY SUCH COURT THAT ANY SUCH ACTION OR PROCEEDING BROUGHT IN ANY
SUCH COURT HAS BEEN BROUGHT IN AN INCONVENIENT FORUM.

                  13.09 Counterparts. This Agreement may be executed in any
number of counterparts and by the different parties hereto on separate
counterparts, each of which when so executed and delivered shall be an original,
but all of which shall together constitute one and the same instrument. A
complete set of counterparts executed by all the parties hereto shall be lodged
with each Borrower and the Administrative Agent.

                  13.10 Effectiveness. This Agreement shall become effective on
the date (the "Effective Date") on which each of the Borrowers, each Agent and
each of the Lenders shall have signed a counterpart hereof (whether the same or
different counterparts) and shall have delivered the same (including by way of
facsimile transmission) to the Administrative Agent at the Notice Office or at
the office of the Administrative Agents' counsel. The Administrative Agent will
give the U.S. Borrower and each Lender prompt written notice of the occurrence
of the Effective Date.

                  13.11 Headings Descriptive. The headings of the several
sections and subsections of this Agreement are inserted for convenience only and
shall not in any way affect the meaning or construction of any provision of this
Agreement.

                  13.12 Amendment or Waiver; etc. (a) Except as expressly
provided in Section 13.26(b), neither this Agreement nor any other Credit
Document nor any terms hereof or thereof may be changed, waived, discharged or
terminated unless such change, waiver, discharge or termination is in writing
signed by the respective Credit Parties party thereto and the Required Lenders,
provided that no such change, waiver, discharge or termination shall, without
the consent of each Lender (other than a Defaulting Lender) (with Obligations
being directly affected thereby in the case of the following clause (i)), (i)
extend the final scheduled maturity of any Loan or Note or extend the stated
maturity of any Letter of Credit beyond the Revolving Loan Maturity Date or
extend the duration of any Interest Period beyond six months, or reduce the rate
or extend the time of payment of interest (other than as a result of any waiver
of the applicability of any post-default increase in interest rates) or Fees
thereon, or reduce the principal amount thereof (except to the extent paid in
cash) (it being understood that any amendment or modification to the financial
definitions in this Agreement shall not constitute a reduction in any rate of
interest or fees for purposes of this clause (i), notwithstanding the fact that
such amendment or modification actually results in such a reduction), (ii)
release all or substantially all of the Collateral (except as expressly provided
in the Credit Documents) under all the Security Documents, (iii) amend, modify
or waive any provision of this Section 13.12 (except

                                     -185-

<PAGE>

for technical amendments with respect to additional extensions of credit
pursuant to this Agreement which afford the protections to such additional
extensions of credit of the type provided to the U.S. Borrower Term Loans,
European Borrower Dollar Term Loans, European Borrower Euro Term Loans and the
Multicurrency Facility Revolving Loan Commitments on the Effective Date), (iv)
reduce the percentage specified in the definition of Required Lenders (it being
understood that, with the consent of the Required Lenders, additional extensions
of credit pursuant to this Agreement may be included in the determination of the
Required Lenders on substantially the same basis as the extensions of Term Loans
and Multicurrency Facility Revolving Loan Commitments are included on the
Effective Date), (v) consent to the assignment or transfer by either Borrower of
any of its rights and obligations under this Agreement or (vi) release the U.S.
Borrower's Guaranty; provided further, that no such change, waiver, discharge or
termination shall (q) amend, modify or waive any condition precedent set forth
in Section 6 with respect to the making of Multicurrency Facility Revolving
Loans, Swingline Loans or the issuance of Letters of Credit, without the written
consent of the Majority Lenders holding Multicurrency Facility Revolving Loan
Commitments, (r) increase the Commitments of any Lender over the amount thereof
then in effect without the consent of such Lender (it being understood that
waivers or modifications of conditions precedent, covenants, Defaults or Events
of Default or of a mandatory reduction in the Total Commitment shall not
constitute an increase of the Commitment of any Lender, and that an increase in
the available portion of any Commitment of any Lender shall not constitute an
increase in the Commitment of such Lender), (s) without the consent of each
Issuing Lender affected thereby, amend, modify or waive any provision of Section
2 or alter its rights or obligations with respect to Letters of Credit, (t)
without the consent of the Swingline Lender, alter its rights or obligations
with respect to Swingline Loans, (u) without the consent of each Agent affected
thereby, amend, modify or waive any provision of Section 12 as same applies to
such Agent or any other provision as same relates to the rights or obligations
of such Agent, (v) without the consent of the Collateral Agent, amend, modify or
waive any provision relating to the rights or obligations of the Collateral
Agent, (w) except in cases where additional extensions of term loans and/or
revolving loans are being afforded substantially the same treatment afforded to
the Term Loans and Multicurrency Facility Revolving Loans pursuant to this
Agreement as originally in effect, without the consent of the Majority Lenders
of each Tranche which is being allocated a lesser prepayment, repayment or
commitment reduction as a result of the actions described below, alter the
required application of any prepayments or repayments (or commitment reduction),
as between the various Tranches, pursuant to Section 4.01 or 4.02 (excluding
Section 4.02(b)) (although the Required Lenders may waive, in whole or in part,
any such prepayment, repayment or commitment reduction, so long as the
application, as amongst the various Tranches, of any such prepayment, repayment
or commitment reduction which is still required to be made is not altered), (x)
without the consent of the Majority Lenders of the respective Tranche affected
thereby, amend the definition of Majority Lenders (it being understood that,
with the consent of the Required Lenders, additional extensions of credit
pursuant to this Agreement may be included in the determination of the Majority
Lenders on substantially the same basis as the extensions of Loans and
Commitments are included on the Effective Date), (y) except in cases where
additional extensions of term loans and/or revolving loans are being afforded
substantially the same treatment afforded to the Term Loans and Multicurrency
Facility Revolving Loans pursuant to Section 1.14 (as originally in effect) and
except for technical amendments which are consistent with the intent of the
provisions of such Section and do not adversely affect the

                                     -186-

<PAGE>

protections afforded to the Lenders pursuant to said Section, without the
consent of the Majority Lenders of each Tranche adversely affected thereby,
amend, modify or waive any provisions of Section 1.14 or (z) without the consent
of the Supermajority Lenders of the respective Tranche, reduce the amount of or
extend the date of, any U.S. Borrower Term Loan Scheduled Repayment, European
Borrower Dollar Term Loan Scheduled Repayment or European Borrower Euro Term
Loan Scheduled Repayment (except that, if additional Loans are made pursuant to
a given Tranche, the Scheduled Repayments of such Tranche may be increased on a
proportionate basis without the consent otherwise required by this clause (z)),
or amend the definition of Supermajority Lenders (it being understood that, with
the consent of the Required Lenders, additional extensions of credit pursuant to
this Agreement may be included in the determination of the Supermajority Lenders
on substantially the same basis as the extensions of Loans and Commitments are
included on the Effective Date). Notwithstanding anything to the contrary
contained above in this Section 13.12(a), the Administrative Agent and/or the
Collateral Agent shall be permitted to enter into such amendments and/or
modifications to the Intercompany Subordination Agreement, the Foreign
Subsidiaries Guaranties and the Foreign Security Documents which may be required
in the discretion of the Administrative Agent and/or the Collateral Agent which
are of a technical nature and/or are, in the judgment of the Collateral Agent,
required by applicable law, in the interests of the Secured Creditors or (in the
case of Foreign Security Documents) necessary or desirable to preserve,
maintain, perfect and/or protect the security interests purported to the granted
by the respective Foreign Security Documents.

                  (b)      If, in connection with any proposed change, waiver,
discharge or termination of or to any of the provisions of this Agreement as
contemplated by clauses (i) through (v), inclusive, of the first proviso to
Section 13.12(a), the consent of the Required Lenders is obtained but the
consent of one or more of such other Lenders whose consent is required is not
obtained, then the U.S. Borrower shall have the right, so long as all
non-consenting Lenders whose individual consent is required are treated as
described in either clause (A) or (B) below, to either (A) replace each such
non-consenting Lender or Lenders (or, at the option of the U.S. Borrower if the
respective Lender's consent is required with respect to less than all Tranches
(or related Commitments), to replace only the respective Tranche or Tranches of
Commitments (and related Obligations) and/or Loans of the respective
non-consenting Lender which gave rise to the need to obtain such Lender's
individual consent) with one or more Replacement Lenders pursuant to Section
1.13 so long as at the time of such replacement, each such Replacement Lender
consents to the proposed change, waiver, discharge or termination or (B)
terminate the Multicurrency Facility Revolving Loan Commitment of such
non-consenting Lender (if such Lender's consent is required as a result of its
Multicurrency Facility Revolving Loan Commitment), and/or repay outstanding
Obligations under each Tranche of such Lender which gave rise to the need to
obtain such Lender's consent, in accordance with Sections 3.02(b) and/or 4.01,
provided that, unless the Commitments which are terminated and Loans and other
Obligations which are repaid pursuant to preceding clause (B) are immediately
replaced in full at such time through the addition of new Lenders or the
increase of the Commitments and/or outstanding Loans of existing Lenders (who in
each case must specifically consent thereto), then in the case of any action
pursuant to preceding clause (B), the Required Lenders (determined both (x)
after giving effect to the proposed action and (y) as if the Commitments, Loans
and related Obligations being terminated and/or repaid (and not replaced) were
not outstanding) shall specifically consent thereto, provided further, that the
U.S. Borrower shall not have the right to replace a Lender, terminate its
Commitment or repay its Loans or other Obligations solely as a

                                     -187-

<PAGE>

result of the exercise of such Lender's rights (and the withholding of any
required consent by such Lender) pursuant to the second proviso to Section
13.12(a).

                  13.13 Survival. All indemnities set forth herein including,
without limitation, in Sections 1.10, 1.11, 2.06, 4.04, 12.07, 13.01 and 13.17,
shall survive the execution and delivery of this Agreement and the making and
repayment of the Loans and the other Obligations.

                  13.14 Domicile of Loans and Commitments. Each Lender may
transfer and carry its Loans and/or Commitments at, to or for the account of any
branch office, subsidiary or affiliate of such Lender. Notwithstanding anything
to the contrary contained herein, to the extent that a transfer of Loans
pursuant to this Section 13.14 would, at the time of such transfer, result in
increased costs under Section 1.10, 1.11, 2.06 or 4.04 from those being charged
by the respective Lender prior to such transfer, then the Borrowers shall not be
obligated to pay such increased costs (although the Borrowers shall be obligated
to pay any other increased costs of the type described above resulting from
changes after the date of the respective transfer).

                  13.15 Confidentiality. (a) Each of the Lenders agrees that it
will use its reasonable efforts not to disclose without the prior consent of
either Borrower (other than to its directors, employees, auditors, counsel or
other professional advisors, to affiliates or to another Lender if the Lender or
such Lender's holding or parent company in its sole discretion determines that
any such party should have access to such information) any information with
respect to the U.S. Borrower or any of its Subsidiaries which is now or in the
future furnished pursuant to this Agreement; provided that any Lender may
disclose any such information (a) as has become generally available to the
public, (b) as may be required or appropriate (x) in any report, statement or
testimony submitted to any municipal, state or Federal regulatory body having or
claiming to have jurisdiction over such Lender or to the Federal Reserve Board
or the Federal Deposit Insurance Corporation or similar organizations (whether
in the United States or elsewhere) or their successors or (y) in connection with
any request or requirement of any such regulatory body, (c) as may be required
or appropriate in response to any summons or subpoena or in connection with any
litigation, (d) to comply with any law, order, regulation or ruling applicable
to such Lender, and (e) to any creditor or any prospective transferee or
participant in connection with any contemplated transfer or participation of any
of the Obligations or any interest therein by such Lender; provided that such
creditor or prospective transferee or participant agrees to be bound by this
Section 13.15 to the same extent as such Lender.

                  (b)      Each Borrower hereby acknowledges and agrees that
each Lender may share with any of its affiliates or its investment advisors any
information related to the U.S. Borrower or any of its Subsidiaries (including,
without limitation, any nonpublic customer information regarding the
creditworthiness of such entities), provided that such Persons shall be subject
to the provisions of this Section 13.15 to the same extent as such Lender and
shall only use such information in connection with matters relating to this
Agreement.

                  (c)      Each Borrower hereby represents and acknowledges
that, to the best of its knowledge, neither any Agent nor any Lender, nor any
employees or agents of, or other persons affiliated with, any Agent or any
Lender, have directly or indirectly made or provided any statement (oral or
written) to such Borrower or to any of its employees or agents, or other

                                     -188-

<PAGE>

persons affiliated with or related to such Borrower (or, so far as such Borrower
is aware, to any other person), as to the potential tax consequences of the
Transaction.

                  (d)      Notwithstanding anything contained in this Agreement
or in any other document, agreement or understanding relating to the
transactions contemplated by this Agreement, each party (and each employee,
representative, or other agent of such party) is authorized to disclose to any
and all persons, beginning immediately upon commencement of discussions
regarding the transactions contemplated by this Agreement, and without
limitation of any kind, the U.S. federal, state or local tax treatment and tax
structure of such transactions, and all materials of any kind (including
opinions or other tax analyses) that are provided to such party (or any
employee, representative, or other agent of such party) relating to such tax
treatment and tax structure. For purposes of this authorization, the "tax
treatment" of a transaction means the purported or claimed tax treatment of the
transaction, and the "tax structure" of a transaction means any fact that may be
relevant to understanding the purported or claimed tax treatment of the
transaction. None of the parties to the transactions contemplated by this
Agreement provides U.S. tax advice, and each party should consult its own
advisors regarding its participation in the transactions contemplated by this
Agreement.

                  13.16 Waiver of Jury Trial. EACH OF THE PARTIES TO THIS
AGREEMENT HEREBY IRREVOCABLY WAIVES ALL RIGHT TO A TRIAL BY JURY IN ANY ACTION,
PROCEEDING OR COUNTERCLAIM ARISING OUT OF OR RELATING TO THIS AGREEMENT, THE
OTHER CREDIT DOCUMENTS OR THE TRANSACTIONS CONTEMPLATED HEREBY OR THEREBY.

                  13.17 Register. The Borrowers hereby designate the
Administrative Agent, and the Administrative Agent agrees, to serve as the
Borrowers' agent, solely for purposes of this Section 13.17, to maintain a
register at one of its offices in New York, New York (the "Register") on which
it will record the Commitments from time to time of each of the Lenders, the
Loans made by each of the Lenders and each repayment in respect of the principal
amount of the Loans of each Lender. Failure to make any such recordation, or any
error in such recordation shall not affect the Borrowers' obligations in respect
of such Loans. With respect to any Lender, the transfer of the Commitments of
such Lender and the rights to the principal of, and interest on, any Loan made
pursuant to such Commitments shall not be effective until such transfer is
recorded on the Register maintained by the Administrative Agent with respect to
ownership of such Commitments and/or Loans prior to such recordation all amounts
owing to the transferor with respect to such Commitments and/or Loans shall
remain owing to the transferor. The registration of an assignment or transfer of
all or part of any Commitments and/or Loans shall be recorded by the
Administrative Agent on the Register only upon the acceptance by the
Administrative Agent of a properly executed and delivered Assignment and
Assumption Agreement pursuant to Section 13.04(b). Coincident with the delivery
of such an Assignment and Assumption Agreement to the Administrative Agent for
acceptance and registration of assignment or transfer of all or part of a
Commitment and/or Loan, or as soon thereafter as practicable, the assigning or
transferor Lender shall surrender the Note evidencing such Commitment and/or
Loan, and thereupon one or more new Notes in the same aggregate principal amount
shall be issued to the assigning or transferor Lender and/or the new Lender. The
Borrowers agree to indemnify the Administrative Agent from and against any and
all losses,

                                     -189-

<PAGE>

claims, damages and liabilities of whatsoever nature that may be imposed on,
asserted against or incurred by the Administrative Agent in performing its
duties under this Section 13.17.

                  13.18 English Language. This Agreement and all other Credit
Documents shall be in the English language, except as required by applicable
local law (in which event certified English translations thereof shall, upon the
request of the Administrative Agent, be provided by the U.S. Borrower to the
Administrative Agent). All documents, certificates, reports or notices to be
delivered or communications to be given or made by any party hereto pursuant to
the terms of this Agreement or any other Credit Document shall be in the English
language or, if originally written in another language, shall, upon request of
the Administrative Agent, be accompanied by an accurate English translation upon
which the other parties hereto shall have the right to rely for all purposes of
this Agreement and the other Credit Documents.

                  13.19 Special Provisions Regarding Pledges of Equity Interests
in, and Promissory Notes Owed by, Persons Not Organized in Qualified
Jurisdictions. The parties hereto acknowledge and agree that the provisions of
the various Security Documents executed and delivered by the Credit Parties
require that, among other things, all promissory notes (including, without
limitation, Intercompany Notes) issued by, and Equity Interests in, various
Persons owned by the respective Credit Party be pledged, and delivered for
pledge, pursuant to the Security Documents. The parties hereto further
acknowledge and agree that each Credit Party shall be required to take all
actions under the laws of the jurisdiction in which such Credit Party is
organized to create and perfect all security interests granted pursuant to the
various Security Documents and to take all actions under the laws of each
Qualified Jurisdiction to perfect the security interests in the Equity Interests
of, and promissory notes (including, without limitation, Intercompany Notes)
issued by, any Person organized under the laws of said jurisdictions. Except as
provided in the immediately preceding sentence, to the extent any Security
Document requires or provides for the pledge of promissory notes (including,
without limitation, Intercompany Notes) issued by, or Equity Interests in, any
Person organized under the laws of a jurisdiction other than those specified in
the immediately preceding sentence, it is acknowledged that, as of the Initial
Borrowing Date, no actions have been required to be taken to perfect, under
local law of the jurisdiction of the Person who issued the respective promissory
notes or whose Equity Interests are pledged, under the Security Documents. The
Borrowers hereby agree that, following any request by the Administrative Agent
or Required Lenders to do so, each Borrower shall, and shall cause its
Subsidiaries to, take such actions (including, without limitation, the execution
of Additional Security Documents, the making of any filings and the delivery of
appropriate legal opinions) under the local law of any jurisdiction with respect
to which such actions have not already been taken as are determined by the
Administrative Agent or Required Lenders to be necessary or desirable in order
to fully perfect, preserve or protect the security interests granted pursuant to
the various Security Documents under the laws of such jurisdictions. If
requested to do so pursuant to this Section 13.19, all such actions shall be
taken in accordance with the provisions of this Section 13.19 and Section 8.11
and within the time periods set forth therein. All conditions and
representations contained in this Agreement and the other Credit Documents shall
be deemed modified to the extent necessary to effect the foregoing and so that
same are not violated by reason of the failure to take actions under local law
(but only with respect to Equity Interests in, and promissory notes issued by,
Persons organized under laws of jurisdictions other than Qualified
Jurisdictions) not required to be taken in accordance with the provisions of
this Section 13.19, provided that to the extent any representation or warranty
would

                                     -190-

<PAGE>

not be true because the foregoing actions were not taken, the respective
representation of warranties shall be required to be true and correct in all
material respects at such time as the respective action is required to be taken
in accordance with the foregoing provisions of this Section 13.20 or pursuant to
Section 8.11.

                  13.20 Powers of Attorney; etc. The U.S. Borrower is hereby
authorized by, and on behalf of, the European Borrower to give Notices of
Borrowing, Notices of Conversion and other notices and directions in connection
with the extensions of credit and repayments thereof to be made pursuant to this
Agreement to the European Borrower (including without limitation notices as to
the application of proceeds of such extensions of credit). The European Borrower
hereby grants to the U.S. Borrower an irrevocable power-of attorney, in the
European Borrower's name, to take the actions contemplated above in this Section
13.20 and in the last sentence of Section 1.13 hereof. Furthermore, the European
Borrower agrees that the Agents and the Lenders may at any time rely upon any
notices, instructions or other information furnished by the U.S. Borrower.

                  13.21 Waiver of Sovereign Immunity. Each of the Borrowers, in
respect of itself, its Subsidiaries, its process agents, and its properties and
revenues, hereby irrevocably agrees that, to the extent that such Borrower, its
Subsidiaries or any of its properties has or may hereafter acquire any right of
immunity, whether characterized as sovereign immunity or otherwise, from any
legal proceedings, whether in the United States, any other Qualified
Jurisdiction or elsewhere, to enforce or collect upon the Loans or any Credit
Document or any other liability or obligation of such Borrower or any of its
Subsidiaries related to or arising from the transactions contemplated by any of
the Credit Documents, including, without limitation, immunity from service of
process, immunity from jurisdiction or judgment of any court or tribunal,
immunity from execution of a judgment, and immunity of any of its property from
attachment prior to any entry of judgment, or from attachment in aid of
execution upon a judgment, such Borrower, for itself and on behalf of its
Subsidiaries, hereby expressly waives, to the fullest extent permissible under
applicable law, any such immunity, and agrees not to assert any such right or
claim in any such proceeding, whether in the United States, any other Qualified
Jurisdiction, or elsewhere. Without limiting the generality of the foregoing,
each Borrower further agrees that the waivers set forth in this Section 13.22
shall have the fullest extent permitted under the Foreign Sovereign Immunities
Act of 1976 of the United States and are intended to be irrevocable for purposes
of such Act.

                  13.22 Judgment Currency. (a) The Credit Parties' obligations
hereunder and under the other Credit Documents to make payments in the
respective Applicable Currency (the "Obligation Currency") shall not be
discharged or satisfied by any tender or recovery pursuant to any judgment
expressed in or converted into any currency other than the Obligation Currency,
except to the extent that such tender or recovery results in the effective
receipt by any Agent or the respective Lender of the full amount of the
Obligation Currency expressed to be payable to the such Agent or such Lender
under this Agreement or the other Credit Documents. If for the purpose of
obtaining or enforcing judgment against any Credit Party in any court or in any
jurisdiction, it becomes necessary to convert into or from any currency other
than the Obligation Currency (such other currency being hereinafter referred to
as the "Judgment Currency") an amount due in the Obligation Currency, the
conversion shall be made, at the Euro Equivalent or the Dollar Equivalent
thereof, as the case may be, and, in the case of other currencies, the rate of

                                     -191-

<PAGE>

exchange (as quoted by the Administrative Agent or if the Administrative Agent
does not quote a rate of exchange on such currency, by a known dealer in such
currency designated by the Administrative Agent) determined, in each case, as of
the day on which the judgment is given (such day being hereinafter referred to
as the "Judgment Currency Conversion Date").

                  (b)      If there is a change in the rate of exchange
prevailing between the Judgment Currency Conversion Date and the date of actual
payment of the amount due, each Borrower covenants and agrees to pay, or cause
to be paid, such additional amounts, if any (but in any event not a lesser
amount), as may be necessary to ensure that the amount paid in the Judgment
Currency, when converted at the rate of exchange prevailing on the date of
payment, will produce the amount of the Obligation Currency which could have
been purchased with the amount of Judgment Currency stipulated in the judgment
or judicial award at the rate or exchange prevailing on the Judgment Currency
Conversion Date.

                  For purposes of determining the Dollar Equivalent or the Euro
Equivalent or any other rate of exchange for this Section, such amounts shall
include any premium and costs payable in connection with the purchase of the
Obligation Currency.

                  13.23 Limitation on Additional Amounts. Notwithstanding
anything to the contrary contained in Section 1.10, 1.11, 2.06 or 4.04 unless a
Lender gives notice to the Borrower that it is obligated to pay an amount under
any such Section within six months after the later of (x) the date the Lender
incurs the respective increased costs, Taxes, loss, expense or liability,
reduction in amounts received or receivable or reduction in return on capital or
(y) the date such Lender has actual knowledge of its incurrence of the
respective increased costs, Taxes, loss, expense or liability, reductions in
amounts received or receivable or reduction in return on capital, then such
Lender shall only be entitled to be compensated for such amount by the Borrower
pursuant to said Section 1.10, 1.11, 2.06 or 4.04, as the case may be, to the
extent the costs, Taxes, loss, expense liability, reduction in amounts received
or receivable or reduction in return on capital are incurred or suffered on or
after the date which occurs six months prior to such Lender giving notice to the
Borrower that it is obligated to pay the respective amounts pursuant to said
Section 1.10, 1.11, 2.06 or 4.04. This Section 13.23 shall have no applicability
to any Section of this Agreement other than said Sections 1.10, 1.11, 2.06 or
4.04.

                  13.24 Post Closing Actions. Notwithstanding anything to the
contrary contained in this Agreement or the other Credit Documents, the parties
hereto acknowledge and agree that the U.S. Borrower and its Subsidiaries shall
be required to take the actions specified in Schedule XVIII as promptly as
practicable, and in any event within the time periods set forth in Schedule
XVIII. The provisions of Schedule XVIII shall be deemed incorporated by
reference herein as fully as if set forth herein in its entirety. All provisions
of this Credit Agreement and the other Credit Documents (including, without
limitation, all conditions precedent, representations, warranties, covenants,
events of default and other agreements herein and therein) shall be deemed
modified to the extent necessary to effect the foregoing (and to permit the
taking of the actions described above within the time periods required above,
rather than as otherwise provided in the Credit Documents); provided that (x) to
the extent any representation and warranty would not be true because the
foregoing actions were not taken on the Initial Borrowing Date the respective
representation and warranty shall be required to be true and correct in all
material respects at the time the respective action is taken (or was required to
be

                                     -192-

<PAGE>

taken) in accordance with the foregoing provisions of this Section 13.24 and (y)
all representations and warranties relating to the Security Documents shall be
required to be true immediately after the actions required to be taken by this
Section 13.24 have been taken (or were required to be taken). The acceptance of
the benefits of each Credit Event shall constitute a covenant and agreement by
each Borrower to each of the Lenders that the actions required pursuant to this
Section 13.24 will be, or have been, taken within the relevant time periods
referred to in this Section 13.24 and that, at such time, all representations
and warranties contained in this Credit Agreement and the other Credit Documents
shall then be true and correct in all material respects without any modification
pursuant to this Section 13.24. The parties hereto acknowledge and agree that
the failure to take any of the actions required above, within the relevant time
periods required above, shall give rise to an immediate Event of Default
pursuant to this Agreement.

                  13.25 USA Patriot Act Notice. Each Lender hereby notifies each
Borrower that pursuant to the requirements of the USA Patriot Act (Title III of
Pub.: 107-56 (signed into law October 26, 2001)) (the "Patriot Act"), it is
required to obtain, verify, and record information that identifies each
Borrower, which information includes the name of each Borrower and other
information that will allow such Lender to identify each Borrower in accordance
with the Patriot Act, and each Borrower agrees to provide such information from
time to time to any Lender.

                  13.26 Special Provisions Regarding Dutch ASCS.

                  (a)      The Borrowers jointly and severally represent and
warrant to each of the Lenders and the Agents that, as of the Initial Borrowing
Date, they have, in accordance with the requirements of the Dutch Exemption
Regulation and the Dutch Policy Guidelines, verified the status of each Person
which is a Lender hereunder on the Initial Borrowing Date and that each such
Lender is either (a) a PMP and/or (b) is exempted because it forms a restricted
circle (besloten kring) with the European Borrower.

                  (b)      The Borrowers jointly and severally covenant and
agree that for so long as this Agreement is in effect and until the Total
Commitment and all Letters of Credit have been terminated, and the Loans, Notes
and Unpaid Drawings, together with interest, Fees and all other Obligations
(other than any indemnities described in Section 13.13 which are not then due
and payable) incurred hereunder, are paid in full, they shall notify the
Administrative Agent upon any change to the definition of PMP under the Dutch
Exemption Regulation, the Dutch Policy Guidelines, or any other applicable law
of the Netherlands or governmental rule, regulation, order or guideline (having
the force of law under the laws of the Netherlands) and shall, upon the request
of the Administrative Agent following any such notice, provide an updated
Schedule XIX reflecting any such change to the definition of PMP to the
Administrative Agent and Schedule XIX hereto shall be deemed to be replaced by
such updated Schedule XIX.

                  (c)      At the time of each assignment of any European
Borrower Term Loans or any Multicurrency Facility Revolving Loan Commitment (or
outstandings pursuant thereto) pursuant to Section 13.04 which requires the
consent of either Borrower, the Borrowers shall be deemed to jointly and
severally represent and warrant to each of the Lenders and Agents that, as of
the date of such assignment they have, in accordance with the requirements of
the Dutch Exemption Regulation and the Dutch Policy Guidelines, verified the
status of the respective

                                     -193-

<PAGE>

assignee and that such assignee constitutes an Eligible Transferee in accordance
with the last proviso to the definition of Eligible Transferee contained herein.

                  (d)      At the time of each assignment of any European
Borrower Term Loans or any Multicurrency Facility Revolving Loan Commitment (or
outstandings pursuant thereto) which does not require the consent of either
Borrower, the respective assignee shall be deemed to represent and warrant that,
as of the date of their respective assignment, it is an Eligible Transferee.

                  SECTION 14. U.S. Borrower's Guaranty.

                  14.01 The U.S. Borrower's Guaranty. In order to induce the
Lenders to enter into this Agreement and to extend credit hereunder and to
induce the Lenders or any of their respective Affiliates to enter into Interest
Rate Protection Agreements or Other Hedging Agreements, and in recognition of
the direct benefits to be received by the U.S. Borrower from the proceeds of the
Loans, the issuance of the Letters of Credit and the entering into of Interest
Rate Protection Agreements or Other Hedging Agreements, the U.S. Borrower hereby
unconditionally and irrevocably guarantees, as primary obligor and not merely as
surety the full and prompt payment when due, whether upon maturity, acceleration
or otherwise, of any and all of the U.S. Borrower Guaranteed Obligations to the
Guaranteed Creditors. If any or all of the U.S. Borrower Guaranteed Obligations
to the Guaranteed Creditors becomes due and payable hereunder, the U.S. Borrower
unconditionally promises to pay such indebtedness to the Guaranteed Creditors,
on demand, together with any and all expenses which may be incurred by the
Guaranteed Creditors in collecting any of the U.S. Borrower Guaranteed
Obligations. This U.S. Borrower's Guaranty is a guaranty of payment and not of
collection. This U.S. Borrower's Guaranty is a continuing one and all
liabilities to which it applies or may apply under the terms hereof shall be
conclusively presumed to have been created in reliance hereon. If any claim is
ever made upon any Guaranteed Creditor for repayment or recovery of any amount
or amounts received in payment or on account of any of the U.S. Borrower
Guaranteed Obligations and any of the aforesaid payees repays all or part of
said amount by reason of (i) any judgment, decree or order of any court or
administrative body having jurisdiction over such payee or any of its property
or (ii) any settlement or compromise of any such claim effected by such payee
with any such claimant (including the European Borrower or any other U.S.
Borrower Guaranteed Party), then and in such event the U.S. Borrower agrees that
any such judgment, decree, order, settlement or compromise shall be binding upon
the U.S. Borrower, notwithstanding any revocation of this U.S. Borrower's
Guaranty or any other instrument evidencing any liability of the European
Borrower or any U.S. Borrower Guaranteed Party, and the U.S. Borrower shall be
and remain liable to the aforesaid payees hereunder for the amount so repaid or
recovered to the same extent as if such amount had never originally been
received by any such payee.

                  14.02 Bankruptcy. Additionally, the U.S. Borrower
unconditionally and irrevocably, guarantees the payment of any and all of the
U.S. Borrower Guaranteed Obligations to the Guaranteed Creditors whether or not
due or payable by the European Borrower or any other U.S. Borrower Guaranteed
Party upon the occurrence of any of the events specified in Section 10.05, and
unconditionally promises to pay such indebtedness to the Guaranteed Creditors,
or order, on demand.

                                     -194-

<PAGE>

                  14.03 Nature of Liability. The liability of the U.S. Borrower
hereunder is exclusive and independent of any security for or other guaranty of
the U.S. Borrower Guaranteed Obligations whether executed by the U.S. Borrower,
any other guarantor or by any other party, and the liability of the U.S.
Borrower hereunder is not affected or impaired by (a) any direction as to
application of payment by the European Borrower, any other U.S. Borrower
Guaranteed Party or any other party, or (b) any other continuing or other
guaranty, undertaking or maximum liability of a guarantor or of any other party
as to the U.S. Borrower Guaranteed Obligations, or (c) any payment on or in
respect of any such other guaranty or undertaking, or (d) any dissolution,
termination or increase, decrease or change in personnel by the European
Borrower or any other U.S. Borrower Guaranteed Party or (e) any payment made to
the Guaranteed Creditors on the U.S. Borrower Guaranteed Obligations which any
such Guaranteed Creditor repays to the European Borrower or any other U.S.
Borrower Guaranteed Party pursuant to court order in any bankruptcy,
reorganization, arrangement, moratorium or other debtor relief proceeding, and
the U.S. Borrower waives any right to the deferral or modification of its
obligations hereunder by reason of any such proceeding, or (f) any action or
inaction of the type described in Section 14.05, or (g) the lack of validity or
enforceability of any Credit Document or any other instrument relating thereto.

                  14.04 Independent Obligation. No invalidity, irregularity or
unenforceability of all or any part of the U.S. Borrower Guaranteed Obligations
or of any security therefor shall affect, impair or be a defense to this U.S.
Borrower's Guaranty, and this U.S. Borrower's Guaranty shall be primary,
absolute and unconditional notwithstanding the occurrence of any event or the
existence of any other circumstances which might constitute a legal or equitable
discharge of a surety or guarantor except payment in full in cash of the U.S.
Borrower Guaranteed Obligations. The obligations of the U.S. Borrower hereunder
are independent of the obligations of the European Borrower, any other U.S.
Borrower Guaranteed Party, any other guarantor or any other party, and a
separate action or actions may be brought and prosecuted against the U.S.
Borrower whether or not action is brought against the European Borrower, any
other U.S. Borrower Guaranteed Party, any other guarantor or any other party and
whether or not the European Borrower, any other U.S. Borrower Guaranteed Party,
any other guarantor or any other party be joined in any such action or actions.
The U.S. Borrower waives, to the full extent permitted by law, the benefit of
any statute of limitations affecting its liability hereunder or the enforcement
thereof. Any payment by the European Borrower or any other U.S. Borrower
Guaranteed Party or other circumstance that operates to toll any statute of
limitations as to the European Borrower or such other U.S. Borrower Guaranteed
Party shall operate to toll the statute of limitations as to the U.S. Borrower.

                  14.05 Authorization. The U.S. Borrower authorizes the
Guaranteed Creditors without notice or demand (except as shall be required by
applicable statute and cannot be waived), and without affecting or impairing its
liability hereunder, from time to time to:

                  (a)      change the manner, place or terms of payment of,
         and/or change or extend the time of payment of, renew, increase,
         accelerate or alter, any of the U.S. Borrower Guaranteed Obligations
         (including any increase or decrease in the rate of interest thereon),
         any security therefor, or any liability incurred directly or indirectly
         in respect thereof, and this U.S. Borrower's Guaranty made shall apply
         to the U.S. Borrower Guaranteed Obligations as so changed, extended,
         renewed, increased or altered;

                                     -195-

<PAGE>

                  (b)      take and hold security for the payment of the U.S.
         Borrower Guaranteed Obligations and sell, exchange, release, impair,
         surrender, realize upon or otherwise deal with in any manner and in any
         order any property by whomsoever at any time pledged or mortgaged to
         secure, or howsoever securing, the U.S. Borrower Guaranteed Obligations
         or any liabilities (including any of those hereunder) incurred directly
         or indirectly in respect thereof or hereof, and/or any offset
         thereagainst;

                  (c)      exercise or refrain from exercising any rights
         against the European Borrower, any other U.S. Borrower Guaranteed Party
         or others or otherwise act or refrain from acting;

                  (d)      release or substitute any one or more endorsers,
         guarantors, the European Borrower, any other U.S. Borrower Guaranteed
         Party or other obligors;

                  (e)      settle or compromise any of the U.S. Borrower
         Guaranteed Obligations, any security therefor or any liability
         (including any of those hereunder) incurred directly or indirectly in
         respect thereof or hereof, and may subordinate the payment of all or
         any part thereof to the payment of any liability (whether due or not)
         of the European Borrower or any other U.S. Borrower Guaranteed Party to
         their respective creditors other than the Guaranteed Creditors;

                  (f)      apply any sums by whomsoever paid or howsoever
         realized to any liability or liabilities of the European Borrower or
         any other U.S. Borrower Guaranteed Party to the Guaranteed Creditors
         regardless of what liability or liabilities of the European Borrower or
         such other U.S. Borrower Guaranteed Party remain unpaid;

                  (g)      consent to or waive any breach of, or any act,
         omission or default under, this Agreement, any other Credit Document,
         any Interest Rate Protection Agreement or Other Hedging Agreement or
         any of the instruments or agreements referred to herein or therein, or
         otherwise amend, modify or supplement this Agreement, any other Credit
         Document, any Interest Rate Protection Agreement or Other Hedging
         Agreement or any of such other instruments or agreements; and/or

                  (h)      take any other action that would, under otherwise
         applicable principles of common law, give rise to a legal or equitable
         discharge of the U.S. Borrower from its liabilities under this U.S.
         Borrower's Guaranty.

                  14.06 Reliance. It is not necessary for the Guaranteed
Creditors to inquire into the capacity or powers of the European Borrower or any
other U.S. Borrower Guaranteed Party or the officers, directors, partners or
agents acting or purporting to act on its or their behalf, and any U.S. Borrower
Guaranteed Obligations made or created in reliance upon the professed exercise
of such powers shall be guaranteed hereunder.

                  14.07 Subordination. Any of the indebtedness of the European
Borrower or any other U.S. Borrower Guaranteed Party now or hereafter owing to
the U.S. Borrower is hereby subordinated to the U.S. Borrower Guaranteed
Obligations of the European Borrower or such other U.S. Borrower Guaranteed
Party owing to the Guaranteed Creditors; and if the Administrative Agent so
requests at a time when an Event of Default exists, all such

                                     -196-

<PAGE>

indebtedness of the European Borrower or such other U.S. Borrower Guaranteed
Party to the U.S. Borrower shall be collected, enforced and received by the U.S.
Borrower for the benefit of the Guaranteed Creditors and be paid over to the
Administrative Agent on behalf of the Guaranteed Creditors on account of the
U.S. Borrower Guaranteed Obligations of the European Borrower or such other U.S.
Borrower Guaranteed Party to the Guaranteed Creditors, but without affecting or
impairing in any manner the liability of the U.S. Borrower under the other
provisions of this U.S. Borrower's Guaranty. Prior to the transfer by the U.S.
Borrower of any note or negotiable instrument evidencing any of the indebtedness
of the European Borrower or any other U.S. Borrower Guaranteed Party to the U.S.
Borrower, the U.S. Borrower shall mark such note or negotiable instrument with a
legend that the same is subject to this subordination. Without limiting the
generality of the foregoing, the U.S. Borrower hereby agrees with the Guaranteed
Creditors that it will not exercise any right of subrogation which it may at any
time otherwise have as a result of this U.S. Borrower's Guaranty (whether
contractual, under Section 509 of the Bankruptcy Code or otherwise) until all
U.S. Borrower Guaranteed Obligations have been irrevocably paid in full in cash.

                  14.08 Waiver. (a) The U.S. Borrower waives any right (except
as shall be required by applicable statute and cannot be waived) to require any
Guaranteed Creditor to (i) proceed against the European Borrower, any other U.S.
Borrower Guaranteed Party, any other guarantor or any other party, (ii) proceed
against or exhaust any security held from the European Borrower, any other U.S.
Borrower Guaranteed Party, any other guarantor or any other party or (iii)
pursue any other remedy in any Guaranteed Creditor's power whatsoever. The U.S.
Borrower waives any defense based on or arising out of any defense of the
European Borrower, any other U.S. Borrower Guaranteed Party, any other guarantor
or any other party, other than payment in full in cash of the U.S. Borrower
Guaranteed Obligations, based on or arising out of the disability of the
European Borrower, any other Guaranteed Party, any other guarantor or any other
party, or the unenforceability of the U.S. Borrower Guaranteed Obligations or
any part thereof from any cause, or the cessation from any cause of the
liability of the European Borrower or any other U.S. Borrower Guaranteed Party
other than payment in full in cash of the U.S. Borrower Guaranteed Obligations.
The Guaranteed Creditors may, at their election, foreclose on any security held
by any Agent or any other Guaranteed Creditor by one or more judicial or
nonjudicial sales, whether or not every aspect of any such sale is commercially
reasonable (to the extent such sale is permitted by applicable law), or exercise
any other right or remedy the Guaranteed Creditors may have against the European
Borrower, any other U.S. Borrower Guaranteed Party or any other party, or any
security, without affecting or impairing in any way the liability of the U.S.
Borrower hereunder except to the extent the U.S. Borrower Guaranteed Obligations
have been paid in full in cash. The U.S. Borrower waives any defense arising out
of any such election by the Guaranteed Creditors, even though such election
operates to impair or extinguish any right of reimbursement or subrogation or
other right or remedy of the U.S. Borrower against the European Borrower, any
other U.S. Borrower Guaranteed Party or any other party or any security.

                  (b)      The U.S. Borrower waives all presentments, demands
for performance, protests and notices, including, without limitation, notices of
nonperformance, notices of protest, notices of dishonor, notices of acceptance
of this U.S. Borrower's Guaranty, and notices of the existence, creation or
incurring of new or additional U.S. Borrower Guaranteed Obligations. The U.S.
Borrower assumes all responsibility for being and keeping itself informed of the
European

                                     -197-
<PAGE>

Borrower's and each other U.S. Borrower Guaranteed Party's financial condition
and assets, and of all other circumstances bearing upon the risk of nonpayment
of the U.S. Borrower Guaranteed Obligations and the nature, scope and extent of
the risks which the U.S. Borrower assumes and incurs hereunder, and agrees that
the Guaranteed Creditors shall have no duty to advise the U.S. Borrower of
information known to them regarding such circumstances or risks.

                  (c)      Until such time as the U.S. Borrower Guaranteed
Obligations have been paid in full in cash, the U.S. Borrower hereby waives all
rights of subrogation which it may at any time otherwise have as a result of
this U.S. Borrower's Guaranty (whether contractual, under Section 509 of the
Bankruptcy Code, or otherwise) to the claims of the Guaranteed Creditors against
the European Borrower, any other U.S. Borrower Guaranteed Party or any other
guarantor of the U.S. Borrower Guaranteed Obligations and all contractual,
statutory or common law rights of reimbursement, contribution or indemnity from
the European Borrower, any other U.S. Borrower Guaranteed Party or any other
guarantor which it may at any time otherwise have as a result of this U.S.
Borrower's Guaranty.

                  (d)      The U.S. Borrower hereby acknowledges and affirms
that it understands that to the extent the U.S. Borrower Guaranteed Obligations
are secured by Real Property located in California, the U.S. Borrower shall be
liable for the full amount of the liability hereunder notwithstanding the
foreclosure on such Real Property by trustee sale or any other reason impairing
the U.S. Borrower's or any Guaranteed Creditor's right to proceed against any
U.S. Borrower Guaranteed Party or any other guarantor of the U.S. Borrower
Guaranteed Obligations. In accordance with Section 2856 of the California Code
of Civil Procedure, the U.S. Borrower hereby waives:

                  (i)      all rights of subrogation, reimbursement,
         indemnification, and contribution and any other rights and defenses
         that are or may become available to the U.S. Borrower by reason of
         Sections 2787 to 2855, inclusive, 2899 and 3433 of the California Code
         of Civil Procedure;

                  (ii)     all rights and defenses that the U.S. Borrower may
         have because the U.S. Borrower Guaranteed Obligations are secured by
         Real Property located in California, meaning, among other things, that:
         (A) the Guaranteed Creditors may collect from the U.S. Borrower without
         first foreclosing on any real or personal property collateral pledged
         by any Credit Party, and (B) if the Guaranteed Creditors foreclose on
         any Real Property collateral pledged by any Credit Party, (1) the
         amount of the U.S. Borrower Guaranteed Obligations may be reduced only
         by the price for which that collateral is sold at the foreclosure sale,
         even if the collateral is worth more than the sale price, and (2) the
         Guaranteed Creditors may collect from the U.S. Borrower even if the
         Guaranteed Creditors, by foreclosing on the Real Property collateral,
         have destroyed any right the U.S. Borrower may have to collect from any
         U.S. Borrower Guaranteed Party, it being understood that this is an
         unconditional and irrevocable waiver of any rights and defenses the
         U.S. Borrower may have because the U.S. Borrower Guaranteed Obligations
         are secured by Real Property (including, without limitation, any rights
         or defenses based upon Section 580a, 580d or 726 of the California Code
         of Civil Procedure); and

                                     -198-

<PAGE>

                  (iii)    all rights and defenses arising out of an election of
         remedies by the Guaranteed Creditors, even though that election of
         remedies, such as a non-judicial foreclosure with respect to security
         for the U.S. Borrower Guaranteed Obligations, has destroyed the U.S.
         Borrower's rights of subrogation and reimbursement against any U.S.
         Borrower Guaranteed Party by the operation of Section 580d of the
         California Code of Civil Procedure or otherwise.

                  (e)      The U.S. Borrower warrants and agrees that each of
the waivers set forth above is made with full knowledge of its significance and
consequences and that if any of such waivers are determined to be contrary to
any applicable law of public policy, such waivers shall be effective only to the
maximum extent permitted by law.

                  14.09 Payments. All payments made by the U.S. Borrower
pursuant to this Section 14 shall be made in the respective Applicable Currency
in which the U.S. Borrower Guaranteed Obligations are then due and payable
(giving effect, in the circumstances contemplated by Section 1.14, to any
conversion occurring pursuant thereto). All payments made by the U.S. Borrower
pursuant to this Section 14 will be made without setoff, counterclaim or other
defense, and shall be subject to the provisions of Sections 4.03, 4.04 and
13.22.

                                     * * * *

                                     -199-

<PAGE>

                  IN WITNESS WHEREOF, the parties hereto have caused their duly
authorized officers to execute and deliver this Agreement as of the date first
above written.

                                       EXIDE TECHNOLOGIES, as a Borrower
                                           and a Guarantor

                                       By: /s/ Nicholas J. Iuanow
                                          --------------------------------------
                                          Name:  Nicholas J. Iuanow
                                          Title: V.P and Corporate Treasurer

                                       EXIDE GLOBAL HOLDING
                                          NETHERLANDS C.V.,
                                          as a Borrower

                                       By: Exide Technologies,
                                           its general partner

                                       By  /s/ Craig H. Muhlhauser
                                          --------------------------------------
                                          Name:  Craig H. Muhlhauser
                                          Title: Chairman and CEO

<PAGE>

                                       DEUTSCHE BANK AG NEW YORK
                                        BRANCH,
                                        Individually and as Administrative Agent

                                       By: /s/ Mary Kay Cole
                                          --------------------------------------
                                          Name: Mary Kay Cole
                                          Title: Managing Director

                                       By: /s/ Scottye Lindsey
                                          --------------------------------------
                                          Name: Scottye Lindsey
                                          Title: Director

                                       DEUTSCHE BANK SECURITIES INC.,
                                        as Sole Lead Arranger and Book Running
                                        Manager

                                       By: /s/ Illegible
                                          --------------------------------------
                                          Name:
                                          Title:

                                       By: /s/ David S. Bailey
                                          --------------------------------------
                                          Name: David S. Bailey
                                          Title: Managing Director

<PAGE>

                                       CREDIT SUISSE FIRST BOSTON,
                                        Individually, as Syndication Agent and
                                        as Book Running Manager

                                       By: /s/ David Miller
                                          --------------------------------------
                                          Name: David Miller
                                          Title: Managing Director

                                       By: /s/ Doreen B. Welch
                                          --------------------------------------
                                          Name: Doreen B. Welch
                                          Title: Associate

<PAGE>

                                       FLEET NATIONAL BANK,
                                        as Syndication Agent pursuant to Section
                                        12.01(c)

                                       By: /s/ Kenneth S. Struglia
                                          --------------------------------------
                                          Name: Kenneth S. Struglia
                                          Title: Director

<PAGE>

                             SIGNATURE PAGE TO THE CREDIT AGREEMENT DATED
                             AS OF MAY 5, 2004, AMONG EXIDE TECHNOLOGIES,
                             EXIDE GLOBAL HOLDING NETHERLANDS C.V., THE
                             LENDERS FROM TIME TO TIME PARTY HERETO,
                             CREDIT SUISSE FIRST BOSTON AND FLEET
                             SECURITIES, INC., AS SYNDICATION AGENTS,
                             DEUTSCHE BANK AG NEW YORK BRANCH, AS
                             ADMINISTRATIVE AGENT, CREDIT SUISSE FIRST
                             BOSTON, AS BOOK RUNNING MANAGER AND DEUTSCHE
                             BANK SECURITIES INC., AS SOLE LEAD ARRANGER
                             AND BOOK RUNNING MANAGER

                             NAME OF INSTITUTION:

                             Commerzbank AG, New York and Grand Cayman Branches
                             --------------------------------------------------

                             By:  /s/ Charles W. Polet
                                 ----------------------------------------------
                                 Name:  Charles W. Polet
                                 Title: Assistant Treasurer

<PAGE>

                             SIGNATURE PAGE TO THE CREDIT AGREEMENT DATED
                             AS OF MAY 5, 2004, AMONG EXIDE TECHNOLOGIES,
                             EXIDE GLOBAL HOLDING NETHERLANDS C.V., THE
                             LENDERS FROM TIME TO TIME PARTY HERETO,
                             CREDIT SUISSE FIRST BOSTON AND FLEET
                             SECURITIES, INC., AS SYNDICATION AGENTS,
                             DEUTSCHE BANK AG NEW YORK BRANCH, AS
                             ADMINISTRATIVE AGENT, CREDIT SUISSE FIRST
                             BOSTON, AS BOOK RUNNING MANAGER AND DEUTSCHE
                             BANK SECURITIES INC., AS SOLE LEAD ARRANGER
                             AND BOOK RUNNING MANAGER

                             NAME OF INSTITUTION:

                             Bayerische Hypo-und Vereinsbank AG, New York Branch
                             --------------------------------------------------

                             By:  /s/ Miriam Trautmann
                                 ----------------------------------------------
                                 Name:  Miriam Trautmann
                                 Title: Associate Director

                             By:  /s/ Salvatore Esposito
                                 ----------------------------------------------
                                 Name:  Salvatore Esposito
                                 Title: Managing Director

<PAGE>

                             SIGNATURE PAGE TO THE CREDIT AGREEMENT DATED
                             AS OF MAY 5, 2004, AMONG EXIDE TECHNOLOGIES,
                             EXIDE GLOBAL HOLDING NETHERLANDS C.V., THE
                             LENDERS FROM TIME TO TIME PARTY HERETO,
                             CREDIT SUISSE FIRST BOSTON AND FLEET
                             SECURITIES, INC., AS SYNDICATION AGENTS,
                             DEUTSCHE BANK AG NEW YORK BRANCH, AS
                             ADMINISTRATIVE AGENT, CREDIT SUISSE FIRST
                             BOSTON, AS BOOK RUNNING MANAGER AND DEUTSCHE
                             BANK SECURITIES INC., AS SOLE LEAD ARRANGER
                             AND BOOK RUNNING MANAGER

                             NAME OF INSTITUTION:

                             Sumitomo Mitsui Banking Corporation
                             --------------------------------------------------

                             By:  /s/ Susumu Ogawa
                                 ----------------------------------------------
                                 Name:  Susumu Ogawa
                                 Title: General Manager

<PAGE>

                             SIGNATURE PAGE TO THE CREDIT AGREEMENT DATED
                             AS OF MAY 5, 2004, AMONG EXIDE TECHNOLOGIES,
                             EXIDE GLOBAL HOLDING NETHERLANDS C.V., THE
                             LENDERS FROM TIME TO TIME PARTY HERETO,
                             CREDIT SUISSE FIRST BOSTON AND FLEET
                             SECURITIES, INC., AS SYNDICATION AGENTS,
                             DEUTSCHE BANK AG NEW YORK BRANCH, AS
                             ADMINISTRATIVE AGENT, CREDIT SUISSE FIRST
                             BOSTON, AS BOOK RUNNING MANAGER AND DEUTSCHE
                             BANK SECURITIES INC., AS SOLE LEAD ARRANGER
                             AND BOOK RUNNING MANAGER

                             NAME OF INSTITUTION:

                             RZB Finance LLC
                             --------------------------------------------------

                             By:  /s/ Astrid Wilke
                                 ----------------------------------------------
                                 Name:  Astrid Wilke
                                 Title: Vice President

                             By:  /s/ Juan M. Csillagi
                                 ----------------------------------------------
                                 Name:  Juan M. Csillagi
                                 Title: Group Vice President

<PAGE>

                               Table of Contents

<TABLE>
<CAPTION>
                                                                                                                      Page
                                                                                                                      ----
<S>                                                                                                                   <C>
SECTION 1. Amount and Terms of Credit..........................................................................         1
     1.01 Commitments..........................................................................................         1
     1.02 Minimum Borrowing Amounts, etc.......................................................................         6
     1.03 Notice of Borrowing..................................................................................         7
     1.04 Disbursement of Funds................................................................................         8
     1.05 Notes................................................................................................         9
     1.06 Conversions..........................................................................................        13
     1.07 Pro Rata Borrowings..................................................................................        14
     1.08 Interest.............................................................................................        14
     1.09 Interest Periods.....................................................................................        16
     1.10 Increased Costs; Illegality; etc.....................................................................        17
     1.11 Compensation.........................................................................................        21
     1.12 Change of Lending Office.............................................................................        21
     1.13 Replacement of Lenders...............................................................................        22
     1.14 Special Provisions Applicable to Lenders Upon the Occurrence of a Sharing Event......................        23

SECTION 2. Letters of Credit...................................................................................        28
     2.01 Letters of Credit....................................................................................        28
     2.02 Minimum Stated Amount................................................................................        30
     2.03 Letter of Credit Requests............................................................................        30
     2.04 Letter of Credit Participations......................................................................        30
     2.05 Agreement to Repay Letter of Credit Drawings.........................................................        33
     2.06 Increased Costs......................................................................................        35

SECTION 3. Fees; Commitments...................................................................................        36
     3.01 Fees.................................................................................................        36
     3.02 Voluntary Termination or Reduction of Multicurrency Facility Revolving Loan Commitments and
             Adjustments of Multicurrency Facility Revolving Loan Commitments..................................        38
     3.03 Mandatory Reduction of Commitments...................................................................        39

SECTION 4. Prepayments; Repayments; Taxes......................................................................        40
     4.01 Voluntary Prepayments................................................................................        40
     4.02 Mandatory Repayments and Commitment Reductions.......................................................        42
     4.03 Method and Place of Payment..........................................................................        50
     4.04 Net Payments.........................................................................................        50

SECTION 5. Conditions Precedent to Credit Events on the Initial Borrowing Date.................................        53
     5.01 Execution of Agreement; Notes........................................................................        53
     5.02 Officer's Certificate................................................................................        53
     5.03 Opinions of Counsel..................................................................................        53
     5.04 Company Documents; Proceedings.......................................................................        54
</TABLE>

                                       -i-

<PAGE>

<TABLE>
<CAPTION>
                                                                                                                      Page
                                                                                                                      ----
<S>                                                                                                                   <C>
     5.05 Adverse Change, etc..................................................................................        55
     5.06 Litigation...........................................................................................        55
     5.07 Approvals............................................................................................        55
     5.08 Consummation of the Transaction......................................................................        55
     5.09 Subsidiaries Guaranties; Intercompany Subordination Agreement........................................        58
     5.10 Pledge Agreements....................................................................................        58
     5.11 U.S. Security Agreement..............................................................................        59
     5.12 Foreign Security Agreements..........................................................................        60
     5.13 Mortgages; Title Insurance; Surveys; etc.............................................................        61
     5.14 Employee Benefit Plans; Shareholders' Agreements; Management Agreements; Collective Bargaining
            Agreements; Existing Indebtedness Agreements; Tax Allocation Agreements............................        62
     5.15 Solvency Certificate; Insurance Certificates; etc....................................................        63
     5.16 Financial Statements; Pro Forma Financial Statements; Projections....................................        64
     5.17 Payment of Fees......................................................................................        64
     5.18 Consent Letter.......................................................................................        64

SECTION 6. Conditions Precedent to All Credit Events...........................................................        65
     6.01 No Default; Representations and Warranties...........................................................        65
     6.02 Notice of Borrowing; Letter of Credit Request; etc...................................................        65

SECTION 7. Representations and Warranties......................................................................        65
     7.01 Company Status.......................................................................................        66
     7.02 Company Power and Authority..........................................................................        66
     7.03 No Violation.........................................................................................        66
     7.04 Litigation...........................................................................................        66
     7.05 Use of Proceeds; Margin Regulations..................................................................        67
     7.06 Governmental Approvals...............................................................................        67
     7.07 Investment Company Act...............................................................................        67
     7.08 Public Utility Holding Company Act...................................................................        67
     7.09 True and Complete Disclosure.........................................................................        67
     7.10 Financial Condition; Financial Statements............................................................        68
     7.11 Security Interests...................................................................................        69
     7.12 Compliance with ERISA................................................................................        69
     7.13 Capitalization.......................................................................................        71
     7.14 Subsidiaries.........................................................................................        71
     7.15 Intellectual Property, etc...........................................................................        72
     7.16 Compliance with Statutes; Agreements, etc............................................................        72
     7.17 Environmental Matters................................................................................        72
     7.18 Properties...........................................................................................        73
     7.19 Labor Relations......................................................................................        73
     7.20 Tax Returns and Payments.............................................................................        73
     7.21 Scheduled Existing Indebtedness......................................................................        74
     7.22 Insurance............................................................................................        74

SECTION 8. Affirmative Covenants...............................................................................        74
     8.01 Information Covenants................................................................................        74
</TABLE>

                                      -ii-

<PAGE>

<TABLE>
<CAPTION>
                                                                                                                      Page
                                                                                                                      ----
<S>                                                                                                                   <C>
     8.02 Books, Records and Inspections.......................................................................        79
     8.03 Insurance............................................................................................        79
     8.04 Payment of Taxes.....................................................................................        80
     8.05 Existence; Franchises................................................................................        80
     8.06 Compliance with Statutes; etc........................................................................        80
     8.07 Compliance with Environmental Laws...................................................................        81
     8.08 ERISA................................................................................................        81
     8.09 Good Repair..........................................................................................        83
     8.10 End of Fiscal Years; Fiscal Quarters.................................................................        83
     8.11 Additional Security. Additional Guaranties; Actions with Respect to Non-Guarantor Subsidiaries;
            Further Assurances.................................................................................        83
     8.12 Foreign Subsidiaries Security........................................................................        87
     8.13 Use of Proceeds......................................................................................        88
     8.14 Ownership of Subsidiaries............................................................................        88
     8.15 Permitted Acquisitions...............................................................................        89
     8.16 Maintenance of Company Separateness..................................................................        91
     8.17 Performance of Obligations...........................................................................        91
     8.18 Conduct of Business..................................................................................        91

SECTION 9. Negative Covenants..................................................................................        93
     9.01 Changes in Business; etc.............................................................................        93
     9.02 Consolidation; Merger; Sale or Purchase of Assets; etc...............................................        93
     9.03 Liens................................................................................................        97
     9.04 Indebtedness.........................................................................................       100
     9.05 Advances; Investments; Loans.........................................................................       103
     9.06 Restricted Payments; etc.............................................................................       106
     9.07 Transactions with Affiliates.........................................................................       108
     9.08 Consolidated Interest Coverage Ratio.................................................................       108
     9.09 Leverage Ratio.......................................................................................       108
     9.10 Minimum Consolidated EBITDA..........................................................................       109
     9.11 Minimum Asset Coverage...............................................................................       110
     9.12 Capital Expenditures.................................................................................       110
     9.13 Limitation on Voluntary Payments and Modifications of Indebtedness; Modifications of Certificate of
            Incorporation, By-Laws and Certain Other Agreements; Issuances of Capital Stock; etc...............       111
     9.14 Limitation on Issuance of Equity Interests...........................................................       112
     9.15 Limitation on Certain Restrictions on Subsidiaries...................................................       113
     9.16 Limitation on the Creation of Subsidiaries and Joint Ventures........................................       114

SECTION 10. Events of Default..................................................................................       115
     10.01 Payments............................................................................................       115
     10.02 Representations, etc................................................................................       115
     10.03 Covenants...........................................................................................       115
     10.04 Default Under Other Agreements......................................................................       115
     10.05 Bankruptcy, etc.....................................................................................       116
     10.06 ERISA...............................................................................................       116
     10.07 Security Documents..................................................................................       117
</TABLE>

                                      -iii-

<PAGE>

<TABLE>
<CAPTION>
                                                                                                                      Page
                                                                                                                      ----
<S>                                                                                                                   <C>
     10.08 Guaranties..........................................................................................       117
     10.09 Judgments...........................................................................................       117
     10.10 Ownership...........................................................................................       118
     10.11 Denial of Liability.................................................................................       118
     10.12 Governmental Action.................................................................................       118

SECTION 11. Definitions........................................................................................       119

SECTION 12. The Agents.........................................................................................       166
     12.01 Appointment.........................................................................................       166
     12.02 Nature of Duties....................................................................................       167
     12.03 Certain Rights of the Agents........................................................................       168
     12.04 Reliance by Agents..................................................................................       168
     12.05 Notice of Default, etc..............................................................................       168
     12.06 Nonreliance on Agents and Other Lenders.............................................................       168
     12.07 Indemnification.....................................................................................       169
     12.08 Agents in their Individual Capacities...............................................................       169
     12.09 Holders.............................................................................................       169
     12.10 Resignation of the Agents...........................................................................       170
     12.11 Collateral Matters..................................................................................       171
     12.12 Delivery of Information.............................................................................       171
     12.13 Special Appointment of Collateral Agent (Germany)...................................................       172
     12.14 Special Appointment of Collateral Agent (France)....................................................       173
     12.15 Special Appointment of Collateral Agent (Quebec)....................................................       173
     12.16 Special Appointment of Collateral Agent (Belgium)...................................................       174
     12.17 Special Appointment of Collateral Agent (Austria)...................................................       175
     12.18 Special Appointment of Collateral Agent (Italy).....................................................       176
     12.19 Special Appointment of Collateral Agent (Poland)....................................................       177

SECTION 13. Miscellaneous......................................................................................       177
     13.01 Payment of Expenses, etc............................................................................       177
     13.02 Right of Setoff.....................................................................................       178
     13.03 Notices.............................................................................................       179
     13.04 Benefit of Agreement................................................................................       180
     13.05 No Waiver; Remedies Cumulative......................................................................       182
     13.06 Payments Pro Rata...................................................................................       183
     13.07 Calculations; Computations..........................................................................       183
     13.08 Governing Law; Submission to Jurisdiction; Venue....................................................       184
     13.09 Counterparts........................................................................................       185
     13.10 Effectiveness.......................................................................................       185
     13.11 Headings Descriptive................................................................................       185
     13.12 Amendment or Waiver; etc............................................................................       185
     13.13 Survival............................................................................................       188
     13.14 Domicile of Loans and Commitments...................................................................       188
     13.15 Confidentiality.....................................................................................       188
     13.16 Waiver of Jury Trial................................................................................       189
     13.17 Register............................................................................................       189
</TABLE>

                                      -iv-

<PAGE>

<TABLE>
<CAPTION>
                                                                                                                      Page
                                                                                                                      ----
<S>                                                                                                                   <C>
     13.18 English Language....................................................................................       190
     13.19 Special Provisions Regarding Pledges of Equity Interests in, and Promissory Notes Owed by, Persons
            Not Organized in Qualified Jurisdictions...........................................................       190
     13.20 Powers of Attorney; etc.............................................................................       191
     13.21 Waiver of Sovereign Immunity........................................................................       191
     13.22 Judgment Currency...................................................................................       191
     13.23 Limitation on Additional Amounts....................................................................       192
     13.24 Post Closing Actions................................................................................       192
     13.25 USA Patriot Act Notice..............................................................................       193

SECTION 14. U.S. Borrower's Guaranty...........................................................................       194
     14.01 The U.S. Borrower's Guaranty........................................................................       194
     14.02 Bankruptcy..........................................................................................       194
     14.03 Nature of Liability.................................................................................       195
     14.04 Independent Obligation..............................................................................       195
     14.05 Authorization.......................................................................................       195
     14.06 Reliance............................................................................................       196
     14.07 Subordination.......................................................................................       196
     14.08 Waiver..............................................................................................       197
     14.09 Payments............................................................................................       199
</TABLE>

SCHEDULE I       List of Lenders and Commitments
SCHEDULE II      Lender Addresses
SCHEDULE III     Real Properties
SCHEDULE IV      Scheduled Existing Indebtedness
SCHEDULE V       Pension Plans
SCHEDULE VI      Existing Investments
SCHEDULE VII     Subsidiaries
SCHEDULE VIII    Insurance
SCHEDULE IX      Existing Liens
SCHEDULE X       Capitalization
SCHEDULE XI      Certain Security Documents, etc.
SCHEDULE XII     Non-Guarantor Subsidiaries
SCHEDULE XIII    Transactions with Affiliates
SCHEDULE XIV     Tax Matters
SCHEDULE XV      Initial Qualified Jurisdictions
SCHEDULE XVI     Restructuring Charges
SCHEDULE XVII    Asset Dispositions
SCHEDULE XVIII   Post Closing Actions
SCHEDULE XIX     Dutch PMP Definition

                                   -v-

<PAGE>

EXHIBIT A-1   -  Form of Notice of Borrowing
EXHIBIT A-2   -  Notice of Conversion/Continuation
EXHIBIT B-1   -  Form of U.S. Borrower Term Note
EXHIBIT B-2   -  Form of European Borrower Dollar Term Note
EXHIBIT B-3   -  Form of European Borrower Euro Term Note
EXHIBIT B-4A  -  Form of U.S. Borrower Multicurrency Facility Revolving Note
EXHIBIT B-4B  -  Form of European Borrower Multicurrency Facility Revolving Note
EXHIBIT B-5A  -  Form of U.S. Borrower Swingline Note
EXHIBIT B-5B  -  Form of European Borrower Swingline Note
EXHIBIT C     -  Form of Letter of Credit Request
EXHIBIT D     -  Form of Section 4.04(b)(ii) Certificate
EXHIBIT E-1   -  Form of Opinion of Kirkland & Ellis LLP
EXHIBIT E-2   -  Form of Opinion of AKD Prinsen Van Wijmen
EXHIBIT F     -  Form of Officers' Certificate
EXHIBIT G-1   -  Form of U.S. Subsidiaries Guaranty
EXHIBIT G-2   -  Form of Foreign Subsidiaries Guaranty
EXHIBIT H     -  Form of U.S. Pledge Agreement
EXHIBIT I     -  Form of U.S. Security Agreement
EXHIBIT J     -  Form of Solvency Certificate
EXHIBIT K     -  Form of Assignment and Assumption Agreement
EXHIBIT L     -  Form of Intercompany Note
EXHIBIT M     -  Form of Shareholder Subordinated Note
EXHIBIT N     -  Form of Consent Letter
EXHIBIT O     -  Form of Intercompany Subordination Agreement
EXHIBIT P        Form of Joinder Agreement

                                  -vi-

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00065-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00065-of-00352.parquet"}]]